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QUOTATION
"Being good, conveying as it does the notion of value, implies being an 
end or goal, and this is the starting-point of causal action, the cause of 
causality itself; for no agent acts except for some goal, and no matter 
would acquire form unless an agent acted on it ....In causal action every­
thing starts with the good end which motivates the agent to act, and so 
elicit the final of the effect. In the caused thing we find the opposite order: 
first, the form itself brings with it existence; next, there is the operative 
power which brings perfection of existence (for a thing is perfect, Aristo­
tle says, when it can reproduce itself); so that finally, the thing realises the 
notion of goodness. It is usual to distinguish three different meanings of 
good: the useful, the worthy and the delightful. For whatever is of value, 
and can satisfy desire, is good. That which satisfies as a stage on the way 
to something else we call useful; that which satisfies itself we call worthy, 
and the satisfaction found in it delight. So the primary sense of good is 
worthy, the second delightful and the third useful.
St Thomas Aquinas, Summa Theologiae
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ABSTRACT
Hypothesis: Increased platelet reactivity is a thrombogenic risk factor for the
development of premature coronary heart disease (CHD), transforming coronary 
artery atherosclerotic disease, that is coronary artery disease (CAD), into the clinical 
problems of acute and chronic CHD.
Aim: To determine if males with premature CHD and angiographically
proven CAD differ in platelet reactivity in comparison to a control group without 
CHD, and if present to attempt to determine if any difference was due to other fac­
tors, particularly CHD risk factors.
To determine if measures of platelet reactivity bear any relationship 
with angiographically defined CAD, whether to the extent of mural involvement or 
the number/severity of discrete obstructive lesions.
Method: This was a case-control study of 53 males with premature CHD and
48 age and socioeconomically matched controls without CHD. Besides specific plate­
let function measures, included in the comparison were the known main risk factors 
and a number (although not all) of more recently described and potentially important 
risk factors. The usual demographic information and a dietary diary were also ob­
tained. A number of preparatory studies were also undertaken to evaluate specific 
potential areas of bias that may have confounded the results of the case-control 
study. In addition, the relationship between angiographic CAD and CHD risk factors 
and platelet function were evaluated
Results: As expected, the major risk factors for CHD were significantly dif­
ferent. Measures of platelet reactivity were also significantly different between the 
two groups indicating an increased platelet reactivity in the CHD group. However, 
no difference in measures of in vivo platelet activation was present, suggesting no 
on-going platelet activation in stable CHD patients.
Lipoproteins and fatty acid levels were independently associated with the extent of 
coronary artery atherosclerosis assessed angiographically, but not with the a com­
posite score of number and severity of discrete obstructive coronary artery lesions. 
Increased platelet response to adrenaline correlated positively and independently with 
the composite severity score for the number and severity of discrete CAD lesions.
Conclusions: The results of this study, together with existing data, indicate that 
increased platelet reactivity is a risk factor for CHD and for the presence of severe 
obstructive coronary artery lesions in young males. There is substantial evidence, 
although not complete, that increased platelet reactivity is a causative risk factor for 
the development of CHD and obstructive CAD.
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CHAPTER 1
THE PATHOPHYSIOLOGY OF ACUTE CORONARY SYNDROMES, 
CORONARY HEART DISEASE AND ATHEROSCLEROSIS. 
THE ROLE OF THE PLATELET.
1
1.1 THROMBOSIS IN THE CORONARY CIRCULATION
1.1.1. Coronary Artery Thrombosis
The development of an occlusive thrombus superimposed on a fissured or ulcerated 
atherosclerotic plaque has been established as a prime component in the development 
of acute myocardial infarction (AMI).1'4 This concept was expressed by James 
Herrick as long ago as 1912.5 Although the term acute myocardial infarction was 
originally considered synonymous with acute coronary thrombosis, 5,6 the role of 
occlusive coronary thrombi in AMI had not always been fully accepted and there had 
been a great deal of controversy until recently.7 The observations that many patients 
with AMI did not have thrombus present,8 that coronary thrombosis occurred with­
out causing AMI,6 and that pathological studies suggested that coronary thrombosis 
was a result rather than a cause of AMI,9 all contributed to the argument. However, 
recent studies using improved techniques have provided clear evidence of a role for 
thrombosis in the pathogenesis of AMI, and indeed, the other acute coronary syn­
dromes.1'4 There is a consistent relationship between the acute clinical syndromes of 
coronary artery disease (CAD) and the presence of arterial thrombi and/or platelet 
aggregates within the coronary circulation. This is particularly evident in AMI.
1.1.2. Acute Myocardial Infarction
Convincing evidence for the involvement of thrombosis in the pathogenesis of AMI 
has come from a number of sources. Firstly, many pathological studies have shown 
thrombus located in the proximal portion of a coronary artery supplying infarcted 
myocardium.6,1013 Secondly, the delivery of intracoronary thrombolytic agents can 
reopen occluded arteries in the setting of AMI.14 Furthermore, with the use of radio­
isotopes, the central portion of a thrombus subtending an infarct has been shown to 
be radio-negative,15 indicating that the initial thrombus formed prior to administra­
tion of the radioisotope, and therefore early in infarct development or antecedent to 
infarction. The incorporation of 125I-fibrinogen into coronary artery thrombi after the 
onset of typical ischaemic chest pain demonstrates that an occlusive thrombus may, 
however, propagate after the onset of necrosis.16
1.1.3 Unstable Angina
The mechanisms involved in unstable angina are probably similar to those occurring 
in AMI, although other potential causes include rapidly progressive narrowing of 
coronary arteries from atherosclerosis, rapid accumulation of intimal foam or 
smooth muscle cells, coronary artery spasm, and platelet aggregation in the presence 
of coronary artery spasm and/or atherosclerotic narrowing.17
Angiographic features of coronary thrombosis in patients with unstable angina have 
been well documented.18'21 Thrombolysis in patients with unstable angina increases 
the patency of arteries supplying the ischaemic area of myocardium, which suggests 
that thrombus, in association with atherosclerotic lesions, is involved in the pathoge­
nesis of unstable angina.19 Lesions consistent with intraluminal thrombus have been 
reported in 70% of patients with unstable angina, and only in 16% of patients with 
stable symptoms.20 The lesions frequently seen in unstable angina antemortem are
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similar to postmortem angiographic lesions, namely ruptured atherosclerotic plaques 
with associated thrombi.22 Furthermore, progression of CAD occurs more common­
ly in patients with unstable angina 21’20 and can evolve from a previously insignifi­
cant stenosis.20 The common morphological features of disease progression in un­
stable angina are a disrupted atherosclerotic plaque and/or a partially lysed throm­
bus.20 Clinical features of unstable angina also support a common aetiological basis 
with AMI. There is a significant increase in the incidence of AMI occurring shortly 
after the onset of unstable angina and a history of unstable symptoms prior to the 
onset of AMI.17 This association is suggestive of similar pathophysiological mechan­
isms in both conditions, a concept that has important clinical applications. The valid­
ity of these studies has found strong support from the direct observation of intra­
luminal coronary thrombosis by angioscopy in unstable angina.4,23
1.1.4. Sudden Cardiac Death
Many individuals who die suddenly of ischaemic heart disease have an actively pro­
gressing thrombotic process in association with a ruptured atherosclerotic plaque.2,24 
Electrocardiographic evidence of AMI or ischaemia has been reported in up to two- 
thirds of resuscitated survivors of sudden coronary death (Cobb et al 1980). Platelet 
aggregates have been demonstrated in intra-myocardial vessels of patients dying 
suddenly and unexpectedly of ischaemic heart disease.25 Those dying suddenly after 
developing unstable angina have evidence of an ongoing thrombotic process in a 
major coronary artery.26 In addition, many patients with unstable angina and sudden 
cardiac death have platelet aggregates confined to vessels immediately downstream 
of a major epicardial coronary artery containing thrombus on a disrupted atheros­
clerotic plaque.27 Coronary thrombosis is found in most deaths caused by AMI and 
platelet/fibrin microemboli have been frequently observed.15 Although the terminal 
event in sudden cardiac death is usually some form of ventricular electrical instabili­
ty, it appears that in many sudden cardiac deaths, the pathologic process may include 
the rapid formation of a plaque fissure, or rupture, with subsequent thrombus forma­
tion and myocardial ischaemia. The first manifestation of this process may be a fatal 
ventricular arrhythmia. Nevertheless, coronary artery thrombosis does not occur in 
all cases of sudden cardiac death,28,29 and, indeed, has been reported in as few as 
19% of sudden deaths.30,31
1.1.5 Plaque Fissuring and Progression of CAD
Disruption of small atherosclerotic plaques with ensuing mural thrombosis and fibro- 
tic organisation of the thrombus may contribute to the progression of atherosclerosis. 
Exactly how prevalent this process is, and of what clinical significance, remains 
unknown.32 Plaque fissuring is most frequently associated with an eccentric lipid 
pool in the arterial intima, and the lateral margin of plaques is the most common site 
of intimal tearing.33 The site of plaque fissuring is influenced by variation in the 
mechanical strength of the cap of the plaque tissue due to focal foam cell accumula­
tion.33 Alternative, or co-existing mechanisms also probably contribute, since intimal 
tears can occur where there is no lipid pool within the intima.33 Other factors appear 
to be involved in the progression of CAD since the extent of atherosclerosis only in 
part determines the prognosis of clinical coronary heart disease (CHD). Coronary 
thrombosis and CHD may not be the simple and direct result of the presence of
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atheroma alone, 11,34' 37 and CHD is not a simple, proportional function of coronary 
atherosclerosis.37 Some individuals with severe atherosclerosis do not experience 
occlusive episodes, and others with less severe disease develop major clinical mani­
festations.38,39
1.1.6 Determinants of Plaque Fissuring and Thrombosis
1.1.6.1 Local factors related to atherosclerotic lesions. The degree and depth 
of plaque disruption is a prime determinant of the extent of intra-luminal thrombosis 
subsequently occurring.40,41 In addition, the degree of residual arterial stenosis can 
cause increased platelet deposition, due to increased shear stress induced platelet 
aggregation.42 This observation is indicative of the increased thrombogenic potential 
of more severe stenoses that have been observed in clinical studies.43
1.1.6.2 Local factors causing platelet activation. Localised platelet activation 
and platelet secretion at the site of plaque rupture potentiates thrombus formation.44' 
46 Moreover, residual thrombus has a strongly thrombogenic surface47 and disruption 
of the thrombus by intrinsic fibrinolytic mechanisms may increase platelet activation, 
which also occurs with pharmacologically induced thrombolysis.48'50
1.1.6.3 Vasoconstriction. Platelet and thrombin dependent transient vasoconstric­
tion accompanying plaque disruption may further increase shear stress induced plate­
let aggregation, and further aggravate the potential for ongoing thrombosis.41,51
1.1.6.4 Systemic thrombogenic factors. The search for a systemic thrombogenic 
or hypercoaguable state has been a long-term quest52' 55 and continues to attract con­
siderable a tten tion . 41,56 Known potential factors include increased platelet 
sensitivity,57' 59 increased circulating fibrinogen levels60'62 and factor VII levels,60 
defective fibrinolysis56 and increased blood viscosity.63,64
1.1.6.5 Metabolic and hormonal influences on thrombosis. The effects of 
abnormal lipoprotein levels and plasma fatty acids on thrombosis and platelet func­
tion are potentially detrimental.53,65' 67 Enhanced platelet reactivity at the site of 
vascular damage in experimental hypercholesterolaemia has been well documented.68 
Lipoprotein(a), a molecule similar to low density lipoprotein (LDL), has a glycopro­
tein, apolipoprotein(a), which has close structural homology with plasminogen.69 
This lipoprotein when occurring in increased amounts is a risk factor for CHD, 
possibly as a thrombogenic risk factor with a causative association with CHD 
events.69 The potential for increased secretion of adrenaline in patients with CHD, 
and in association with other risk factors,41 has important implications since this 
hormone contributes to platelet aggregation.70'72 Many other promising metabolic 
abnormalities, such as increased homocysteine levels, may provide further insight 
into the thrombotic component of CHD.73
1.2 PLATELET FUNCTION IN ACUTE CORONARY SYNDROMES
Platelet activation appears to play a pivotal role in the development of the acute ob­
structive ischaemic syndromes of CHD. The evidence for this comes from a number
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of sources indicating that platelet activation is important in the pathophysiological 
process of acute coronary thrombosis. It remains unclear, however, whether preex­
isting platelet activation predisposes to thrombus formation.
1.2.1 Acute Myocardial Infarction and Platelets
Platelet activation has been demonstrated in patients with unstable angina and early 
during AMI.45,74 Changes in some measures of platelet function indicating platelet 
activation are well documented. Firstly, an elevation of beta-thromboglobulin (BTG) 
early during AMI has been reported.75'81 Increased BTG levels has been reported to 
be d irectly  proportional to the severity of CAD.77 O ther studies have found in­
creased levels of BTG in patients with CAD which does not increase further with 
A M I,82 while others have shown increases in BTG only in a m inority of patients 
with A M I.83 Secondly, most reports have also found an elevated platelet factor 4 
(PF4) in the early phases of AMI.84'88 However, others have failed to demonstrate 
an increase in PF4 except in association with invasive procedures or platelet de­
granulation in vitro.89 Another study reported an increase in PF4 in stable chronic 
CHD and no further increase associated with AMI.87 Thirdly, a metabolic product of 
thromboxane A2 (TXA2) excreted in the urine would appear to be a reliable measure 
of platelet activation since it is not associated with artefactual changes due to sam­
pling procedures.45 The m etabolic product, 2,3,dinor-throm boxane B2 is clearly 
elevated in the urine of patients with AMI and unstable angina.45'90 Increased TXA2 
form ation m ust therefore occur at least in the early phase of AMI and unstable 
angina. W hether there is a pre-morbid increase contributing to the initiation of the 
events is uncertain. Interestingly, platelet hyper-reactivity may be related to progno­
sis in AMI59 and CHD.91 Finally, activation of prostacyclin (PGI2) synthesis occurs 
in these conditions,45,90,92 although there may not be an increase in PGI2 production 
in many patients during the acute thrombotic phase of AMI.93
Measures of platelet survival time do not appear to be strongly influenced by acute 
ischaemic syndromes of CHD. Platelet survival time is shortened in chronic CHD,94' 
96 although during AMI there appears to be no additional measurable reduction in 
platelet mean lifespan above that observed in chronic CAD.96
Clinical studies with aspirin support the evidence for platelet involvement in these 
acute occlusive coronary  artery  syndrom es o f unstable angina and A M I.97' 103 
Although the mechanism(s) for the beneficial influence of aspirin has not have been 
fully delineated, it is assumed to be the inhibitory effect on platelet cyclooxygenase, 
thereby inhibiting platelet aggregation. Aspirin has also been effective in secondary 
reduction of coronary occlusive events after A M I,104,105 probably by preventing 
rethrombosis.
1.2.2 Unstable Angina and Platelets
The clinical syndrome of unstable angina encompasses a diverse spectrum of patients 
and clinical presentations. Within those groups diagnosed as having unstable angina 
pectoris, there are certain  subgroups with an increased risk of early m yocardial 
infarction (MI) and even death.17,106' 109 Angiographic,18'20,26,110' 115 autopsy,26,112 as 
well as angioscopic4,23 evidence indicates that thrombus formation over a fissured
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atherosclerotic plaque plays a key role in the development of unstable angina. Not 
surprisingly then, platelet activation has been demonstrated in unstable angina re­
flected  by elevated plasma levels of p latelet derived proteins, BTG and 
PP474,76,8i,83.ii6 purthermore, increased production of TXA2 as measured by urinary 
metabolites is evident.45,74 In unstable angina, there is a higher thromboxane B2 
(TXB2) metabolite excretion in patients with persistent ischaemic symptoms than in 
those that respond to treatment. Similarly, higher levels are found in those with post 
infarctional angina.74 Enhanced excretion of TXB2 metabolite is frequently associat­
ed with angiographic evidence of thrombosis.74 In addition, prospective clinical trials 
have shown a reduction in CHD events and in mortality with antiplatelet drugs.97'98 
Heparin also decreases the incidence of AMI associated with unstable angina.103,117
1.3 PLATELETS, PLATELET FUNCTION AND CORONARY HEART 
DISEASE RISK FACTORS
The major risk factors associated with CHD may also independently contribute to 
increased platelet reactivity in individuals with CHD. The clinical, pathological or 
epidemiological relevance of this to the development of CAD and CHD remains 
clouded. The concept of risk factors for CHD is discusssed fully in section 1.4.
1.3.1 Platelets and Tobacco Use
Cigarette smoking is a major risk factor associated with the development of clinical 
CHD. The frequency of various forms of arterial thrombosis, the overall mortality 
from CAD and that of sudden death alone, all increase with the number of cigarettes 
smoked by the individual.118'120 The mechanism(s) by which smoking increases the 
likelihood of developing CAD are unknown, although various factors, including 
platelet dysfunction, have been incriminated. Chronic smokers have shortened plate­
let survival and increased platelet turnover.121 However, platelet survival time is 
lengthened in smokers, with or without CAD, who abstain from smoking.57 An acute 
effect of smoking may be to increase platelet aggregability,122 independently of the 
nicotine concentration.123
1.3.2 Platelets and Dyslipoproteinaemia
Various forms of hyperlipoproteinaemia appear to induce changes in platelet compo­
sition and function. However, both the effects of hyperlipoproteinaemia on platelet 
composition, reactivity and function, and the contribution of any such effects to 
atherogenesis are poorly understood and controversial. Hypercholesterolaemia 
(Fredrickson’s types Ila and lib) may be associated with increased platelet sensitivity 
to aggregating agents,124 and a reduction in platelet survival time,125 although this is 
contentious.126 An increased sensitivity to aggregation appears to be associated with 
an increased cholesterol content of the platelet membrane.127 In vitro cholesterol 
loading of platelets results in a marked augmentation of TXA2 production in the 
presence of thrombin,128 a finding consistent with the observation of an increased 
production of TXA2 in type Ila hyperlipoproteinaemia.124 Moreover, a low fat diet 
has been reported to decrease the aggregability of platelets,129 and a large meal of 
saturated fats causes increased platelet reactivity.130 If there are significant changes
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in platelet function in association with the hyperlipidaemias occurring in those sus­
ceptible to CHD, such changes may be detectable before atherosclerosis becomes 
advanced. These aspects are discussed more fully in Chapter 5.
1.3.3 Modifications of Low-Density Lipoproteins
Characteristics of low-density lipoprotein (LDL) particles, other than the plasma 
concentration, can influence platelet behaviour.131,132 Oxidative modification of LDL 
has gained considerable attention because of the substantial evidence indicating that 
the process occurs in vivo, and the com pelling evidence for its role in 
atherogenesis.133 Oxidised LDL has numerous biological properties,131 including an 
ability to interact with platelets and increase their aggregability.134 Also, in theory, a 
deficiency of antioxidants within the body may reduce PGI2 production, and hence 
promote platelet aggregability.132 However, the effects on platelet aggregation of 
antioxidant supplementation remain inconsistent.132,135
Other types of LDL modification, such as the non-enzymatic glycosylation of 
LDL,136,137 may also be important in the atherogenic process.133 Moreover, platelet 
aggregation is increased in the presence of glycated LDL.137
1.3.4 Blood Glucose
The adverse effects of abnormal glucose metabolism on platelets has been extensive­
ly investigated and previously reviewed.138 For example, elevated blood glucose in­
fluences adenosine diphosphate (ADP)-induced platelet aggregation,139 thromboxane 
and PGI2 biosynthesis,140,141 and raised plasma adrenaline and hyperglycaemia after 
MI may activate platelets which could contribute to poor outcome in such patients.75 
Whether such influences on platelet function account for or contribute to the in­
creased risk in diabetics for the development of clinical syndromes related to ather­
osclerosis remains uncertain. Other potential sources for increasing risk include 
abnormal lipoprotein metabolism142 and glycosylation of proteins such as the protein 
in LDL, thereby possibly making the molecule atherogenic.133,136,137 Moreover, 
fibrinogen is elevated in diabetics143,144 and there are potential adverse effects on 
coagulation and fibrinolysis.144
1.3.5 Hypertension and Platelet Function
A relationship between blood pressure (BP) and platelet aggregation appears to 
exist.145'147 For example, patients with a mean arterial BP greater than 120 mmHg 
have an increased tendency for platelet aggregation to ADP and adrenalin, which is 
normalised when the mean arterial pressure is reduced by treatment.146 Although the 
relationship between the systolic or diastolic BP of individuals or groups and platelet 
function has not been extensively evaluated, the concept is reviewed elsewhere.147
1.4 CORONARY HEART DISEASE RISK FACTORS
A risk factor is a statistical predictor of disease and its identification is usually based 
on associations demonstrated between the predictor and the disease in epidemiologi­
cal studies. As a consequence, a risk factor may or may not be causally related to
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the disease. For example, it may be a secondary manifestation of a more basic 
underlying abnormality or an early symptom of the disease.
1.4.1 Epidemiology
The established "causative" risk factors of CHD fail to account for the total in­
cidence of CHD.39,148'158 Nor do they explain the absence of clinical CHD in persons 
with these risk factors.148 Furthermore, the known risk factors have a limited ability 
to predict disease in an individual,152 and this low predictive accuracy limits their 
use for identifying persons with asymptomatic CAD. Indeed, the low predictive 
accuracy for identify individuals with CHD also applies to groups.153,159 The results 
of the Pooling Project defined a wide range of factors increasing the risk for CHD 
within different populations, and demonstrated significantly increased risk with 
levels of associated factors well below the 95th percentile, particularly when occur­
ring in combination.148 These observations have profound implications for public 
health and the prevention of premature CHD. For the individual, these results have 
illustrated major limitations in the ability to prospectively predict disease occurrence, 
even when the strongest risk factors are combined. Quantification of risk factors in 
the form of a decile risk has been used to determine the likelihood of developing 
CHD.160 In those with the lowest risk it was 5%, and in those with the highest risk it 
was 21.4% over 8 years.160 This synergistic effect of the major risk factors also 
remains to be explained. Use of risk factor profiles can identify 10% of the general 
population who will have 22% of the CHD in the population.160
A number of observations made in epidemiological studies further illustrate the 
incomplete foundation that known major risk factors make for explaining all CHD. 
Firstly, international population studies reveal a significant variation in CHD mortal­
ity in different countries.161 This variation is probably only partly due to population 
differences in blood cholesterol levels.162 It should be emphasised that cross-cultural 
comparisons do indicate that CAD is rare in populations with cholesterol levels less 
than 4.2 mmol/1.162 However, regional differences within some countries cannot be 
wholly explained on the basis of differences in levels of the 3 major risk factors for 
CHD. Secondly, the Framingham Study logistic, useful for predicting CHD in high 
risk population groups, over-estimates CHD incidence in "low risk countries". This 
indicates that the influence of risk factors in the predominantly Caucasian population 
of Framingham is greater than in non-Westernised countries. The reason for this 
observation is unknown, but may simply be due to the lack of underlying atheros­
clerosis in populations with low cholesterol levels leaving no substrate for the other 
"causative" risk factors to act upon and result in obstructive lesions causing clinical 
CAD. Thirdly, even though total cholesterol levels predict long term CHD mortality 
it is not a major factor in predicting all-cause mortality.159 The association between 
cholesterol and CHD at "borderline hyperlipidaemia" may reflect the correlation of 
cholesterol with other risk factors.159 Finally, and of particular relevance for the 
hypothesis in this Thesis, the incidence of CHD in France is relatively low compared 
to other Western Countries with equal intake of saturated fats and population cho­
lesterol levels.163 Moreover, other risk factors for CHD, including BP levels, body- 
mass index, and cigarette use for men are no lower in France than in other industri­
alised countries.163,164 One proposed explanation for this variation is the inhibition of 
platelet reactivity by alcohol.164
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Even though population studies have shown that all of the variance for CHD devel­
opment in a population cannot be explained by the major risk factors, 148 there are 
caveats to this observation. A limited number of risk factors have been included in 
these studies. There may also be the effects of longitudinal trends on the variables 
investigated, either increasing if favourable, or decreasing if unfavourable. Further, 
the majority of persons who have a MI are in the second, third and fourth quintiles 
for cholesterol level, as are the majority of persons who do not have CHD.165,166
1.4.2 Risk Factors and Coronary Artery Pathology
The strength of association between CHD risk factors and pathologically defined 
atherosclerosis also has limitations. The observation that atherosclerosis is closely 
associated with major risk factors is only true if the correlation is estimated on a 
group basis. The correlation is much weaker when estimated on an individual 
basis. 152 For instance, correlation coefficients between cholesterol level prior to 
death and quantitatively evaluated coronary atherosclerosis range from 0.15 to 0.35 
for the individual analysis, but 0.76 for groups. This indicates that individuals with 
higher cholesterol levels are not all equally susceptible to CHD. 152 Furthermore, 
there is a progressive rise in the prevalence of all major risk factors with age, in 
parallel with a continual reduction in the predictive accuracy. 151,167 When comparing 
homogeneous age-sex-race groups without significant risk factors, the range of the 
extent of CAD in any single arterial segment is similar between groups, but there is 
up to a 5 fold difference in the mean measure for the extent of disease for all the 
coronary arterial tree between the groups. 153 That is, the median varies between 
groups. Variability among arteries in the same individual implies that the response of 
the arterial wall differs, assuming that the composition of the blood reaching each 
artery is identical. Indeed, there is a wide variation in the extent of raised lesions in 
male smokers and non-smokers with an enormous overlap despite significant differ­
ences in mean values. 158 Even though the presence of CAD in a population corre­
lates with the incidence of CHD, and CHD cases almost always have more atheros­
clerosis on the average than non-CHD cases in the same location, the incidence of 
CAD is significantly greater than the incidence of CHD, implicating other factors as 
well as the presence of atherosclerosis in the development of CHD.39 Furthermore, 
even after classifying cases according to risk factors in a prospective autopsy study, 
there can be individual variation in the extent of raised atherosclerotic lesions, and 
the risk factors may only explain about 26% of the individual variation in raised 
lesions. 168
Important determinants of whether an individual develops CHD may be local factors 
within the artery and/or may be related to the morphology of the atherosclerotic 
plaque. Indeed, mechanical, hydraulic and cellular/molecular characteristics of the 
plaque may be important determinants in the development of clinically significant 
lesions. 169 For instance, although the distribution of circumferential tensile stress 
across the intima is altered by the atherosclerotic plaque, and areas of high stress 
correlate with the site of intimal tears,33 these sites are also affected by variation in 
the mechanical strength of the intimal cap.33 Sites of intimal tears appear to be weak 
points which are largely determined by focal accumulation of foam cells33
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1.4.3 Risk Factors and Angiographic CAD
Although risk factors are clearly associated with both clinical manifestations of CAD 
and angiographically demonstrated CAD, they are not accurate predictors of angio­
graphic C A D .149 Between 9% and 17% of male subjects have no definable risk 
factor for CHD in the presence of angiographically defined CAD.149 In addition, 
limited gains accrue from the use of discriminant function analysis in correctly allo­
cating patients into angiographically defined disease and non-disease groups accord­
ing to the major risk factors.149 This topic is elaborated on in Chapter 8.
1.4.4 Genetic and Hereditary Factors
Family studies consistently demonstrate a prominent familial grouping of CHD. In 
males, there is likely a genetic predisposition to both premature CHD,154,155,170' 175 
and the major risk factors for CHD.154,155,165,173,176 The familial occurrence of CAD 
is well documented by case-control,177'180 prospective,181 and twin studies.182,183 No 
discrete genetic mode of inheritance has emerged for the majority of family aggre­
gates with CAD and only occasionally have single gene disorders accounted for the 
development of premature CAD in a general population.184 A family history of MI is 
an independent risk factor for MI, and the number of relatives and the age at which 
they are affected is related to the strength of the association.180
The tendency for first degree relatives of CAD patients to have more adverse risk 
factors than the general population has been well documented,176,178,185 particularly 
so when CAD is m anifest at a young age.176 The major risk factors per se have a 
substantial familial component, whether of genetic or environmental origin. It may 
be that the contribution o f genetic factors is greater than can be attributed to the 
inheritance of the major risk factors alone.186 For most of the important risk factors, 
familial associations arise from both a shared genotype and a shared environment.187
The fam ilial nature of CAD may be explained in part by common environmental 
factors shared by family members. Nonetheless, the classic risk factors do not entire­
ly predict familial occurrence of CHD, even if the genetic risk factors are eliminat­
ed.165,173 It is even possible that the risk ratio for a positive family history of CHD is 
greater than for the highest quintile of cholesterol levels,165 and that the contribution 
of heredity may exceed that of environment.173
The exact nature of the genetic factors, which are independent of the known risk fac­
tors and which impart a predisposition to CAD, are obscure. In addition, for young 
males, the heredity association is particularly im portant,170 and it may even be re­
stricted to younger m en.188 The relationship in females is less certain.175,188 Unfor­
tunately specific inheritance patterns, genetic m echanism s or gene-environm ent 
interactions for CAD have not been well defined and require more intense evalua­
tion.154,155,170,173 Diseases attributable to multifactorial inheritance are caused by the 
small effects of many genes, and only in a small number of cases are determined by 
single genes of large effect.189,190
It is assumed that there are multiple predisposing hereditary factors that interact with 
environmental triggers to produce CAD, rather than a single gene mode of inherit-
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ance. Evidence exists, however, that in patients susceptible to CHD there are single 
major gene influences, and, although research has concentrated on lipid disorders, 
there may be major gene influences other than through lipoprotein abnormalities.165 
For instance, ’abnormal’ platelet response to ADP have been found more often in 
the close relatives of young men with AMI than in a general population.191 Indeed, 
other heritable risk factors appear to contribute strongly to the occurrence of prema­
ture CAD.192
Risk factors other than those currently known must mediate the effects of the family 
aggregation of C A D .193 The presence o f an environm entally  sensitive inherited  
abnormality of platelet reactivity is one possibility that requires evaluation.
1.4.5 Sex Differences in CHD
Differences in known risk factors fail to explain the male sex predominance in either 
atherosclerosis or CHD incidence.152,155,194' 196 However, there is an absence of de­
tailed studies of the variability in CHD susceptibility between men and w om en.196 
T here  are also unexp lained  d ifferences in the p rognosis re la ted  to CAD risk  
factors197 and the presence of CHD.194,195,197 For example, women appear to have 
much lower rates of CHD than men at the same values of cholesterol and increased 
risk at higher levels of cholesterol.198 Furthermore, there are important differences 
in the natural history,195 the risk factor p rofile194,195,198,197 and pathology199,200 of 
CHD in women compared to males. However, most young women with overt CHD 
have a detectable risk factor, but also have a high rate of non-atherosclerotic MI.200
1.4.6 Conclusion
Despite the concerns discussed above, epidemiological evidence is persuasive that 
the 3 m ajor risk factors (tobacco use, hypertension and hypercholesterolaemia) are 
causative in their association with CHD,161 in particular, lipid abnormalities.201 Even 
though a calculated attributable risk for these factors may be as high as 90%,202 their 
lack of diagnostic specificity and low predictive accuracy for the developm ent of 
CHD remains to be explained. Many individuals remain free of the clinical manifes­
tations o f CAD even when multiple risk factors are present.148,160,166,203,204 Further­
more, their poor predictive accuracy persists into old age 151.160.167-205 and, while 
certain factors are significantly correlated with angiographic findings, their value for 
predicting the severity of CAD disease is also very lim ited.149,206,207 Indeed, in the 
younger patient the progression of coronary atherosclerosis into distinct coronary 
artery stenosis may largely be determined by mechanisms other than the presently 
known risk  factors.207 Based on present evidence, there seems to be at least two 
processes involved in the developm ent of atherosclerotic vascular disease, one in 
response to localised  lipid accum ulation w ithin the vessel wall and the o ther a 
thrombotic response leading to more rapid development of stenotic coronary artery 
lesions.9
1.5 THE CONCEPT OF THROMBOGENIC RISK FACTORS
In this section it will be argued that, beside the pivotal role that coronary thrombosis
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has in the pathogenesis of the acute ischaemic syndromes of CHD, a predisposition 
to arterial thrombosis may exist as a risk factor for the different stages leading to the 
clinical expression of CHD. That is, thrombogenic risk factors may be important in 
the pathogenesis of atherosclerotic plaque formation as well as obstructive thrombo­
sis.
1.5.1 Coronary Thrombosis
As discussed above, thrombus superimposed on a fissured atherosclerotic plaque is 
usually present in the coronary artery supplying infarcted myocardium , 1,3,13 and 
other acute coronary artery syndromes.208'210
1.5.2 Progression of CAD
The formation of severe atherosclerotic lesions may develop following recurrent 
episodes of localised thrombus formation, 10,11 with concomitant fragmentation of 
thrombus. 115 Support for this concept arises from a number of pathological studies. 
Microemboli and/or microinfarcts found in the myocardium distal to evolving coro­
nary thrombi, indicate the dynamic aspect of intravascular thrombosis.3,25,211 Fibrin 
appears to be a major component of atherosclerotic lesions,212 which is compatible 
with the incorporation of fibrin into the lesion following recurrent mural thrombosis. 
Alternatively, this fibrin may be formed from fibrinogen found within the intima.34 
In addition, intimal haemorrhage, a well known complication of atherosclerosis,213" 
215 may cause rapid progression of atherosclerotic lesions. These haemorrhages may 
be due to intimal dissection from the lumen,2,11,216 or arise as a sequelae to neo- 
vascularisation of the intima.213,214,217,218
In an autopsy study of the evolution of atherosclerotic lesions in young individuals, 
fibrous caps were found to form slowly.9 When platelets and fibrin accumulated on 
the endothelial surface, the caps thickened and reduced the arterial lumen quickly. 
The deposition of platelets and fibrin on the surface of atherosclerotic lesions was 
thought to be the cause of the collagenous caps and the main cause of the rapid 
progression to lumen stenosis. This was found to be an uncommon process up to the 
third decade when most caps were thinner with little collagenous thickening when 
compared with cases having thrombotic deposits.9 The latter were observed in the 
third decade of life in some subjects and were episodic in their occurrence.9 This 
autopsy study provides evidence of lesion progression consistent with angiographic 
studies showing rapid lesion development in areas of minimal disease. On the other 
hand, lipid cores often begin to develop soon after puberty and increase linearly over 
time.9 Proliferation of smooth muscle cells and synthesis of collagen forming the cap 
develops after a lipid core evolves.9
1.5.3 Extent and Severity of CAD
The concept that coronary thrombosis and CHD may not be the simple and direct 
result of the presence of atherosclerosis alone, has been previously considered on the 
basis of results from historical and epidemiological necropsy studies. 11,34' 37 The 
suggestion that "ischaemic heart disease is not a simple, proportional function of 
coronary atherosclerosis"37 is an important concept in understanding the aetiology of
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CHD. There are a significant number of individuals who have AMI and are subse­
quently shown to have angiographically near normal, or normal, coronary arteries, 
particularly younger patients.219"222 Younger patients also have less extensive coro­
nary atheroma.207 Furthermore, in necropsy studies, substantial differences in the 
frequency of myocardial fibrosis have been observed which correspond only mod­
erately to the frequency of coronary occlusions, and which do not relate at all to the 
frequency of lesser narrowing of the coronary lumen.35 If plaque fissuring, subse­
quent coronary thrombosis, and hence coronary occlusion were related to the arterial 
burden of atherosclerosis alone, it would be reasonable to assume some quantitative 
association between the extent of myocardial fibrosis due to Mis and coronary ather­
osclerosis. When the prevalence of coronary atherosclerosis recorded in postmor­
tems in the United Kingdom for the years 1908-13 was compared with that for the 
years 1944-49, there appeared to be some reduction in the amount of mural atheros­
clerosis in the population, while at the same time there was a tenfold increase in 
deaths from ischaemic heart disease.37 Obviously there must be other factors operat­
ing to produce CHD, other than simply the presence of atherosclerosis, albeit an 
important prerequisite.
1.5.4 Circadian Variation of Coagulation and Myocardial Ischeamia
Evidence now exists that AMI is not entirely or necessarily a random event occur­
ring at any time of the day. The circadian variation in the occurrence of AMI is well 
documented,223,224 the peak onset being between 6.00am and 12.00am.223 The au­
thors of these publications have documented an extensive number of older studies 
from throughout the world showing a remarkable similarity in the time of onset of 
rest angina and AMI. In addition to the circadian variation in clinically apparent and 
also asymptomatic CHD, there is increasing support for the presence of a circadian 
rhythm of the some of the components of thrombus formation, predisposing to a 
hypercoaguable state during the peak period for the onset of AMI. Numerous chang­
es occur during this period. A decrease in fibrinolytic activity of blood,225 increased 
in vitro platelet aggregation,226 increased in vivo platelet activation in patients with 
atherosclerotic vascular disease,227 increased metabolism of pharmacological doses 
of heparin,228 and also increased blood fibrinogen levels in normal subjects226 have 
all been demonstrated. Thus, an increase in coagulability may be sufficient to coin­
cidentally sustain thrombus formation on the random occurrence of plaque rupture. 
Alternatively, an environmental and/or heritable factor may be required to create a 
sufficiently hypercoaguable state.
1.5.5 Age and CAD
The distribution of coronary atherosclerosis in the elderly is similar to that in young­
er age groups,229 although there are differences in the pathological 
composition.230,231 Increased calcification and fibrosis, and atrophy of the media 
occur with aging.229 The incidence of CAD increases from approximately 46% in 
the 6th decade, to 84% in the 9th decade.232 Not surprisingly, the Framingham 
Study demonstrated a continuing increase in the frequency of the clinical events of 
CHD with age in women. However, in men the incidence of clinical events declined 
in the 7th and 8th decades, but subsequently rose in the 9th and 10th decades.205 The 
increased risk of CHD in males occurred in the 6th decade in the Framingham
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Study, but in the 7th decade in eastern Finland.233 If the acute occlusive syndromes 
of clinical CAD were a random event related to the chance occurrence of plaque 
rupture, then there should be a progressive, unabated rise in the incidence of CHD 
with age since the occurrence of coronary atherosclerosis increases with age. The 
prevalence, however, may decline due to attrition from premature deaths.
In the very elderly, the incidence of clinical CAD is approximately equal in men and 
women.205,234 Indeed, age is the strongest cardiovascular risk factor.202,235 Further­
more, in patients who die suddenly of ischaemic heart disease, coronary thrombosis 
in the presence of significant CAD was found more frequently in a younger age 
group, despite a tendency for the older group to have more extensive disease.36 
Although, more than 60% of sudden deaths in the elderly are associated with severe 
CAD,229 thrombus formation may play less of a role in the older patient with CHD 
manifestations.36 Nevertheless, the relative contributions of stenosis, thrombosis and 
arterial spasm in the development of acute ischaemic syndromes in the elderly are 
unknown.229
1.6 ATHEROGENESIS
Old theories about the pathogenesis of atherosclerosis, although not as sophisticated 
as their modern equivalents, do resemble in broad principle current perceptions. One 
of the earliest documented postulates was the ’insudation’ theory of Virchow (1821- 
1902). He proposed that atherosclerosis resulted from a chronic inflammation of the 
intima with intimal damage being a very early step in the process. In his hypothesis, 
a principal factor in progression of plaque formation was an increase in passage into 
and accumulation of plasma constituents in the intima, although this occurred late in 
the sequence.236 Although Virchow’s fame relates to his contribution to the under­
standing of thrombosis and embolism, he did not develop an active interest in coro­
nary thrombosis.236
In contrast, the ’encrustation’ theory of Rokitansky (1804-1878) postulated that small 
mural thrombi on areas of arterial wall intimal injury become organised and invaded 
by smooth muscle cells with gradual subsequent growth. Rokitansky is quoted as 
saying that "the deposit is an endogenous product derived from blood, and for the 
most part from fibrin".236 His theory attributes more weight to environmental factors 
causing endothelial injury and the triggering of arterial thrombus. The lipid occur­
ring in the plaque was felt to be a passive phenomena and a secondary product of a 
’sponge-like’ action of thrombus and breakdown of platelets and white cells. Baron 
Karl von Rokitansky felt that chronic inflammation as proposed by Rudolph Virchow 
was not an important feature in the development of atherosclerosis.236
Current evidence supports the probable occurrence of both processes in the pathoge­
nesis of atherosclerosis. At present all theories need to embrace the fact that atheros­
clerosis development begins early in life and is a process continuing over many 
years.7,9,237 In addition, manifestation in the form of the clinical syndromes may be a 
further step in the development of atherosclerosis resulting from superimposed 
thrombosis on ruptured lesions.2,4,115,238
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1.6.1 Response to Injury Hypothesis
Normally, endothelial cells form a continuous non-reactive and non-thrombotic layer 
which also mediates metabolic exchange through the arterial wall.239 It is a perme­
ability barrier controlling the passage of small and large molecules from plasma into 
the arterial wall. The endothelial surface is polarised and the luminal surface is non­
reactive. Synthesis and secretion of connective tissue proteins is a major function of 
the endothelium. Types III and IV collagen are produced beneath the luminal surfac­
es and a myriad of glycoproteins and proteoglycans are secreted from the luminal 
surface. These latter factors contribute to the thrombo-resistant activity of the en­
dothelial surfaces.
The response to injury hypothesis postulates that injury occurs specifically to the 
lining of the endothelium of the artery.240'242 This injury may be non-specific, of 
various forms, intermittent or continuous, and acute or chronic. If the injury is 
limited, the process may be reversible and the integrity of the arterial wall reconsti­
tuted. If the injury is severe, continuous and/or repeated, then progression may 
occur due to continuing interaction of the components derived from the blood at sites 
where lesions were already formed. Injury may modify the equilibrium of the en­
dothelium between cell proliferation and cell destruction. This modification would 
determine if a lesion progressed, remained constant or regressed.242,243 The endothel­
ial injury may be of very diverse forms,244 including mechanical,245,246 injury from 
chemical compounds such as the lipoproteins, 241,247 toxins, 248 immunological 
insults,249 and even infective agents such as viruses.250 These diverse range of agents 
causing endothelial injury may lead to separation between endothelial cells with 
subsequent altered endothelial permeability and even frank desquamation of cells.
The major elements in this scheme are cells within the blood, namely monocytes and 
platelets, and cells in the arterial wall, such as the endothelial and smooth muscle 
cells. Sufficiently severe injury would result in the adhesion of platelets and mono­
cytes to the endothelial wall. Thereafter, monocytes may penetrate the intima and 
also platelets may aggregate leading to mural thrombus formation. During this 
process, activation of platelets and monocytes leads to the release of substances 
which further interact with the arterial wall cells. These may in fact stimulate migra­
tion of smooth muscle cells from the media into the intima and induce proliferation 
of smooth muscle cell growth.251 It has also been noted that the most severe atheros­
clerosis in rabbits occurs in areas where endothelial cells had grown over previously 
denuded areas but not in areas denuded and covered by platelets.252
Abnormalities of lipid and lipoproteins can also be incorporated into this hypothesis. 
An increase in binding of lipoprotein lipid by proteoglycans associated with newly 
covered endothelial areas253 appears to increase cholesterol synthesis and decrease 
hydrolysis of cholesterol.254 Lipoproteins have been shown to injure arterial en­
dothelium and produce increased permeability to macromolecules.244,255 There is 
also evidence that monocytes can penetrate the intact endothelium in the presence of 
excessive amounts of LDL cholesterol in the blood resulting in changes similar to 
that following loss of endothelial integrity.242 Indeed, the probable interaction of 
arterial injury, lipoprotein insudation, and platelet interaction contributes to the 
pathogenesis of atherosclerosis 244,255
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1.6.2 The "Cholesterol" Hypothesis and Oxidatively Modified LDL
The nature of the relationship between cholesterol and atherosclerosis has been 
debated for most of this century. Abnormal lipoprotein metabolism, of which an 
elevated cholesterol is but one measurable mode of expression, clearly plays an 
important part in the development of atherosclerosis. 133,256'260 What exactly should 
be done for an individual from the general population with a moderately elevated 
cholesterol, however, is still debated . 261' 265 The results of some studies,266 and 
potential adverse problems,264 still provide concern for population based primary 
prevention. A therapeutically positive approach is recommended for the treatment of 
an elevated cholesterol for the purposes of secondary prevention.267'275
Over many years, research into atherosclerosis concentrated on the role of circulat­
ing lipoproteins, providing a cogent body of evidence for their role in 
atherogenesis.256 More recently, as seen in the foregoing discussion, attention has 
also focused on cellular and molecular abnormalities in the arterial wall and circula­
tion.242,276,277 Indeed, more recent data provides support for proposals interrelating 
the cellular process and circulating lipoproteins. 131,133,259,260
The evidence that oxidative modification of LDL may play a role in atherosclerosis 
has been increasing rapidly over the last few years. 133,278 Oxidative modification of 
lipids, that is lipid peroxidation, is a free radical mediated process that involves the 
peroxidative degradation of lipid material. In its broadest sense, lipid peroxidation 
includes the peroxidase reactions of all types of lipid materials, including free fatty 
acids, phospholipids, triglycerides, and cholesterol. Particular attention has focused 
on the peroxidation of LDL.260 This process forms an important part of the oxidative 
modification of LDL hypothesis for atherogenesis which has become a well estab­
lished concept.260 Such oxidative modification of LDL allows the uptake of lipids by 
intimal monocyte derived macrophages and accumulation of lipids, in various forms, 
in the wall of the artery. 131’133,259,260 Indeed, the cytotoxicity and chemotactic effects 
of modified LDL may induce functional changes in endothelial cells allowing pene­
tration of the endothelium by circulating cells and lipoproteins, or by the direct 
denudation of the endothelium, accelerating the fatty streak formation. 133 Because of 
these, and other facts discribed below, oxidised LDL is thought to be potentially 
more atherogenic than native LDL cholesterol.
As implied above, a large body of epidemiological, biochemical, and experimental 
animal data exists in support of the hypothesis, and this information has been exten­
sively reviewed .260,278 Increased lipid peroxidation products are present in the 
plasma of patients with occlusive arterial disease. Oxidised LDL is rapidly taken up 
by the scavenger LDL receptor of macrophages, is chemotactic for circulating 
monocytes, and is cytotoxic for cells in culture and it can release a chemotactic 
factor from endothelial cells in culture.260 Experimental animal evidence has indicat­
ed that oxidatively modified LDL may occur in vivo.278 Also, reasonably secure but 
not totally conclusive evidence exists in animal models that oxidative modification 
plays a significant role in atherogenesis.278 Moreover, anti-oxidants inhibit the 
progression of atherosclerosis in LDL receptor deficient and cholesterol fed rabbits 
independent of any cholesterol lowering.278 Clearly, sufficient support for this theory 
exists implicating it as the processing linking the lipoprotein and the cellular hy-
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potheses of atherogenesis. Such persuasive support mandates further vigorous study 
into the oxidative modification hypothesis, especially since in vivo information is 
limited.260,278 Indeed, some investigators believe that the available evidence for this 
hypothesis is sufficient to warrant clinical intervention trials to test the oxidative 
modification hypothesis.278 As indicated in sections 1.3.3. and 1.6.3, there may also 
be a connection between this process and some of the thrombogenic aspects of 
CHD.132,134
1.6.3 The Role of the Platelet in Atherogenesis
Atherosclerosis is a disease process which begins in childhood and is not associated 
with occlusive arterial lesions until many years later.7,9,237 Hence, clinical symptoms 
appear when the disease is usually at an advanced stage, decades after the onset of 
the first pathological changes.9,242 As discussed, one proposed mechanism of athero­
genesis involves the development of vascular endothelial injury resulting from 
haemodynamic, mechanical, chemical or other factors. This endothelial damage may 
result in increased localised permeability of the vessel wall and localised adhesion of 
platelets which release platelet factors that may have a pathological effect in the 
milieu of abnormal endothelium, exposed intima and abnormal blood flow adjacent 
to the endothelium.242,279 Subsequently, this process could lead to progressive cellu­
lar and interstitial changes eventually resulting in atheroma formation. Such a role 
for platelets in the pathogenesis and evolution of CAD is an attractive and compel­
ling concept that has been the subject of intensive investigation.171,280,281
A role for platelets can also be postulated for the atherogenesis hypothesis involving 
oxidative modification of LDL. Oxidised LDL interacts with platelets and promotes 
their aggregation more so than native LDL.134 A deficiency of antioxidants may 
reduce the level of PGI2 production and lead to the promotion of platelet aggregabil- 
ity.132 An important feature of the oxidative modification of LDL hypothesis is that 
the loss of endothelial cells is not an essential feature as an initiating factor for the 
promotion of atherosclerosis, although such an outcome could also be caused by 
modified LDL.133 Therefore, oxidised LDL may initiate endothelial injury and the 
subsequent sequence of events described in the response-to-injury hypothesis, with 
the adherence and aggregation of platelets, the release of platelet derived growth 
factor, the generation of additional growth factors and the growth of smooth muscle 
cells leading to a thickening of atherosclerotic areas.133,242 The platelet, along with 
lipoproteins and monocytes, would clearly contribute to the pathophysiology of 
atherosclerosis in such a combination of events.
1.6.4 Other Hypotheses for the Pathogenesis of Atherosclerosis
Quite clearly the formation of atheroma is a complex and incompletely understood 
process, and numerous other theories have been proposed to explain the formation of 
atherosclerosis. There is a seminal and comprehensive body of literature supporting 
a directly active role of lipoproteins in the cellular processes occurring within the 
vascular wall which may stimulate the formation and progression of atheromatous 
lesions independent of other processes,242,282'286 A monoclonal theory of cellular 
development of atheroma suggests that atherosclerotic plaque arise from a single 
line of cell.287'290 However, isoenzymatically similar cells may arise late in plaque
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formation291 and the kind of diet given to induce atherosclerosis may influence the 
nature of the clonal growth.292 Furthermore, immunohistochemical studies293,294 
have demonstrated that polyclonal cells occur within the inflammatory infiltrates of 
atheroma, including both B and T cells.294 The presence of inflammatory cells within 
atherosclerotic plaques has also emanated in a significant body of literature detailing 
possible primary immunological295 and infective roles in atherogenesis.296,297
1.6.5 Conclusion
The oxidative modification and the response to injury hypotheses, as primary pro­
cesses in the development of atherosclerosis, alone or in combination, remain to be 
proven, as does a role that the platelet may play in atherogenesis. However, clinical 
evidence suggestive of an interaction between platelets and the arterial wall in the 
early stage of atherosclerosis does exist.281 If some form of platelet dysfunction is 
involved in atherogenesis, then such a platelet abnormality is likely to be demonstra­
ble at an early stage in the formation of atherosclerotic lesions, that is, during child­
hood or adolescence. If this were so platelet dysfunction may be detectable in young 
individuals with a high risk of CAD. Whether increased platelet reactivity is a fea­
ture early in the disease process or whether it solely contributes to later pathophysio­
logical processes resulting in the acute thrombotic clinical syndromes is unknown 
and continues to require critical evaluation. It may even be secondary to underlying 
vascular pathology and therefore not be involved in the inception or early progres­
sion of atheroma. However, this is less likely in view of the current evidence indicat­
ing a lack of platelet activation in stable CHD 45,74,298
1.7 THE ROLE OF PLATELETS IN THROMBOSIS
In the following section, the importance of platelets to arterial thrombosis is briefly 
highlighted since platelets have such a central role in haemostasis,299' 301 and throm­
bosis plays such an important part in CHD. The thrombotic process results from an 
interaction between platelets, the vessel wall, the coagulation system and the fibrino­
lytic system. Normally after superficial endothelial injury only a monolayer of plate­
lets adheres to exposed subendothelium.302 However, thrombus formation can occur 
following more severe damage following exposure of the components of the vessel 
wall which activate both platelets and the coagulation system.302 Localised haemos­
tatic plug formation and arterial thrombosis are comparable processes with the same 
blood constituents responding to vascular injury.299 Platelet aggregation plays a vital 
role in both physiologic and pathological haemostatic reactions.
1.7.1 Initial Platelet Responses Leading to Aggregation
Primary responses in haemostasis include localised vasoconstriction at the site of 
vessel injury and platelet adhesion to the exposed sub-endothelial basement mem­
brane and collagen. When platelets adhere to collagen or interact with thrombin 
there is a profound release reaction of platelet secretory products. Many of the 
compounds released are platelet aggregating agonists (adenosine diphosphate, 
thrombin, serotonin) and they can act synergistically to amplify the response of 
platelet activation to low concentrations of other aggregating agents.299 The effects
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of platelets and their secretory and metabolic products on the vessel wall are well 
documented.239,244,303 Platelet dense-granules release ADP, adenosine triphosphate 
(ATP), calcium, serotonin, magnesium and other substances. The alpha-granules 
contain important compounds including platelet derived growth factor (PDGF), 
BTG, PF4, factor VIII related antigen, von Willebrand factor (VWF), albumin, 
thrombospondin, fibrinogen, fibronectin, antiplasmin, alpha-2-antitrypsin, alpha-2- 
macroglobulin, as well as chemotactic factors.299 Acid hydrolases are released from 
the lysosomal granules. Following the release reaction platelet aggregation occurs 
and with this, phospholipases C and A2 are activated. Phospholipase A2 cleaves 
arachidonic acid from platelet membrane phospholipid. A combination of phospholi­
pase C, diglyceride lipases and monoglyceride lipases free arachidonic acid from 
phosphatidyl inositol.299 Activated platelets release potent vasoactive agents such as 
serotonin, histamine and TXA2.304
Platelet adhesion is an integral step in the maintenance of vascular integrity and is 
mediated by a number of platelet surface receptors with a high affinity for the adhe­
sive glycoproteins in the sub-endothelium, such as fibronectin and collagen.301 It 
would appear that many of these ligands act on inactivated platelets which, in normal 
circumstances, are protected from these glycoproteins by the endothelium.301 Platelet 
secretory products, such as ADP and serotonin, and TXA2 manufactured following 
activation of the cyclooxygenase pathway, are formed locally further enhancing 
platelet activation.300
1.7.2 Platelet Receptor Function
In addition to the release and production of platelet agonists, platelet receptor expo­
sure is involved in aggregation. Glycoprotein (GP)IIb/IIIa receptors, when activated 
are exposed and bound by a number of glycoproteins, the most important being 
fibrinogen.301 Fibrinogen and other glycoproteins, such as von Willebrand factor and 
thrombospondin bind to the GPIIb/HIa receptor allowing stable platelet aggregates to 
form.305,306 The exposure of the GPIIb/IIIa receptor is the final common pathway 
fundamental to platelet aggregation.307 The exposure of this receptor is directly 
augmented by the released contents of platelet storage granules. Further, it is both 
directly and indirectly enhanced by the formation of TXA2.308 Of particular impor­
tance is the fact that all of the platelet agonists can lead to the exposure of the 
GPIIb/IIIa receptor and subsequently platelet aggregation independent of the cy­
clooxygenase pathway.301
1.7.3 Interaction with the Coagulation System
The adhesion and aggregation of platelets promotes coagulation at multiple stages of 
the intrinsic coagulation pathway resulting in the deposition of fibrin.309 This throm­
botic process can be enhanced when adjacent platelets are activated by thrombin 
which is formed locally after activation of the coagulation system. Factor Xa and 
prothrombin are activated following exposure to specific membrane binding sites for 
coagulation enzymes, zymogens and cofactors.310 The binding of activated clotting 
factors to platelet receptors results in the capacity of platelets to protect factor XIa 
and Xa from inactivation.310 Initiation of the coagulation cascade results in fibrin 
formation, reinforcing the platelet plug. Normally the fibrinolytic system is then
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activated, digesting the haemostatic plug. New growth of endothelial cells of the 
vessel completes the repair process.311,312 Platelets may impair endogenous fibrinoly­
sis as they are a source of factor XIII activity which crosslinks fibrin, reducing its 
sensitivity to plasmin.313 However, platelets bind plasminogen directly, a process 
which is augmented after interaction with thrombin and platelet associated fibrino­
gen,314 thus localising plasminogen in the vicinity of platelet aggregates. Neverthe­
less, platelets also release a plasminogen activator inhibitor315 and platelet-rich 
thrombi appear to be resistant to thrombolysis,316 and the process of fibrinolysis 
influences platelet function, with numerous mechanisms being documented in vivo 
and in vitro for both inhibition and activation.301 Of clinical importance is the activa­
tion of platelets associated with pharmacological doses of thrombolytic agents.47'49
Thus, it is clear that activated platelets affect other important components of the 
haemostatic system. As stated, activated platelets demonstrate enhanced factor Xa 
activity and prothrombin activation accelerating the formation of thrombin.317 Fur­
ther, aggregation of platelets concentrates activated clotting factors in one localised 
site. Platelets influence the expression of the fibrinolytic system, having both profi­
brinolytic and antifibrinolytic effects.301
1.7.4 Summary - Platelets and Thrombus Formation
In summary, at least four separate but related pathways result in platelet activation 
and the formation of stable irreversible platelet aggregates which may subsequently 
progress to intra-arterial thrombus. Firstly, the adherence to collagen or interaction 
with thrombin and other platelet agonists induces the platelet release reaction and 
thence aggregation. This reaction can occur independent of TXA2 
generation.300,301,312 However, in normal circumstances, stimulated platelets release 
arachidonic acid from phospholipids in the platelet cell membrane through the action 
of phospholipases C and A2,299,311 setting in progress the second major step in the 
sequence. Cyclooxygenase then converts arachidonic acid to the endoperoxides 
PGG2 and PGH2. Then TXA2, a powerful stimulator of platelet aggregation, is 
formed from thromboxane synthetase.299,300 Thirdly, the platelet agonists lead to the 
exposure of GPIIb-IIIa receptors allowing binding of fibrinogen to physically join 
the platelets to form aggregates. Finally, the formation of fibrin stabilises the platelet 
aggregates to form a thrombus. Further vessel contraction occurs under the influence 
of TXA2 and serotonin. Chemotactic factors released can attract leukocytes to the 
local thrombus. Subsequently clot retraction consolidates the platelet plug; the 
thrombus may be incorporated into the wall leading to wall thickening; parts may 
break away as plasmin lyses the fibrin and platelets deaggregate; or the thrombus 
may propagate further into the arterial lumen.299 This brief review highlights the 
importance of the interaction between platelets and fibrinogen in the formation of 
platelet aggregates, and this interaction has important implications for the hypothesis 
of this Thesis.
1.8 SUMMARY
Atherosclerosis can be viewed as a common source epidemic.318 The determinants of 
common-source epidemics include susceptibility, pathogenesis and virulence of the
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agent(s), and the length of the incubation period.318 Identification of the susceptible 
individual has been of prime concern, hence the investigation of risk factors. Despite 
considerable efforts, still, little is known about the determinants of susceptibility to 
CAD.318
The content of the discussion in this introductory Chapter supports the idea that risk 
factors may be thought of in terms of being precipitators and/or potentiators of 
susceptibility to clinical CAD .202 Such a consideration has also arisen from the 
observations of Cornfield and Detre.319 The predisposition to thrombosis and/or 
platelet aggregation within the coronary circulation could be considered a precipita­
tor and/or potentiator for the acute clinical syndromes. This predisposition could 
arise from differences in the pathology of the atherosclerotic plaque, functional 
abnormalities within the arterial endothelium adjacent to plaques, imbalances within 
the normal mechanisms of intra-arterial thrombin formation and fibrinolysis, local or 
systemic platelet hyperactivity, or a combination of any number of these possibili­
ties. More recently the existence of factors which are directly or indirectly thrombo- 
genic has appropriately received more attention.60
The results of angiographic studies support the concept that CHD progression invol­
ves two fundamental processes. The first consists of atherosclerotic lesions progress­
ing to plaque fissuring, platelet aggregation and subsequent healing, with or without 
minor progression. The second process occurs after plaque fissuring and platelet 
aggregation, with progression to thrombosis and partial occlusion of the coronary 
artery, and/or complete occlusion, and/or lysis, and/or thrombus incorporation into 
the plaque.4 In both circumstances the platelet may play a pivotal role.
At present there is unequivocal evidence that the activation of platelets and involve­
ment in thrombosis within coronary arteries occurs in the acute obstructive myocard­
ial ischaemic syndromes. Circulating activated platelets, however, are not a feature 
of stable chronic CHD, as far as can be currently measured.45,298 Whether more 
reactive platelets are present in individuals who are susceptible to the development of 
CAD and/or CHD remains to be elucidated. Mural thrombosis over atherosclerotic 
plaques would appear to be an ongoing process without necessarily any clinical 
consequences at the time.238 Why an individual progresses to an occlusive arterial 
event is unknown but probably results from numerous interacting components, one 
possibility being the presence of genetically derived and/or environmentally induced 
hyperactive platelets given the appropriate stimuli.
Heightened platelet reactivity may be important in platelet involvement in the early 
stages of atherosclerosis or the later clinical manifestations. If such platelet dysfunc­
tion does exist, it may require intermediary pathophysiological changes to become 
manifest. Such a proposal accommodates the concept of an interaction between the 
environmental "triggers" and the presently unaccounted for inheritance factor. 
Another possibility is that part, or all, of the familial predisposition to CAD is relat­
ed to an abnormality in platelet function. Therefore an evaluation of platelet function 
in young individuals at increased risk of the development of CAD and in those 
manifesting their susceptibility by the clinical manifestation of the disease is of 
value. The thesis that thrombosis is an active component in the development of CHD 
and CAD, and is unrelated to chance requires further clarification. This is particular-
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ly important since an understanding of postulated thrombogenic factors, whether 
environmental and/or heritable, may have important implications for identifying 
susceptible individuals more accurately, thereby improving methods of prevention 
and enabling implementation of more definitive treatment.
1.9 THE QUESTION ASKED IN THIS THESIS
1.9.1 The Basic Question
Do individuals with premature CHD have a platelet abnormality resulting in hyper- 
responsiveness to physiological and/or pathological stimuli, and, if so, is such an 
abnormality a primary factor or produced by other influences?
1.9.2 Why Ask the Question ?
The foregoing discussion provides the rationale as to why this question is important 
and requires evaluation. The salient issues can be summarised as follows:
1. Some evidence exists implicating increased platelet reactivity in patients 
with CHD and in those with some of the important risk factors. Evidence indicating 
that platelets are quiescent between acute events does not exclude the possibility of 
platelet hyper-responsiveness upon stimulation or provocation in vivo.
2. An unequivocal role of platelets in the acute thrombotic occlusive clini­
cal syndromes of CHD has been established. However, the relative importance of 
platelets as an initiator and/or potentiator of thrombosis in these events is unknown.
3. Coronary angiographic data indicates that atherosclerotic plaques en­
large rapidly and sporadically. This may be due in part to mural thrombosis causing 
sudden rapid progression of lesions. Another reason for such changes may also be 
due rapid accumulation of modified LDL and foam cell formation within an atheros­
clerotic plaque.
4. Pathological studies provide persuasive evidence for platelet-fibrin 
deposition in intramural lesions.
5. The presence or absence of CHD does not simply relate to the extent of 
coronary atherosclerosis.
6. Current risk factors do not account for all cases of CAD or CHD. They 
also cause premature disease in only a minority of individuals with one or more risk 
factors.
7. The importance of abnormal levels of certain circulating lipoproteins 
cannot be under valued and seem to be a necessary prerequisite for the development 
of the early stages of atherosclerosis. However, abnormal blood lipoproteins do not 
have a critical influence on the expression of the clinical manifestation of atheros­
clerosis, and the presence of lesions does not inevitably lead to CHD.
8. Premature CHD has a familial component which remains incompletely 
explained by the heritability of conventional risk factors.
9. The influence of thrombogenic risk factors on the expression of CHD is 
only now being appropriately evaluated and defined. Indeed, a large body of biologi­
cal evidence already exists indicating an important role of platelets in atherogenesis.
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The relevance of addressing the question stated is substantiated by the foregoing 
discussions and the outcome will contribute to the currently developing model for the 
pathogenesis of CHD.
1.10 THESIS FORMAT
The main study was a case-control study of males, aged less than 50 years, with 
premature CHD, and an age, sex and socioeconomically matched control group 
without CHD. Because of major potential confounding factors and areas of correct­
able bias, a number of additional studies were undertaken.
Firstly, a group of male subjects with known CHD were evaluated to determine if 
case group subjects needed to be separated into those with and without active myo­
cardial ischaemia, as assessed by exercise testing. This group was also used to 
determine if it was essential to select subjects in the CHD case group who could 
have their cardiac medications stopped. That is, whether continuation of cardiac 
medications altered the in vivo measures of platelet function that were used in the 
case-control study.
Secondly, the major lipoproteins were evaluated in greater detail because of the im­
portant potential for confounding the results by their influence on platelet function. 
Furthermore, the evaluation of the current diet and alcohol intake for both the case 
and control group was performed given the potential influence of dietary factors on 
platelet function.
Thirdly, the fibrinogen level may have a major effect on platelet function. This 
necessitates a detailed evaluation of this risk factor, particularly in relation to platelet 
function tests.
In addition, a number of "new" CHD risk factors have come into prominence over 
recent years. These risk factors may have a potential confounding influence on the 
case-control study proposed and the use of platelet function tests. The "new" risk 
factors were evaluated in more detail, using another study population prior to the 
case-control study, were specific measures of hostility and other behavioural meas­
ures, central body obesity and blood glucose levels, and plasma fatty acid content. 
The influence of these factors was evaluated because of their possible confounding 
effect on the results. These factors and their interaction with platelet function meas­
ures are discussed in Appendices 1,2 and 3.
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CHAPTER 2
MATERIALS AND METHODS
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2.1 INTRODUCTION
General methods and materials are described in this chapter. Specific methods are 
described in appropriate chapters.
2.2 MATERIALS
2.2.1 General
All glassware was washed in distilled deionised water and further cleaned by soaking 
in Pyroneg solution, then scoured with a brittle brush, followed by extensive rinsing 
with tap water and then at least two rinses with distilled water. Glassware was then 
oven dried at approximately 80°C. Apart from platelet aggregation cuvettes and for 
the incubation of whole blood for serum TXB2 measurement, glassware was not 
used with blood, platelet rich plasma (PRP) or platelet poor plasma (PPP). The 
aggregation cuvettes were treated in a solution of chromic acid overnight and then 
washed as described above. The clean cuvettes were soaked for pretreatment with 
siliconising solution (Coatasil) for 2 min, then drained and washed with distilled 
water, and drained overnight. Syringes used were all polypropylene (Terumo).
2.2.2 Thromboxane B2 Assay Materials
2.2.2.2 Tris gelatin buffer. Stock Tris buffer 150 nM, pH 7.4 stored at 4°C was 
diluted 1:10 and 500mg/litre of gelatin was dissolved by stirring while warmed to 
approximately 37°C.
2.2.23 TXB2 antibody. The antibody (from Seragen for the assays in the studies 
described in Chapter 4 and Advanced Magnetics Inc, Cambridge MA, USA, for the 
remaining assays) was diluted in Tris gelatin buffer and stored in aliquots at -20°C 
for use in later assays.
2.2.2.4 TXB2 Standards. The TXB2 standards (Upjohn, Kalamazoo, Mich, 
USA) were dissolved in Tris gelatin buffer and divided into aliquots of 100ng/ml and 
stored at -20°C prior to use in batch assays.
2.2.2.5 3H-TXB2 antigen. The radiolabelled antigen (tritiated TXB2, 200 
curies/mmol) was supplied by Amersham, UK. The specific radioactivity of the 
antigen was initially 25 microcuries in 250 ul. This was diluted to give a stock solu­
tion of 0.02 microcuries/ul. Between 10 to 15 ul of this stock solution was diluted 
with 2.5 ml of Tris gelatin buffer to give approximately 5000 cpm for the total count 
of the working solution.
2.2.2.6 Dextran coated charcoal. To 10ml of Tris gelatin buffer were added 
10mg dextran, 10mg bovine serum albumin and 60mg charcoal, or the equivalent 
proportion. They were mixed by stirring on ice for 10 min.
2.2.2.1 Scintillant. Five ml of xylene and triton in aqueous solution was added to 
the supernatant prior to counting in the beta-counter.
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2.2.3 Materials for Platelet Aggregation Studies
2.2.3.1 Citrate anticoagulant. The citrate solution was 0.1 M trisodium citrate 
at pH 7.4 and stored at 4.0°C as a stock solution.
2.2.3.2 Reagent Diluent. Reagent diluent (RD) was diluted from stock solutions. 
Stock I RD consisted of 160 gm sodium chloride, 4 gm potassium chloride, 20 gm 
sodium hydrogen carbonate and lg sodium dihydrophosphate dissolved in one litre 
of distilled water. Five ml of stock I was added to 100 ml of distilled water and the 
pH adjusted to 7.4 to be used as the working RD for the day.
2.2.3.3 Alcohol. Pure alcohol (May and Baker Pty Ltd, Victoria, Australia) was 
used to stop the platelet aggregation response by addition (lOul) to the aggregation 
cuvette at a predetermined time.
2.2.3.4 Adenosine diphosphate. Adenosine diphosphate (ADP), grade 1 sodium 
salt (Sigma Chemical Co, St Louis, Mo, USA), was stored at -20°C at an initial 
concentration of lOmM and diluted in RD at -4°C to the required dilution prior to 
use as a platelet aggregating agonist.
2.2.3.5 Collagen. Lyophilised soluble calf skin collagen (Bio/Data Corporation) 
at a concentration of 1.9mg/ml was stored at 4°C prior to reconstitution with dis­
tilled water, pH 7.0. Following reconstitution it was stored at 4°C for a maximum of 
30 days.
2.2.3.6 Adrenaline. Adrenaline bitartrate salt (Sigma Chemical Co, St Louis, 
Mo, USA) was stored in aliquots of lOmM at -20°C and diluted in RD at -4°C to the 
required concentration prior to use as a platelet aggregating agonist.
2.2.3.7 Platelet rich plasma (citrated). Nine ml of blood was collected into 1ml 
of sodium citrate (0.1M trisodium citrate, pH 7.4, 4.0°C). The PRP was prepared 
by centrifugation at 100g for 15 min. The upper 2/3 of the supernatant was separated 
and stored air free at 37°C in stoppered syringes. PRP was used within 2 hr of 
sampling.
2.2.3.8 Platelet poor plasma (citrated). After separation of PRP, the remaining 
fraction was centrifuged at 8000g (Eppendorf Microcentrifuge 3200, Eppendorf In­
struments Ltd, Hamburg, West Germany) for 2.5 min and the upper 2/3 of this 
supernatant was collected as PPP.
2.2.4 Platelet Count Ratio Method Materials
2.2.4.1 EDTA-Formaldehyde solution. This solution contained sodium chloride 
(0.14 M) potassium hydrogen phosphate (0.01 M), sodium-EDTA (0.001 M) and 
formaldehyde (1% vol/vol) in distilled water and adjusted to pH 7.36.
2.2.4.2 EDTA solution. Sodium chloride (0.35 M) and sodium EDTA (0.001 M) 
were dissolved in distilled water and adjusted to pH 2.26.
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2.3 THROMBOXANE B2 ASSAY METHODS
2.3.1 TXB2 Collection and Storage
Blood was collected after a 12 hr fast, with the patient rested and supine, and with 
minimal venous stasis. Using a 19 gauge "butterfly" needle with a 15 cm plastic 
tube, 9ml of blood was collected into a syringe containing 1ml of ice-cold anticoag­
ulant (EDTA lOmM, PGE1 lug/ml) and kept on ice until PPP was prepared within 
15 min (2000 rpm for 60min). The middle 1/3 of the PPP fraction was frozen at 
-70°C prior to batch processing
Blood for serum TXB2 measurement was collected into a plastic syringe and 1ml 
aliquots were immediately transferred into glass tubes for incubation at 37°C for 60 
min. Serum was separated (2000rpm for 5 min) and stored at -70°C prior to batch 
processing.
2.3.2 TXB2 Assay Procedure
The radioimmunoassay (RIA) is based on a competitive reaction between TXB2 and 
3H-TXB2 for a limited number of binding sites on a TXB2 specific antibody. The 
amount of 3H-labelled TXB2 bound by the antibody will be inversely proportional to 
the concentration of unlabeled TXB2 present in the plasma or serum samples. The 
antibody bound 3H-TXB2 is separated by precipitation with dextran coated charcoal 
solution. After centrifugation the radioactivity of unbound 3H-TXB2 remaining in 
the supernatant is measured in a beta counter (Packard Tri-Carb 460 liquid scintilla­
tion counter, Packard Instrument Co, Downers Grove, 111, USA). A standard curve 
is constructed by measuring the proportion of 3H-TXB2 unbound and remaining in 
the supernatant in the presence of the TXB2 standards which have been precisely 
diluted from a known standard. The standard values are plotted on logit graph paper 
with a range between 4pg per sample to 250pg per sample. The unknown samples 
were diluted to fit within the linear section of the standard graph. All samples and 
standards were assayed as duplicates and the results averaged. If a large discrepancy 
occurred, that sample was re-assayed. The volumes and order of addition followed a 
specific format, which was always observed and was as follows:
Buffer* or Standard 3H-TXB2 TXB2 Ab
sample (ul) (ul) (ul) (ul)
TC 900 - 100 -
NSB 200* - 100 -
Bo 100* - 100 100
Standards - 100 100 100
Samples 100 - 100 100
TC = total count, NSB = non-specific binding, Bo = zero binding, tracer = 3H- 
TXB2, Ab = antibody
Following addition to the assay tubes (3DT tubes), the combination was incubated 
for 2 hr at 25°C before being immediately centrifuged for 15 min at 4°C and 1000g. 
Without disturbing the sediment, the supernatant was decanted from each tube into
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scintillation vials immediately after centrifugation. A fixed volume (5ml) of scintill- 
ant fluid was added to each vial and counting was performed in a liquid scintillation 
counter. The approximate total count was 5000 cpm, the non-specific binding (NSB) 
was usually less than 1/20 of the total count, and the zero binding ranged between 
40-50% of the total count. The seven standards used for the standard curve were 
250, 125, 63, 32, 16, 8 and 4 pg/100ul of solution.
2.4 BETA-THROMBOGLOBULIN ASSAY
2.4.1 Introduction
Beta-thromboglobulin (BTG) is released from platelet alpha-granules following 
activation and degranulation of the platelet. The presence of BTG in plasma has been 
regarded as an in vivo marker of platelet activation.76,77,88,320'324 BTG has been 
reported to be present in increased concentrations in plasma of patients with various 
vascular disorders.76,77,321,323
2.4.2 Beta-thromboglobulin Measurement
BTG was measured with a RIA kit (Amersham International) developed for the
immunoassay of human BTG in PPP. The range covered by the assay is 10- 
225ng/ml. BTG levels in normals using this kit is approximately 26ng/ml with 95% 
of values being below 52ng/ml. Each batch of BTG RIA kits has a within assay 
coefficient of variation (CV) less than 7.5% on a control plasma value of 45ng/ml. 
The between assay CV of kits from 2-14 weeks was found to be 9.9%, 10.7% and 
15.3% in three different laboratories.
The RIA method depends on competition between BTG and 125I-labeled BTG for a 
limited number of binding sites on a BTG specific antibody. The amount of 125I- 
labeled BTG bound by the antibody will be inversely proportional to the concentra­
tion of unlabeled BTG present in the PPP samples. The antibody bound 125I-labeled 
BTG is separated by precipitation with an ammonium sulphate solution. After centri­
fugation and removal of the supernatant, the precipitated radioactivity is measured in 
a gamma counter. A standard curve is constructed by measuring the proportion of 
125I-labeled BTG bound in the presence of a series of BTG standards which have 
been calibrated against a primary BTG standard (Amersham) and range from 10- 
225ng/ml. All samples and standards were assayed as duplicates and the results 
averaged. If a large discrepancy occurred, that sample was re-assayed in a subse­
quent batch run.
2.5 PLATELET COUNT RATIO METHOD
2.5.1 Background
The platelet count ratio (PCR) refers to the ratio of the difference in platelet counts 
between platelet-rich plasma separated from blood anticoagulated with EDTA and 
EDTA-formalin. Platelet aggregates can be stabilised by withdrawing whole blood
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into formaldehyde solution which protects them from the deaggregatory action of 
EDTA.325,326 Deaggregation is a function of the calcium chelating ability of the 
EDTA, and the EDTA also prevents ex vivo aggregation and clotting. Nevertheless, 
the PCR may reflect platelet aggregate formation during collection and hence may 
give a measure of ex vivo platelet reactivity.
2.5.2 Platelet Count Ratio Determination
The PCR was determined by a modification of the method of Wu and Hoak.325'328 
Using minimal initial venous stasis, and following a clean venepuncture with a 19G 
"butterfly" needle free flowing venous blood was obtained without a tourniquet. The 
initial 0.5ml of venous blood was discarded and one ml blood samples were collect­
ed into separate syringes containing 4 ml of either buffered sodium EDTA solution 
(sodium EDTA solution 0.001 mol/litre, pH 7.26) or buffered sodium EDTA-for- 
maldehyde solution (formaldehyde 1% wt/vol, sodium EDTA 0.001 mol/litre, pH 
7.36). The solutions and blood were mixed by gentle inversion. Aggregates disperse 
in the former and are fixed in the latter. Following 15 min incubation at room 
temperature, the samples were centrifuged in plastic tubes at 100g (800 rpm) for 10 
min, at 22°C. Platelet counts were determined in the supernatant with a Coulter 
Counter (model ZF). The PCR was calculated as the ratio of the platelet count in 
EDTA-formaldehyde solution over that in the EDTA solution. The first syringe 
contained 4ml of EDTA solution and the second 4ml of EDTA-formaldehyde and 
triplicate samples were taken in the same order and the three averaged. If one 
sample was discordant then the process was repeated.
2.6 PLATELET AGGREGATION METHODS
2.6.1 Background
Platelet aggregation was studied employing commonly used spectrophotometric 
methods.329,330 Platelet aggregation was studied with a dual channel aggregometer 
(Payton Dual Channel Aggregation Module, Payton Associates, Ontario, interfaced 
with a Riken-Denshi SP-H6P Chart Recorder, Riken-Denshi Co Ltd, Japan).329,330 
The number of platelets in the PRP was determined with a Coulter Counter. The 
baselines for light transmission 10% to 90% were set with PRP and PPP respective­
ly. Silicone-coated stir bars (1 by 5 mm) were added to siliconised glass cuvettes 
warmed to 37°C with the stir speed at approximately 900 rpm. Aggregation was 
measured as an increase in percent light transmission.
The epidemiological aspects of in vitro aggregability of platelets has been evaluated 
in the Northwick Park Heart Study.331 Aggregability increases with age and fibrino­
gen levels, is less in women than men at all ages (being partly accounted for by 
differences in haemoglobin and haematocrit), varies in races with white races having 
more aggregability than black, is less in male smokers compared with non-smokers, 
and there is a mild relation between increased alcohol intake and reduced aggregabil- 
ity.331
Aggregation is an in vitro measure of platelet function, following exposure to
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specific agonists. In this study, the agonists used were collagen, adrenaline and ADP 
(see sections 2.2.3A, 2.2.3.5 and 2.2.3.6).
2.6.2 Platelet Aggregation Quantitation
Following blood collection into a 10ml syringe containing 1ml of sodium citrate, the 
syringe was sealed and placed on ice until PPP and PRP were prepared within 15 
min of sampling (see 2.23.1 and 2.2.3.8).
2.6.2.1 LT50. The lag time to 50% of maximal alteration in light transmission 
(LT50) measured in seconds.332
2.6.2.2 Maximum rate of change in light transmission (R). The maximal rate 
of change in light transm ission was determ ined from the maximum slope of the 
aggregation curve.333 The maximum rate o f aggregation for collagen, ADP and 
adrenaline will be abbreviated as RCOL, RADP and RADR respectively.
2.6.2.3 Threshold concentration. The lowest concentration of aggregating agent 
able to produce greater than 50% second phase aggregation.
2.6.3 Standardisation of Aggregation Methods
Previously it has been considered that platelet aggregation tests using ADP and adre­
naline were most likely to differentiate between hypersensitive and "normal" control 
platelets.334 However, there are numerous factors which must be standardised for in 
vitro testing, including experimental conditions, intrinsic and extrinsic factors asso­
ciated with platelet hypersensitivity, dietary fats, other disease states and other fac­
tors.77,311,312,334'337 To endeavour to standardise the conditions under which aggrega­
tion m ethods w ere used, the c rite ria  described  below w ere adhered  to for all 
studies.336
(a) Controls and subjects. Age and sex matched controls were used as there is a 
possib le  age-dependent enhancem ent of p la te let responses to co llagen .336 Sex 
matched controls are required because the haematocrit affects the concentration of 
citrate and hence Ca++.336 The subjects needed to be fasting and non-smoking for 12 
hr.
(b) Plasma handling. Plasma was kept in a polystyrene syringe to prevent acti­
vation of factor XII, the syringe was stoppered to prevent loss of carbon dioxide and 
subsequent increase in pH of the plasma, and the plasma was stored at 37°C in a 
water bath.
(c) Timing in the protocol. The time from venepuncture until aggregation tests 
for the patients and controls was standardised between 1 and 2.5 hr, the centrifuga­
tion was standardised (100g for 15 min) and was carried out within 15 min of blood 
collection.
(d) Platelet count. Plasma samples also had a platelet count routinely performed. 
Differences in platelet aggregation are negligible if the platelet count is maintained 
over a range 200,000 to 300,000/m3.336
(e) Aggregomater. The aggregomater was calibrated before each test by setting 
the reading to 10% for PRP and 90% for the PPP. The sample holder was set to a
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tem perature of 37°C, the PRP was stirred at a constant rate of 900rpm , and the 
length, width and consistency of the stir bars were the same.
(f) Storage o f platelet rich plasma and the effect o f time. The results of platelet 
function tests, including platelet aggregation, are dependent on the time the samples 
to be tested are stored. When platelets are stored as PRP there is an initial increase 
in aggregation312,346,350,351. The changes in platelet aggregation with time are thought 
to be due to intrinsic changes within the p latelet rather than externally m ediated 
effects from plasm a346. Nevertheless, the potential for platelet aggregation to de­
crease with time after collection of blood and when stored at 37°C 347. Therefore, 
the time which the PRP was left standing prior to aggregation was standardised to 
between 1 and 2.5 hours. The order in which the tests were perform ed were also 
standardised for each agonist and was the same in both groups.
2.6.4 Collagen-induced aggregation
2.6.4.1 Background. Collagen induces platelet adherence, the release reaction, 
platelet aggregation and thromboxane production. Collagen-induced aggregation is 
thought to be mainly due to the action of ADP and TXA2 on platelets.336 However, 
other additional factors would also appear to be involved, including additional path­
ways for dense granule secretion in the initial response,338 the presence of albumin 
on the platelet surface,339 the presence of leukocytes and fibrinogen,340,341 the inter­
action of red cells,342 and possibly other alternate pathways.338,341
The collagen for in vitro platelet aggregation needs to be a suspension of collagen 
fibrils or acid soluble collagen.336 Shape change occurs within 15-20 sec of contact, 
and a subsequent lag phase dependent on the concentration and mixing of the colla­
gen with platelets, as well as the responsiveness of the platelets.336
2.6.4.2 Method. To detect conditions in which collagen-induced aggregation is 
enhanced, a concentration of collagen that causes less than maximum aggregation of 
control platelets must be used.336 In this study an amount of collagen that caused less 
than maximal aggregation was documented. This was determined by titration of the 
collagen from a concentration known to invariably cause aggregation and the PRP 
samples were then exposed to decreasing amounts of collagen until no aggregation 
was observed.
The concentration of collagen used was 1.9 ug/ul, and the starting volume was 25 ul 
added to 500 ul PRP giving a final concentration of 90 ug/ml PRP. This final con­
centration of collagen always caused maximal aggregation. The added volumes of 
collagen to the PRP were:
Volume Final Concentration in PRP
25 ul 
20 ul 
15 ul 
10 ul 
5 ul
90 ug/ml 
73 ug/ml 
55 ug/ml 
37 ug/ml 
19 ug/ml
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2.6.5 ADP-induced Aggregation
2.6.5.1 Background. After exposure to ADP platelets undergo shape change, 
and in the presence of appropriate conditions (temperature, pH, carbon dioxide and 
calcium concentration343'345), concentration of ADP and fibrinogen, platelets can be 
induced to aggregate. The results of platelet function tests depend on the time inter­
val between blood collection and the test. There is an increase in aggregation with 
time344 which is a platelet related effect and not plasma related.346 Others, however, 
have found ADP-induced platelet aggregation may decrease.347
Recent evidence in animal models suggests that ADP is involved in activating plate­
lets in v/vo.348 At sites of vascular injury, enough ADP is released from damaged 
cells to induce platelet aggregation.348 In humans there is substantial evidence that 
ADP is released from red cells and induces activation and aggregation of platelets349 
and is influenced by flow conditions.349 Furthermore, ADP generated in whole blood 
ex vivo triggers spontaneous aggregation of platelets.349 Indeed, there is a large body 
of in vitro and ex vivo evidence for the dependence of the haemostatic aggregation of 
platelets on free ADP in blood.348
2.6.5.2 Method for ADP-induced aggregation. A series of decreasing concen­
trations of ADP (25 ul) were added to 500 ul of PRP. Maximal platelet aggregation 
was achieved by adding 25 ul of ADP at a concentration of 1.0 mM (added concen­
tration). Decreasing concentrations of ADP in increments were then added to deter­
mine the threshold concentration for ADP-induced aggregation. The order of addi­
tion of these concentrations was (added concentration ADP) 1000.0 uM, 100.0 uM, 
50.0 uM, 25.0 uM and 12.5 uM.
2.6.6 Adrenaline Induced Platelet Aggregation
2.6.6.1 Background. Platelets have approximately 100 alpha-receptors on each 
cell surface and binding of adrenaline promotes platelet aggregation.312 In citrated- 
PRP, adrenaline causes aggregation and the release of platelet granule contents, 
although such reactions do not occur in PRP that has been anticoagulated with hiru­
din.350 The response of human platelets to adrenaline is influenced by conditions of 
aggregation such as calcium concentration, the presence of fibrinogen and the time 
PRP is allowed to stand at room tem perature prior to stim ulation with an 
agonist.312,350,351
Subthreshold aggregatory concentration of ADP or collagen, which are in them­
selves insufficient to cause platelet aggregation, may do so with the addition of 
adrenaline.312 Indeed, adrenaline potentiates aggregation induced by a number of 
agonists.70'72,337,352,353 However, fibrinogen is not required for adrenaline-induced 
potentiation of ADP-induced aggregation.350 There is also considerable variability in 
the responsiveness to adrenaline of platelets obtained from normal subjects 354,355
2.6.6.2 Method for Adrenaline-induced aggregation. A series of decreasing 
concentrations of adrenaline (25 ul) were added to 500 ul of PRP. Maximal platelet 
aggregation was attained by adding 25 ul of adrenaline (added concentration of 1.0 
mM). Decreasing concentrations of adrenaline were then added to determine the 
threshold concentration for adrenaline-induced aggregation. The order of addition of 
these concentrations was the same as for ADP.
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2.7 PLATELET COUNT
2.7.1 Method
Platelet numbers in peripheral blood collected in an EDTA coated tube were meas­
ured with an automated Coulter Counter. The numbers are expressed as 109/litre.
2.7.2 Quality Control
Blood cell quality control methods employed stabilised cell suspensions of human 
and fixed human and avian erythrocytes and stabilised mammalian platelets in a 
plasma like fluid with preservative (Diff-trol 8 plus, Hematology Control, Abnormal 
High and Abnormal Low, American Dade, American Hospital Supply Corporation). 
This product was used in the quality control for the determination of red and white 
cell counts (WCC), haematocrit (He), mean red cell volume (MCV), haemoglobin 
(Hb), red cell distribution width (RDW), platelet count and MPV.
2.8 PLATELET VOLUME
2.8.1 Method of Measuring Platelet Volume
When particle shape, electrolyte resistance, electronic amplification and capillary 
aperture diameter are kept constant, a Coulter Counter produces electrical impulses 
whose amplitude are proportional to the volume of the individual particles passing 
through its aperture.356 From the discussion in section 6.1, it is clear that standardi­
sation of procedures for collection and processing of blood to measure MPV is 
essential given the plethora of potential confounding factors related to the methodol­
ogy. Therefore, in this study the collection time was always between 9 and 10 am, a 
large bore needle (19G) was used, blood was collected with minimal haemostasis, 
the same equipment and procedure was always used and the same individual always 
collected the blood. The anticoagulant was EDTA and the blood was processed 
within 3 to 5 hours after the collection. Prior to processing, the blood was stored at a 
constant ambient room temperature. The same Coulter counter S-plus was used for 
all the platelet count and MPV measurements. Blood for MPV measurement was 
collected in tubes containing EDTA and was processed within 2 hr of collection.
Blood cell quality control was performed using stabilised cell suspensions (Dade, 
Diff-Trol 8 Plus for high levels and Dade, Diff-Trol 8 Plus for low levels). This 
reagent consists of stabilised human and fixed human and avian red cells and stabi­
lised mammalian platelets in a plasma-like fluid containing preservative. The MPV 
(in fl) for the reagent using a non-azide diluent is 9.0 with a range of 7.5 to 10.6 fl. 
The measurement was undertaken in the Clinical Haematology service laboratory at 
Woden Valley Hospital, Woden, ACT.
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2.9 METHODOLOGY FOR OTHER LABORATORY MEASURES
2.9.1 Dyslipoproteinaemia
Blood (fasting state) was obtained for measurement of total cholesterol, triglycerides 
and high density lipoprotein cholesterol (HDL). Measurement of these parameters 
was undertaken in a research laboratory (Prof Leon Simons, University of NSW, St 
Vincents Hospital, Sydney) with established high quality control of sample meas­
urement and precision of measurement.357'359 Concomitant cholesterol measurements 
were made in a service laboratory (Woden Valley Hospital Department of Biochem­
istry, Woden, ACT), the blood being taken simultaneously. The plasma cholesterol 
was measured by a standard enzymatic colorimetric test in kit form (Roche Diagnos­
tics, MA kit 30). Triglycerides were also measured by a standard enzymatic deter­
mination of glycerol after enzymatic hydrolysis of triglycerides (Roche Diagnostics, 
s, MA-kit 10). The HDL was measured in serum after non-HDL cholesterol frac­
tions were separated by precipitation with heparin and manganese chloride.
Serum cholesterol was measured by carrier-bound technology on a Kodak Ektachem 
700 analyser, based on the enzymatic method previously described.357 After hydro­
lysing cholesterol esters to cholesterol, hydrogen peroxide is generated from the 
catalysed oxidation of total cholesterol. The peroxide oxidises a leuco dye in the 
presence of peroxidase to produce a dye having maximal absorption at 670 nm. The 
density of the dye, being proportional to the concentration of cholesterol, is meas­
ured by reflectance spectrophotometry at 540nm.
Apolipoproteins A1 and B were analysed by peak rate nephelometry on a Beckman 
ARRAY Protein Analyser.360 In the reaction, antibody to human apolipoprotein is 
exposed to the apolipoprotein and the increase in light scatter resulting from the 
antigen-antibody interaction is converted to peak rate signal which is a function of 
the apolipoprotein concentration in the sample. Following calibration, the peak rate 
signal for the particular assay is converted to concentration units by the analyser. 
Coefficients of variation values of <5% for within run precision and <8% for 
between run precision for both apolipoproteins was obtained by replicate testing of 
59 control samples.
The service laboratory participates in an internal external quality control programme 
and has regularly ranked in the top twenty laboratories in Australia for both accuracy 
and precision. External quality control methods employed demonstrated within 
laboratory coefficient of variation for the measures to be less than 5%. Internal 
quality control for the laboratory is run daily and coefficients of variation for cho­
lesterol of 2% or less is obtained at both low (2.5 mmol/1) and high values (6.5 
mmol/1).
Blood was collected from the same venepuncture for the measurement of serum cho­
lesterol in separate laboratories, and plasma cholesterol in one of the laboratories. 
The blood was collected for all patients in the morning (between 0830 and 1030 
hrs), after an overnight fast (>12 hrs), in the supine position and with minimal (<2 
min) venous occlusion. The specimen was kept on ice and processed within 2 hr. 
The plasma samples, which were collected in heparinised tubes, were analysed on
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the same day in the local laboratory; the serum samples for the second laboratory 
were stored at -20°C for 1 to 2 weeks prior to shipping for analysis; and the local 
laboratory serum specimens were stored at -70°C for <12 months prior to analysis. 
The specimens for analysis in the research laboratory were shipped overnight in ice 
within a temperature-controlled container. These methods are as recommended to 
minimise variance incurred through sample collection, handling and shipping.361
Assessment of these measurements and the quality control is provided in Chapter 5.
2.9.2 Blood Glucose Level
The fasting blood glucose level was measured for each patient as a screening test to 
determine overt glucose intolerance. All cases of glucose intolerance will not be de­
tectable by this method. This measurement was performed in a service laboratory 
(Woden Valley Hospital, Department of Biochemistry, Woden, ACT).
2.9.3 Fibrinogen
Fibrinogen was measured by the heat precipitation method.362,363 Fibrinogen was 
selectively precipitated at 56°C, and the optical density (measured as absorbance) of 
the plasma was subsequently quantitated at a wavelength of 540nm to allow calcula­
tion of the fibrinogen level. The test was standardised routinely once per month, and 
whenever fresh buffer was prepared. Standardisation was performed using a refer­
ence plasma assayed for fibrinogen which was at a known concentration. This was 
performed in a service laboratory (Coagulation Laboratory, Department of Haema­
tology, Woden Valley Hospital, Woden, ACT).
2.9.4 Glycosylated Haemoglobin Estimation
The colourimetric method for the estimation of haemoglobin glycosylation was based 
on the principles developed by Fluckiger and Winterhalter364 and modified by Parker 
and colleagues.365,366 Subramanian and coworkers utilised further modifications by 
separating the globin chains prior to the assay with acid-acetone extraction.367 
However, the more simple method used demonstrates both very good reproducibility 
(%CV=3) and comparability with high performance liquid chromatographic meth­
ods.366 The method does not depend upon altered physical properties of the haemo­
globin (Hb) molecule, but rather on estimated ketoamine-linked hexoses direct- 
ly  364,368 Ketoamine linked hexoses on the glycosylated haemoglobin (HbAlC) are 
converted to hydroxymethylfurfural (HMF) by limited hydrolysis in a weak 
acid,364,368 and the HMF is then transformed to a coloured complex with thiobarbi- 
turic acid.364 Thus, HbAlC is boiled in phosphoric acid (2.5M) resulting in the 
liberation of 5-HMF. The coloured compound derived from the reaction with thio- 
barbituric acid was measurable photometrically at 443 nm. The units were expressed 
in nmoles of HMF/10mg of Hb and the reference range was 5.0 to 10.0 nmol 
HMF/10mg Hb. This method measures total glycosylated proteins and therefore the 
erythrocytes were carefully washed to remove plasma prior to the preparation of the 
hemolysate.366 Intracellular proteins will be present in the hemosylate and are 
measured along with the glycosylated hemoglobin.366 This measurement was per­
formed in the Department of Biochemistry, Woden Valley Hospital, Woden, ACT.
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2.10 METHODS FOR DOCUMENTING CLINICAL RISK FACTORS
2.10.1 Hypertension
Indirect blood pressure (BP) measurement was made with a cuff and mercury 
sphygmomanometer. The pressure was measured in the prone position whilst fasting, 
without restricting clothing, and in a similar ambient temperature. Systolic pressure 
is the first perception of sound, and the diastolic pressure is the loss of perception of 
sound (Korotoff phase V). Although intra-arterial measurements will be obtained at 
the time of the catheterisation, these were not used because of inherent variables 
affecting the BP at the time of, and related to, cardiac catheterisation.
The prior diagnosis of hypertension, the time since diagnosis of hypertension, and 
the period of time treatment has been administered was documented. An electrocar­
diograph (ECG) was obtained and the presence of left ventricular hypertrophy was 
determined by standard criteria.369
2.10.2 Tobacco Intake
The current use or non-use, time of onset, time of cessation if applicable, usual 
number of "tailor" made used daily, and the equivalent "pack years" were docu­
mented. The pack years is the equivalent number of years of smoking 20 cigarettes 
per day. For example, an individual smoking 40 cigarettes per day for 10 years has a 
20 packyear smoking history.
2.10.3 Family Medical History in First Degree Relatives
The first degree family history was documented on historical grounds. The age of 
diagnosis, time of death if applicable, whether this was due to CHD, and the pres­
ence of other risk factors in the family members were recorded.
2.11 METHOD FOR ANGIOGRAPHIC ASSESSMENT
The severity of CAD can be measured semi-quantitatively by the grading of coro­
nary angiograms. A distinction between diffuse atheromatosis and severity of dis­
crete lumen stenosis can be made by separate scoring methods.207 These scoring 
methods have previously been independently validated.207 The same internal consist­
ency of the scoring system against an alternative scoring method has been validated 
in this study. More importantly, the intra-observer error (reproducibility and reliabil­
ity) for the method used was acceptable, the coefficients of variation ranging bet­
ween 4% and 9% for the main angiographic scores used in the Thesis.298 The 
methods used and the validation of the methods are described in detail in Chapter 8.
2.12 EXERCISE TEST PROTOCOL
All subjects who had exercise tests were fasting. The exercise convention used was 
the Bruce protocol which is a maximum graded treadmill exercise test in the upright
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position. All exercise tests were performed at approximately the same time of day, 
between 9.00 and 11.00 a.m., and following an initial 1/2 hr supine rest period. The 
electrocardiogram was continuously monitored and rhythm strips recorded every 
minute, at the onset of angina, and until any ECG changes returned to the resting 
state. The criteria for an ischaemic ECG response, when compared with the baseline 
tracing, were either: (1) horizontal or downsloping ST segment depression of 1 mm 
or more; or (2) > 2mm upsloping ST segment depression at 80 msec after the J 
point for 3 consecutive complexes.
2.13 CASE-CONTROL METHODOLOGY
2.13.1 Definition of a Case-Control Study
A case-control study is an example of an observational analytic epidemiological 
investigation which can provide a qualitative description of a particular disease in a 
specific population at a given time, and allowing quantitative assessment of charac­
teristics within the population in relation to the disease. Subjects are selected on the 
basis of whether they do (cases) or do not (controls) have the disease under study.370 
The discussion on the choice of methodology and design is given in Chapter 4.
2.14 GENERAL STATISTICAL ANALYSIS
The following section describes the methods employed for the case-control study of 
young males with CHD, which is the main component of this study. Additional sta­
tistical methods, when employed, will be described in the appropriate section.
2.14.1 Data Management
The results were stored on the Australian National University’s previous VAX 
"main frame" computer for statistical analysis using the Statistical Package for Social 
Sciences programme. Subsequently, these programmes where transferred onto a Sun 
Computer and accessed through a Sun Workstation.
Consultation with an applied statistician (Dr Owen Dent, Australian National Uni­
versity) was undertaken for confirmation of the appropriate planning of data collec­
tion, design of the research proposal, and methods for analysis of results.
2.14.2 Study Groups
The main study is a case-control study with 48 control and 53 case subjects unless 
otherwise stated. In the other associated studies undertaken, the number of subjects 
evaluated will be defined in the particular section.
2.14.2.1 Patients. Males with proven CAD by coronary angiography who were 
aged less than 50 years at the time of diagnosis and most, but not all, were incident 
cases.
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2.14.2.2 Controls. Males from a population control group who were age, race, 
socioeconomically and community matched to the study group.
2.14.2.3 Selection of the case-control study groups. The study groups were 
selected from specific populations and the method of selection is described below. 
For the preparatory studies, the description of the study groups will be provided 
within the specific section and appendix. The limitations o f case-control studies are 
reviewed in Chapter 4. In addition, the problems associated with angiographic stud­
ies are discussed in Chapters 8 and 9.
The same exclusion criteria, as described in Chapter 3, were applied to the case and 
control groups. The admission criteria for the case group are described in section 
42.4.
1. Selection of cases. The case group were selected because they had 
presented with CHD and not because they had undergone cardiac catheterisation. All 
case subjects, however, had undergone coronary angiography because of clinical 
indications or because the supervising cardiologist considered their young age at 
presentation to be an indication.
The case group had clinically stable CHD for approximately 3 months. Exclusion 
criteria included diabetes mellitus; a stroke, coronary artery bypass grafting 
(CABG), percutaneous transluminal coronary angioplasty (PTCA) or an acute 
myocardial infarction (AMI) within 3 months; any significant medical illness, liver 
and renal disease; those unable to cease aspirin or non-steroidal anti-inflammatory 
drugs; and any recent surgery or acute illness, in particular, infective or inflamma­
tory disorders.
2. Selection of Controls. The control group were selected by the case 
group. The case group subjects were requested to ask a friend or work colleague to 
volunteer for the control group. Except for 4 subjects, all the controls were recruited 
in this way. The former 4 control group subjects were selected from hospital per­
sonnel in the same age and socioeconomic groups as their case group subject who 
were unable to ascertain a control case. Of these, 3 controls were naive to the labo­
ratory and one was familiar with the laboratory.
Even though the control subjects were personal friends or co-workers of the subjects 
in the case group, they were required to fit into specific selection and exclusion cri­
teria. Those in the control group were required to have had no cardiac symptoms, 
normal resting supine ECGs and a normal maximal exercise treadmill test and exer­
cise 12 lead ECG. The exercise test was performed after the control subjects volun­
teered and a normal result was a selection requirement. They were not selected on 
the presence or absence of CHD risk factors, although the possibility of a self-selec­
tion bias exists.
2.14.3 Variables
Information about each patient and control were documented as outlined (Tables 2.1 
and 2.2).
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2.14.4 Descriptive Statistics for the Measured Variables
A descriptive assessment of variables was obtained, including histograms plotted for 
visual inspection of the shape of the distribution, the variability (spread) and to look 
for unusual outlying measures. Normally distributed data was described by the mean 
and standard deviation (and variance) for the relevant variables of each group. 
Further measures of central tendency, namely the medium, mode skewness and 
kurtosis, were determined for variables which may have skewed distributions. This 
allowed an assessment to be made of the distribution for the variables prior to the 
univariate, bivariate and multivariate analysis. Those variables measured on a con­
tinuous scale were described by:-
1. Histogram (shape and spread of the distribution)
2. Mean and median as measures of central tendency
3. Standard deviation and variance
4. Skewness and kurtosis
5. 95% Confidence limits (indicating the limits for the mean of the population 
from which the sample was selected).
The above statistics were obtained for all variables in each study group when 
appropriate, using the Statistical Package for Social Sciences (SPSSX) program.
2.14.5 Measures of Association
Measures of association between variables across groups and between variables 
within groups were undertaken by the appropriate correlation and regression meth­
ods (following the appropriate transformation if the distribution was non-normal and 
the transformation gave a normal distribution) for continuous variables.
2.14.6 Univariate Analysis
2.14.6.1 Comparisons. The difference of the means between two groups that have 
a normal distribution was assessed with the Student t-test and paired t-test were 
appropriate. Testing the differences between the means of the same variable for 
more than two groups (normal distribution) was by the analysis of variance 
(ANOVA) programme on the SPSSX.
2.14.6.2 Variable Distributions. If the variables were not normally distributed, 
then pretest transformation of continuous variables was performed to obtain a normal 
distribution. If such transformation was unable to change the distribution into a 
Gaussian distribution, then distribution-free methods to test for differences between 
means of groups was used. This later choice was not required. The variables with a 
skewed distribution were all skewed to the left and were transformed to a normal 
distribution logarithmically. The variables which had a distribution skewed to the left 
were the LT50 of ADP, adrenaline and collagen, the rate of aggregation with ADP, 
adrenaline and collagen, the lag phase before the shape change with collagen induced 
aggregation (LAG), WCC, triglycerides, TXB2 produced in clotted whole blood and 
beta-thromboglobulin. When they were logarithmically transformed their frequency 
distribution approximated a normal curve.
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2.14.6.3 Categorised Data. The Chi-square test for testing of proportions and 
association of categorised data within groups was used when appropriate.
2.14.6.4 Regression to the Mean. Regression to the mean refers to the phenome­
non that an extreme variable on its first measurement will tend to be closer to the 
centre of the distribution on later measurements550. The possible influence of this 
potential circumstance is more fully discussed in section 9.4.3 when within person 
variability is reviewed as a potential limiting factor for the study.
2.14.7 Bivariate Analysis
2.14.7.1 Linear Associations. Bivariate scatter diagrams are examined for evi­
dence of nonlinear relationships. Pearsons product moment correlation coefficients 
were reported as the measure of association between variables if there was a linear 
relation.
2.14.7.2 Comparisons of means. Analysis of variance was used to examine the 
distinct groups which were qualitatively different with respect to the dependent 
variable. It provides a method of simultaneous comparison of means in order to 
decide if a relationship exists between variable(s) within a group and across the 
separate groups.
2.14.7.3 Variable Distribution. Distribution-free methods can be used for com­
parison of variables which do not have a normal distribution. More commonly, in 
this study, linear bivariate regression analysis with appropriate transformations for 
continuous variables was performed. Logarithmic transformation of the continuous 
variables resulted in normalisation of the values for the variables indicated in section 
2.14.6.2.
2.14.8 Multivariate Analysis
2.14.8.1 Background. The simplest approach to evaluate the relationship of a 
characteristic to the occurrence of future disease is to classify individuals in regard 
to the characteristic, and subsequently compare classes by their incidence rates of 
disease in a prospective study.162 An adequate, although less satisfactory alternative 
is to evaluate the relationship(s) in a cross-sectional case-control study, which also 
may involve classification of some of the continuous variables to be examined into 
discontinuous intervals. Unfortunately problems arise with classification because 
most biological characteristics are continuous variables, and classifying into discon­
tinuous intervals results in loss of information and implies that associated risk is also 
discontinuous. More importantly, several characteristics can be simultaneously 
involved in influencing the development of disease.
An alternative to the classification of variables to examine for any relationship bet­
ween a characteristic and disease, is to apply appropriate mathematical models. Re­
gression analysis is one such model, and examines the predictive relationship bet­
ween continuous numerical variables. The variable considered to be influenced by 
other factors is the dependent variable, and those potentially exerting that influence 
are the independent variables. The identification of the appropriate independent
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variables is required in advance, along with the dependent variable, so that the 
number of potential independent variables are known before the analysis. The inde­
pendent variable, within each group, is free to take on different values, and is also 
numerical.
In this study, a correlation matrix to assess dependent-independent and dependent- 
dependent relationships was examined. The number of variables to be examined was 
limited to those considered essential and with substantial preexisting justification for 
examination. This restriction is necessary in order to decrease the likelihood of a 
type I statistical error, and was also preferred for the regression analysis.
2.14.8.2 Regression analysis. Selected clinical and laboratory variables which 
were significantly correlated with a predefined dependent variable were used in 
multivariate linear regression analysis. The application of multivariable linear re­
gression analysis allows the determination for each variable an estimate of its inde­
pendent contribution to the variance of the dependent variable. However, regression 
analysis does not deal with the problem of simultaneous influence of other variables 
that may be interrelated.
The logistic regression model can be used to yield a probability of the risk which 
groups have in relation to the independent variable, knowing their dependent varia­
bles. This estimated probability has no greater discriminating power than multiple 
linear regression, but has the advantage of easier interpretation.
2.14.8.3 Definition. Multivariate linear regression analysis will be used to identify 
subsets of independent variables that are most useful for predicting the dependent 
variable. This is achieved by developing an equation that summarises the relationship 
between a dependent variable and a set of independent variables1177,1178.
2.14.8.4 Procedure for selecting the independent variables to enter the regres­
sion model. The procedure for choosing the independent variables will be by step­
wise forward and backward selection. First the variable will be chosen by forward 
selection. The variable which is considered for entry into the statistical model is that 
with the largest positive or negative correlation with the dependent variable. If the 
criteria for selection are present, the second variable is then selected based on the 
highest partial correlation. The first variable is also examined to see whether it 
should be removed according to the removal criterion. After each step, variables 
already in the equation are examined for removal.
The entry criteria used will be a p value equal to or less than 0.05 for the correlation 
coefficient. The removal criterion will be a minimum F value of 2.71 in order to 
remain in the model, and a maximum probability of F being 0.10 for the variable. 
Variable selection will end when no more variables meet the entry and removal 
criterion.
2.14.8.5 Summary statistics. The summary statistics reported will include the 
partial regression coefficient (B), the standard error of the regression coefficient (SE 
B), the standardised regression coefficient (Beta) and the coefficient of determination
ay-
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The partial regression coefficients (B) is the coefficient for a particular variable after 
adjustment for other independent variables in the equation. This coefficient does not 
give the relative magnitude or a measure of relative importance of the association of 
the independent variable with the dependent variable after adjustment, unless the 
units of all the variables entered into the regression equation are the same.
The coefficient of determination (R ) gives a measure of the goodness of fit for asq
variable in a linear regression model. The statistic is the square of the correlation 
coefficient between the observed value of the dependent variable and the predicted 
value of that value determined from the line of best fit from the scattergram. If all 
the observations fall on the regression line, Rscj=l. If there is no linear relationship 
between the dependent and independent variables, Rsq=0, that is, there is no linear 
association. Partitioning the sum of squares of the dependent variable gives the 
proportion of the variation in the dependent variable "explained" by the model and 
the independent variable.
2.15 ETHICAL CONSIDERATIONS IN HUMAN EXPERIMENTATION
The Division of Clinical Sciences (John Curtin School of Medical Research, Austra­
lian National University) considered the research project described and approved it 
as consistent with the "Statement on Human Experimentation" adopted by the Na­
tional Health and Medical Research Council. The Division assumed responsibility 
for ensuring that the work continued to meet the requirements of that statement. The 
studies undertaken in this thesis were all approved by the Ethics Committee, Woden 
Valley Hospital, Woden ACT.
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Table 2.1. Patient and control characteristics documented.
1. Age
2. Date of onset of symptoms and diagnosis
3. Date, type and number of myocardial infarction(s)
4. ECG and exercise stress test (controls)
5. Stability of angina
6. Time and type of coronary artery bypass grafting
7. Family history (first degree relatives)
8. Time of diagnosis and treatment of hypertension
9. Tobacco intake
10. Presence of clinical peripheral vascular disease
11. Weight, height, body mass index
12. Skinfold thickness
13. Systolic and diastolic BP (phase I and V)
14. Arcus senilis, xanthomata, xanthelasma
15. Medications
16. Alcohol intake, current past and within 24 hr of 
blood collection
17. Usual dietary intake - fats, cholesterol and fatty acids
18. Behaviour and psychometric measures from questionnaires
19. Blood glucose level
20. Coronary angiography scores
Table 2.2. Laboratory Measures.
1. Platelet Function Measures
1. Plasma platelet count
2. Mean platelet volume
3. Platelet count ratio
4. Plasma Betathromboglobulin
5. Plasma Thromboxane B2 (TXB2)
6. TXB2 produced in clotted whole blood
7. Platelet aggregation
8. TXB2 produced in response to agonists adrenaline, ADP and collagen
2. Lipoproteins
1. Total cholesterol (past and present)
2. Total triglyceride (past and present)
3. LDL-cholesterol (calculated)
4. HDL-cholesterol (past and present)
3 Miscellaneous
1. Fibrinogen, coagulation parameters
2. Glycosylated haemoglobin, blood glucose level
3. Full blood count parameters, ESR, Electrolytes, liver and renal function, and 
urate
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CHAPTER 3
DEMOGRAPHIC FEATURES 
AND CORONARY HEART DISEASE RISK FACTORS 
OF THE STUDY POPULATION
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3.1 COMPARISON OF THE MAJOR RISK FACTORS FOR 
CORONARY HEART DISEASE
3.1.1 Coronary Heart Disease Risk Factors
3.1.1.1 Introduction. The term "risk factor" has a num ber of connotations, 
including (1) a statistical correlate of CHD, usually em erging from m ultivariate 
analysis of longitudinal epidemiological studies; (2) a factor that has been identified 
as a cause o f CHD; or (3) a characteristic that predisposes that person to CHD.371 
An extensive medical and biological literature has identified over 270 factors which 
have an association with CHD.202 These factors have been identified according to 
epidem iological criteria, mostly with a statistical association without necessarily 
im plicating, and certainly not proving causation. In fact, cause and effect relation­
ships have not been dem onstrated for the vast m ajority of risk factors.202,235 The 
main risk factors, however, do have a possible causal relationship with CHD. They 
include hypertension, tobacco use, hypercholesterolaemia, reduced HDL cholesterol 
levels and diabetes.371 Increasing age, the male sex, and a family history of CHD in 
a first degree relative are other important factors, although these are not amenable to 
change. Additional risk factors which may prove to be causal and correctable include 
an elevated fibrinogen,60,62,372'374 specific behavioural factors,375'378 abnormal tissue 
and blood fatty acid profile,379'382 and the combination of upper-body obesity, glu­
cose intolerance, hypertriglyceridaemia and hypertension.383'386
H ypertension, elevated cholesterol and smoking contribute heavily to the risk of 
developing CHD. However, once CHD or CAD has developed, it was previously 
thought that the presence o f these factors may then not alter the prognosis to any 
great extent.387'389 More recent data, however, suggests that this observation may not 
be entirely accurate.390 In fact there are different risks for patients having angina, 
with or without a prior MI.389 The prognosis of the individual with established CAD 
is considered  to be re la ted  prim arily to the nature of the CHD at the tim e of the 
diagnosis, viz the extent and severity o f CAD and the ventricular contractile func­
tion.387,388
3.1.1.2 Risk Factor Intervention. The synergistic interaction of the major risk 
factors for the development of CHD166,391 has lead to the use of multivariate analysis 
to quantitatively combine risk factors into a composite risk function to increase their 
p redictive accuracy .160,371 This same interaction places em phasis on the need to 
evaluate any individual risk factor by an appropriate multivariate analysis. This is 
particularly  so if one accepts a proposed hypothesis that all other risk factors are 
associated with CHD through only one independent and causal factor, such as in­
creased LDL cholesterol.391 However, a quantitative reduction in single risk factors, 
disregarding others, may impede any favourable effects on reducing mortality and 
morbidity from CHD.392 Improved prognostic outcome by attempting to modify the 
major correctable risk factors has been recently dem onstrated.393'398 Nevertheless, 
the efficacy for such risk factor intervention has been questioned, particularly with 
alteration of lipoproteins in primary prevention 263,263,265.392.394,399-403
3.1.1.3 Summary. Clearly, whether in those with or without established CHD, a 
know ledge o f all the major risk factors is required in order to evaluate a potential
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new factor. The appropriate use of multivariate analysis when employed as a method 
to control for the influence of the established factors, necessitates that all the relev­
ant factors are entered into the regression model. Moreover, a complete understand­
ing of the causal risk factors and their interaction is necessary in order to plan 
appropriate therapeutic or epidemiological intervention. Indeed, a greater under­
standing of the exact mechanisms relating the CHD risk factors to atherogenesis is 
mandatory in order to identify precisely those at risk to ensure that any intervention 
will be appropriate in terms of the cost benefit ratio. The need for such an approach 
has been highlighted in regard to the lowering of cholesterol for the primary preven­
tion of CHD, considering the concerns about the medical cost benefit ratio.264
In this section, the case and control groups are described and compared with regard 
to their demographic, clinical and risk factor profile. This is to help clarify for the 
case and control groups, those variables that are important in distinguishing the two 
groups; to determine if these distinguishing variables are consistent with those in the 
literature; and to determine those variables appropriate for use in multivariate analy­
sis, recognising the inherent problems of such methods.404 The inter-relationship 
between the major risk factors within each of the study groups has also been evaluat­
ed. Any such relationships with measures of platelet function are discussed in Chapt­
er 7. In addition, the relationship of the traditional risk factors with angiographically 
defined CAD will be considered in Chapters 5 and 8.
3.1.2 Methods
3.1.2.1 Study populations. The patient population consisted of 53 males with 
CAD proven by coronary angiography, who were aged less than 50 years at the time 
of examination. The control group consisted of 48 males from a normal population 
group who were age, race and community matched to the study group. The control 
subjects had no cardiac symptoms, normal resting supine ECGs and a normal 
maximal exercise treadmill test and exercise 12 lead ECG. The control subjects were 
ascertained via the case volunteers and were required to be of a similar age and from 
a similar socioeconomic group without known cardiac disease.
Clinical information about each case and control was obtained. The case group was 
required to have clinically stable CHD for at least 12 weeks. Exclusion criteria 
included individuals with diabetes, a stroke, coronary artery bypass grafting 
(CABG), percutaneous transluminal coronary angioplasty (PTCA) or non-cardiac 
surgery within 3 months, any significant medical illness, liver and renal disease, 
unable to cease aspirin or NSAIDs, and any recent acute illness, in particular, infec­
tive or inflammatory disorders.
Information documented included age, date of onset of symptoms and diagnosis, 
date, type and number of MI(s), family history (first degree relatives) and family 
risk factors and time of diagnosis and treatment of hypertension, tobacco intake, 
time of use and lifetime volume, presence of clinical peripheral vascular disease, 
systolic and diastolic BP (phase I and V Korotoff sounds), the presence of xanthoma­
ta or xanthelasma, the type and amount of medications, and alcohol intake (current, 
past and within 24 hours of blood collection). Judging from the failure to form 
TXB2 in clotted whole blood (see Chapter 7), 3 individuals in the case group were
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considered to have taken aspirin, and so were excluded from further analysis of 
platelet function. The anthropomorphic measurements taken were weight, height, 
body mass index (BMI), and triceps and skinfold thickness. The description of these 
measures, the methods involved and their limitations are discussed in Appendix 2.
3.1.2.2 CHD risk factors. The methodology for the lipoprotein measurements is 
described in the methods section in Chapter 2. The past lipoprotein values are histor­
ical levels obtained from the patients or their local medical practitioners and the 
laboratory methods used are not always known.
Indirect BP measurement was made with a cuff and mercury sphygmomanometer as 
described in Chapter 2, section 2.11.1. The prior diagnosis of hypertension, the time 
since diagnosis of hypertension, and the time of treatment was obtained from the 
patient.
Methods for obtaining the family history of CHD and the use of tobaco are described 
in Chapter 2. Current use of tobacco in those claiming abstinence was not excluded 
biochemically by urine analysis.
Other variables measured included fibrinogen, HbAlC, blood glucose level and full 
blood cell count parameters and the methods are described in Chapter 2. Coagulation 
parameters, viz activated partial thromboplastin time (APTT), the prothrombin time 
(PT) and thrombin clotting time (TCT), electrolytes and liver and renal function tests 
were measured by the Pathology Department of Woden Valley Hospital.
3.1.2.3 Statistical analysis. The simplest approach to evaluate the relationship of 
a characteristic to the occurrence of future disease is to classify individuals in regard 
to the characteristic, and subsequently compare classes by their incidence rates of 
disease in a prospective study.162 An adequate, although less satisfactory alternative 
is to evaluate the relationship(s) in a cross-sectional case-control study, which may 
also involve classification of some of the continuous variables to be examined into 
discontinuous intervals. Unfortunately problems arise with classification because 
most biological characteristics are continuous variables, and classifying into discon­
tinuous intervals results in loss of information and implies that associated risk is also 
discontinuous. More importantly, several characteristics can be simultaneously 
involved in influencing the development of disease. In this section the major risk 
factors are evaluated as continuous variables or as categorical variables.
A full description of the methodology for the analysis of the data is described in 
Chapter 2.
3.1.3 Results
The mean age of the control group and the case group were the same, 43.3+/-0.9 
and 44.6+/-0.7 respectively (Table 3.8).
3.1.3.1 Anthropomorphic Measures. The height, weight and BPs were identical 
in each group. The BMI was slightly but not significantly greater in the case group. 
The case group had significantly greater scapular skinfold thickness which is a meas-
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ure of central body obesity (Table 3.1).
3.1.3.2 Clinical characteristics. In the case group only 9 patients had not had a 
prior myocardial infarct and 44 patients had at least one acute MI, the majority being 
anterior and inferior infarcts (Table 3.2). The mean time from a previous infarct 
was 242 days (median 115, standard deviation 317, minimum 12 weeks and maxi­
mum 2.7 years). The majority of cases where on cardiac medications and 9 controls 
were on medications for hypertension or other disorders (Table 3.3).
3.1.3.3 Family history. Fathers of the subjects in the case group had a significan­
tly greater frequency of CHD (Table 3.4). This difference remained of borderline 
significance even when the unknown cases in both groups were assumed not to have 
had CHD (Table 3.4). The number of paternal deaths due to CHD were not suffi­
ciently frequent to obtain any reliable information. There were no differences in the 
known frequency of the major risk factors between the fathers of subjects in both 
study groups. However, this information was frequently unknown for hypertension 
and hyperlipidaemia, making any conclusions invalid.
In the two study groups, no differences were found in maternal risk factors, includ­
ing the diagnosis of CHD (Table 3.5). However, even though the number of un­
known observations appears to be relatively low, the sample number in the two 
groups impart the possibility of a type II statistical error.
The frequency of hypertension was significantly greater in siblings of the patient 
group, but there were no significant differences in any of the other major risk factors 
(Table 3.6). There were more smokers among the siblings of cases, but again the 
difference was not significant. Interestingly, there were more reported diabetics 
within the siblings of controls rather than the siblings of the cases (Table 3.6).
3.1.3.4. Lipoprotein variables. Of no surprise was the observation that the case
group had significantly higher mean total blood cholesterol and triglyceride levels, 
and a lower HDL level. The past cholesterol level was much greater in those who 
had had it recorded. However the overlap in individual values between the groups 
was large, as it was for all the other lipoprotein values (Table 3.7). The apoprotein 
B level was greater, and the apoprotein A1 level was lower in the case group com­
pared to the controls (Table 3.7). The cholesterol level was not significantly differ­
ent for the value from the alternate laboratory, but the HDL and triglyceride levels 
were (Table 3.7).
3.1.3.5 Tobacco use. There were significantly more previous tobacco users in 
the case group (Table 3.9). In addition, in the case group smokers in general smoked 
a greater amount over their lifetime (Table 3.8).
3.1.3.6 Hypertension. More cases than controls were diagnosed as having hyper­
tension, and the number of cases requiring treatment was similarly greater. Both 
these differences did not, however, attain statistical significance with the study 
sample number (Table 3.9). The highest previously recorded systolic and diastolic 
BP recalled by the subjects were significantly greater in the case population (Table 
3.8). The BPs at the time of examination were not significantly different, which was
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presumably related to adequate treatment, or possibly due to previous Mis (Table 
3.8).
3.1.3.7 Blood glucose levels. The blood glucose level and HbAlC were greater 
in the case group even though overt diabetics were excluded. There were no outliers 
in the frequency distribution and the variables were normally distributed (Table 
3.10).
3.1.3.8 Fibrinogen. The fibrinogen level in the case group was greater than in 
the controls and in these two study groups it was normally distributed (Table 3.8).
3.1.3.9 Alcohol use. A slightly greater percentage of controls continued to use 
alcohol at the time of the interview (Table 3.9). Alcohol use is evaluated in more 
detail in Chapter 5.
3.1.3.10 Haematological measures. The case group had a significantly higher Hb 
and a lower MCV than the controls. The He, WCC, PT and APTT were not signifi­
cantly different between the two groups (Table 3.10).
3.1.4 Discussion
3.1.4.1 Sex as a risk factor. In populations in which CHD is a major health 
problem, the incidence of CHD is markedly lower in premenopausal women than in 
men, although there is a convergence after menopause. By the 8th decade the in­
cidence is almost equal in the two sexes.196 National mortality data in some Western 
countries suggests that the decreasing sex difference in CHD after 50 years of age is 
due to a declining rate of increase in men rather than an acceleration in women.196 
This data suggests that factors other than age per se are more important in the devel­
opment of CHD, even though atherosclerosis continues to accumulate with age. The 
cause for the difference may be due to a mortality bias from premature deaths.
The relationship of risk factors to CHD also appears to be different in females. 
Women have much lower rates of CHD than men at the same values of 
cholesterol,198,405 menopause has an unfavourable effect on lipids,406 diabetes melli­
tus seems to be a greater risk factor for females than males407,408 and the genetic 
component to the liability to cardiac death may be greater in women.409 Women who 
die from CHD appear to have a similar relative risk but lower absolute and attribut­
able risk for smoking, diastolic BP and social class than men.405 However, the 
overall impact of CHD risk factors in women is poorly understood, the reason(s) for 
the different natural history are unknown and the pattern of risk associated with 
factors pertaining solely to women is even less well understood. Indeed, the evalua­
tion of CHD risk factors in longitudinal epidemiological studies indicate that some 
other factors protect women against CHD, such as natural oestrogen 405
Considering these and other concerns, it was considered prudent to again endeavour 
to make the study population as homogeneous as possible and initially exclude young 
women with CHD. The mothers of the two study groups had no significant differ­
ences in the incidence of CHD or CHD risk factors, although this may simply be a 
type II statistical error.
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3.1.4.2 Age as a risk factor. Since aging itself is a well recognised and powerful 
risk factor for the development of CHD,410 a group of males with premature CHD 
and a narrow age range and an age matched control group were selected to exclude 
the influence of age on atherosclerosis and risk factors. In addition, choosing a 
young group would presumably reduce the confounding effect of the longer term 
influence of the major risk factors which themselves increase with age.161,202
3.1.4.3 Family history. A number of previous case-control studies have evaluat­
ed the familial occurrence of CHD as a primary objective.177"180,411'413 An increased 
risk of CHD in relatives of individuals with the disorder may in part be due to genet­
ic factors.177,411,413 This relationship was found to be highest when parental death 
from the disease occurred prem aturely,177,411 particularly in males who have both 
pa ren ts  dying  o f C H D .411 S im ilar pa tte rn s  w ere not d e tec tab le  in o ld e r age
411groups.
The familial component for premature CHD is also related to the aggregation of risk 
factors in fam ilies.179,411 The magnitude of this contribution is controversial, with 
som e s tu d ies  d em o n stra tin g  th is as the m ajo r or to ta l cause  o f the fa m ilia l 
pattern.178,414,415 The relative importance of the individual risk factors is similarly 
variable.179,221,414,415 The inherent problems in these studies is that a prim ary risk 
factor may reflect a genetic tendency to the major risk factors, or a shared environ­
mental influence common within families.415 There may even be a familial aggrega­
tion for an increased susceptibility to the effects of the major risk factors.415 Never­
theless, support for case-control studies demonstrating a separate association of an 
independent genetic contribution is impressive.170,188,416 In particular, prospective 
studies endorse the possibility  o f heritable factors as im portant determ inants o f 
cardiovascular mortality mainly in younger m en,171,181,188,417 and that CHD occurs 
p a rtly  as a fa m ilia l d iso rd e r, p a r tic u la r ly  ev id en t in m ales w ith  p rem a tu re  
C H D .171,181,188,417 One large prospective study indicates that a history of AMI in 
either parent is associated with an increased risk of CAD among men independent of 
diet or established risk factors.417 Indeed, the weight of evidence indicates that the 
distinct familial contribution to the major risk factors fails to account for all of the 
inherited component188,416 and that other familial risk factors remain to be found.416
The primary aim of this present study was not to examine familial aggregation of 
CHD. The study number is too small to evaluate the independence of such an asso­
ciation by adjusting for other CHD risk factors. Further, a positive recall bias in 
those having an AMI cannot be controlled for without independent validation of the 
subjects personal observations and recollections.
The significantly increased incidence of paternal CHD in this study is concordant 
w ith the literature. H ow ever, this observation, and that for the siblings and the 
maternal history, cannot be interpreted as a positive or negative finding in view of 
the limitations discussed above. However, the selection of young males as the study 
population was in part motivated by the evidence that premature CHD in males does 
have a significant and independent familial aggregation,181,188,416,418 which is unex­
plained. The selection of such a group may therefore increase the possib ility  of 
detecting such unidentified risk factors by reducing the "noise" from interactive 
confounding factors and heterogeneous study populations.
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3.1.4.4 Lipoproteins. A relationship between increased platelet aggregability and 
platelet reactivity with dyslipoproteinaemias has been well established,126,128,419'426 
highlighting the importance of carefully documenting the lipoprotein profile of the 
study group. This aspect is discussed in Chapter 5.
3.1.4.5 Hypertension. It also appears possible that a relationship between BP and 
platelet aggregation exists.145' 147 The fact that hypertension was treated, particularly 
in the case group, many of whom were on vasoactive medications for other reasons, 
may be a potentially important confounding factor which cannot be effectively con­
trolled for in this cross-sectional study. Appropriate interpretation of the results must 
be made given this potential major bias.
3.1.4.6 Blood glucose. Raised plasma adrenaline and hyperglycaemia after MI 
may activate platelets, and this could contribute to a poor outcome in such patients.75 
A relationship between platelet function and abnormal glucose metabolism is well 
established, although not fully clarified, and illustrates the necessity for excluding 
diabetic individuals. Since abnormal glucose homeostasis may play a role in the 
pathogenesis of CHD, even in non-diabetics, an evaluation of relationships with 
glucose haemostasis has been undertaken. This aspect is discussed in Appendix 2.
3.1.4.7 Tobacco use. Previous studies have suggested that platelets may be acti­
vated during chronic cigarette smoking57,427,428 and that the metabolism of platelets is 
altered. For example, increased production of thromboxane may be a direct effect of 
smoking.428,429 Furthermore, there appears to be an acute effect of cigarette smoking 
on in vitro*30,122 and in vivo platelet function, although this is controversial.431,432 
Smoking cessation lessons the risk of death or MI in older and younger persons with 
CAD.433 Indeed, the increased risk of a first MI among cigarette smokers declines 
soon after cessation, both for men and women, and is largely dissipated within two 
or three years.434 In fact, the risk of smoking would appear to be associated only 
with current smoking, and the duration of the smoking habit is less im portant.435 
M oreover, non-atherogenic mechanisms may be important in the aetiology of MI 
among women who are cigarette sm okers.436 A rapid regression in risk o f CHD 
within the first year of quitting smoking is difficult to explain solely on the basis of 
vascular disease,429 and may be related to a reversal in abnormalities of platelet and 
haemostatic function.429
In this study, very few controls or cases were current tobacco users. Therefore, in 
light of the foregoing discussion, there is a high probability that the study may suffer 
from the confounding influence resulting from the cessation of smoking. On the 
other hand, the fact that the majority did not use tobacco at the time o f  the evalua­
tion, enables the detection o f any abnormal platelet function in the case group inde­
pendent o f acute tobacco use.
3.1.4.8 Cardiac medications. Beta-blockers without intrinsic sympathomimetic 
activity are associated with an increase in the triglyceride level and a decrease in the 
HDL cholesterol level.389 Despite these unfavourable changes, after AMI, there is a 
reduction in risk associated with the use of beta-blockers.389 Thiazides also influence 
lipids, resulting in an increase in total cholesterol.437 The longterm outcome of these 
changes are unknown.438 More importantly, a number of cardiac drugs influence
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platelet function in vitro and may do so in vivo as well. Therefore, a separate evalua­
tion of the influence of the more common types of cardiac medications was under­
taken as a preliminary evaluation. The results are presented and discussed in Chapter 
4.
3.1.4.9 Conclusion. This section details important comparisons between the two 
groups in this case-control study, in particular with regards to the major risk factors 
for CHD. It is clear that the differences between the two groups are consistent with 
those found in the literature and clinical practice. Important potential confounding 
factors apparent from these results are the differences in the lipoproteins, glucose 
homeostasis, plasma fibrinogen levels, possibly previous tobacco consumption and 
BP levels. Furthermore, methodological bias may arise from the greater use of 
cardiac drugs in the case group. These issues of methodological bias and the pres­
ence of confounding factors are addressed in Chapters 4 and 8.
3.2 MARITAL STATUS, EDUCATION AND EMPLOYMENT
3.2.1 The Necessity of Matching the Case and Control Groups 
for Socioeconomic Status
3.2.1.1 Introduction. The factors attempted to be matched for the case and con­
trol groups were age, sex and socioeconomic status. Therefore, to ensure this pre­
evaluation matching was successful, an analysis of the education level achieved and 
marital status was undertaken. In addition, the reasons as to the necessity of this 
approach will be discussed.
3.2.1.2 Socioeconomic Status as a risk factor for CHD. An increased overall 
mortality in the lower socioeconomic groups of Western countries is well document­
ed.439'442 Indeed, the potential contribution of the risk for the lower socioeconomic 
groups to overall mortality is considerable.442 Furthermore, an association between 
CHD and low social and economic class has been consistently demonstrated.440"448 
These numerous reports have originated from a number of different countries and 
from varied investigators using diverse methodologies, factors which enhance the 
validity of the observations. Not only do lower socioeconomic groups have an in­
creased incidence of CHD, but the symptoms of the disease and the functional im­
pairment is greater. Symptoms of cardiovascular disease, impaired working capaci­
ty, functional disability, anxiety and sleeping disorders have been reported among 
unskilled workers in a number of different surveys.449
3.2.1.3 Shift Work. An association between shift work and increased risk for the 
development of CHD has been well described.450,451 This particularly applies to the 
first two decades of shift work, with a decrease in the association subsequently prob­
ably being due to positive selection taking place in the study group.452 In addition, 
the association was independent of age and smoking habits.452 The more recent 
observations450'452 have been consistent, although earlier studies found either no 
relationship between shift work and cardiovascular disease,453,454 or a similar but not 
significant direction to the association.455,456 However, the earlier studies had a 
number of design faults that could lead to erroneous results which the contemporary
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studies attempt to rectify, improving the reliability of the observation.452
One possible mechanism that may enhance the risk for shift workers is the higher 
incidence of blood lipid abnormalities.452,453,457,458 The abnormalities appear to be 
independent of smoking habits, obesity, dietary factors and leisure activity458 Shift 
workers have been reported to have an increased consumption of tobacco,452 
although there is a risk independent and in addition to this increased consumption 452
3.2.1.4 Risk factors for CHD and socioeconomic group. Socioeconomic and 
social support variables have clearly been related to CHD risk factors.459,460 Life­
style and an uneven distribution of established risk factors for CHD may be the most 
obvious explanations for the differences in CHD between social class.442 The in­
creased incidence of hypertension in the lower socioeconomic groups has been uni­
formly reported from a number of diverse Western populations,442'445 including 
Australia.445 Differences between populations with regard to the other major risk 
factors have been noted. The frequency of tobacco use and the levels of blood cho­
lesterol are increased in lower socioeconomic groups in Great Britain443 but not 
Sweden442 Tobacco use and tobacco-related illness, including CHD, is greater in 
lower socioeconomic groups in Australia.461 Blood lipid abnormalities are not con­
sistently related to educational level, except possibly for HDL and triglyceride levels 
in women taking a more beneficial direction with education level.462 A height dif­
ference, lower socioeconomic groups being on the average shorter than higher 
socioeconomic groups442,443 may reflect differences in genetic constitution as well as 
nutritional factors during childhood.442
3.2.1.5 Geographic Variations. Pronounced variations in cardiovascular mortali­
ty have been identified in a number of Western countries463 The British Regional 
Heart Study indicates that such a variation in CHD rate among middle aged men 
cannot be directly and solely explained by their genetic inheritance, or by perinatal 
and postnatal dietary differences.463 Indeed, prevalence studies between population 
groups within the United Kingdom demonstrate differences in mortality between 
areas, in particular lower mortality in areas were employed men constituted the 
patient population.464 Differences in community or medical services, smoking habits 
or unemployment rates appeared to offer an explanation for the variations in CHD 
mortality.464
3.2.2 Results
The level of education achieved by the individuals in the case and control groups is 
listed in Table 3.11. A contingency table with a 9 by 2 matrix containing the number 
of subjects that were classified as part of each column and row, with each subject 
appearing in only one cell, was employed for the analysis. The Chi-square statistic 
with Yates correction was used to quantitate any association between the columns 
and rows, that is whether being in either the case or control group influenced the 
education level. There was no measurable difference between the study groups and 
the level of education attained (Chi-square statistic=8.2899, p=0.4057).
Dividing the groups into those achieving some tertiary level of education or matricu­
lation to a University, both of which correlate with socioeconomic status, provided a
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2 by 2 contingency table for the application of the Chi-square statistic with the 
Fisher exact test (Table 12). Again, there was no significant difference between the 
groups (Chi-square statistic=l .2681, Fisher exact test 2-tailed p=0.2316, with an 
Odds ratio=0.585).
The overall marital status of the two groups was also not significantly different 
(Table 13).
3.2.3 Discussion
There is no major difference in the socioeconomic status as measured by marital 
status and education level. By using community matched controls, mainly being 
friends of the case group, it is probable that the potential bias associated with the 
socioeconomic status of the two groups has been prevented or at least reduced. 
Nevertheless, the socioeconomic difference may be due to measurable risk factors 
already taken into account within the study design.
3.2.3.1 Vegetarians, Seventh Day Adventists and Coronary Heart Disease.
Mortality from CHD appears to be lower in vegetarians compared to non-vegetar­
ians, particularly among men.465,466 The assumptions that vegetarianism confers 
some protection against CHD appears valid although the exact reason has not been 
determined,465'467 Predictably vegetarians have lower serum cholesterol and body 
mass index (Weight/height squared),465,468 although it remains unclear whether the 
low cholesterol levels of vegetarians are due to meat abstension and/or the high 
intake of vegetables.466
The epidemiological relationships to the incidence of CHD and CHD risk factors 
have been extensively studied in Seventh-Day Adventists.465 Adventist men have 
lower rates of CHD mortality, although the information regarding Adventist women 
is conflicting.465 This religious group have lower rates of cholesterol and BP, but 
also lower levels of HDL.465 Available information indicates that the lower risk for 
CHD in Adventist men is probably related to their dietary habits, non-smoking sta­
tus, greater social support and possibly their better exercise habits.465
However, the low BP and cholesterol levels found in Adventists may be due to a 
selection bias.469 In addition, the effect of psychosocial factors within this population 
has been difficult to determine. Examination of the data from the Tromso Heart 
Study has further underlined the difficulty in identifying specific aspects of Adven­
tists lifestyle responsible for the mortality differential.469 Review of the overall 
information available suggests that the lower levels of BP and cholesterol in re­
ligiously active Adventists is not due to a selection bias or religious factors other 
than those influencing life-style.469
There were no differences in the frequency of vegetarians in the two study groups as 
documented in Chapter 5. However, the religous status of the two groups was not 
documented, although a significant difference is unlikely. This lack of documenta­
tion is unlikely to lead to a bias within the study, especially given the probability that 
the difference in CHD incidence in religious groups compared to the general popula-
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tion is due to differences in risk factors. Nevertheless, the possibility of a difference 
exists and could lead to a bias which confounds the results.
3.2.3.2 Conclusions. The lower socioeconomic groups in Western countries are 
more affected by the incidence of CHD, the symptoms and disability arising from 
the disease and the risk factors associated with CHD. Further, specific occupational 
characteristics prevalent in the lower socioeconomic groups have in themselves a 
risk association with CHD, both the type of work performed and when it is under­
taken. The existence of possible confounding factors related to the life-stye of the 
socially and economically disadvantaged, particularly in relation to dietary factors, 
cannot be dismissed. Seventh-Day Adventists provide a relatively homogeneous 
population with specific life-style charactistic which appear to carry a low CHD risk, 
as do vegetarians. These studies implicate dietary factors and smoking habits. The 
differences between the socioeconomic groups are qualitatively similar to those 
demonstrated between Adventists and non-Adventists, and vegetarian groups and 
non-vegetarians. Specifically, Seventh-Day Adventists, vegetarians, higher soci­
oeconomic groups and non-shift workers have lower intakes of tobacco, saturated fat 
in their diet, lower blood cholesterol and lower BP than non-Adventists, non-vege­
tarians, lower socioeconomic groups and shift workers. There are clear indications 
that specific life-style characteristic contribute and provide a potential area for inter­
vention in lower socioeconomic groups, both from a primary prevention and second­
ary prevention perspective.
Given the similarity in the education level and marital status of the two groups, and 
the possibility that the documented differences in CHD risk between socioeconomic 
groups is related to risk factor and dietary differences, it is unlikely that any major 
bias will have occured in the case-control study described in this Thesis.
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Table 3.1. Anthropomorphic measures.
Controls Cases 95% Cl
Mean+/-SE______ Mean+/-SE___________
BMI (kg/m2) 25.7+/-5.0 
Triceps (cm) 12.3+/-1.0 
Scapula (cm) 13.8+/-0.7 
Height (cm) 176.0+/-1.2
Weight (kg) 80.0+/-1.7
26.6+/-5.0 -5.01 to 23.07, p=0.2072
12.5+/-0.7 NS
17.1+/-0.9 0.96 to 5.64, p=0.0064
175.0+/-1.1 NS
80.8+/-1.5 NS
BMI=body mass index, triceps=triceps skinfold thickness,
scapular=scapular skinfold thickness, CI=confidence interval of the mean dif­
ference, NS=no significant difference.
Table 3.2. Myocardial infarcts in the case group.
Number of MI Position of MI
Nil MI 9 Anterior 18
Single MI 40 Inferior 21
Two MI 3 Lateral 7
Three MI 1 Indeterminant 3
Numbers refer to the number of subjects. 
MI=myocardial infarction.
Table 3.3. Medications used by subjects in the two groups.
Controls Cases
Beta-blockers 0 24
Calcium blockers 3 22
Nitrates 0 13
Vasodilators 2 0
Antiarrhythmics 0 3
Digoxin 0 2
Diuretics 1 4
Theophylline 1 0
Others 5 4
Numbers refer to the number of subjects.
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Table 3.4. Father’s medical history relevant to CHD.
Controls Cases
Diagnosis of CHD:
Present 11 21 Chi-S = 8.0816
Absent 36 26 p = 0.0176
Unknown 1 6
Present 11 21 Fishers’ Test
Absent 36 26 p = 0.0492
(disregarding missing values) OR = 2.643
Present 11 21 Fishers’ Test
Absent 37 32 p = 0.0886
(assuming missing values negative) OR = 2.207
Death due to CHD:
Present 7 13 Chi-S = 1.1189
Absent 14 16 p = 0.5712
Unknown 1 3
Present 7 13 Fishers’ Test
Absent 14 16 p = 0.3005
(disregarding missing values) OR = 0.615
Diagnosis of Hypertension:
Present 8 8
Absent 34 30 NS
Unknown 6 15
Tobacco Use:
Present 28 34
Absent 19 17 NS
Unknown 1 2
Diagnosis of Diabetes:
Present 1 4
Absent 46 46 NS
Unknown 1 3
Diagnosis of Hyperlipidaemia:
Present 0 0
Absent 23 17 NS
Unknown 25 36
Chi-S=Chi square statistic, OR=odds ratio, NS=no significant difference.
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Table 3.5. Mother’s medical history relevant to CHD.
Controls___________Cases
Diagnosis of CHD:
Present 11 11
Absent 36 41 NS
Unknown 1 1
Death due to CHD:
Present 7 8
Absent 8 9 NS
Unknown 1 1
Diagnosis of Hypertension:
Present 11 17
Absent 32 31 NS
Unknown 5 5
Tobacco Use:
Present 11 18
Absent 36 34 NS
Unknown 1 1
Diagnosis of Diabetes:
Present 4 6
Absent 43 45 NS
Unknown 1 2
Diagnosis of Hyperlipidaemia:
Present 5 5
Absent 19 20 NS
Unknown 24 28
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Table 3.6. Siblings’ medical history relevant to CHD.
Controls___________Cases
Diagnosis CHD in Brother:
Present 2 4
Absent 45 47 NS
Unknown 1 2
Diagnosis CHD in Sister:
Present 1 0
Absent 46 52 NS
Unknown 1 1
Death due to CHD:
Present 0 0
Absent 48 53 NS
Diagnosis of Hypertension:
Present 5 18 Chi-S = 8.1345
Absent 38 32 p = 0.0171
Unknown 5 3
Present 5 18 Fishers’ Test
Absent 38 32 p = 0.0253
(disregarding unknowns) OR = 0.234
Tobacco Use:
Present 11 18
Absent 36 34 NS
Unknown 1 1
Diagnosis of Diabetes:
Present 7 1 Fishers’Test
Absent 40 51 p = 0.0253
Unknown 1 1 OR = 8.925
Diagnosis of Hyperlipidaemia:
Present 7 3
Absent 26 34 NS
Unknown 15 16
See Table 4 for abbreviations.
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Table 3.7. Lipoprotein measures in the two study groups.
Variable Controls
Mean+/-SE
Cases
Mean+/-SE
95% Cl Mean Diff
Past chol 
(mmol/1)
5.7+/-0.3
(n=15)
6.1+/-0.3
(n=27)
-0.53 to 1.33, p=0.39
Present Choi 
(mmol/1)
4.9+/-0.1 5.2+/-0.1 0.02 to 0.58, p=0.037 *
Triglycerides
(mmol/1)
U+/-0.1 1.9+/-0.2 0.15 to 0.31, pcO.0001 *
HDL chol 
(mmol/1)
1.00+/-0.04 0.86+/-0.03 -0.24 to -0.04, p =0.0057 *
Chol/HDL 5.2+/-0.2 6.3+/-0.2 0.54 to 1.66, p=0.0002 *
Apoprotein A 
(mmol/1)
1.50+/-0.07
(n=37)
1.21+/-0.04
(n=44)
0.14 to 0.44, p=0.0003 *
Apoprotein B 
(mmol/1)
0.82+/-0.04
(n=37)
0.95+/-0.03
(n=44)
0.20 to 0.24, p=0.0098 *
ApoA/ApoB 2.00+/-0.15
(n=37)
1.31+/-0.06
(n=44)
0.39 to 0.99, p<0.0001 *
Alternate Chol 
(mmol/1)
5.45+/-0.13
(n=46)
5.64+/-0.15
(n=52)
-0.59 to 0.21, p=0.3469
Alternate Trig 
(mmol/1)
1.11+/-0.12
(n=46)
2.24+/-0.24
(n=52)
-1.73 to -0.53, p=0.0003 *
Alternate HDL 
(mmol/1)
1.29+/-0.07
(n=46)
0.95+/-0.03
(n=52)
0.20 to 0.48, p<0.0001 *
Alternate=measurement performed in an alternative service laboratory using plasma, 
chol=cholesterol, trig=triglyceride, HDL=HDL cholesterol, CI=confidence interval of 
the mean difference. Values are expressed as mean+/-SE.
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Table 3.8. Other risk factors for CHD.
Controls
Mean+/-SE
Cases
Mean+/-SE
95%  Cl Mean Diff
Age (years) 43.3+/-0.9 44.6+/-0.7 NS
Fibrinogen
(mg/100ml)
230 +/-8 275 +/-10 18.61 to 71.39, p=0.0011 *
Packyears
(Years)
22 +1-4.1 
(n=19)
37 +7-3.4 
(n=34)
-0.09 to 0.27, p=0.33
Previous SBP 
(mmHg)
128 +/-3 
(n=36)
144 +/-5 
(n=35)
4.44 to 27.56, p=0.007 *
Previous DBP 
(mmHg)
83 +1-3 
(n=35)
93 +/-3 
(n=37)
2.52 to 17.48, p=0.0095 *
Current SBP 
(mmHg)
125 +1-22 123 +/-1.6 NS
Current DBP 
(mmHg)
80 +/-1.6 79 +/-1.9 NS
BSL
(mmol/1)
4.9+/-0.08 5.2+/-0.10 0.04 to 0.56, p=0.0222 *
HbAlC 7.3+/-0.1 7.8+/-0.2 0.05 to 0.95, p=0.0307 *
Creatinine 99 +1-2 97 + 1-3 NS
umol/1
Packyears=equivalent number of years of smoking at 20 cigarettes per day, 
SBP=systolic BP, DBP=diastolic BP, previous=highest previous BP recalled by the 
subject, current=at the time of the subject’s interview for the study, BSL=blood 
glucose level, HbAlC=glycosylated Hb level, NS=no significant difference,
* = significant difference, CI=confidence interval of the mean difference.
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Table 3.9. Other risk factors for CHD.
Controls Cases Fishers’ Exact Test
Current smokers 7 4 p=0.34 OR=2.1
Previous smokers 19 (40%) 34 (64%) * p=0.04 OR=0.4
Known hypertension 12 (25%) 21 (40%) ii p
 
>—>‘ OR=0.5
Treated hypertension 9 (19%) 19 (34%) p=0.08 OR=0.4
Previous Alcohol use 44 (92%) 44 (83%) p=0.13 OR=3.0
*=significant difference between groups, OR=odds ratio.
Table 3.10. Haematological values in the two study groups.
Controls Cases 95% Cl Mean Diff
_____________ Mean+/-SE_________ Mean-i-/-SE______________________
Hb (gm/dl) 14.8+/-0.01 15.1+/-0.1 0.09 to 0.51, p =0.0055
He (%) 43.2+/-0.4 43.6+/-0.3 -0.58 to 1.38, p =0.4202
MCV 90.4+/-0.6 89.0+/-0.5 -2.55 to -0.25, p=0.0173
RDW 12.9+/-0.08 12.8+/-0.09 NS
WCC 6196 +/-255 6698 +/-233 NS
PT 13.3+/-0.1 13.6+/-0.4 NS
APTT 24.4+/-0.4 24.2+/-0.8 NS
Hb=haemoglobin, Haematocrit=Hc, MCV=mean red cell volume, WCC=white cell 
count, PT=prothrombin time, APTT=activated partial thromboplastin time, NS=no 
significant difference, CI=confidence interval of the mean difference.
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Table 3.11. Education level achieved.
Education Level Case Group________ Control Group
Primary school alone 3 1
Junior high school alone 4 3
Junior high school certificate 11 8
Senior high school alone 4 -
Senior high school certificate 6 7
Matriculation 3 5
Tertiary education not graduated 8 9
Graduated tertiary education 12 10
Post-graduate qualifications 2 5
Table 3.12. Case and control group divided into those 
with and without some tertiary education.
Tertiary Education
or matriculation_________________ Case Group________ Control Group
Yes 25 29
No 28 19
Table 3.13. Marital Status
Marital Status____________ Case Group________ Control Group
Never married
Married
Separated
Divorced
Widowed
4 (7.5%) 
41 (77.4%)
5 (9.4%)
3 (5.7%)
2 (4.2%) 
40 (83.3%)
5 (10.4%)
1 (2.1%)
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CHAPTER 4
EVALUATION OF POTENTIAL AREAS OF 
MAJOR METHODOLOGICAL BIAS
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4.1 CASE-CONTROL STUDIES
In this section, the limitations of the case-control method are outlined. The following 
discussion illustrates that a "simple" case-control study requires careful prepatory 
evaluation because of the number of potential confounding factors. These include 
confounding factors arising from methodological bias which may degrade the final 
information and invalidate the conclusions. The case-control method is cross-sec­
tional and begins after several innate biases have already occurred, some being 
uncorrectable. Further attempts to correct some of the bias may augment existing 
bias or create an "investigative bias".370,470,471 Nevertheless, in the planning of a 
case-control study, an analysis of major potential areas of bias arising from the 
design of the study should be undertaken.472,471
4.1.1 Definition of a Case-Control Study
A case-control study is an example of a cross-sectional study, the purpose of which 
is not only to give a qualitative description of disease in a population at a given time, 
but to also allow quantitative assessment of characteristics within the population in 
relation to the disease.370,470,471,473 In simple terms, a case-control study compares 
people with and those without disease. The comparison is to see if they differ in 
their exposure to a suspected cause or contributing influence for the disease. In 
doing so, cases are assumed to be representative of the population with the disease. 
Similarly, the controls are assumed to be representative of the population in which 
the disease cases arose, but who do not have the disease in question at the time. The 
comparison group is used to support or refute the inference of an association for any 
particular factor. The presence of any confounding factors influencing the relation­
ship between the variable in question and the outcome, needs to be adequately 
matched. Comparability of the groups can be improved by correct matching of such 
potentially confounding factors which already are known to influence the outcome. 
Alternatively, their effects can be allowed for in the appropriate analysis, provided 
they are recognised prior to the commencement of a cross-sectional study and are 
adequately documented.471,472
4.1.2 Rational for the Use of the Case-Control Method
Experimental and observational studies, in an attempt to elucidate some of the aetio- 
logical factors of CHD and atherosclerosis, have demonstrated an association bet­
ween the acute symptomatic CAD syndromes and measures of increased platelet 
activity (Chapter 1). Evidence supporting a similar association between increased 
platelet reactivity with stable CHD and/or atherosclerosis, is more tenuous. An 
established way to evaluate such a possibility is firstly to determine whether the 
characteristics in question occur more frequently or are greater in persons with the 
disease. Then, prospectively determine whether persons with the attribute(s) develop 
the disease more frequently than those without. Therefore, an initial evaluation of an 
hypothesis can be by the cross-sectional case-control study in which the characteris­
tics being examined are identified in both the cases and controls at the time of the 
data collection. The proportion of cases possessing the variables of interest is 
compared to the corresponding proportion in a control group. A higher prevalence of 
the study factors in cases compared with the controls indicates a possible association
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between these factors and the disease.
The question of causal inference between the study variables and the disease would 
need to be subsequently evaluated. This is particularly important when the study fac­
tors are physiological variables, which are more likely to be influenced by the dis­
ease itself, or by treatment.
Experimentation and determination of biological mechanisms provide the most direct 
evidence for causal relationships. Although such evidence is usually not available 
from case-control studies, the method can be used in epidemiological investigations 
to detect potential causal relationships between the variables and disease. Indeed, 
such methods are often the most appropriate, or even only methods, to investigate 
phenomena occurring in free-living intact humans. They may provide sufficient 
knowledge to justify more extensive evaluation or for the confirmation of existing 
information.
4.1.3 Definition of a Case
A case defines a group of individuals who have a disease which, as far as possible, 
is a homogeneous aetiological entity. Existing knowledge, whether manifestational, 
epidemiological or experimental, should be used to define such a homogeneous 
condition.473 Each eligible case in the target population should have an equal chance 
of inclusion in the study, irrespective of exposure to the study variable. In a popula­
tion based case-control study, cases have the study disease occurring within a de­
fined geographical area during a specified period of time. Ideally the case group 
should comprise a representative random sample of that population with the 
disease.370,470,471
4.1.4 Definition of a Control Group
The control group is used to compare the presence of an abnormality, or evidence of 
exposure to the variable(s) in question in the cases, with that in individuals who are 
free of the study disease. In fact, a control provides an estimate of exposure rate to 
the characteristics being studied among individuals free of the disease. This would 
be the expected rate in the cases if there were no association between the study 
disease and the variables. Accordingly, the control individuals should be not only 
free of the disease but similar to the cases with regards to the likelihood of exposure 
to the variables in question during the time period of the risk for the development of 
disease. The controls should also have an equal chance of selection, irrespective of 
the presence or absence of study variables. As with cases, the control group can be 
hospital-based or population based. Any factors which are already known to be 
associated with the disease must be taken into account. Even if an association is only 
strongly suspected, such a possible relationship should be matched or adjusted for in 
the analysis. It is also possible, even in random selection, that some factors may not 
be evenly distributed in the control population, particularly with smaller sample 
sizes.370,470,471
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4.2 LIMITATIONS OF CASE-CONTROL STUDIES
4.2.1 Disadvantages of Case-Control Studies
As with all cross-sectional studies, by definition, it is only possible to estimate the 
prevalence of disease, and not the incidence. The prevalence depends on a balance 
between the rate at which new cases arise and the rate at which established cases are 
removed from the population. The removal rate is dependent on recovery rate, 
mortality rate and factors such as migration. These and other limitations affecting 
cross-sectional studies also apply to case-control studies and, therefore, will affect 
the reliability of the analysis and, as a consequence, the conclusions.
An understanding of the possible confounding factors of the case-control methodolo­
gy is necessary, some of the more important being outlined below. Firstly, there is 
the potential for selective removal, such as the systematic omission of less healthy 
individuals leading to under assessment. Those subjects with the disease who are not 
characterised because of death may have different study features as compared to the 
survivors. Secondly, characteristics observed at the time of the study may not be the 
same as those present during the formation of the disease, the characteristics under 
study being altered by treatment or the illness. These difficulties with case-control 
studies arise from the fact that the methods involved proceed from the result to the 
cause and effect relationships, thus following a paradigm which is retrospective.471 
Thirdly, the cases and/or controls selected may not be representative of the disease 
in the population, or of the population as defined. This uncertainty in ascertainment 
presents the problem of selection bias. The assumption of complete representation 
would only be correct if all patients with the disease received attention or were 
detected, and the prevalence of the variables under study was the same in the control 
group as in the general population. Finally, it is not always possible to ensure that 
known confounding factors or study variables are equally distributed between 
groups. Some factor which is unidentified by the investigator may be responsible 
both for the exposure and the disease, being the outcome of the exposure. Blindness 
to outcome can be difficult to achieve, allowing observer bias to enter the compari­
sons. The inability of the method to assess the incidence of the disease, and the fact 
that it involves a late examination of those affected earlier, means those with fatal or 
short episodes will be missed. Mild or asymptomatic cases, and those in which 
evidence of exposure disappears or is modified by disease, may also be missed.
These examples of the disadvantages inherent in the case-control methodology illus­
trate the necessity to consider and identify the various sites of innate bias within the 
study. Also the possible, indeed one should assume probable, confounding factors 
which may distort the study results need to be delineated as far as is possible, prior 
to commencement of a study in order to make appropriate changes in the method and 
protocol.370,470,471,473,473 The areas of potentially major bias are discussed in detail in 
the following sections.
4.2.2 Bias in the Case-Control Study
In a case-control study, the compared groups need to be similar in all respects except 
for the outcome being investigated. This is to ensure that any difference found in the
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pertinent study characteristics is indeed a true finding and not distorted by bias. The 
principle of "ceteris paribus" can then be applied.471 Therefore, correct matching for 
major variables which may influence the variables being investigated must be incor­
porated into the design. Post-stratification can be used for less important confound­
ing variables, or for those factors with uncertain effect.370,470,471 To ensure the 
correct study design that takes appropriate care to avoid and to define any confound­
ing factors, it is necessary to systematically examine the design for each potential 
methodological bias.
4.2.2.1 Susceptibility bias. Susceptibility bias occurs at the selection of groups 
for comparison, and refers to the bias introduced into a study if the baseline groups 
have different prognostic expectations for the outcome of interest. Subjects in one 
group may have negative prognostic features, or alternatively, the "healthy worker 
effect", both of which can provide major disadvantages or advantages for the out­
come. This form of bias arises from problems such as self selection, suitable com­
pliance to the study, vulnerability to a manoeuver or attribute, and even patterns of 
referral or migration. Ideally, randomisation of the selection of subjects reduces the 
likelihood of differences in allocation producing disparate groups.
In case-control studies, susceptibility bias can be reduced by ascertaining all the 
cases within a population over a given period of time. The controls should then be 
randomly selected from the same population, differing in the outcome only. In the 
attempt to obtain perfect matching of cases, overmatching may be induced. This can 
reduce the validity or statistical efficiency of the case-control comparison, and in­
crease the cost and the complexity of a study. Matching variables should be selected 
from those that have the strongest relationship to the study disease. As mentioned 
previously, alternatives to matching will need to be applied to the analysis. In fact, 
the use of a combination of matching and regression analysis generally removes 
more bias than matching alone.370,470,471 Post-stratification of variables which may 
contribute to bias within the study and confound the results, and the application of a 
regression model, may be used in the design, rather than stratified sampling or 
frequency matching. The former two methods offer well validated alternative ap­
proaches.370,470,471
4.2.2.2 Performance bias. Performance bias can arise when the compared varia­
bles (or maneuvers) do not receive the same proficiency in the method of analysis 
(or administration). The attribute being studied may have been contaminated by the 
action of other known or unknown variables. One pertinent form of "performance" 
bias depends on the sensitivity and specificity of the methods of measuring the varia­
bles being examined. A negative result may be a false negative, as the method used 
may not be sensitive enough to detect a difference. This can arise from major vari­
ability of the characteristic over time, or the method used may not detect the appro­
priate abnormality. In order to minimise this particular bias, attempts can be made to 
keep the data collectors unaware of the main hypothesis. Also, the identity of the 
cases and controls may be hidden from those performing the measurement of the 
variables.370,470,471
4.2.2.3 Detection bias. Detection bias can be a source of major bias in the case- 
control design. It arises when the outcome is detected unequally in the groups being
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compared, but is mostly due to differences in medical surveillance. The surveillance 
of the groups to allocate cases and controls often requires diagnostic testing. Inequal­
ities can occur in the performance of diagnostic tests and also in their interpretation. 
If the cases are ascertained following a particular diagnostic test or clinical event, 
and the diagnostic test is highly sensitive for the correct diagnosis, then ideally the 
same investigation should be undertaken in the control group. In practice this may be 
impractical, if not unethical, depending on the investigation concerned. The detec­
tion bias in the controls may be overcome by using another control group who have 
undergone the diagnostic test concerned, and who have a normal result.
The existence of a co-morbid outcome (another outcome that can influence the vari­
able to be studied) may evoke increased medical attention, and influence the decision 
to undertake the diagnostic test used in the ascertainment of cases. The use of appro­
priately matched control groups, post-stratification of subgroups and/or regression 
analysis reduces this innate bias in the study design.370,470,471
4.2.2.4 Transfer bias. Transfer bias may occur in the groups collected for the 
comparison of their results. After the outcome has occurred, there may be individu­
als who are lost to follow-up. Therefore, different types of outcome for the attribute 
being examined, may not be suitably represented in the data collected which is to be 
used for analysis. This particularly applies to case-control studies, where the out­
come has occurred and the diagnosis of the outcome is the method of ascertaining 
the study group. Attrition of individuals with the outcome being examined, before 
inclusion in the case-control study, creates a group which is incompletely representa­
tive of the possible outcome group. This provides a source of bias difficult to coun­
teract. Such individuals may possibly have differing results for the study variables 
than those found in the survivors. Their enforced exclusion may distort the results in 
the study group, compared with the original intact population.
4.2.3 Means of Reducing Methodological Bias
4.2.3.1 Sampling procedures. Unbiased ascertainment of eligible cases and 
controls is the prime aim of selection procedures within a case-control design. The 
procedure used for selection of a sample must ensure that each individual in the 
population has an equal chance of appearing in the study. Therefore, the subjects in 
this study:-
1. were not identified by the individual’s exposure status in regard to the 
study factors, apart from the outcome (viz CHD).
2. are serial eligible cases arising within a defined period of time which 
were identified and asked to enter the study.
3. for the control group were selected and evaluated at the same time as 
the case group.
4. in the case and control group, individuals with conditions known to or 
which possibly may have predisposed to or against the study variable were excluded. 
Controls can be selected from a variety of sources to avoid the bias arising from dif­
ferences in the composition of groups for comparison.
Nevertheless, some forms of bias cannot be controlled for in a case-control study.471
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As discussed above, a protopathic (first the pathology) bias refers to that arising 
when the outcome has already taken place but is not adequately recognised before a 
manoeuver is allocated, or, the outcome has occurred and the consequence of this 
outcome is the attribute being studied.471
4.23.2 Selection of controls. Matching of controls involves pairing one or more 
controls to each case on the basis of their similarity with respect to preselected 
variables. Such variables considered for matching are those that are risk factors for 
the study outcome, independent of the study attribute. Individual cases and controls 
can be pair-matched for factors, so that each are alike except for the factor under 
investigation. The controls were defined specifically to be socioeconomically equiv­
alent to the case group. To avoid bias in comparing groups differing in composition, 
methods of selection such as adjustment procedures similar to age adjustment, were 
employed.
Some individuals in the control group may have subclinical CAD if the criteria for 
the clinical outcome is angiographic CAD. This study uses clinical criteria for the 
presence of CHD to select cases, and the absence of such criteria for the control 
group selection. Therefore the potential for misclassification of controls by disease 
status for angiographic CAD exists, but not for the presence of CHD. However, 
such misclassification will dilute the differences between the groups that result in the 
development o f CAD, but possibly may enhance the differences that result in the 
presentation in the form of CHD. Some degree of this form of bias must occur in all 
epidemiological studies with clinical endpoints, and the awareness of this bias will 
add caution to the inferences derived from the observations.474
An alternative to matching is the specific comparison for each variable by stratifying 
for each factor level (stratified sampling). Post-stratification of variables and regres­
sion analysis are two main alternatives to matching used in the case-control study 
from this work.
4.2.4 Guidelines Used for the Case-Control Study Design
4.2.4.1 Establish research hypothesis. Platelet hyperreactivity is an aetiological 
factor in the pathogenesis of coronary artery atherosclerosis enhancing the premature 
development of the disease. This hyperreactivity results in a primary increase in 
platelet function and arises from an inherited platelet functional abnormality, and/or 
occurs secondarily from the effects on platelet function of the major risk factors for 
CAD.
Platelet hyperreactivity is an aetiological factor in the premature development of the 
acute clinical manifestations of the various forms of symptomatic CAD. Increased 
reactivity may be a primary abnormality, possibly inherited, and/or secondarily due 
to the effects of risk factors on platelet function.
4.2.4.2 Establish aims for the hypotheses. The aims of the research which arise 
from this hypothesis involve the investigation of platelet function in young individu­
als at increased risk for the development of CAD. It was necessary to determine if 
platelet dysfunction exists in young persons (age < 50 years) with proven CAD. If
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measurable differences in platelet function were to be found, an evaluation of wheth­
er they were a secondary effect resulting from an association with other factors such 
as the major CHD risk factors was undertaken.
4.2.4.3 Define the study variables before commencement. Variables examined 
for an association with the disease outcome (platelet function variables) are defined 
in Chapters 2 and 3. It was particularly important to determine areas of bias due to 
possible confounding variables in order to define those variables required for match­
ing, to establish admission criteria and define exclusion criteria.
4.2.4.4 Define admission and exclusion criteria. The locus in the time scale of 
the disease for this study was after the diagnosis, and ipse facto, after the clinical 
manifestation of the disease (unless the diagnosis was achieved before the clinical 
manifestation due to confounding variations of the medical surveillance of the dis­
ease). The baseline state of the disease in the study protocol was clinically manifest 
disease and the CAD was objectively evaluated by coronary angiography.
Admission criteria depend on the hypothesis and baseline state of the study disease, 
and include:-
1. Age less than or equal to 50 years of age
2. Documented myocardial infarction (pain with ECG changes and 
cardiac isoenzyme rise) or other clinical manifestation such as stable
or previous unstable angina.
3. Angiographically proven CAD
4. Males only study groups
5. The cases were not selected if the diagnosis was made as an 
incidental finding, but only after presenting with clinical events.
The clinical status and the possible confounding factors of the patients were fully 
documented at the time of entry to the study. The exclusion criteria were predeter­
mined and based on the same principles of exclusion as used in a randomised clinical 
trial (defined in Chapter 3).
4.2.5 Conclusions.
The evaluation of bias is an important requirement for planning and appraising the 
results of any case-control study. The studies reported in this Chapter will concen­
trate on some potentially major areas of bias in the design of the study. Other poten­
tially confounding factors occurring in the analysis of the results which may contrib­
ute substantially to further bias in the outcome of the study are evaluated and dis­
cussed in Chapters 5 and 6, and Appendices 1,2 and 3.
4.3 PLATELET FUNCTION AND MYOCARDIAL ISCHAEMIA
4.3.1 Introduction
Pathological studies and clinical research have clearly demonstrated that platelets are
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involved in the development of the acute obstructive ischaemic clinical syndromes of 
CAD.24,26,27,40,41,45,59,115,280,475 The question, however, of whether platelet activation 
and myocardial ischaemia are associated in those individuals with chronic stable 
CHD, or in those who have provocable myocardial ischaemia, is important for the 
selection of subjects when evaluating platelet function. It is possible that when blood 
flow increases in the presence of significant narrowing of the epicardial coronary 
arteries platelets are activated and aggregate more easily.476
Numerous methods of measuring platelet function have been used to investigate such 
a relationship. The release of platelet specific proteins in response to exercise in­
duced m yocardial ischaem ia has yielded conflicting results.477'486 There is little 
available inform ation on TXB2 levels in serum or plasm a follow ing exertional 
ischaemia, and those reports available give divergent results.487'489 An increased in 
vitro aggregation response to ADP following exercise has been a more consistent,489' 
491 but not universal finding.479 These discrepancies require further clarification.
This section evaluates the effect of short term vigorous exercise, and exercise in­
duced myocardial ischaemia, on specific measurements of platelet function in pa­
tients with CHD. Procedural standardisation, patient selection, medications, severity 
of CAD, and CHD risk factors are particularly emphasised. Variations in such fac­
tors may have contributed to previous conflicting findings. Moreover, this investiga­
tion aimed to determine whether, in the selection of subjects for the case-control 
study, the exclusion of those with exercise-induced myocardial ischaemia was neces­
sary since platelet actviation might be present in those with myocardial ischaemia but 
not in those without. This is also of clinical importance given the increased risk of 
sudden death during acute and unaccustomed exercise in individuals with CHD,492' 
494 and the demonstration of thrombosis and platelet aggregate formation in patients 
with ischaemic sudden death.26,27
4.3.2 Methods
4.3.2.1 Patient population. The study consisted of 27 male subjects with proven 
CAD, who were asymptomatic, or had chronic stable angina. In 25 patients CAD 
was proven by coronary arteriography (at least one lesion with a luminal narrowing 
> 50%), and 2 patients had an AMI documented by new Q wave formation on their 
ECG and an associated rise in the creatine kinase MB isoenzyme. The mean age of 
the group was 53 years, ranging from 35 to 69 years. Stable angina was defined as 
exertional chest pain with no rest pain,472 without an increase in severity or frequen­
cy, and with stable functional capacity. Group I consisted of 13 patients with exer­
cise induced ECG changes of myocardial ischaemia. The 14 patients in group II had 
neither symptoms nor exercise induced ECG changes to indicate active exertional 
m yocardial ischaemia. Specific exclusion criteria were applied to perm it accurate 
interpretation of exercise ECG changes, to reduce confounding factors interfering 
with the platelet function studies, and to ensure maximum safety for the patients 
(Table 4.1).
4.3.2.2 Study Protocol. The study protocol was approved by the hospital ethics 
committee, and informed consent was obtained from each patient before participa­
tion. All drugs were ceased for at least 5 days before an exercise treadmill test, apart
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from sublingual nitrates taken as required. Aspirin and nonsteroidal antiinflamma­
tory drugs were ceased for at least 2 weeks. All patients underwent a maximum 
treadmill test, blood being taken immediately before and after the test. They then 
commenced routine antianginal drugs for 4 weeks, with no antiplatelet drugs of any 
form being taken. Of the original 27 patients, 24 again ceased all medications, apart 
from sublingual nitrates, for a minimum of 5 days before undergoing another tread­
mill test. The repeat exercise tests were to the same workload as the first, under the 
same conditions, and at the same time of day.
4.3.2.3 Exercise Protocol. The exercise protocol is described in section 2.12.
4.3.2.4 Laboratory Investigation. Blood was taken before and after each exercise 
test using minimal stasis and a 19 gauge "butterfly" needle with a 15 cm plastic tube. 
The measurement of plasma TXB2, BTG, serum TXB2, the PCR and the haemato- 
logical indices are fully described in Chapter 2.
4.3.2.5 Coronary angiograms. The coronary angiograms were graded according 
to a semi-quantitative scoring method.207 A full description and validation of the 
methods is provided in Chapter 8.
4.3.2.6 Data Analysis. The differences between means of dependent samples 
were tested using the paired t-test, and a comparison between group means was 
made by the two sample t-test for all continuous variables apart from BTG and 
serum TXB2, which had skewed distributions. Linear correlations were measured by 
Pearson’s correlation coefficient. For plasma BTG and serum TXB2, differences 
between paired samples were tested with the Wilcoxon matched pairs signed-ranks 
test, and correlations were measured using the Spearman rank correlation coeffi­
cient.
4.3.3 Results
4.3.3.1 Patient Profile (Table 4.2). Those with a positive exercise test were 
older and had a significantly lower left ventricular score (LVS) indicating fewer 
segmental wall motion abnormalities of the left ventricle. Those with a negative 
exercise test had a higher coronary stenosis score (CSS) due to a greater number 
having total coronary artery occlusions, but for the number of patients studied this 
difference did not attain statistical significance. There were no differences between 
the two groups in the amount of cigarette smoking, levels of the blood lipids, body 
weight and the extent of coronary atherosclerosis expressed as the coronary athero­
matous score (CAS) and the mean CAS (mCAS). No patient had leg claudication, 
and all had palpable peripheral pulses.
4.3.3.2 Plasma BTG and TXB2. There were no differences in the resting 
plasma TXB2 levels between the two groups, nor was there a detectable change in 
plasma TXB2 levels following maximum exercise. In 54% of the samples, the 
plasma TXB2 levels were below the sensitivity of the RIA of 40 pg per ml. The 
measurement of small amounts of plasma TXB2 (between 40 and 100 pg per ml) did 
not distinguish the ischaemic from the non-ischaemic group, nor the pre and post 
exercise samples.
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The resting BTG was the same in both groups. Following exercise, there was a 
small but significant increase in the BTG level. This occurred in both groups in the 
second treadmill test, although only in the negative test group with the first exercise 
test (Fig 4.1).
4.3.3.3 Serum TXB2. There was a small but significant increase in the formation 
of TXB2 in serum following exercise. However, this increase only occurred in the 
ischaemic group, and was not observed in non-ischaemic group (Fig 4.2). The rest­
ing serum TXB2 levels in the ischaemic group was significantly lower than the level 
in non-ischaemic subjects (Fig 4.2).
4.3.3.4 Platelet count ratio (Table 4.3). The PCR was consistently lower in the 
non-ischaemic group at rest, but this difference was not statistically significant. A 
decrease in the PCR following the first treadmill test, was observed in the non- 
ischaemic group but not in the ischaemic group. This change was not reproduced in 
the subsequent treadmill test.
4.3.3.5 Blood Cell Indices (Table 4.4). There was a significant increase follow­
ing exercise in the Hb, the He, the platelet count (PC) and the WCC, in both study 
groups. The values were the same for the ischaemic and non-ischaemic groups at 
rest and after exercise.
4.3.4 Discussion
For the appropriate conduct of a case-control study to evaluate platelet function in 
patients with stable CHD, it was necessary to determine if symptomatic or inducible 
ischaemia influenced platelet function since this could be a potential source of bias. 
A clinically important role has been clearly demonstrated for the involvement of 
platelets and thrombus in the acute occlusive ischaemic syndromes of unstable angi­
na, AMI and sudden ischaemic death.24,26,27 However, numerous studies of the role 
of platelets in effort induced myocardial ischaemia have produced conflicting results. 
Not only does a cause-effect relationship between platelet activation and exercise 
induced ischaemia remain unresolved, but indeed, even the presence of measurable 
changes has not been consistently demonstrated.
In addition to the requirements of conducting the case-control study, this study 
allows an evaluation of in vivo platelet function with exercise in patients with exer­
tional ischaemia and therefore may contribute to an understanding of mechanisms 
resulting in the increased risk of sudden death associated with exercise in individuals 
with CHD. Indeed, the results of this study indicate that during exercise-induced 
myocardial ischaemia in a stable CHD population, platelets are not activated as 
assessed by the parameters measured. In particular, measures of in vivo platelet 
function were unaffected by the presence or absence of exertional myocardial 
ischaemia. The results support previous work showing no relationship between exer­
tional ischaemia and plasma TXB2488 or plasma BTG levels.481
An increase, however, in plasma BTG following exercise has been previously 
documented.495 In the present study, the plasma BTG clearly increased in those 
individuals undergoing maximal exercise and the increase in the ischaemic group
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was attenuated. Those with negative exercise tests were able to exercise to work­
loads which were maximal or near maximal for their age. In contrast, those with 
evidence of myocardial ischaemia attained lower levels of exercise, were limited by 
their cardiac response to exercise, and were below their predicted achievable work­
load. If the increase in BTG is a non-specific response to exercise itself, those with 
limitations due to ischaemia may not perform sufficient work to elicit an increase in 
BTG, even though the workload was sufficient to cause an increase in the platelet 
count, Hb and He.
The effect of exercise on the PCR in patients with CHD remains unresolved. A 
significant overall decrease in the PCR following exertion in the first treadmill test 
could not be reproduced in the third test under similar conditions. The reason for 
this is not apparent, but may be due to a training effect occurring between the two 
treadmill tests, or alternatively, to variability in platelet reactivity over time. The 
resting PCR in patients with CAD was previously shown to be significantly lower 
than in normal subjects.496 In that same study, following short-term strenuous exer­
cise, the PCR decreased in the CAD patients irrespective of the presence of ECG 
changes of myocardial ischaemia.496 In our study, the decrease in the PCR in the 
first treadmill test predominantly occurred in the non-ischaemic group. The PCR did 
not decline in those with exertional ischaemia, indicating that platelets do not 
become more reactive following exertional ischaemia, as measured by this method. 
It is possible, however, that platelet aggregation measured by whole blood aggrega­
tion methods may be influenced by pacing induced tachycardia,476 although this is 
controversial.44,497'501
Measurement of TXB2 is used as an estimate of the activity of platelet prostaglandin 
metabolism. Serum TXB2 provides a measure of the platelet response to endogenous 
agonists during ex vivo clotting. These agonists may be present before the clot is 
formed and/or produced during its formation. In this study, those individuals who 
had objective evidence of ischaemia, produced less TXB2 in serum, but had a 
modest increase following exercise. This increase was not apparent in the non- 
ischaemic group, who also had significantly higher resting levels of serum TXB2. 
Reuben and colleagues did not find an increase in serum TXB2 after exercise in a 
group of patients with CAD who had a positive exercise test for myocardial ischae­
mia.489 However, their exercise test was a symptom limited treadmill test, exercise 
being ceased with the first onset of angina. All patients were receiving conventional 
anti-anginal medications which were continued throughout the study, and it is possi­
ble that these drugs prevented any increase in serum TXB2.502 The plasma TXB2 
levels did not relate to exercise or exercise-induced ischaemia. The plasma TXB2 
levels however may not reflect true circulating TXB2 levels, its presence being due 
to technical factors, such as release during blood collection.503
An explanation of the changes observed in the serum TXB2 levels cannot be deter­
mined from this study. One possibility, however, is that increased substrates are 
formed during exercise induced ischaemia which will increase prostaglandin metabo­
lism by those cells involved in the clotting process. A similar increase in prostaglan­
din activity may occur during reversible platelet aggregation and/or non-obstructive 
thrombus formation on ruptured atheromatous plaque, and so increase localised 
thrombus formation.
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A lower serum TXB2 was evident in the ischaemic group. This reduced production 
of TXB2 with clotting in patients with known inducible myocardial ischaemia has 
also been observed by others.489'504 It is possible that intermittent platelet activation 
may be occurring in patients with active myocardial ischaemia, depleting the poten­
tial for serum TXB2 production. Nevertheless, there is no evidence to support this 
suggestion from those measures of in vivo platelet activation in this population with 
exertional ischaemia. There was no significant difference between platelet counts or 
cholesterol levels in the two groups to account for the difference.504,505 The differ­
ences found in platelet function cannot be attributed to the severity of CAD. There 
was no significant difference in the extent of coronary atheroma in the two study 
groups as measured by the mean CAS. Even though there was a tendency in the 
group with a negative exercise test to have a higher stenosis severity score (mean 
CSS), in vivo platelet reactivity was the same as for the ischaemic group. The group 
with positive exercise tests, who were older, may have more extensive peripheral 
vascular disease to account for the differences in serum TXB2. However, there were 
no clinically detectable differences, and again, measures of in vivo platelet activation 
were the same in both groups. The higher serum TXB2 in the non-ischaemic group 
may be age related, given the significantly younger age of the non-ischaemic group.
The haemoconcentration, increase in white cell numbers and rise in peripheral plate­
let numbers which occurred with exercise, have been previously well documented 
and substantiated.347,506 The changes in the blood cell indices occurred in both 
groups, with greater changes occurring in those attaining higher workloads.
4.3.5 Summary
1. In light of the foregoing observations, in order to detect a measurable 
difference in in vivo platelet function between young males with CHD and a normal 
control group, the exclusion of subjects with ongoing measurable myocardial 
ischaemia is not required.
2. Short-term maximally strenuous exertion may cause activation of plate­
lets irrespective of the presence of ischaemia. The avoidance of such exertion in rou­
tine unmonitored activity by CHD patients is advised for many important cardiologi­
cal reasons, and possible platelet activation may be an additional factor. Whether 
antiplatelet drugs will help to reduce the incidence of adverse consequences associat­
ed with such exercise remains to be determined.
3. Exercise-induced myocardial ischaemia does not appear to activate 
circulating platelets, nor are previously activated circulating platelets associated with 
exertional ischaemia.
4. It is possible, however, that including subjects with exertional ischae­
mia will reduce the possibility of detecting a difference in serum TXB2, since those 
with exertional ischaemia may produce less TXB2. Therefore, if a difference is 
demonstrated between the case and control group to be evaluated, then it is more 
likely to be a true difference.
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4.4 PLATELET FUNCTION AND ANTI-ISCHAEMIC MEDICATIONS
4.4.1 Introduction
An inhibitory effect of beta-blockers on platelet function has been clearly demon­
strated in vitro at relatively high concentrations507'510 and also at therapeutic concen­
trations.510 However, conflicting data exists as to the effect of orally administered 
therapeutic doses of beta-blockers in normal individuals,509'515 and in those with 
CHD.483,491,516 In vitro inhibitory effects of calcium entry blockers on platelets have 
also been well documented,517'526 although controversy has also arisen regarding 
evidence for an effect in persons receiving oral calcium entry blockers.521,527'529 In 
vitro studies have demonstrated different modes of action for these two group of 
drugs on platelets. Thus, a combination of beta-blockers and calcium entry blockers 
may be sufficiently effective in suppressing platelet activity in vivo to be measurable. 
Furthermore, in vitro findings may not reflect the in vivo effects because of artifacts 
inherent in the preparation of PRP530 and metabolic changes in other blood compon­
ents which may influence platelet activation such as the release of ADP from red 
blood cells.349 Clearly, in vitro findings cannot be equated unquestionably to the in 
vivo situations, which must be evaluated specifically and independently. The inhibi­
tion of in vitro platelet function by nitrates has also been the subject of frequent 
reports.531
In the selection of subjects for a case-control study, it is of importance to determine 
whether or not it is necessary to stop cardiac medications used by the volunteers. 
This study therefore examines the in vivo effects of a combination of a beta-blocker 
(metoprolol) and calcium entry blocker (nifedipine) on platelet function at rest and 
after exercise. The effect of these anti-ischaemic drugs on platelet function before 
and after exertional ischaemia was also evaluated.
4.4.2 Methods
4.4.2.1 Patient population. The study population is the same group described in 
section 4.2.2.1, and the results constitute part of a single study.
4.4.2.2 Study Protocol. The methods have previously been described in full 
detail298 and in section 4.2.2.2. Importantly, all drugs were ceased for at least 5 days 
before the first exercise test. Aspirin and nonsteroidal antiinflammatory drugs were 
ceased for at least 2 weeks. Blood was sampled immediately before and after each 
maximal exercise test. After the first exercise test, 26 of the volunteers commenced 
metoprolol 50 mg twice daily and nifedipine 10mg three times daily for approximate­
ly 4 weeks. The patients were then exercised at the same time in the morning, 1.5 to 
2 hours after taking the medications. Then 24 patients stopped the medications for a 
minimum of 5 days before undergoing a third treadmill test. Three patients withdrew 
for reasons unrelated to the study or drug side effects. All subjects performed a 
maximum treadmill exercise test.
4.4.2.3 Investigations. The laboratory investigations and angiographic scoring 
details are described in Chapters 3 and 8 respectively.
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4A.2.4 Data Analysis. The data analysis methods are described in Chapter 2 and 
section 4.2.2.
4.4.3 Results
4.4.3.1 Plasma BTG and TXB2. The resting BTG level was slightly higher in 
the group with positive exercise tests whilst not on medication, but the difference 
was not significant (Fig. 4.4). Following exercise there was a small but significant 
increase in the BTG levels, which occurred in both the positive and negative stress 
test groups in the second and third treadmill test, although only in the negative test 
group for the first exercise test (Fig. 4.4). A significant increase in plasma BTG 
level in both groups following exercise was not altered by the study medications 
(Fig.4.4).
No difference was observed in resting plasma TXB2 levels between the two groups, 
nor were there detectable changes in plasma TXB2 levels following maximum exer­
cise. The medications had no measurable effect on the plasma TXB2 levels before or 
after exercise.
4.4.3.2 Serum TXB2. A modest but significant increase in TXB2 levels with 
exercise was observed in both tests without medications, and this increase was 
diminished in the presence of the study medications (Fig. 4.5). This small but signif­
icant increase in the formation of TXB2 in serum following exercise occurred in the 
ischaemic group, but not in non-ischaemic group (Fig. 4.5). There was also a signif­
icantly lower level of the resting serum TXB2 in the ischaemic group compared to 
the non-ischaemic subjects (Fig. 4.5).
4.4.3.3 Platelet count ratio. The PCR decreased following exercise in the initial 
exercise test without medications. This decrease was not reproducible in the third 
exercise test without the study medications. No significant change was demonstrated 
in the PCR whilst subjects were on medications (Fig. 4.3). The PCR was consistent­
ly lower in the non-ischaemic group, but this difference did not attain statistical 
significance. The mean PCR at rest was the same in subjects with or without medica­
tions, and when they were divided into positive or negative exercise groups (Fig. 
4.3).
4.4.3.4 Blood Cell Indices. The medications had no affect on these variables at 
rest or after exercise (Table 4.4).
4.4.4 Discussion
Anti-platelet therapy has been clearly identified as having a protective effect follow­
ing acute ischaemic coronary events.97,98,104 An in vitro inhibitory effect on platelet 
function by both beta-blockers and calcium  entry blockers has been well 
established.507'509,510,517,519'526. The in vivo effects on platelets of these classes of 
drug are less well defined and controversial.509,511"515,521,527'529
In the previous section, evidence was provided that in patients with stable CHD 
exertional myocardial ischaemia does not activate circulating platelets.298 This result
78
confirmed previous reports485 and has subsequently been verified by another 
study.532 Predictably, specific anti-platelet drugs have no significant effect on objec­
tive measures of exertional myocardial ischaemia in patients with chronic stable 
angina.533 However, our observations suggested that brief strenuous exercise with 
the induction of myocardial ischaemia creates a milieu in whole blood which leads to 
increased TXB2 release during in vitro thrombus formation.298 Unstable angina is 
associated with disease p rogression ,114,534 intracoronary thrombus 
formation,23,26,115,535,536 and also the production of increased amounts of excreted 
thromboxane metabolites.537,538 Moreover, pathological evidence exists for the 
involvement of thrombus in disease progression.34,539
Given that thrombus formation may be involved in the formation of new stenoses 
and occlusions, a mechanism for drugs to prevent such lesion development is to 
contribute to the inhibition of thrombus formation. The combination of a beta-block­
er and a calcium entry blocker is more effective in the prophylactic treatment of 
symptomatic CHD than the use of single drugs.540 Beta-blockers reduce the in­
cidence of recurrent CHD events after an AMI, including the thrombotic event of 
recurrent MI.541,542 However, calcium entry blockers have not as yet been shown to 
be effective against further obstructive ischaemic events after an acute myocardial 
infarct,543 except possibly in specific subsets of patients.544 Yet, as discussed, they 
appear to lessen the development of new occlusive lesions in patients with 
CHD.545,546 Some understanding of the mechanisms of the anti-ischaemic effect of 
these drugs has been provided following extensive investigation,547 although the 
m echanism (s) for the possible secondary preventative effect has not been 
clarified.546,548 An inhibitory action on platelet reactivity and a reduction in a con­
tinuing thrombotic tendency, is one possible contributing mechanism that requires 
further investigation.
The results fail to demonstrate any effect on specific measures of in vivo platelet 
function by the combination of a beta-blocker and calcium entry blocker. Plasma 
TXB2 and BTG levels at rest did not change. A modest increase in plasma BTG 
levels with exercise was unaffected by the addition of the medications or the pres­
ence of exertional ischaemia. An initial significant difference between the PCR 
before and after exercise was not reproducible in the repeat test without treatment. It 
is possible that the repeat test without medication by chance failed to demonstrate a 
true difference. However, this is probably unlikely, the repeated measures of the 
PCR may represent the phenomenon of regression to the mean.549 In the absence of 
a control or placebo group, the average of two or more measures for classification of 
the initial variable for comparison can be used.550 Using this method to reduce the 
effect of regression in the PCR measures, that is averaging the values for the first 
and third measurement when not on treatment, then there is no difference before and 
after exercise, and with and without treatment.
Following exercise, the serum TXB2 levels increased significantly in the group with 
a positive exercise test but not in the group with a negative exercise test.298 Although 
the increase in serum TXB2 level was small, the change within the group was clear­
ly attenuated by the drug combination. Serum TXB2 measures prostaglandin activity 
of blood cells during thrombus formation ex vivo. The production of prostaglandin 
metabolites will be influenced by platelet agonists present in the blood, or formed
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during thrombus production. Suppression of TXB2 formation may arise from a 
number of factors, including a reduction in agonist concentration, reduced platelet 
prostaglandin metabolism, and/or reduced platelet response to endogenous agonists. 
The beta-blocker propranolol in vitro appears to have inhibitory activity on BTG 
release and TXB2 production by whole blood and on spontaneous clotting at concen­
trations near the therapeutic range.510 This may be due to an inhibition of collagen 
and thrombin-induced platelet aggregation and TXB2 synthesis.510 The present find­
ings are consistent with these in vitro observations, although the mechanism of the 
effect of the drug combination on platelet prostaglandin activity measured ex vivo 
cannot be deduced from this study. Inhibition of platelet function in vivo following 
the infusion of isosorbide mononitrates at increasing does has been reported and 
includes a reduction in TXB2 production in PRP following agonist induced aggrega­
tion.531 The degree of inhibition was related to the rate of the infusion and it was 
concluded that the variability of the functional platelet response was related to the 
haemodynamic response.531 Eight of 11 patients in the study population had stable 
CHD with exercise ECG changes of myocardial ischaemia but characterisation 
according to the presence of inducible ischaemia was not reported. However, the 
observations suggest a relationship to the decrease in BP. Therefore it is possible 
that the abolition in the increase in serum TXB2 is related to the decrease in BP 
response to exercise whilst on the study medications rather than a direct effect on the 
platelet.
The explanations for the increased serum TXB2 production after exercise in ischae­
mic patients cannot be determined from the current study. However, it would appear 
from the lack of response seen with the measures of in vivo platelet activity, that this 
increase is unlikely to be due to an increase in circulating platelet activation. It is 
when platelets are activated during thrombus formation ex vivo, following exertional 
myocardial ischaemia, that a capacity for increasing thromboxane production occurs. 
Should this increase in prostaglandin production occur during thrombus formation in 
vivo, then a greater stimulus would be available for propagation of thrombus. 
Whether or not the combination of drugs contributes to a reduction in platelet pros­
taglandin activity in vivo and diminished thrombus propagation during endothelial 
desquamation, or atherosclerotic plaque rupture, can only be speculative.
The results of the International Nifedipine Trial on Antiatherosclerotic Therapy 
(INTACT) study confirmed previous experimental studies demonstrating a signifi­
cant reduction in newly formed coronary artery lesions (stenoses and occlusions) in 
patients on nifedipine compared to placebo, especially in the presence of early 
CAD.546 A proposed explanation, which will be briefly stated and elaborated on 
subsequently, ensues from the proposal that disruption of small atherosclerotic 
plaques with subsequent mural thrombosis and fibrotic organisation of thrombus 
seems to contribute to the progression of atherosclerosis.32 Firstly, nifedipine reduc­
es the development of new lesions.546 Our results show that the combination of 
nifidepine and metoprolol reduces the amount of thromboxane produced during 
whole blood clotting ex vivo. Progression of CAD involves new lesion formation 
that is not entirely related to the underlying atherosclerosis, implicating additional 
mechanisms such as thrombosis. Pathological evidence exists for the involvement of 
thrombus in disease progression.34,539 and clinical syndromes (unstable angina and 
AMI) are associated with new lesion development, in association with a fissured
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plaque, and increased thromboxane production. Moreover, increased TXB2 produc­
tion occurs in whole blood clotting in the presence of provoked ischaemia.298 There­
fore, a reduction in throm boxane production m ight reduce the likelihood of the 
production of those new CAD lesions that involve thrombosis.
Such a scenario implies that disease progression, particularly the formation of dis­
crete lesions, has a major non-atherosclerotic component, namely thrombus forma­
tion. The following brief review of disease progression, as interpreted from angio­
graphic studies, supports this concept. Despite being able to say which areas of the 
vessel have a common site of progression,551 the use of previous angiogram s to 
predict which vessels in an individual would be involved in progression has not been 
reliable.552 In fact, not only does knowledge of the initial pathology not provide the 
ability to accurately predict progression, but the frequency of progression does not 
appear to be related to the initial number of vessels with greater than 50% luminal 
obstructions or lum inal occlusions.552 Furtherm ore, although angiographically  
normal coronary arteries have a low rate of progression,553 those with some intralu­
minal disease without a significant luminal obstruction have a rate of progression 
almost equivalent to those with established CAD.554 Undoubtedly progression occurs 
in old existing atheromatous lesions. However, new areas of significant narrowing 
frequently occur in previously apparently normal segments555 and the progressive 
nature of the disease is quite episodic.556 Indeed, progression of occlusive CAD 
occurs commonly in areas that have previously been minimally diseased in patients 
w ith o u t in it ia lly  c lin ic a l d isea se  re q u ir in g  a PTCA  or c o ro n a ry  bypass 
grafting.555,557,558. Anatomical studies have shown that a substantial percentage of 
lesions associated with coronary artery thrombosis and AMI are moderate in severi-
ty  12,559
In summary, a high incidence of progression of CAD in vessels that are normally 
minimally diseased has been well documented.20,555,557,558,560 although the progres­
sion  to to ta l o c c lu s io n  a lso  o ccu rs  fre q u e n tly  in very  sev e re ly  n a rro w ed  
lesions.21,43,555 The progression of coronary atherosclerosis is a highly unpredictable 
process that follows a non-linear course and information about its dynamics derived 
from sequential coronary arteriograms hardly improves prediction of future progres­
sion.561 Knowledge of the initial pathology does not allow accurate prediction of 
where new lesions will occur.551,562,563 In addition, there appear to be time depend­
ent and time independent factors.551,564 The time dependence does not appear to be 
present for those developing unstable angina and progression compared with individ­
uals having chronic stable angina and disease progression.
4.4.5 Summary
1. There is no evidence of activated circulating platelets following exer­
tional ischaemia and no measurable effect of the drug combination of metoprolol and 
nifedipine on in vivo measures of platelet activity.
2. An increase in prostaglandin biosynthesis ex vivo in whole blood asso­
ciated with exercise induced myocardial ischaemia is attenuated by a combination of 
a beta-blocker and a calcium entry blocker. The drugs may produce their effect by 
reducing myocardial ischaemia, BP or, alternatively, by directly decreasing blood
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cell prostaglandin formation.
3. In addition, it may be possible that a reduction of whole blood prosta­
glandin activity during thrombus formation in individuals with myocardial ischaemia 
may contribute to the protective effect of these drugs against acute, and transient 
obstructive thrombotic coronary episodes.
4. For evaluation of platelet function in a cross-sectional study, such a 
potentially confounding factor will not be a major bias. For patient safety, all car­
diovascular medications were not ceased beforehand. This allowed the serial selec­
tion of patients with stable premature CHD, rather than waiting and only selecting 
patients without medications, or who are sufficiently stable to ethically stop medica­
tions.
4.5 VARIABILITY OF SERUM TXB2 LEVELS AND INTERACTION
WITH OTHER PLATELET FUNCTION TESTS AND BLOOD 
CELL INDICES
4.5.1 Introduction
The significance of variability in the production of thromboxane in clotting whole 
blood, and indeed, whether there is any variability at all, remains controversial. In 
some clinical syndromes with altered platelet activation, the capacity of platelets to 
form thromboxane in serum remains unchanged, although biosynthesis in vivo 
appears to be increased.332,565,563 This is not surprising given that the normal rate of 
thromboxane synthesis in vivo only represents a fraction (probably less than 0.1%) 
of the capacity of platelets to generate thromboxane.565 Furthermore, pharmacologi­
cal inhibition of serum thromboxane formation must be virtually complete before 
thromboxane dependent platelet activation is influenced in vivo.565 The use of serum 
TXB2 measurements may be of value as a guide to the adequacy of dosage with 
platelet-inhibitory drugs by providing a measure of cyclo-oxygenase inhibition.503,565 
Indeed, the inhibition of whole blood TXB2 production by platelet-inhibiting drugs 
may give a measure of platelet function inhibition in individuals with increased plate­
let activation and aggregability when exposed to an appropriate stimulus. Other than 
these latter two possibilities, no clinically useful role for the measurement of serum 
TXB2 has been elucidated.
4.5.1.1 Whole blood clotting and thromboxane B2 formation. Variation in the 
maximum amount of TXB2 produced by platelets during clotting ex vivo may have 
no clinical relevance. Nevertheless, in vitro experiments indicate that the maximum 
amount of TXB2 that can be produced may vary. For example, exogenous thrombin 
will further increase the amount of TXB2 produced.566 Moreover, when human 
platelets are treated with thrombin to induce the release of their alpha and dense 
granule constituents, additional TXB2 can be formed in response to other platelet 
agonists, albeit less than by platelets not depleted of their granule contents.567 In 
contrast, arachidonic acid induced TXA2 formation does not differ between throm­
bin-treated platelets and non-treated platelets,567 and the addition of extra thrombin 
produces significantly less TXB2 by thrombin-treated platelets than by control
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samples.568 Furthermore, collagen stimulation leads to reduced TXB2 formation in 
degranulated platelets, but more TXB2 is produced than when thrombin is used as 
the agonist with the same platelets.567 Pretreatment of platelets with thrombin does 
not lead to recovery with respect to thrombin inducible TXB2 synthesis when plate­
lets are incubated in the presence or absence of exogenous arachidonic acid.568 
Indeed, impaired thromboxane synthesis in pre-activated platelets may result from an 
agonist-specific, irreversible desensitisation to thrombin.568 These experiments in­
dicate that the production of thromboxane is, in part, dependent on prior exposure to 
platelet agonists, in particular thrombin.
Therefore it would appear that substrate availability and/or degree of agonist stimu­
lation, and not the enzyme system, is the limiting factor in the production of TXB2 
in serum. The observations demonstrate the very real potential for platelet agonists 
and metabolic substrates of thromboxane to influence the ability of platelets to form 
TXB2 leading to variability in TXB2 formation in association with clotting.
4.5.1.2 Thromboxane Synthesis in Different Diseases. Diabetics may have an 
altered capacity to generate TXB2 in clotting whole blood.569 Subjects with non-insu­
lin dependent (NIDDM) and insulin dependent diabetes mellitus (IDDM) have both 
been found to have a reduced capacity to synthesise TXB2 in response to endog­
enous stimuli released during whole blood clotting with the synthesis of TXB2 being 
influenced by the degree of diabetic control.569 Others however, have found that 
platelets obtained from subjects with NIDDM synthesise significantly higher 
amounts of TXB2 than those with IDDM and matched controls.570 Yet again, in 
another study, the ability to generate TXB2 did not differ between diabetics and 
controls.571 The platelets from diabetics with microangiopathy or from diabetics 
taking oral hypoglycaemic agents produced reduced amounts of TXB2 during clot­
ting.571 Additionally, a wide variability is present in all the groups studied, and there 
is a significant overlap in values for individuals.
Reduced platelet TXB2 formation has been noted in patients with renal failure.566,572. 
In uraemic patients, there may be up to a 60% decrease in TXB2 formation in clot­
ting whole blood.566 Exogenous thrombin failed to restore normal TXB2 production 
in uraemic patients, whereas TXB2 production increased upon the addition of 
thrombin to serum in normal subjects. These characteristics are consistent with a 
functional defect of the enzyme cyclooxygenase. In another study, patients with 
chronic renal failure produced less serum TXB2 than age- and sex-matched 
controls.572
An important influence on the production of TXB2 in serum appears to be the other 
cell constituents in blood. For example, the reduction in TXB2 synthesis observed in 
association with renal impairment occurred in the presence of a lower He and a 
different platelet count.572 This study indicates that the decrease in TXB2 production 
may not be due to a cyclooxygenase defect, but rather to differences in other blood 
parameters which could influence TXB2 production, including He and platelet 
count.572 Indeed, there is evidence to suggest that TXB2 formed during clotting 
should be divided by the platelet count.572,573 It would appear that there is a depend­
ence of TXB2 production in PRP on the platelet count.573 The TXB2 production in 
clotting whole blood in normal subjects also appears to be related to the He and the
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platelet count.572
Soon after an AMI, male patients with no other diseases present, when compared to 
an age- and sex- matched control group, show a large decrease in platelet cyclooxy­
genase end-products formed during clotting of whole blood.574
4.5.1.3 Intra-individual variability in normals. Some studies suggest that in 
normal subjects there is no clinical or statistically significant correlation between 
serum TXB2 levels and age, BMI, BP, tobacco use, cholesterol level, triglyceride 
level, or blood glucose level.504,575 However, as indicated above, it would appear 
th a t the  serum  TX B 2 lev e l is re la te d  to the n u m ber o f  p la te le ts  in w hole  
blood.504,572,575 Furthermore, repeat blood sampling over successive days in healthy 
subjects dem onstrates an intra-subject variability in serum TXB2 levels o f 14+/- 
5%.576
4.5.1.4 Influence of extrinsic factors on serum TXB2. The formation of TXA2 
in whole blood, measured as its stable m etabolite TXB2, reflects the capacity of 
platelets to form TXA2 in response to thrombin and other endogenous platelet ago­
nists. TXA2 is the main product of cyclooxygenase metabolism in platelets,577,578 but 
TXA2 is also produced by polym orphonuclear leukocytes579 and m onocytes.580 
However, thrombin formed during blood coagulation preferentially stimulates plate­
lets compared to monocytes,581 and the amount of TXB2 produced directly correlates 
with the whole blood platelet count in normal individuals.504,572
Serum TXB2 levels have been used as an ex vivo measure of platelet activation in a 
num ber o f m edical conditions.566,569 However, the capacity of platelets to form 
TXB2 ex vivo (m easured as the levels of TXB2 in clotted whole blood) may not 
differ in various clinical conditions associated with platelet activation ex v/vo.563,582 
If the maximum amount of TXB2 formed in clotted whole blood is fixed and inde­
pendent of the biological milieu and clinical conditions, it would be an inappropriate 
measure for the investigation of differences in platelet function between different 
clinical groups.
4.5.1.5 Summary. W hether the differences in serum TXB2 levels between the 
control and case groups (discussed in Chapter 6) have any relationship to differences 
in p la te let function/m orphology, or w hether they are due to factors in the blood 
w hich influence platelets is uncertain. For exam ple, it is possible that substrate 
availability and/or an agonist effect may cause the variability.566'568 There is ample 
evidence that serum TXB2 production may be influenced by the platelet count and 
He,572,573 by renal impairment,566,572 by diabetes mellitus569'571 and following recent 
AMI.574
Because of these observations, we have reexamined the possible contribution to the 
production of TXB2 by other cells involved in clot formation as a possible cause of 
the differences found between the case and control groups. Only individuals without 
diabetes, renal impairment and a recent AMI can be included in the study popula­
tions evaluated, reducing the confounding effects on serum TXB2 production and 
allow ing a more valid evaluation of the influence of blood cell indices on serum 
TXB2 production. In addition, if the maximum amount of TXB2 remains fixed and
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not variable for an individual, then a relationship between the amount of TXB2 
formed and measures of platelet reactivity would not be expected. Therefore, the 
relationship between the synthesis of TXB2 in clotted whole blood and standard 
measures of platelet activation in the study groups was also examined.
4.5.2 Methods
4.5.2.1 Patient population. The three groups evaluated in this analysis were the 
young male group of patients with CHD (the case group described in Chapter 3), the 
young male control group without clinical CHD (the control group described in 
Chapter 3) and an older group with stable CHD involved in the exercise study (de­
scribed in sections 4.2.2.1 and 4.2.3.1). The exercise group has been included in 
this analysis because of the potential influence of cardiovascular drugs on serum 
TXB2 production.
4.4.2.2 Laboratory and clinical methodology. Methods used in this evaluation 
are described in Chapter 2.
4.5.2.3 Statistical analysis. An analysis of covariance was used to demonstrate 
the effect of specific uncontrolled variables, which are intrinsic to the subjects, on 
the mean values of variables used in the comparison of groups. As with the regres­
sion models used, the analysis of covariance provides a statistical rather than an 
experimental method to control and adjust for the effects of one or more uncon­
trolled variables.583 The influence of the covariate is removed using a linear regres­
sion method, residual sums of squares are then used to provide variance estimates 
that are then employed in tests of significance.583 Adjusted means of the dependent 
variable are obtained, and the adjusted mean shows which part of the variation in the 
means between groups remains when the variation due to the covariate is 
removed.583 Necessary in the analysis is the calculation of the within group variable 
variance and the between group variable variance.
In this analysis, the covariates used were obtained simultaneously as the dependent 
variable, using the same blood sample. In addition, the variables assessed are intrin­
sic attributes of the subjects studied. Furthermore, a number of assumptions are 
made in this analysis. In view of the lack of overt familial forms of hyperlipoprotei- 
naemia or other known genetic influences on the dependent variable, it will be 
assumed that the differences between the groups are not genetically determined for 
the factors analysed. A direct causal effect is assumed between the dependent vari­
able and the covariates. The statistical assumption for the presence of homogeneous 
regression coefficients is also made in this method (MANOVA in the SPSSX).
4.5.3 Results
4.5.3.1 Platelet count. There was no measurable relationship between the platelet
count and plasma TXB2 levels, plasma BTG levels, Hb, He or WCC in the young 
normal (control) group. A very small but consistent positive relation between the 
platelet count and the serum TXB2 level was present in the groups with CHD, but 
not in the young normal group (Table 4.5).
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4.5.3.2 Serum Thromboxane B2. The amount of TXB2 formed after incubation 
for 1 hour at 37°C had a significant negative relationship with the PCR in the older 
CHD group and in the young control group (Table 4.5). Although the correlation 
with the PCR is only small, there is clearly a reproducible association in these 
groups but not in the young CHD group. Besides the platelet count, the serum TXB2 
level correlated with Hb, He and WCC in the two CHD groups but not in the control 
group (Table 4.5). The serum TXB2 level correlated negatively with the BTG level 
in the normal group (r=-0.38, p<0.005), although the serum TXB2 level was not 
related to the plasma TXB2 or plasma BTG levels in patients with CHD.
Using a stepwise regression model, with serum TXB2 as the dependent variable and 
age, Hb, He, WCC and PC as the independent variables, only the PC and WCC re­
mained significantly and independently associated with serum TXB2 levels in the 
young case group, while the WCC was the only variable associated with serum 
TXB2 level in the older CHD group (Table 4.6). There were no significant associa­
tions in the control group for the regression analysis using the same variables.
An analysis of covariance was performed using MANOVA (SPSSX), with the de­
pendent variable being the serum TXB2 level, the covariates being Hb, He, PC and 
WCC, and the case and control groups being analysed as factors, that is, as categor­
ical variables defined in two groups. In fact, these two groups were analysed togeth­
er by the analysis of covariance method. The cases and controls were considered as 
categorical values and defined as two factors in the analysis of covariance. The 
adjusted means for serum TXB2 values, that is the means adjusted for the effects of 
the covariates Hb, He, WCC and PC, remained very different for the case group 
(adjusted logarithmic mean being 4.56 ng/ml) compared to the control group (adjust­
ed logarithmic mean being 1.33 ng/ml). The summary of the analysis is presented in 
Table 4.7. The means are expressed as the logarithm since the serum TXB2 value 
was originally logarithmically transformed to obtain a normal distribution to allow 
Gaussian statistical methods to be used.
4.5.3.3 Platelet Count Ratio. The PCR is a measure of ex vivo platelet reactivi­
ty. A consistent and significant relationship between the PCR and other blood cell 
indices was only observed in the older CHD group (Table 4.8), but not in the young 
CHD group, except for a negative relationship with the WCC (r=-0.45 ,p<0.001). 
The PCR correlated negatively with serum TXB2 levels in the control group and in 
the older CHD group. In order to evaluate the importance of other cells in determin­
ing the association between the serum TXB2 level and the PCR in the older CHD 
group, the correlation was further examined using partial correlations. This method 
adjusts for the effects of independent variables on any of the measured zero order 
partial correlations. The association between the serum TXB2 levle and the PCR 
diminished after adjusting for Hb, He, WCC and PC, although only to a small 
degree (Table 4.9).
4.5.3.4 In vitro platelet aggregation. A positive association was demonstrated 
between the reactivity of platelets in PRP to specific platelet agonists and serum 
TXB2 values in both the control group and the case group. In particular, in the 
control group, a strong consistent association existed between platelet aggregation 
and the amount of TXB2 formed (Table 4.10). This measurement was not performed
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in the older group with CHD.
4.5.3.5 Influence of cardiac medications on the associations. In the older CHD 
group, the associations observed between the serum TXB2 and the blood cells, hB 
and He were not affected by the use of nifedipine and metoprolol (Tables 4.5, 4.8 
and 4.9).
4.5.4 Discussion
The question of whether serum TXB2 levels reflect an intrinsic variation in platelet 
reactivity remains controversial, since such variation may simply be due to differ­
ences in the number of blood cells contributing to its formation. For this reason we 
examined the relationship between serum TXB2 levels, blood cell indices and 
measures of platelet reactivity. In this respect, the type of patient with CHD which is 
evaluated is of prime concern since there appears to be a difference in in vivo plate­
let reactivity if one of the clinical complications of coronary atherosclerosis is pres­
ent.
4.5.4.1 TXB2 production and the clinical circumstances. Patients with stable 
CHD appear not to have persistent activation of circulating platelets45,298 in contrast 
to those with unstable angina or an AMI.45,46 Therefore the latter groups would be 
more appropriate to evaluate the relationship between serum TXB2 levels and in vivo 
platelet activation and determine if variability in serum TXB2 levels quantitatively 
reflects platelet reactivity. In practice however, the use of intravenous drugs, aspir­
in, invasive investigations and indwelling intravenous cannulae introduce factors 
which themselves significantly alter platelet function making it ethically difficult to 
study this group because of the need to withdraw such factors. Therefore, we have 
utilised the concept of reproducibility of results under the same conditions to validate 
positive associations, particularly when multiple statistical comparisons are being 
made. Also of particular importance, the study was designed to limit exogenous 
factors which have the potential to affect platelet function.
4.5.4.2 TXB2 production and cardiac medications. Prior to discussing the 
potential variability of serum TXB2 levels, it is necessary to address the issue of a 
possible major confounding factor in measurement of platelet function, namely the 
effect of cardiovascular drugs. This problem has been discussed in section 4.2. One 
group (an older CHD group with stable clinical disease) was examined in whom all 
medications were stopped to see if any bias may arise from the effect of cardiovascu­
lar drugs on platelet function.502 In fact no effect was found for cardiovascular drugs 
on serum TXB2 levels and plasma TXB2 or plasma BTG levels in this group at rest 
and over time. Therefore the absence of an effect in the young CHD case group is 
likely to be real, despite the continuation of cardiovascular drugs in the case group 
with CHD. In addition, the lack of an association between the PCR and serum TXB2 
levels in the young CHD group is also unlikely to be confounded by the continuation 
of medications, since the relationship was not influenced by the presence or absence 
of medications in the older CHD group. Furthermore, the significant difference in 
serum TXB2 levels between the two young study groups is unlikely to be confound­
ed by the continuation of medications. Indeed, if an affect existed it would more 
likely result in a reduction in the difference found since it is possible that cardio-
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vascular medications may reduce serum TXB2 production.502
4.5.43 Serum TXB2 production and other measures of platelet function. The
serum TXB2 levels were not associated with measures of in vivo platelet function in 
any of the study groups. The patient groups examined were clinically stable and did 
not have measurable activation of circulating platelets, as assessed by assays of 
plasma BTG and plasma TXB2.298
The PCR gives a measure of platelet reactivity which is probably a measure of reac­
tivity in response to the passage of blood through the blood collection apparatus.584 
In the older CHD group there was a weak linear correlation between the ability of 
platelets to aggregate in whole blood in response to an ex vivo exogenous stimulus 
(blood collection), and the level of serum TXB2 produced ex vivo in response to 
endogenous agonists during whole blood clotting. This older CHD group, with 
increased platelet aggregate formation (lower PCR), had a greater production of 
TXB2 in clotted whole blood. This relationship was also present in the normal 
population group. It would appear that whole blood TXB2 levels provide a quantita­
tive measure of platelet reactivity since maximum TXB2 synthesis during clotting 
appears to be directly related to the ability of the platelets to form aggregates ex 
vivo. However, in the presence of possible in vivo activation of platelets, other fac­
tors may be operative since maximum serum TXB2 production has been found to be 
reduced in such circumstances.569 Moreover, platelets which have been degranulated 
by thrombin ex vivo manifest impaired synthesis of TXB2 in response to endogenous 
thrombin and collagen.567 Therefore, if platelets have been partly degranulated in 
vivo by partial activation within the circulation, then ex vivo synthesis of TXB2 may 
be affected. However, even though the assays of plasma TXB2 and BTG may only 
be crude measures of in vivo platelet activation, the lack of an association between 
serum TXB2 levels and these measures mitigates against such a possibility. Further­
more, if platelets were activated in vivo, during or in the absence of thrombin forma­
tion, a relationship between whole blood TXB2 and the PCR may not be demonstra­
ble.
4.5.4.4 Serum TXB2 production and blood cells. Serum TXB2 levels in a 
normal population study group have been reported to be influenced by whole blood 
platelet numbers and He.572 In our group of CHD patients, there was a weak positive 
correlation between the whole blood TXB2 concentration and the platelet count in 
both CHD groups, but not in the normal group. This relationship was of borderline 
significance in the study groups, and indicates the importance of other factors in the 
production of serum TXB2 in these patients. Such factors may not contribute to the 
level formed in normals, but may reduce the strength of any relationship between 
serum TXB2 production and platelet count within groups with cardiovascular dis­
ease. This finding emphasises the point that the measurement of a parameter of cell 
function and activation may be less influenced by the total number of cells present 
than by other sub-cellular components present in association with altered function.
Nevertheless, the results presented do not support the need to make direct arithmetic 
adjustments to the clotted whole blood TXB2 levels for the different PC, Hb and 
WCC observed. There was only a weak linear relationship between serum TXB2 
and platelet count and He.572 Furthermore, our observations show that differences
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exist between populations and that other blood cell indices influence the level in only 
one group, namely the CHD patients. Therefore, a simple adjustment of the total 
serum TXB2 for an arbitrary platelet count value may introduce extra bias, whether 
for intra- or inter-group comparisons. In the evaluation of relationships between 
continuous numerical variables or categorical data, within or between groups, it 
would be preferable to adjust the serum TXB2 value for the platelet count using 
statistical methods which would take into account the weakness of any association, 
and when necessary weight adjustments appropriately. When the relationship bet­
ween the serum TXB2 level and the PCR was adjusted for other relevant variables 
(viz platelet count, Hb, He and WCC) using partial correlations, the strength of the 
relationship was reduced, indicating a contribution to both the whole blood TXB2 
level and the PCR by platelets, red blood cells and white cells. This finding is bio­
logically defensible, since TXA2 can be formed by white cells, and red blood cells 
can release platelet agonists, such as ADP, particularly if there is any haemolysis 
during clotting.
The problems of type I statistical errors in studies with relatively small numbers are 
highlighted in this study. However, the likelihood of this form of error can be 
reduced by testing or controlling for all realistic confounding factors with any posi­
tive association.
4.5.4.5 Influence of other variables on serum TXB2 production. Other aspects 
influencing the serum TXB2 production and which have important implications for 
the results o f this study have been evaluated in sections 7.1 and 7.4. The results of 
this evaluation demonstrate the small but significant contribution to serum TXB2 
levels by factors external to the platelet, in particular the presence of white cells in 
the clotting blood. In addition, other plasma factors influence the serum TXB2 lev­
els, especially blood glucose levels and specific plasma fatty acids in the normal 
group. In contrast, in the young CHD group, a major influence on TXB2 produc­
tion proved to be an intrinsic measure of platelet morphology, namely the mean 
platelet volume (MPV). This variable, the MPV, appears to have a greater in­
fluence in young CHD patients than the whole blood milieu. In normal subjects, the 
effect of extrinsic variables in the blood are more important. Therefore, not only can 
different population groups vary in their capability of producing TXB2, but the fac­
tors influencing the level can be qualitatively different. These observations are fur­
ther discussed in Chapter 7.
4.5.5 Summary
1. The clinical usefulness of serum TXB2 values remains to be defined, 
although significant variability between individuals reduces its likely utility for clini­
cal purposes.
2. Our results supported, however, that whole blood TXB2 levels may be 
of value in the investigation of groups of patients with conditions associated with 
platelet activation.
3. The findings indicated that when comparing serum TXB2 levels bet­
ween groups adjustments may be necessary to ensure that variations in the platelet
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count and other whole blood cell indices are not contributing to differences observed 
in the whole blood TXB2 levels.
4. It can be concluded that in patients with stable CHD who have no evi­
dence of measurable in vivo platelet activation, that the serum TXB2 is not related to 
measures of in vivo platelet function.
5. It is clear that serum TXB2 production is influenced by both platelet 
specific factors and environmental factors in the circulation, both molecular and 
cellular. Specifically, there was a relationship between serum TXB2 levels and plate­
let morphology (MPV) as well as blood cell indices in the young CHD group. In 
contrast, in the control group serum TXB2 was related to the degree of platelet 
reactivity as indicated by the stronger relationship with in vitro platelet aggregation, 
the PCR and plasma BTG levels.
6. The observations provided further evidence for potential variation in 
serum TXB2 levels in different disease states.
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Table 4.1. Patient Exclusion Criteria
Electrocardiographic Criteria:
1. Left bundle branch block.
2. 2nd/3rd degree heart block, resting heart rate < 50/min
3. Any causes for false positive or negative test.
Underlying Diseases
1. Known or predictable complications to beta-blockers.
2. Congestive heart failure, valvular or congenital heart 
disease, myocarditis, or Prinzmetal angina.
5. Diabetes mellitus, significant electrolyte, renal, 
thyroid, hepatic or haematological disorder.
6. Known or detected bleeding diathesis.
Medications
1. Clinical safety for withdrawal of all medications.
2. Any aspirin or drug affecting platelet function.
Table 4.2. Patient Risk Factors and Coronary Artery Scores
Exercise Test: Positive Negative
Age (years) 59 +/- 9 50 +/- 9 *
Smoking (pack years) 27 +/- 22 28 +/- 26
Weight (kg) 81 +/- 12 82 +/- 8
Cholesterol (mmol/1) 6.4 +/- 1.3 6.0 +/- 1.0
Triglycerides (mmol/1) 1.96+/-0.71 2.02+/- 1.16
HDL (mmol/1) 1.02 +/- 0.27 0.98 +/- 0.40
mean CAS 2.1 +/- 1.8 2.7 +/- 1.6
mean CSS 3.9+/-3.1 6.1 +/- 3.0 **
Left ventricular score 3.1 +/- 1.9 5.7 +/- 2.5 ##
Collateral score 5.9 +/- 2.2 4.4 +/- 2.2
* p=0.025 ** p=0.092 ## p=0.014
CAS=coronary artery score; CSS=coronary stenosis score; HDL=high density lipopro­
tein cholesterol.
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Table 4.3. Platelet Count Ratio
Exercise Test Positive Negative
1 pre 0.87 +/-0.12 0.81 +/-0.14
post 0.83 +/-0.09 0.74 +/-0.14 *
2 pre 0.87 +/-0.09 0.79 +/-0.13
post 0.86 +/-0.11 0.80 +/-0.12
3 pre 0.86 +/-0.09 0.82 +/-0.11
post 0.84 +/-0.12 0.81 +/-0.13
means (+/-SD), * p<0.02, pre=before and post=after exercise
Table 4.4. Blood cell indices for the combined groups before and after exercise.
Test_________ Before Exercise___________ After Exercise
PC (10) 1
2
3
Hb gm/dl 1
2
3
He % 1
2
3
WCC 1
2
3
246+/- 51 
245 +/- 50 
246+/- 51 
14.5+/- 1.1 
14.3 +/- 1.0 
14.2 +/- 0.9 
43+/- 3 
42+/- 3 
41+/- 3 
6089 +/-1608 
5981 +/-1501 
5883 +/-1534
287 +/- 62 * 
286+/-49 * 
282+/- 37 * 
15.4+/- 1.1 * 
15.2+/- 1.1 * 
15.0 +/- 1.0* 
46+/-3 * 
45+/-3 * 
44+/-3 * 
8500 +/- 2557* 
8710+/-2414* 
9550 +/- 2338*
* pcO.001, PC=platelet count, Hb=haemoglobin, Hc=haematocrit, 
WCC=total white cell count.
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Table 4.5. C orrelation coeffic ien ts for serum  TXB2 and p la te le t count, PCR, 
haemoglobin, haematocrit and whole blood WCC.
PCR PC Hb He WCC
A. Exercise study CHD group for 3 separate measurements:
1 -0.46 # 0.24 0.19 0.17 0.22
3 -0.41 * 0.27 A 0.35 * 0.31 * 0.32*
5 -0 .29A 0.39* 0.35 * 0.30 A 0.27 A
B. Young CHD group:
-0.08 0.43## 0.29* 0.26* 0.42##
C. Young normal group:
-0.28 * 0.01 0.18 0.01 -0.03
Ap<0.09, *p<0.05, #p<0.01, **p<0.005, ##p<0.001
Table 4.6. Regression analysis with serum TXB2 as the dependent variable and Hb, 
He, WCC, PC and age as the independent variables.
Independent
Group Variable B SEB Beta Rsq p
Old CHD WCC 0.72 0.15 0.91 0.82 0.005
Young CHD PC
WCC
0.002
1.072
0.0002 0.322 
0.482 0.303
0.18
0.263
0.022
0.031
See Table 7.1 and 7.2 for abbreviations.
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Table 4.7. Analysis of covariance with serum TXB2 as the dependent variable, and 
Hb, He, PC and WCC as the covariates.
(1) Tests of significance for serum TXB2:
Sources of 
Variation
Sums of 
Squares DF MS F sig F
Within cells 4.51 45 0.10
Regression 1.80 4 0.45 4.50 0.004
Constant 0.77 1 0.77 7.73 0.008
(2) Correlation between the covariate and the predicted dependent variable (serum 
TXB2):
Variable________ Hfc________ He__________ WCC______ PC
serum TXB2 0.5074 0.4657 0.7628 0.7969
(3) Regression analysis of within cells:
Covariate B Beta signif lower 95%CI UDper 95%CI
Hb 0.0109 0.2073 0.491 -0.2049 0.0421
He -0.0009 -0.0479 0.874 -0.0127 0.0108
WCC 0.8716 0.2492 0.084 -0.1233 1.8664
PC 0.0020 0.3283 0.018 0.0004 0.0036
See Table 7.1 and 7.2 for abbreviations.
Table 4.8. Correlation coefficients of the PCR with PC, Hb, He 
and WCC in the older CHD group.
Sample PC Hb He WCC
1 -0.07 -0.46# -0.46# 1 o Ln '1 * *
3 -0.29 -0.53 ** -0.53 ** -0.17
5 -0.16 -0.33 * -0.34 * -0.39 *
Ap<0.09, *p<0.05, #p<0.01, **p<0.005, ##p<0.001
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Table 4.9. Partial correlation coefficients between whole blood TXB2 and PCR (1), 
with adjustments for PC (2), Hb (3), He (4) and WCC (5) separately, and all combined 
( 6) .
TXB2 PC Hb He WCC Combined
ID ___________(2) (3}__________(4)_________ (5)__________ (6)
PCR1 -0.46# -0.46# -0.42* -0.43* -0.41* -0.41*
PCR3 -0.49# -0.46* -0.40* -0.42* -0.48# -0.41*
PCR5 -0.29A -0.25A -0.21 -0.20 -0.21 -0.15
Ap<0.09, *p<0.05, #p<0.01, **p<0.005, ##p<0.001
Table 4.10. Linear correlations for CONTROLS and CASES with serum TXB2 and 
measures of in vitro platelet aggregation.
Variable Control Case Variable Control Case
LT50ADR -0.28# -0.12 RADR 0.17 0.33*
LT50ADP -0.18 -0.11 RADP 0.34# 0.13
LT50COL -0.43** -0.53## RCOL 0.33# 0.09
LAGCOL -0.57##
*<0.05 #<0.01 **<0.005 ##<0.001
See Table 7.1 and 7.2 for abbreviations.
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Figure 4.1. BTG (ng/ml) levels before and after exercise in all patients tested (+ /-SD ), 
showing a reproducible small but significant increase in patients with negative exer­
cise tests. in the first (* p <  0.05), and repeat test (# p <  0.005). Pre=pre-exercise value; 
post= post-exercise value.
(__I Positive exercise test
■■ Negative exercise test900 n
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Figure 4.2. Effect of short-term maximum strenous exercise on serum TXB2 (+ /-SD ) 
in patients with negative and positive exercise tests. A significant difference between 
the pre and post exercise serum TXB2 (* p <  0.005), was confirmed in the repeat test (# 
p =0.005) for the group with positive exercise tests only. P re= pre-exercise value; 
post= post-exercise value.
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Figure 4.3. PCR before and after exercise (+ /-S D ), showing a small but significant 
decrease in the first test for the group with a negative exercise test (* p <  0.02), which 
was not reproducible in the subsequent exercise test (# p =0.127). Pre=pre-exercise 
value; post= post-exercise value.
TEST 1 TEST 2 TEST 3
p<0.005
O p<0.05 p<0.005
•  ns
• -----•  POSmVE EXERCISE TEST
O -----O NEGATIVE EXERCISE TEST
POST POST POST
Figure 4.4. Plasma BTG (ng/ml) before (pre) and after (post) exercise in positive and 
negative exercise test groups, (+/-SEM ). Exercise tests 1 and 3 (test 1 and 2) are 
without medications and exercise test 2 (test 2) is with medications. ns= not significant.
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Figure 4.5. Serum TXB2 (ng/ml) before (pre) and after (post) exercise in positive and 
negative exercise test groups, (+/-SE). Exercise tests 1 and 3 (Test 1 and 3) are without 
medications and exercise test 2 is when on medications, ns= not significant.
CHAPTER 5
DIET, LIPOPROTEINS, PLATELET FUNCTION 
AND CORONARY HEART DISEASE
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5.1 RELIABILITY AND VALIDITY OF LIPOPROTEIN MEASURES
5.1.1 Introduction
Reliable and precise measurements of lipoproteins are important for the studies 
undertaken in this Thesis. The lipoprotein levels used for the studies presented in 
Chapters 4 and 8 were performed in the Woden Valley Hospital Biochemistry 
Department, which participates in an external quality control programme and obtains 
good results for reliability and precision. In the main case-control study (described 
in Chapter 3) the levels were measured in two laboratories, and the comparison was 
used to confirm the reliability of the results used for the other studies described in 
Chapters 4 and 8 of this Thesis. In addition, in this section the validity of the rela­
tionship of lipoproteins with angiographically defined CAD is evaluated utilising 
lipoprotein measurements from the two different laboratories. The results also 
provide support for the angiographic scoring system used in the studies and de­
scribed in Chapter 8.
5.1.2 Methods
5.1.2.1 Patients. The case group of young male subjects with CHD used in this 
evaluation is described in Chapter 3.
5.1.2.2 Blood lipid measurements. The methods for the blood lipid measure­
ments are described in Chapter 2.
5.1.3 Results
5.1.3.1 Cholesterol levels. The cholesterol level of those subjects for whom it 
was available before or at the time of their diagnosis (n=27) was significantly higher 
than the levels at the time of the study (Table 5.1)
5.1.3.1 Comparison of cholesterol levels. An analysis of variance was per­
formed to compare all the cholesterol levels. The variance between the group means 
was significantly larger than among the average variance within groups. Thus there 
are significant differences for the values of the group means (F=4.7468, 
p=0.0033). After correcting for multiple comparisons so that the probability was 
only 5% that any one or more of the comparisons would be significant with p<0.05 
by chance alone, a significant difference was only found between the prior cholest­
erol level and the study level (Table 5.2). Small but non significant differences 
(when corrected for multiple comparisons) were found between the serum cholester­
ol levels from the study laboratory, the values from the service laboratory and the 
plasma cholesterol levels from the service laboratory (Table 5.2).
5.1.3.2 Comparison of cholesterol levels. The correlation coefficient between 
the standard laboratory serum cholesterol and the service laboratory was high, with a 
correlation coefficient (r) of 0.93, standard error for the equation (SEE) of 2.76, an 
intercept of 0.10, and slope of 0.77 (SE of the slope=0.04). The same analysis 
between the standard laboratory serum cholesterol measure and the plasma cholest­
erol from the service laboratory gave a correlation coefficient of r=0.90,
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SEE=3.31, intercept=0.18 and slope=0.59 (SE of the slope=0.04). The service 
laboratory serum measurements were slightly higher and became greater with in­
creasing values, although the differences were small. The plasma values correspond­
ed accurately throughout the measured range but were consistently and modestly 
higher than the standard laboratory values.
5.1.3.3 Comparison with angiographic scores. The previous cholesterol meas­
urement (for those patients having had the level documented), was inversely related 
to the number of normal segments, and directly correlated with the extent of disease 
(CAS, mCAS and pCAS), as well as the number of mild and moderate lesions (25- 
50% and 50-75%) (Table 5.3). The serum cholesterol level from the standard labo­
ratory had similar relationships, as did the plasma and serum cholesterol from a 
service laboratory (Table 5.3). The apoprotein B levels had identical or possibly 
more significant relationships to the extent of disease, the number of mild and 
moderate lesions and the number of normal segments than did the cholesterol levels 
(Tables 5.3, 5.4 and 5.5).
Triglyceride levels from both laboratories had no consistent relationships with the 
extent and severity of disease, although there was a positive association with the 
number of normal segments (Tables 5.3, 5.4 and 5.5). The HDL cholesterol had no 
consistent relationship with any of the angiographic measurements (Tables 5.3, 5.4 
and 5.5). Equally, apoprotein A1 levels were not related to any of the angiographic 
measures (Tables 5.3, 5.4 and 5.5). These associations will be further evaluated and 
discussed in the following section of this Chapter.
5.1.4 Discussion
In this section, the relationship between total serum cholesterol from a research 
laboratory (used as the standard laboratory) with well established quality control 
methods, as well as the level in serum and plasma taken from the same blood sample 
and measured in a service laboratory, also with a well established quality control 
programme, have been compared. The linear correlation was similar with all meas­
ures.
The service laboratory maintains an external and internal quality control programme 
and has a CV close to 3% with an external standard, a level aimed for with such 
external standardisation.361,585,586 Sustaining both precision and accuracy of meas­
urements by utilisation of external quality controls is the "sine quo non" for the 
measurement of cholesterol for clinical use.585,586 The results demonstrate that 
measurement of cholesterol by a service laboratory, which maintains good quality 
control methods, can provide results of sufficient accuracy to compare to the results 
from the rigorous standards of a standard laboratory, and this included a measurable 
relationship with CAD. Plasma levels had a slightly higher level which was not sta­
tistically significant. Small differences resulting in reduced accuracy of estimating 
the true mean have previously been noted using various anticoagulants.361 However, 
the reliability would appear to be maintained as the predicted univariate association 
with CAD is sustained.
A significant difference existed between the previous cholesterol level, measured
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prior to the study in those patients for whom it was available, and the measurements 
taken at the time of the study, often many months after the diagnosis. Numerous 
confounding factors may contribute to such a difference, such as changes in diet and 
other sources of clinical variation,586 in addition to the effect of regression to the 
mean of repeated measurements.370 In view of the probability of dietary changes 
having an effect on the current cholesterol level, the previous measurement would be 
expected to more accurately reflect premorbid levels, and hence have a relationship 
with CAD as demonstrated. Indeed, the previous cholesterol, in those patients for 
whom it was available, appears to have a stronger relationship with the extent of 
coronary atherosclerosis than the levels measured at the time of the angiographic 
assessment.
5.1.5 Summary
1. These results demonstrate that cholesterol measurements from a service 
laboratory with appropriate quality control methods can provide information that is 
both precise, accurate and relevant to the disease process. The reliability for the 
clinical use of results from a service laboratory with thorough quality control is well 
validated.
2. The measurements of cholesterol performed in the Woden Valley 
Hospital Biochemistry Department are of sufficient reliability and precision to be 
used as a measure in studies assessing potential confounding factors as described in 
Chapters 4 and 8.
5.2 THE RELATIONSHIP BETWEEN BLOOD LIPOPROTEINS
AND ANGIOGRAPHICALLY DEFINED CORONARY ARTERY 
DISEASE
5.2.1 Introduction
Numerous epidemiological studies have identified individual attributes associated 
with an increased risk of developing CHD, especially abnormalities of plasma lipo­
proteins.258,371,587'589 The close relationship between the severity and extent of 
coronary atherosclerosis and the clinical disease expressed as CHD is beyond disp­
ute. Autopsy studies have demonstrated that elevated serum cholesterol is positively 
and significantly related to coronary atherosclerotic lesions.157 However, other risk 
factors for CHD may be associated with aspects of the processes involved in the 
development of CHD other than the formation of atherosclerosis.202 Which risk 
factors are related to the development of the different stages of atherosclerosis re­
quires further evaluation.157,202 No single lipid or lipoprotein abnormality has been 
shown to adequately discriminate between patients with and without CHD and lipid 
abnormalities have been found to be weak predictors of CAD.590,591 Moreover, 
various lipoproteins appear to have different predictive value for CHD, depending 
on the age of the subjects and the level of other lipoproteins.592
More recent studies employing multivariate analysis and angiographic scoring meth­
ods provide consistent evidence that apoprotein B and LDL cholesterol levels contrib-
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ute significantly to the extent of coronary atherosclerosis,206,207’591’593 particularly in 
males with premature CHD.207 In addition, these lipoproteins may also have some 
influence on disease severity,590,593 although possibly not in young m ales.207,592 
Other lipoproteins, notably HDL cholesterol and the apoprotein A group of lipopro­
teins, exert little or no measurable effect on either severity or extent of coronary 
atherosclerosis.206,207,365,592'597
One study, the original study which used the angiographic scoring system employed 
in the present report, failed to find any correlation between lipid risk factors and a 
stenosis severity score.207 However, the study group in that report comprised young 
males with a recent MI.207 The severity score may, therefore, have been influenced 
by factors that complicate atherosclerosis, such as thrombosis and plaque rupture, 
which may be influenced to a lesser degree by lipoproteins, but nevertheless contrib­
ute to the progression to severe coronary stenosis. However, in another study of a 
more heterogeneous population who had not sustained a recent infarct, apoprotein B 
levels were found to be independently related to a stenosis score.593 These contradic­
tory observations may be due to a selection bias. Therefore, the aims o f the analysis 
in this section were to:
1. Evaluate the relationship of the lipoprotein levels with angiographically 
defined CAD in the study population.
2. Investigate the possibility that a selection bias may explain the presence 
or absence o f an association between cholesterol and apoprotein B levels, and the 
severity of CAD. This is an important consideration since the progression of coro­
nary artery stenosis may be largely determ ined by mechanisms other than those 
which involve lipoprotein abnormalities.202,207,593,598 If the lipoprotein risk factor(s) 
are only re la ted  to the extent of coronary atherosclerosis and not to the discrete 
obstructive lesions, such an observation would support the concept of there being 
independent factors, possibly thrombogenic, contributing to the risk of obstructive 
CAD.
5.2.2 Methods
5.2.2.1 Subjects The study group com prised the 53 young male subjects with 
CHD described in Chapter 3.
5.2.2.2 Lipoprotein measurements. The methods and measurements are de­
scribed in Chapters 2.
5.2.2.3 Coronary angiographic scoring methods. A detailed description is pro­
vided in Chapter 8 and elsewhere.61
5.2.2.4 Statistical assessment. The statistical methods used are as outlined in 
Chapter 2. In addition, lipoprotein levels were categorised into 4 groups with ap­
proxim ately equal numbers of subjects in each group, and the angiographic scores 
com pared between each group. This allowed confirm ation of any relationship by 
using an alternative method of analysis and also if any threshold associations existed 
which could give a false negative result with assessment by correlation. Significance 
differences among the mean angiographic scores of these categorised groups was
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determined by ANOVA (Statistical Package for Social Sciences ,SPSSX). The 
Bonferroni t-test was used to determine differences between the means of particular 
pairs of groups if significant differences were documented, taking into account 
multiple comparisons.
5.2.3 Results
5.2.3.1 Patient characteristics. A full description of the patient characteristics is 
detailed in Chapter 3.
5.2.3.2 Correlation between angiographic scores and lipid values. When 
correlating patient age with the angiographic scores, the older patients in this rela­
tively young group with premature CHD had fewer normal arterial segments as well 
as more severe and more extensive coronary disease (Tables 5.3, 5.4 and 5.5). The 
NYHA classification of functional capacity for the occurrence of angina correlated 
consistently with disease severity, and also with the collateral score and the number 
of arterial segments supplying collaterals, but to a lesser degree with the coronary 
atheromatous score (Tables 5.3, 5.4 and 5.5). The collateral score and the number 
of arterial segments supplying collaterals correlated only with the NYHA functional 
class for angina, and not with any lipoprotein value (Table 5.5). The left ventricular 
score was only associated with the number of previous AMI (Table 5.5).
The previous cholesterol measurements for those patients (n=27) having had the 
level documented was inversely related to the number of normal segments, and 
directly correlated with the extent of disease (CAS, mCAS and pCAS), as well as 
the number of mild and moderate lesions (25-50% and 50-75% luminal narrowing) 
respectively (Table 5.3), as did the current cholesterol level (Table 5.3). The calcu­
lated LDL cholesterol was inversely related to the number of normal segments, and 
was directly related to those scores measuring the extent of disease (CAS and 
mCAS) and the number of lesions of mild to moderate severity (10-20%, 25-50% 
and 50-75% reduction in lumen diameter)(Table 5.3). The LDL cholesterol level 
was not significantly correlated with the severity scores (CSS and mCSS) or the 
number of severe lesions (75-90%, 90-99% and 100% luminal narrowing)(Table 
5.3). The apoprotein B levels had identical and possibly more significant positive 
relationships to the extent of disease, and the number of mild and moderate lesions, 
and correlated inversely to the number of normal segments (Table 5.3, 5.4 and 5.5).
Triglyceride levels had no consistent relationships with the extent and severity of 
disease, although there was an association with the number of normal segments 
(Tables 5.3 and 5.4). The HDL cholesterol level had no consistent relationship with 
any of the angiographic measurements for disease severity or extent of arterial wall 
involvement (Tables 5.3 and 5.4). Apoprotein A1 levels were not related to any of 
the angiographic measures (Tables 5.3, 5.4 and 5.5).
The associations between the lipoprotein measures and the extent scores were sub­
stantiated by categorisation of the lipid variables into 4 groups of approximately 
equal numbers with increasing values, and comparison of the mean angiographic 
scores between each lipid category. The results demonstrated a consistent increase in 
the CAS and the mCAS for the first three incremental categories of apoprotein B
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(Figure 5.1). The number of normal segments decreased with increasing incremental 
categories of the apoprotein B (Figure 5.2). This form of analysis for the categorised 
lipid variables provides an alternative method which supported the validity of the 
significant correlations observed. One way analysis of variance (ANOVA) showed 
that the variances among the group mean of the above angiographic scores were 
significantly larger than the variance within groups for the subjects categorised 
according to apoprotein B levels. Significant differences were present between the 
group means of the CAS and apoprotein B (F=4.142, p=0.0113), of the mCAS and 
apoprotein B levels (F=3.8147, p=0.0163), and between the number of normal 
segments and apoprotein B levels (F=2.9591, p=0.0425). An increase in the CAS 
and mCAS for 4 incremental categories for total cholesterol and LDL cholesterol 
levels was also observed but the ANOVA did not achieve statistical significance. 
The mean number of normal segments decreased with increasing incremental catego­
ries of total and LDL cholesterol levels. For this angiographic measure the variances 
between groups was significantly different to that within groups for both total cho­
lesterol (ANOVA, F=3.2612, p=0.030) and LDL cholesterol levels (F=3.2612, 
p<0.030).
The ANOVA was not significant for the categorised apoprotein B levels and the 
mean severity scores (CSS, mCSS and Jenkins). In addition, the ANOVA was not 
significant for the other lipid variables (triglyceride, HDL cholesterol and apoprotein 
A1 levels), when categorised into 4 groups, and the angiographic scores.
The Bonferroni t-test was used to test for significant differences between the mean 
angiographic scores of particular lipoprotein categories. The Bonferroni p value ad­
justs for the fact that 6 comparisons are made for the 4 categories. The probability is 
thus only 5% that any one (or more) of the comparisons were significant at a value 
of p<0.05 by chance alone. For the apoprotein B categorised groups, the mean 
CAS in the group with the lowest apoprotein B levels was significantly lower, and 
the mean number of normal segments was greater than in any of the apoprotein B 
groups with greater levels (Bonferroni p<0.05). The mean number of normal 
segments in the lowest group of total and LDL cholesterol levels, when categorised 
into the 4 groups, was significantly higher than the third group (Bonferroni 
p<0.05).
5.2.3.3 Multiple regression analysis. Cholesterol, triglyceride, HDL cholester­
ol, apoprotein A1 and apoprotein B levels were entered into a multiple regression 
model as independent variables, and each of the cumulative coronary artery scores 
as dependent variables (Table 5.6). Apoprotein B values maintained an inverse 
independent association with the number of normal segments, and a positive associa­
tion with the extent of disease. Age, but none of the lipoprotein values, was inde­
pendently associated with disease severity (Table 5.6).
5.2.4 Discussion
Coronary artery disease becomes clinically manifested by the intermittent develop­
ment of severe stenotic lesions associated with plaque rupture and intramural or 
luminal thrombosis.40,41 With this knowledge in mind, our results lend support to the 
following concepts: (i) that specific lipoprotein abnormalities are risk factors for
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coronary atherosclerosis which then predisposes the individual to the clinical expres­
sion of CAD; (ii) that the development of severe lesions may relate to factors that 
complicate atherosclerosis, such as plaque rupture, plaque haemorrhage and luminal 
thrombosis, which may have different or additional risk factors;67,115,238,239,302,599 and 
(iii) that atherosclerosis may be an interm ediate risk factor between CHD, as the 
clinical expression of CAD, and abnormal lipoprotein metabolism. Nevertheless, the 
lipoprotein levels are related to moderate lesions which may develop from a rapid 
accumulation of lipid within the plaque. Also, abnormal accumulation of modified 
LDL cholesterol may contribute to the destabilisation of an atherosclerotic plaque 
resu lting  in plaque rupture, and in this way contribute to the form ation o f more 
severe lesions.40,41
5.2.4.1 Cholesterol, LDL and apoprotein B levels and angiographic CAD.
Recently, manual semi-quantitative angiographic scoring systems have been used 
with the intention of discriminating between atherosclerotic disease involving the 
arterial wall and the lesions encroaching into the lumen of the artery.61,207,593 Such 
scoring systems have been used to evaluate CHD risk factors with respect to their 
possible involvement in the atherosclerotic and/or thrombotic component of CHD.61 
In this study we have utilised the more complex of these scoring systems to further 
examine the relationship between angiographic measures of CAD and the major 
lipoproteins.
The majority of angiographic studies have demonstrated a positive relationship bet­
ween total blood cholesterol levels and CAD,206,207,220,365,592'594,600,601 although not 
all studies have shown a correlation,596,602 and some studies have only found rela­
tionships in younger patients.591 However, an independent relationship between the 
various angiographic measures of CAD and total blood cholesterol values is not 
always maintained using multivariate analysis.206,207,590,593
In contrast, a consistent univariate relationship between apoprotein B and LDL cho­
lesterol levels, and CAD has been well established.590,592,594,596,597 An independent 
relationship is preserved using multivariate analysis.206,207,590,593 This relationship 
may be due to an association with the extent of wall involvem ent rather than the 
obstructive severity of atherosclerosis, particularly when such a distinction of angio­
graphic features are separated sufficiently well by appropriate angiographic scoring 
methods and evaluated by multivariate analysis.206 207 Our results are in support of 
this interpretation, although others have found an independent relationship with 
stenosis scores thought to measure obstructive severity.206,590,593,596 However, the 
scoring systems used in these latter studies have a greater in-built bias towards the 
extent of arterial involvement in the stenosis score206.590-593.596 than do other m eth­
ods.207 Multiple minor lesions within a segment of coronary artery is not uncommon 
in addition to more severe stenoses. Previous studies have included mild lesions in 
the stenosis sco re .151,590,596 For exam ple, 3 lesions with <50% narrow ing in a 
segment equals one lesion causing 75-90% narrowing in some studies ,206,593 and in 
another study 4 lesions with <24% narrowing equals one lesion causing 75-99% 
narrowing.596 The stenosis scoring system devised by Hamsten et al,207 which was 
used in our evaluation, is less biased towards having the extent of arterial involve­
ment partly included in the severity score by excluding lesions narrowed <25% 
from this score. Therefore, for the severity score used in this study, if  there are
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m ultiple m inor lesions within a segment, they are less likely to contribute to the 
stenosis score. In addition, the severity scoring system of Hamsten et al207 gives a 
maximum of 16 to a segment, so that in the presence of an occluded segment, minor 
lesions make no impact on the stenosis score for that segment, decreasing the inher­
ent bias found in other scoring methods which have included mild lesions in a steno­
sis score meant to reflect the severity of lesions in the coronary arteries.206,593,596 For 
this reason it seems reasonable to conclude that the stenosis scoring system of 
Hamsten et al207 is more likely to be related to factors such as thrombosis which are 
involved in the development of severe and/or occluded lesions.593 It was for these 
reasons, in part, that we selected this method for the current study. Even though the 
use of a small homogeneous population demonstrated a greater predictive value of 
specific lipoproteins for the extent of involvement of coronary arteries with atheros­
clerosis, given the inevitable relationship between minor lesions and severe stenoses, 
if a larger group had been studied then these same lipoproteins may also have pre­
dicted the severity scores as well.
5.2.4.2 HDL cholesterol and Apoprotein A levels and angiographic CAD.
H D L c h o le s te ro l and ap o p ro te in  A lev e ls  are re la te d  to the p re sen ce  o f 
CHD.365,595,597,603'606 and angiographic m easures.365,603,604,606,607 However, as we 
have found, a relationship between total HDL cholesterol and apoprotein A levels, 
and  an g io g rap h ic  m easu res  o f CAD is not a lw ays ab le  to be 
shown.206,207,590,592,595,608 Our observations support the proposal that HDL cholester­
ol and apoprotein A l levels can be discriminators of disease between groups, but do 
not correlate with disease severity or extent.207,603 It is possible, however, that the 
relationship is age related, and that there is no relation between HDL cholesterol and 
apoprotein A l levels, and angiographic ally defined CAD in younger males.365 Sulli­
van and coworkers,593 using a different scoring system, found an independent rela­
tionship between HDL cholesterol levels and both a stenosis score and a vessel 
involvement score in an older population group which included women. Others,207 
who have investigated younger male patients with CHD, have found no independent 
relationship between stenosis scores and HDL cholesterol levels. Previously we have 
demonstrated an inverse statistical relationship between HDL cholesterol and fibri­
nogen levels, which remains unexplained.61 Fibrinogen increases with age, and in 
the current study population of young males with CHD with a narrow age range, 
fibrinogen did not correlate with any of the coronary artery scores.609 The negative 
association between HDL cholesterol levels and the severity score observed by Sulli­
van et al593 may be confounded by an increase in fibrinogen with age in their older 
population with a greater age spread. Such a potentially confounding influence may 
w ell have been contro lled  for in the present, and in a previous study involving 
younger age groups with a narrow age range.207 Another important potential reason 
for a false negative result being present in the same study may arise from the use of 
total HDL cholesterol measurement.604,606 The largest HDL subclass may account 
for the association between HDL and coronary atherosclerosis.604 However, the 
concentrations of HDL subclasses in plasma probably does not reflect an independ­
ent protective m echanism  against CAD, since the inverse relation betw een the 
plasma level of the largest HDL particles and coronary atherosclerosis is markedly 
influenced by very low density lipoprotein (VLDL) concentrations.604 In patients 
with a VLDL triglyceride level above 1.65 mmol/1, no relation between disease 
severity and HDL subclasses can be demonstrated.604 In the present study the mean
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triglyceride level was 2.44 mmoles/1 which places the majority of the group into the 
hypertriglyceride group as defined in Johansson and coworkers study.604 Therefore, 
from the results of the latter study,604 no correlation would be expected between 
CAD and HDL cholesterol levels, particularly when not divided into subgroups. 
Indeed, the restriction of a relationship to the larger HDL particles,604,606 and the 
influence of triglyceride metabolism604 probably accounts for the major discrepancies 
observed in the literature.
5.2.4.3 Triglyceride levels and angiographic CAD. The triglyceride level had no 
consistent relationship with either the extent or severity of CAD. Our results fail to 
clarify the major inconsistencies found in the literature. Several studies have report­
ed a positive univariate relationship between triglyceride levels and angiographic 
scoring m ethods,592,593,600,601 while others have found no relationship.206,207,591,602 
The large intra-individual variation and the variability over time in triglyceride lev­
els586 may in part explain the variability in the different reports. Most studies ob­
tained blood from fasting subjects in the morning which would help to reduce the 
variance. Nevertheless, the sources of variation are much greater for triglyceride 
levels than for other lipid or lipoproteins values.361,586,610 Indeed, the intra-individual 
variation appears to be between 20-40% under normal metabolic conditions.586 The 
magnitude of this variance would not enable any relationships between CAD and the 
triglyceride levels to be established in study populations of small size. However, the 
smaller number of homogeneous patients contributes to the reliability of the reported 
association between CAD and the other lipoproteins with less measurement variance. 
Furthermore, the sensitivity of the scoring system207 is demonstrated by the results 
in this present smaller population.
5.2.4.4 Age and angiographic CAD. The positive correlation between age and 
the extent of atherosclerosis is well documented in the literature.207,593 The relation­
ship with disease severity is less consistent, with some studies showing an associa­
tion,591,600'602 while others have not shown any correlation.206,207,593 The variability 
in this relationship may arise from the inevitable bias of the severity score to reflect 
extent of disease to some degree, as discussed above. In autopsy studies, while large 
individual variations exist, the frequency of raised atherosclerotic lesions in arteries 
of males without CHD increases with age.157 However, there is no simple relation­
ship between the frequency of raised coronary lesions and the onset of CHD.157 In 
males with CHD, differences in the averaged extent of raised lesions between age 
groups is small.157 Therefore it is not surprising that the available angiographic data 
regarding the relationship between raised lesions and age remains inconclusive. 
Nevertheless, in a previous study, using the same scoring system in a larger popula­
tion group with a broader age range, with multivariate analysis which included the 
standard  risk  factors (except apoprotein B), age rem ained the only independent 
variable for both the extent and severity of CAD, with the extent score having the 
stronger relationship.61
5.2.4.5 Validity of the associations with angiographic CAD scores. The rela­
tively strong relationship between the severity score and the functional class for 
angina emphasises the validity of the scoring system used in this study, although the 
lim itations of angiographic scoring m ethods need to be em phasised.611'613 This 
observation supports clinical expectation, as does the lack of association with the
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extent scores, and also the positive association of functional class for angina with the 
collateral scores. In addition, the only variable associated with the left ventricular 
score was the number of AMI, again a predictable observation. Similarly, the nega­
tive association between age, cholesterol, and apoprotein B levels, and the number 
of normal segments also strengthens the reliability of our observations.
In this study, cholesterol measurements performed before the diagnosis had a strong­
er relationship with the extent of coronary atherosclerosis than the cholesterol 
measurement undertaken during the study. Numerous confounding factors may 
contribute to this observation, and these are delineated in section 5.1.4.
There are important limitations to the subjective assessment of angiographically de­
fined CAD.611'613 There have been significant advances in the quantification of coro­
nary artery stenoses in recent years.614'618 However, little progress has occurred in 
finding a suitable quantitative angiographic correlate with the extent of pathological 
defined CAD to be used in epidemiological studies,593 although valid clinically 
applicable methods are currently being developed.619 The traditional method of risk 
stratification in CAD using coronary angiography has been primarily based on the 
number of diseased arteries and the left ventricular function.620,621 A score express­
ing the extent of CAD and providing information about minimal or moderate lesions 
may contribute additional prognostic information beyond the conventional angio­
graphic studies.621 The validity of the scoring system used in this study appears 
acceptable,207 recognising the limitations of the method.593,611'613
5.2.5 Summary
1. In males with premature CHD, lipoprotein abnormalities are associated 
with atheromatous involvement of the arterial wall, and not with severe lesions en­
croaching into the lumen. Our study supports previous observations,207 and extends 
the validity of the relationship to a time frame at least 3 months, or more away from 
recent unstable CHD.
2. Identification of the clinical, functional and anatomical factors that in­
fluence plaque stability have important clinical consequences.622 This concept is one 
of many that have provided an impetus to determine if thrombogenic risk factors 
provide a link between CAD and its clinical expression as CHD.
3. The development of generalised atherosclerosis may merely be a con­
tributing factor to the clinical expression of CAD in the form of CHD. The forma­
tion of acute severe stenoses may have different risk factors and mechanisms than 
those for the development of diffuse atherosclerosis.4,623
4. However, the lipoproteins are also related to moderate CAD lesions. 
Such lesions may also be predisposed to rupture with subsequent thrombus forma­
tion. This process may occur without additional factors than rapid accumulation of 
lipid material in a lesion, in conjunction with alteration in local haemodynamic and 
shear stress forces, being the cause.
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5.3 LIPOPROTEINS AND PLATELET FUNCTION
5.3.1 Hyperlipoproteinaemia and platelet function
A considerable body of evidence exists demonstrating an adverse effect of hyperli- 
poproteinaem ias on platelet function.65 Given, the present understanding of their 
interaction, the alteration in platelet function occurring in the presence of hyperlipo- 
proteinaemia could feasibly contribute to atherogenesis and/or its progression. The 
changes in platelets that are said to occur in association with elevated lipids could 
also conceivably give rise to the clinical symptomatic forms of the disease.65
The concept of circulating lipoproteins being potentially thrombogenic has long been 
an area of investigation.66,67,624,625 Numerous in vivo and in vitro methods of assess­
ing platelet function have predominantly, although not universally, shown increased 
platelet reactivity in association with hyperlipoproteinaemia.66,67,625 This interaction 
appears to be particularly consistent for hypercholesterolaemia.
5.3.1.1 Platelet aggregation. A relationship between increased platelet aggreg- 
ability and dyslipoproteinaem ias has been well established.65,66,126,421,423,424,626,627 
The available information relating the effect of lipoproteins on platelet sensitivity has 
been obtained from the investigation of subjects with hyperlipoproteinaemia, which 
have in general been supported by studies on isolated platelets.420 There may be a 
threshold level of LDL to effect platelet aggregation, with low LDL concentrations 
having little influence on aggregation.420 There is an altered response by platelets to 
aggregating agents following pretreatm ent with the main lipid density fractions 
(LDL, VLDL and H D L).420,421 Furtherm ore, a greater effect on in vitro p latelet 
aggregation of normal platelets is seen with the lipoprotein fractions from hypercho- 
le ste ro laem ic  pa tien ts  than is seen w ith the frac tions from  norm olip idaem ic  
controls.419 O f further interest is the inverse effect of HDL com pared to LDL and 
VLDL.419'421 Platelets enriched with cholesterol ex vivo are more reactive422 and 
produce more TXB2 on aggregation.126,128,422
In vitro studies have in general supported cross-sectional observational studies. Plate­
let reactiv ity  may be affected by the lipoprotein concentration w ithin a norm al 
population.423 Hypercholesterolaemic individuals may have enhanced in vitro platelet 
reactivity compared to normal subjects.124,424,425 Increased ADP sensitivity in Frie- 
drickson’s Type II hyperlipidaemic patients could result in platelet aggregation in 
vivo under conditions in which none would occur in normals. Even more striking is 
the hypersensitivity of such persons to aggregation by adrenaline. The low concen­
tration of adrenaline required for in vivo aggregation in patients with Type II hyper- 
lipidaemia might occur under certain conditions such as severe stress or trauma.424 
Such observations have not been universal. In another report, specific in vitro plate­
let aggregation responses to collagen and ADP in hyperlipidemic patients with CHD 
did not differ significantly from normals. However, there appeared to be some in 
vivo platelet activation in response to ADP and collagen.426 Platelets from patients 
with type II hyperlipoproteinaem ia are more sensitive to aggregation by ADP, 
adrenaline and co llagen ;124 those from type IV patients did not d iffer from the 
normal control group in their responses to ADP and collagen, but they were more 
sensitive to adrenaline.124 Within a population of healthy males, it has been shown
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that total and LDL cholesterol concentrations influence the sensitivity of platelets to 
adrenaline and less so ADP.420,423 There was no correlation with HDL or VLDL 
concentrations, as observed by others.67 Platelet hypersensitivity is also induced by 
cholesterol incorporation into the platelet membrane.126 Others, however, have been 
unable to find any alteration in the sensitivity of platelets to aggregation by ADP, 
adrenaline and collagen in patients with type II hyperlipidemia,127 although the dif­
ference may be explained by dissimilarities in laboratory methodology.
5.3.1.2 Cyclooxygenase activity and metabolism. The amount of TXB2 pro­
duced after arachidonic acid-induced aggregation of washed platelets may be closely 
correlated with lipid levels.505 These observations support the results of another 
study which examined thrombin induced production of TXB2 in PRP.628 In that 
study, increased TXB2 production was found in both type II and IV patients, but 
more so in the type II patients; the amount of TXB2 correlated with the LDL cho­
lesterol level and the apoprotein B concentration.628 Furthermore, TXB2 production 
in clotting whole blood was increased, as was the rate of synthesis of TXB2, in type 
II subjects.628 The amount of TXB2 produced also correlated with the plasma apo­
protein B levels in type II subjects.628
5.3.1.3 Platelet release reaction. The release of platelet BTG appears to be in­
creased in patients with hyperlipoproteinaemia and peripheral vascular disease. The 
total cholesterol level increases with age, as does the LDL cholesterol level within 
industrialised societies. An increase in plasma BTG levels in old apparently healthy 
subjects has been reported.423,629 Plasma BTG and PF4 levels have been reported to 
have a strong positive correlation with age, being more pronounced in older 
females.630 This sex difference has not been reported by others.423,629 If there is in­
creased platelet reactivity with age, the actual influence of increasing LDL levels, 
or, alternatively, the presence of asymptomatic atherosclerosis, remains to be deter­
mined.
5.3.1.4 Platelet count ratio. Lowe and his colleagues631 studied a group with 
type II hyperlipoproteinaemia and showed a significant reduction in the PCR in 
comparison to an age and sex matched control group. However, individuals with 
clinical arterial disease were included in this study, introducing a susceptibility bias.
5.3.1.5 Possible nature of the platelet-lipioprotein interaction. The presence 
of a cholesterol enriched milieu may alter the lipid and phospholipid content of the 
platelet membrane, and hence its function. Shattil and associates used sonicated 
mixtures of cholesterol and phospholipid (liposomes) to simulate an abnormal envi­
ronment.126 PRP was incubated with the liposomes causing normal platelets to ac­
quire 39% excess cholesterol with no change in the phospholipid or protein content. 
This was accompanied by a marked increase in platelet sensitivity to aggregation by 
adrenaline and ADP, without any effect on the response to thrombin or collagen. 
When platelets were incubated with cholesterol-poor liposomes, there was a 21% 
reduction in platelet cholesterol, and a marked reduction in their sensitivity to adre­
naline.126 Incubation with liposomes which caused no change in the cholesterol 
content, resulted in no alteration in platelet sensitivity to aggregating agents.126 
Using similar methods others have studied the influence of cholesterol content on the 
metabolism of arachidonic acid and found a 23% increase in TXB2 release from
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Cholesterol rich platelets, compared to 14% from cholesterol depleted platelets in the 
presence of throm bin.128 Arachidonic acid and other metabolites were released in 
significantly higher proportions from cholesterol-rich platelets. The overall increased 
aggregatory response was associated with an absolute increase in the amount of 
arachidonic acid released as well as an increase in cyclooxygenase pathway pro­
ducts, with no increase in lipooxygenase pathway products. These findings have 
been confirmed.422 This latter study also examined the effect of an increased mem­
brane cholesterol to phospholipid ratio on phospholipid metabolism; enhanced hydro­
lysis of platelet phosphatides in cholesterol-enriched platelets stimulated by thrombin 
was reported.
It is clear from these and other studies that the lipid com position o f platelets may 
have an influential effect on the function of platelets in man.65,423,627
5.3.2 Methods
The methods for the platelet function studies and lipid measurements are detailed in 
Chapter 2.
5.3.3 Results
In the control group there was no correlation between any m easures of p latelet 
aggregation and blood cholesterol, apoprotein B and triglyceride levels. In the group 
with CHD, the cholesterol level correlated with the rate of platelet aggregation with 
ad ren a lin e  (r= 0 .42 , p< 0 .02) and ADP (r= 0 .2 7 , p < 0 .0 5 ), and in v e rse ly  w ith 
LT50% aggregation with adrenaline (r=-0.27, p<0.05). Apoprotein B only corre­
lated with RADR (r=0.35, p<0.02).
The PCR and the serum TXB2 level did not correlate with any of the lipid measures 
in the case or control group. The plasma BTG level correlated inversely with apo­
protein A and HDL cholesterol levels in the control group (Table 7.11, Chapter 7). 
The MPV correlated inversely with the HDL cholesterol level in the case group, as 
did the triglyceride level (Table 7.1, Chapter 7).
5.3.4 Discussion
The results do not indicate a strong relationship  between the lipoprotein  values 
m easured and platelet function in normal subjects, but do so for in vitro platelet 
aggregation in the case group. The associations observed are consistent with in ­
creased in vitro reactivity of platelets to specific aggregating agents (particularly 
adrenaline) in patients with CHD. A sim ilar relationship was not observed in the 
control population. Previous studies of normal subjects have demonstrated a relation- 
sip between platelet aggregation (particularly adrenaline induced aggregation), and 
increasing cholesterol levels.127,419,422,424,426 A possible explanation for this inconsis­
tency may relate to the lack o f individuals with lipoprotein abnorm alities in the 
control group in this study. M ost previous studies concentrated on groups with 
abnormal lipoprotein profiles. The case group on the average had lipoprotein meas­
ures differing from the controls (e.g. higher cholesterol levels), and in the group 
with CHD the level of cholesterol did have a relationship with platelet aggregation,
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consistent with previously published results.
5.3.5 Summary
The blood cholesterol level must be included in the multivariate analysis of platelet 
function and CAD, when appropriate, in the present case-control study because:
1. A potential bias from changes in lipoproteins in the case group due to 
modification of diet following the diagnosis of the disease exists. There may still be 
an effect present although diluted by this change and hence not detectable with the 
small numbers studied.
2. There exists a large but unclear body of evidence implicating a relation­
ship between lipoproteins and abnormal platelet function.
3. There is consistency in the literature and in the present study indicating 
an influence of the blood cholesterol level on adrenaline-induced platelet aggrega­
tion.
5.4 DIETARY ASSESSMENT OF THE STUDY GROUPS
5.4.1 Specific Dietary Areas of Relevance to Platelet Function
5.4.1.1 Abnormal lipoproteins, diet and atherosclerosis. A strong relationship 
b e tw ee n  d iso rd e rs  o f lip o p ro te in  m e tab o lism  and a th e ro sc le ro s is  is w ell 
docum ented.133,258,371,587'589,632,633 An understanding of the exact pathological and 
m etabolic explanation o f the association, in term s o f cause and effect, rem ains 
incomplete.67,133,198,383,633'636 Nevertheless, the evidence that elevated blood cholest­
erol, in particular LDL cholesterol, is essential for the development of arterial ather­
osclerosis and that the diet of populations and individuals probably plays an import­
ant role, is substantial.637,638
The pathogenic mechanisms and cause-effect relationships for the development of 
CHD have been difficult to define in man. Similarly, the stages in the development 
of symptomatic CHD have also been difficult to delineate.7,381 The present evidence 
supports the concept of the early development of precursor lesions in youth, with a 
long "incubation" period prior to the development of the well known clinical syn­
dromes of CHD.7,639 The habitual diet of those susceptible to atherosclerosis prob­
ably is of major importance in the process.638 For example, dietary induced hyper­
cholesterolem ia leads to changes in the endothelium  and monocytes, resulting in 
increased  m onocyte adherence and m igration to the subendothelium ; and also 
m onocyte accum ulation of lipid to form foam cells in the sudendothelium , and 
m igration of smooth muscle cells to the area. These changes have been shown to 
occur in fatty streak form ation.242 This is relevant because the monocyte and the 
p latelet probably interact with the endothelium  in the process of atherosclerotic 
plaque formation.7,40,242,295,640 Whether of not the dietary influence is of significance 
in the non-susceptible individual or those without other CHD risk factors is another 
issue. M oreover, the diet has other potential adverse effects for those susceptible
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which may be independent of the atherogenic properties, for example, in relation to 
thrombogenic potential (See sections 1.3, 1.4 and 1.5).
5.4.1.2 Habitual diet. The customary diet of a population may well be an essen­
tial environmental factor influencing, and even determining a population’s suscep­
tibility to CHD.633,638 Diet can have an adverse influence on CHD risk in a number 
of ways. Firstly, as discussed above, abnormalities of lipoprotein metabolism are 
important risk factors for CHD258,641 and are influenced by a number of dietary 
factors.162,637,642 Dietary fatty acids, one of the most important factors determining 
plasma lipid concentrations,258,643 are amongst numerous other dietary factors poten­
tially contributing to the development of CHD.644 Secondly, the form and content of 
a diet not only affects serum lipids but also BP, glucose tolerance and diabetes, 
central body obesity and other risk factors.644 Other important dietary components 
include dietary cholesterol, total calories, fibre, electrolytes and alcohol.644 Finally, 
the effect of the habitual diet extends to the function of platelets in vitro,645,646 in­
cluding an effect of alcohol on platelet function.164 That is, the customary diet of an 
individual or population possibly influences the thrombotic risk associated with 
atherosclerosis. Indeed, susceptibility to the thrombogenic influences of a diet may 
be additional to the atherogenic effects, and, as in abnormal lipoprotein metabolism, 
the susceptibility to environmental influences may be determined by a genetic sus­
ceptibility.
5.4.1.3 Dietary fatty acids, plasma lipids and atherosclerosis. Dietary saturat­
ed fatty acids have been implicated as an important factor in the production of in­
creased plasma cholesterol in populations with an increased presence and risk of 
CHD.258,643,647,648 The potential influence of dietary factors is supported by a sub­
stantial body of literature.638,644
A reduction in dietary saturated fatty acid is the most effective single dietary means 
of decreasing blood cholesterol levels.644 However, not all saturated fatty acids 
elevate plasma cholesterol648,649 and the effect of either saturated or unsatuated fatty 
acid on plasma LDL cholesterol levels is dependent upon the concentration of cho­
lesterol in the diet.648 A diet high in stearic acid significantly reduces plasma levels 
of cholesterol and LDL cholesterol compared to a diet high in palmitic acid, the 
reduction being as much as that achieved with a high oleic acid diet.649 Increased 
linoleic acid intake lowers plasma cholesterol although the amounts needed to 
achieve this are large.650 A high intake of polyunsaturated fatty acid and plant pro­
tein, and a low intake of animal protein are associated with lower levels of potential­
ly atherogenic lipoproteins.651 In addition, the balance of evidence available at 
present indicates that monounsaturated fatty acid potentially have beneficial effects 
on blood lipids, either reducing LDL cholesterol or increasing HDL cholesterol 
levels.652,653
The amount of dietary cholesterol is of debatable relevance654,655 for the normolipi- 
demic individual.655 However, a meta-analysis of the effect of dietary cholesterol 
indicates that serum cholesterol is increased by added dietary cholesterol.656 The 
magnitude of the change is greatly influenced by the baseline dietary cholesterol in a 
hyperbolic fashion.656 The higher the dietary cholesterol the less the influence on 
serum cholesterol.656 Moreover, despite the modest average effects of dietary cho-
lesterol, some individuals are more responsive and others less responsive.656 Cho­
lesterol intake also appears to be related to the smaller LDL particles which are an 
important atherogenic lipid component651
5.4.1.4 Dietary fatty acids and platelet function. A broad body of literature has 
accumulated evaluating the influence of plasma fatty acid on platelet function, in 
both in vitro and in vivo studies. Detailed reviews have been written by a number of 
authors illustrating the relationship 65,67’625,646’657'659
A high intake of saturated fatty acid is believed to increase the risk of arterial 
thrombosis.65,625 This may be through a number of mechanisms, including increased 
platelet reactivity which is more affected by saturated fats than by blood lipids.645 An 
apparent opposite effect on platelet reactivity can be achieved by increasing the 
intake of polyunsaturated fatty acid at the expense of saturated fat.645,659 Beneficial 
effects, as measured by less reactive platelets, of diets rich in polyunsaturated fatty 
acid are well documented,660,661 although the exact effects are not fully elucidated.
5.4.1.5 Dietary fish oils and platelet function. The hypothesis that fish oils may 
prevent or retard the development of CHD and atherosclerosis has attracted consid­
erable interest but remains a hypothesis.662 Nevertheless, the effect of fish oil, and 
probably more specifically omega-3 fatty acid (n-3 fatty acid) which comprise a 
dominant component of fish oil, on platelet function has been well documented.662 
The potential protective effect on atherosclerosis of diets enriched with fish oil has 
been partially attributed to the influence of the diet on arterial thrombosis.662 
However, the area at present is in a relative state of uncertainty, so that, even the 
type of fish consumed may influence platelet function differently.663
5.4.1.6 Dietary salicylates. Interest in the levels of salicylates occurring in food 
groups has developed because of their potential effect on atopic conditions such as 
urticaria and asthma.664 Most fruits, many vegetables, some herbs and spices and tea 
contain important sources of food salicylates.664 Cereals, meat, fish and dairy pro­
ducts contain none or negligible amounts.664 The amount of salicylates ranges from 
about 10 to 200 mg/day in Western diets.664
5.4.1.7 Impact of the above observations on the current study. Despite the 
lack of scientific and clinical clarity,662 the potential benefits of fish enriched, and 
therefore n-3 supplemented diets, has been widely disseminated in the press to the 
general public. Similarly, the attempts to change the population’s diet has been a 
prime goal of many National Health Advisory Bodies. This knowledge may clearly 
influence the diet of those individuals who have developed CHD or have strong risk 
factors for its development. A cross-sectional observational case-control study under­
taken after the diagnosis may therefore be biased and hence confounded by the ef­
fects of any changes, conscious or unconscious, in the subjects diet, in particular 
cholesterol-lowering dietary changes. This latter proposal is supported by the lower 
blood cholesterol level found in the subjects with CHD compared to their previously 
known cholesterol level.
115
5.4.2 Dietary Assessment Methodology
5.4.2.1 Methods available. Three main methods for estimating group and indi­
vidual consumption of food have been used in epidemiological studies (although they 
do not constitute the only valid methods). Firstly, a dietary history is directed to­
wards obtaining a qualitative and quantitative assessment of a subject’s usual eating 
pattern. Documentation of a dietary record is undertaken by the subject with the aim 
of measuring current dietary intake and usually spans 7 days or 20 consecutive 
meals.665 An alternative method is the diet-recall interview which is directed toward 
detailing food consumption for a specific period, usually 24 hours. Longer periods 
are subject to defects in memory.665 A dietary recall method has been combined with 
a history of the frequency of the consumption of various foods in order to obtain a 
more accurate measure of the subject’s usual diet.666,667 These methods have been 
evaluated and have been found to have a high degree of correlation between esti­
mates of food consumption and all are suitable for case control studies.665 The 
accurate retrospective measurement of the long-term diet is very difficult and may 
not reflect the current diet.472,668 However, the recall method is the best predictor for 
estimation of past food and nutrient consumption.669 The limitations of the utility of 
these methods must be acknowledged because of the important influence that a dis­
ease itself, and knowledge of the disease, may exert on current food intake.665
Ideally the intake of energy and nutrient content of dietary food should be analysed 
chemically since the energy values and nutrient content of food documented in food 
tables are only estimates from averages. In group survey work, the cost and time 
required for chemical analysis makes the method impractical for most clinical and 
epidemiological research. Assessment of nutrient intake using food tables has 
become an established method for dietary surveys.670
The 24 hr dietary recall method provides reliable estimates of the average intake for 
groups, and the data has been comparable to that obtained by more time consuming 
methods.668 Nevertheless, the reliability and validity of the 24 hr dietary recall 
method is reduced when used to characterise individual patterns of food consump­
tion, or identify individuals having some form of nutritional risk.671 Variation in 
food intake over seasons of the year, days of the week and work periods are major 
sources for intra-individual variance for the short recall methods. The recall method 
is prone to over-reporting low in-takes and under-reporting high intakes with the 
attendant bias of the "flat-slope syndrome".672
A dietary record covering 7 consecutive days, or 20 consecutive meals, has been 
recommended as an adequate time to obtain a degree of validity.665
5.4.2.2 Methodological limitations. The accuracy of self-report methods of as­
sessing food intake had been questioned and the validity of methods for measuring 
normal dietary intake have been notoriously difficult.668 However, there appears to 
be an acceptable correlation between measured food intake and a dietary report, and 
self-reported food intake may be more accurate than previously thought.667
Reliability problems arise when an individual’s "usual" intake has sources of vari­
ability that cannot be attributed to true differences between individuals.673 Such error
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can arise for many reasons,673 as discussed above. The basic assumption that an 
habitual diet exists may be incorrect. There may be inherent errors within food 
composition tables. Recall accuracy of food consumed may be inaccurate. Interview 
variability is a well documented area of bias. A training effect may occur with re­
peated interviews or diary entries. There may be differences in absolute nutrient 
content for non-generically named foods. The day of the week effect due to day to 
day variation can be a substantial confounding factor. Work related differences and 
data handling errors add to these more commonly encountered sources for introduc­
tion of bias described above.666,671,673 Food composition tables are useful and have a 
well recognised utility, although their limitations are conspicuous.666,668
5.4.2.3 Food measurements and estimations. Food diaries can accurately in­
dicate the food eaten by an individual at a given time, if the subject is properly moti­
vated and is able to record carefully the intake with appropriate instruction before­
hand and checking of the record by interview afterwards.674 However, comparison 
of estimated food portions with actual measurements have revealed potentially large 
errors in portion measurements,668 although others have found an acceptably reliable 
agreement. 667 Conducting a dietary survey requiring the subject to measure the 
quantities of foods means creating new practices in the kitchen and at the table which 
may introduce bias in the form of modification of the "normal" diet. An individual’s 
food intake can be affected by the record-keeping procedure itself.472
An estimate of nutrients of special interest can also be difficult. For example, the fat 
content may vary between meat cuts and fat may be added or lost during cooking. 
However, when fat intake is assessed by a dietary history, the correlation between 
repeated measures is high for the same observer, but low for different observers.472
The contribution of systematic errors, such as coding, to the total error of calculated 
intakes for a seven-day period is likely to be small for persons with variable eating 
patterns.675 However, it still will be necessary to standardise the procedures and the 
coding, preferably by using the same interviewer, to reduce variance associated with 
subjective interpretation, thereby increasing the reproducibility of the calculated in­
takes.675
5.4.2.4 Methods of statistical inference. Correlation between dietary informa­
tion and measured parameters will be made with the knowledge that intra-individual 
variation and random errors of measurement may lead to large confidence intervals, 
misclassification and reduced accuracy of correlation coefficients. These effects can 
reduce the power of statistical inference and produce false negative correlations.671 
In such circumstances, the interpretation of any observation, in particular negative 
results, must be considered with caution in the absence of a highly reliable and 
validated estimate. However, if intra-individual variation and measurement error are 
random, there will be no bias in the mean value.668 Comparison of the results of 
dietary survey measures of samples from specific populations can be performed, 
assuming the variations are random about the mean, by comparing the means in the 
upper and lower quintiles of the characteristic being considered.668
Dietary survey methods may show differences in the averages among samples of 
people when there are large differences in the diet at the time of the survey.668 
However, small or inconstant differences are unlikely to be detected. Moreover,
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classification of an individual with respect to their diet, or specific nutrient, may 
give rise to major methodological limitations. For the dietary survey methods, the 
more important areas of bias include the misclassification resulting form wide intra­
individual variation, instability or inconstancy of the diet over time, such as in 
seasonal variation within the distribution of the population over longer periods of 
time.668 As a result of these and other causes of error described above, the intra­
individual variation may be as large as the inter-individual variation.668 If the nutri­
ent content is reported in proportion to total energy consumption, total variance 
tends to fall, inter-individual variance falls, and intra-individual variance also im­
proves, but to a lesser degree.673
5.4.3 Methods
5.4.3.1 Rational for the methodology employed. Since, within a homogeneous 
population, the variation for each individual for any particular dietary factor may be 
as large or larger than inter-individual variations,671 a seven day dietary diary was 
obtained. This approach was undertaken to improve the estimate of the true mean 
intake for any dietary factor for the individual, thereby increasing the ability to dis­
tinguish group differences for homogeneous study populations.671,668 Indeed, the 
methods described above are all applicable to case-control studies. The diet history 
was selected since the current food intake may be influenced by the disease and/or 
knowledge of the diagnosis.665 The main purpose of the dietary assessment was to 
determine if any major differences existed between the case and control group since 
dietary differences have the potential to influence the measurement of a number of 
CHD risk fac to rs.150'469,636,651 as well as some of the p latelet function 
measures.663,676 Assessing specific areas of possible differences between the two 
groups is therefore necessary to determine if areas of bias have arisen from differ­
ences in specific dietary factors, particularly if affecting platelet function parameters.
The main value of the method used will be to determine differences in grouped 
sample averages. The observations will need to be viewed with caution, particularly 
because of the potential for false negative results.
5.4.3.2 Methodology. The nutritional information obtained was the content of the 
subject’s diet for the 7 days before the blood sampling. The diet was assessed as a 
food group analysis. The subject estimated the amount of food by describing the 
number of portions of specific foods and food groups. This was estimated by the 
subject with the assistance of photographs of food models and descriptive measures 
from food tables. All data on nutrient composition of foods for approximated por­
tions was obtained from published sources although the comparison was made only 
with the groups of food types and the number of portions in that group.
The subjects were carefully instructed about the methods of documentation, impor­
tance of continuing their normal diet, on the use of the food model descriptions and 
photographs, and of what a portion of any specific and commonly used food consist­
ed. The initial instructions on how to keep an accurate diary of all food and beverage 
consumed at each meal and between meals were given to the subjects by the same 
individual (the author). The food diary was documented on a single subdivided sheet 
and on a daily sequential basis. The week consisted of meals which were routine and
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Standard for the subject and his family. A follow-up review of the recorded intake 
with the participants was undertaken in order to check for accuracy and complete­
ness. The follow-up assessment was also carried out by the same interviewer.
The dietary diaries were then coded by another person to blind the author to the 
identity of the subject for all the diaries. These were randomly coded and mixed so 
that it was unknown to the author whether the subject was from the case or control 
group. The number of portions of specific foods and groups were documented and 
are outlined in Tables 5.7, 5.8 and 5.9.
5.4.4 Results
The number of portions of meat taken by the case group was lower than the control 
group with a borderline level of significance (Tables 5.7 and 5.9). There was no dif­
ference in the number of portions for individual types of meat, that is, beef, chicken, 
pork and lamb. Nor were there any significant difference in the way the meals were 
prepared, whether fried, grilled, baked or in casserole form. In particular, no dif­
ference was observed for fried foods (Table 5.8). The case group tended to have 
more fish in a baked, grilled or casseroled form, although this was not statistically 
significant because of the high inter-individual differences leading to the high var­
iances for the groups (Table 5.7). The case group consumed significantly less full 
cream milk, substituting low fat milk (Table 5.9). In addition, the case group 
consumed significantly less sweet foods high in fat, such as pastries, cakes, sweet 
pies and so on, than the controls (Table 5.9). Therefore, the total fatty food intake in 
the control group was greater than in the case group.
Of similar importance, the case group consummed significantly more fruit than the 
control group (Table 5.9).
Because the relevance of alcohol to platelet function, this is examined in more detail 
in the next section.
5.4.5 Discussion
The cholesterol level for those with a previous measurement was significantly great­
er than the level measured at the time of the study in the case group (Table 5.1). It 
would be reasonable to assume that the diet for the case group had been modified 
since the diagnosis. To confirm such an assumption it would be necessary to extend 
the dietary assessment by obtaining a previous and current food group recall estima­
tion. This was not performed as the main purpose of the food intake evaluation was 
to determine if there were, in the current diet, any differences which might have 
influenced platelet function, given the potential differences in diet after a diagnosis 
and the possible influence of that change on platelet function. The potential for such 
an effect is highlighted in the introduction of this section which illustrates some clear 
examples were this could occur, For instance, an altered saturated fat, or other fatty 
acid intake, has the potential to measurably influence platelet function.
The presence of a lower intake of food with greater saturated fat and cholesterol 
content in the case group could potentially result in reduced platelet reactivity and
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aggregation. Such an effect could lead to a false negative result when comparing the 
case and control group, or reduce any differences found. Therefore, any measures 
indicating increased platelet reactivity or aggregability in the case group may be less 
than at the time of, or before the diagnosis of CHD was established. This dilution 
bias is unavoidable in the current study because of the case-control design, and the 
lim itation has to be fully recognised and taken into account when interpreting the 
primary study results.
Another important bias that has not been controlled for in this evaluation is response 
bias. The presence of acquiescence, or socially desirable responses, by individuals 
undertaking self-response questionnaires is well documented.471,677,678 Ideally, some 
form of assessment of this potential bias should be administered simultaneously as 
any other self-response inventories.677,678 The lack of such an assessment does pose a 
problem  in in terpretation of the results. H ow ever, the internal consistency with 
regard to the reduction of the total blood cholesterol levels since the time of diagno­
sis in the case group does support a real change in eating behaviour as documented. 
Similarly, the "halo-effect" would also influence the control group, particularly in 
regards to alcohol intake.
5.4.6 Summary
1. The subjects in the group with CHD, on the average, appear to eat less 
fatty foods, less dairy products and more fruit than the control group. There was 
also a reduction in the contemporary cholesterol level compared to previous levels in 
the same group, suggesting that a change in habitual diet has occurred since the 
diagnosis.
2. The influence of the dietary d ifferences could have lead to reduced 
platelet reactivity and measures of aggregation in the case group compared to the 
control group.
5.5 ALCOHOL, PLATELETS AND CORONARY HEART DISEASE
5.5.1 Introduction
5.5.1.1 Alcohol and cardiovascular mortality. An inverse association between 
alcohol consum ption and the risk of CHD has been documented in autopsy, case- 
control, geographic and other types of cohort studies.679 These cohort studies have 
dem onstrated that people who regularly consume small amounts of alcohol are at 
lower risk of CHD than abstainers.680'686 Indeed, evidence supporting the hypothesis 
that moderate alcohol use reduces the risk of CHD obtained from numerous prospec­
tive studies.679,681,686,687 Some prospective studies, however, have shown no relation­
ship between alcohol and CHD when other risk factors are taken into account684
The mortality associations for alcohol intake may follow a U-shaped curve.681,687,688 
Cardiovascular and total mortality rates appear to be greater in non-drinkers and in 
heavier drinkers than light to moderate drinkers.681,687 Nevertheless, even at low 
levels of alcohol intake the risk of death from cancer or stroke was greater than in
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nondrinkers.1687
The apparent protection against CHD of light daily alcohol intake may be a conse­
quence of methodological factors in the design of these studies. Firstly, an increased 
incidence of desirable attributes may be present in the mild to m oderate alcohol 
intake group. A group of light daily drinkers who have the lowest incidence of CHD 
had the lowest mean BP and BMI, and contained the lowest proportion of smokers 
and manual workers.684 Secondly, it is also possible that the observed alcohol-mor­
tality relationships in prospective studies are produced by symptoms and disease 
present at the time of screening, and by the prior movement of subjects into non­
drinking or occasional drinking categories.689 In the British Regional Heart Study the 
alcohol-m ortality  relationships for total and cardiovascular m ortality  were only 
present in men with cardiovascular disease or cardiovascular-related doctor diag­
nosed illnesses at the initial evaluation.689 In the Honolulu Heart Study the incidence 
of CHD in ex-drinkers was almost twice that seen in current drinkers.687 The West­
ern Electric study demonstrated a small decreasing trend in CHD mortality with mild 
to m oderate alcohol use.690 This trend, however, was not statistically  significant 
when differences in BP and cigarette smoking were taken into account.689
The majority of prospective studies relating alcohol intake to cardiovascular disease, 
CHD and total mortality, consistently demonstrate higher total and cardiovascular 
m o rta lity  ra tes fo r non -d rin k ers  and heavy d rin k ers  than  lig h t or m odera te  
drinkers.689 However, the apparent protective effect of alcohol may not be due to the 
m oderate use of alcohol, but instead the downward drift from heavy drinking to­
wards non-drinking under the influence of accumulating ill-health 689 Other investi­
gators have argued that this is not the case and that the increase in mortality in non­
drinkers over moderate drinkers is not due to preexisting disease or differences in 
dietary habits.679 A recent prospective study supports this argument686
5.5.1.2 Potential mechanisms for protection by alcohol against CHD. The
effect on moderate alcohol consumption of lipoprotein and apolipoprotein metabo­
lism offers a biologically plausible mechanism for the apparent protective association 
of alcohol.679 Moderate alcohol intake raises HDL cholesterol,684,686,691,692 and this 
inverse association between HDL cholesterol and alcohol intake has a dose-response 
relation.684 A full review of this association has previously been published.679 Serum 
cholesterol does not show a consistent relationship to alcohol intake,684,692 but serum 
triglyceride is positively associated.679 The inverse association between alcohol and 
CAD does not differ by age or smoking status.686
5.5.2 Methods
In the interview with the case and control subjects, each was asked the approximate 
year that alcohol use commenced, the year ceased if this was the case, the number of 
days per week alcohol was taken, and the usual number of portions per day when 
used. The self-reported number of portions were the number of standard glasses of 
beers, standard glasses of wines and of spirits. The standard glass of beer was de­
fined in the customary terms of those that drink beer, that is, as the equivalent to one 
10 oz glass (or one "middie" of beer). From this information, the duration of alcohol 
intake for those using or having used alcohol, the number of portions per week, the
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percent ceasing alcohol use and when, and the percent of alcohol users was docu­
mented.
Similarly, in the dietary diary, the subjects were requested to document daily the 
equivalent to the number of standard glasses of alcohol used for each type of alcohol 
as described above. The mean number of portions of alcohol used by the groups and 
the number of individuals using alcohol at the time of the assessment was thus 
documented.
The estimated amount of alcohol from the questionnaire and the dietary diary, the 
intake for the two groups and the percent and number of former and current drinkers 
were compared.
5.5.3 Results
5.5.3.1 Group differences. The difference in the estimated number of portions of 
alcohol previously used by both the case and control groups was not significant 
(Table 5.10). In the case group, the estimate was slightly higher than in the controls, 
but because of the wide variance the difference was not significant (Table 5.10). The 
documented number of portions of alcohol in the dietary diary was slightly greater in 
the control group, but, again, the difference was not significant given the large stan­
dard deviation (Table 5.10). There was no difference in the percent of subjects in the 
two groups who previously used alcohol (Table 5.11). The length of time that indi­
viduals used alcohol in the two groups was also the same. The mean number of 
years of drinking for the control and case groups was 22.4+/-10.3 and 21.5+/-11.3 
years respectively (95% confidence interval for the mean difference was -5.2 to 3.4,
p=0.66).
The number of subjects not using alcohol within 24 hr of the platelet function tests 
was similar in both groups (35 in the case group and 31 in the control group). The 
amount of alcohol used by the remaining subjects was also the same (Table 5.10).
However, significantly fewer case subjects admitted to the use of alcohol after the 
diagnosis of their CHD (Tables 5.11 and 5.12). Approximately 18% of subjects 
using alcohol in the case group stopped at the time of their diagnosis (Table 5.12). 
There was a borderline significant difference between the number previously using 
alcohol and the number at the time of the interview for the case group (Table 5.12). 
The number not using alcohol was also confirmed by the dietary diary (Table 5.13). 
In addition, the number of controls using alcohol at the time of the dietary diary was 
less than the number who stated that they used alcohol at the time of the interview 
(Table 5.12).
5.5.3.2 Correlation of weekly alcohol intake and other variables
(i) Coronary heart disease risk factors. The amount of alcohol used per 
week correlated positively with the triglyceride level in both the case and control 
group (Table 5.14). The total cholesterol level was significantly and positively asso­
ciated with the alcohol intake in the control group (Table 5.14). HDL cholesterol 
values did not correlate with this measure of alcohol intake. The alcohol intake
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correlated with the level of cholesterol and LDL cholesterol in the control group 
(Table 5.14).
The control group also demonstrated a relationship between alcohol intake and 
previous cigarette intake (Table 5.14). However, there were very few current 
smokers in both groups (n=23 past smokers in the control group, n=40 past 
smokers in the case group, n=4 currently smoking in the case group, and n=7 
currently smoking in the control group). None of the other measurable risk factors, 
including the BP, BMI, and the fibrinogen level, was associated with alcohol intake.
(ii) Platelet function. No platelet function measurement correlated with 
alcohol intake in this study in the control group. There was an equivocol relationship 
with platelet measures in the case group. The estimated intake of alcohol negatively 
correlated with the MPV and positively with the PCR (Table 5.14). No other meas­
ure of platelet fuction was related.
(iii) Alcohol intake and other parameters. In the control group only, the 
amount of alcohol intake correlated positively with the MCV, the pack years of 
cigarettes and the blood urate level (Table 5.14).
(iv) Alcohol intake and angiographic CAD. The alcohol intake did not 
correlate with any angiographic measure of CAD in the case group.
5.5.4 Discussion
These observations demonstrate that the use of alcohol was frequent in both the case 
and control groups, but there was no major difference between the two groups. 
There was, however, an increased likelihood that the subjects with CHD stopped 
drinking alcohol after their diagnosis. Importantly, there was not a significant dif­
ference in the percent of subjects using alcohol at the time of the evaluation and 
when the blood was collected for the platelet function tests and measurement of risk 
factors for CHD.
The results from this small case-control study confirm that the amount of alcohol use 
can be estimated reasonably well by a single self-report of intake.693 In the control 
group, the mean weekly intake estimated by the dietary record was slightly but not 
significantly higher than estimated in the questionnaire, an observation also reported 
by ohers.693 However, the lower number of control group subjects using alcohol 
during the week of the dietary diary indicates that a single measure of alcohol may 
not reflect the pattern of drinking for a group. Alternatively, this reduction may arise 
from intentional under-reporting, although under-reporting would be expected to be 
less likely for moderate consumption.693 As in other aspects of the dietary diary and 
self-reported measures discussed above, an important bias that has not been con­
trolled for in this evaluation is response bias.471,677,678
The pattern of alcohol intake by the CHD case group in this study supports the 
concept that, at least in part, the increased CHD mortality differences related to 
alcohol intake are due to the downward shift of intake by individuals already with 
disease symptoms.689 As a cross-sectional study, the results cannot negate the ob-
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servations from a large prospective study, that, even taking the downward shift into 
account, there remains an inverse association between alcohol intake and CHD.686 
However, there are a number of other important observations arising from this latter 
study. Firstly, despite an increase in dietary risk factors for CHD in the groups with 
higher alcohol intake, the CHD mortality was less, implying that alcohol can protect 
against the adverse effects of other dietary risk factors. Those drinking more alcohol 
on the average also smoked more and had a more frequent diagnosis of hyperten­
sion, and despite both of these being very powerful risk factors for CHD, there was 
less cardiovascular events in the follow up period.686 If the observations are correct, 
alcohol would have a very powerful protective effect against CHD. Secondly, the 
results confirm that there is no increased risk of CHD in abstainers, although the 
total mortality data were not reported.686 This observation does support the prospect 
that movement of higher risk individuals into the group of abstainers from alcohol, 
but not the light to moderate drinking group, may have been a cause of the U-shaped 
curve for cardiovascular mortality in previous studies.689 The exclusion of non­
drinkers and men with disorders potentially related to CHD which may have lead to 
a prior reduction in alcohol intake, did not affect the relative risk associated with 
alcohol. Thirdly, it would appear that the more an individual drinks alcohol and the 
more often, then the lower the risk of CHD. Obviously, this probably would be 
offset by the total mortality increase well known with high levels of alcohol intake, 
although the data was not presented. From this study, and looking at alcohol intake 
alone, alcohol appears to impart a strong protective effect against cardiovascular 
disease.686
As in all such epidemiological studies, potential areas of bias exist. Firstly, the 
group consisted of upper socioeconomic and educated individuals, a population 
different to that in previous studies.689 This is pertinent since both the risk and in­
cidence of CHD is greater in the lower socioeconomic groups,646 the prevalence of 
risk factors are greater459,460,646 and the prevalence of increased alcohol intake is 
greater.646 Secondly, the results appear to differ from most other prospective studies. 
Almost all prospective studies in heavy drinkers have consistently shown an associa­
tion between increased mortality from CAD and increasing alcohol intake, in con­
trast to moderate alcohol intake.679 Again, there are potential confounding issues 
leading to such spurious results,679 although the observations appear reproducible in 
other studies.689 Thirdly, the groups with higher alcohol intake also used more aspir­
in on a regular basis, a potentially powerful treatment bias considering acute coro­
nary events are included in the outcome analysis.100,103’105,694"698
Using simple linear correlation without adjustment for other risk factors, there was 
no association between HDL cholesterol values and prior total weekly alcohol intake 
in both study groups. However, with greater numbers there may be an association, 
as has been demonstrated in large studies.693 There was an apparent association 
between alcohol intake and triglyceride levels and measures related to LDL cholest­
erol. Others have demonstrated a decrease in LDL cholesterol with alcohol intake,699 
while other studies have shown no relationship.680 It is clear that those who consume 
more alcohol have a diet richer in fat.686 There is evidence that the case group in this 
study changed both the fat content and alcohol content of their diet, which would 
have major confounding influence on any associations that may have been present 
pre-morbidly. This is also supported by the consistent relationship in the controls
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between variables that are known to be influenced by alcohol intake. Those that used 
more alcohol in the control group had a higher MCV, smoked more cigarettes and 
had a higher blood urate level. The increased use of tobacco in those using more 
alcohol is well documented.686
A number of causes of this possible protective effect of alcohol have been postulat­
ed,679,699 in particular an elevation of the HDL cholesterol level.604 If increased HDL 
cholesterol does provide a mechanism by which alcohol use can protect against the 
development of CHD, this would only explain about 50% of the protective effect.699 
It has been postulated that factors influencing haemostasis are potential candidates 
for the added protective effect.164,699,700 Platelet aggregation in response to ADP 
appears to be inhibited by alcohol intake,700 and by the same level of alcohol use that 
protects against C H D .164 There was no m easurable association between alcohol 
intake and platelet function measures, including measures of platelet aggregation in 
the control group in this study. This may again be due to a type II statistical error, 
but even if so, the clinical importance of such an association would only be small. 
However, in the control group, increasing alcohol intake was associated with smaller 
platelet volume and also less platelet aggregate formation during blood collection. 
This equivocol association in the case group would in fact increase the possibility of 
a false negative result because of alcohol use, that is a dilution bias. Nevertheless, a 
difference in these parameters was documented and moreover, there was no measur­
able difference between the alcohol intake of the two groups.
5.5.5 Summary
1. Any associations, or lack of association, between alcohol intake and 
other parameters needs to be interpreted with caution given the major confounding 
influence resulting from the change in diet, including alcohol use, in the case group 
since their diagnosis was first established.
2. The differences in p la te let function dem onstrated  in this study are 
unlikely to be biased by alcohol use resulting in increased platelet reactivity in the 
case group.
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Table 5.1. Lipoprotein measures for the case group patients.
Mean+/-SD Mean+/-SD
Cholesterol(Pr) 
Cholesterol(Sr) 
Triglyceride(St) 
HDL(St) 
Apoprotein B
6.08+/- 1.41 
5.64+/- 1.11 
2.21+/- 0.23 
0.86+ /-  0.21 
0.95+/-0.17
Cholesterol(St) 5.18+/-0.74
Cholesterol (Sm) 5.46+/-0.90
Triglyceride(Sr) 2.24+/-0.17
HDL(Sr) 0.95+/-0.23
Apoprotein A l 1.21+/-0.28
Pr=previous (n=27), 
St=reference laboratory (serum), 
Sr=service laboratory (plasma), 
Sm=service laboratory (serum), 
HDL=HDL cholesterol.
All measures in mmoles/1.
Table 5.2. Analysis of variance of the comparison between all the cholesterol levels.
Comparison mean
d ifferen ce
uncorrected
d va lu e
Bonferroni
p v a lu e
A versus B 0.90 0.0006 p<0.01 **
A " C 0.44 0.0825 p>0.05
A " D 0.62 0.0154 p>0.05
B " C -0.46 0.0199 p>0.05
B " D -0.28 0.0153 p>0.05
C ” D 0.20 0.3568 p>0.05
A = previous cholesterol (Pr, n=27),
B = study serum cholesterol (St, from reference laboratory in serum), 
C = service laboratory plasma cholesterol (Sr),
D = service laboratory serum cholesterol (Sm).
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Table 5.3. Correlations between lipoproteins and angiographically defined athero­
matous disease.
CAS mCAS nCAS dist 50/75% 25/50% 10/25%
DOB (year) -0.27* -0.29* -0.20 -0.19 -0.31* -0.10 -0.12
NYHA FC 0.20 0.23 0.40# 0.13 -0.09 0.19 0.03
Choi (Pr) 0.46# 0.44# 0.48* 0.51# 0.35* 0.45# 0.23
Choi (St) 0.23* 0.27* 0.15 0.40* 0.28* 0.25* 0.29*
Choi (Sr) 0.29* 0.33# 0.29* 0.08 0.36# 0.30* 0.33#
Choi (Sm) 0.26* 0.28* 0.15 0.16 0.28* 0.27* 0.29*
Trig (St) -0.17 -0.20 -0.18 -0.19 -0.26* 0.07 0.02
Trig (Sr) -0.19 -0.21 -0.19 -0.23 -0.15 0.01 -0.11
HDL (St) 0.01 0.03 -0.10 0.01 0.03 -0.03 -0.04
HDL (Sr) -0.05 -0.02 -0.16 0.08 0.09 -0.05 -0.01
Apo B 0.35# 0.35* 0.23 0.26* 0.30* 0.33* 0.36#
Apo A1 0.09 0.12 0.02 0.01 0.13 0.09 0.08
*p<0.05, #p<0.01, All values are the Pearson correlation coefficient.
CSS=coronary stenosis score, mCSS=mean CSS, pCSS=proximal CSS, CAS=coro- 
nary atheromatous score, mCAS=mean CAS, pCAS=proximal CAS, Jenkins=Jenkins 
coronary score, and LVS=left ventricular score. Data are shown as mean +/- SD. See 
the Methods section for an explanation of the scores.
Chol=cholesterol, trig=triglyceride, HDL=HDL cholesterol, Apo B=apoprotein B, 
Apo Al=apoprotein Al, NYHA FC=New York Heart Association functional class for 
angina. See Table 5.1 for other abbreviations.
Table 5.4. Correlations between lipoproteins and angiographically defined measures 
of disease severity.
CSS mCSS pCSS 100% 90/99% 75/90% Jenkins
DOB (year) -0.25* -0.25* -0.22 0.01 -0.34# -0.17 0.28*
NYHA FC 0.31* 0.34# 0.55** 0.41# 0.13 0.03 0.21
Choi (Pr) 0.28 0.27 0.45* 0.09 0.30 0.45# 0.38*
Choi (St) 0.16 0.17 0.18 0.03 0.15 0.25* 0.21
Choi (Sr) 0.21 0.21 0.28* -0.01 0.16 0.30* 0.27*
Choi (Sm) 0.10 0.10 0.07 -0.16 0.20 0.27* 0.22
Trig (St) -0.21 -0.23* -0.13 -0.19 -0.01 0.07 -0.24*
Trig (Sr) -0.19 -0.21 -0.13 -0.20 -0.03 0.01 -0.19
HDL (St) 0.16 0.19 0.07 0.14 0.09 -0.03 0.13
HDL (Sr) 0.16 0.07 -0.12 -0.04 0.03 -0.05 0.07
Apo B 0.17 0.15 0.19 -0.06 0.17 0.33* 0.27*
Apo A1 0.20 0.12 0.09 0.05 0.10 0.09 0.21
*p<0.05, #p<0.01, **p<0.001
See Tables 5.1 and 5.3 for abbreviations.
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Table 5.5. Correlations between lipoproteins, functional class for angina, age and 
number of infarcts and normal segments, LV function and collateral supply.
Norm LVS CS Coll
DOB (years) 0.23* -0.11 -0.10 0.08
NYHAFC -0.15 0.05 0.39# 0.33#
No AMI -0.18 0.42# -0.03 0.13
Choi (Pr) -0.46* 0.09 0.36* 0.13
Choi (St) -0.33# -0.05 0.09 0.05
Choi (Sr) -0.38# -0.03 0.11 0.08
Choi (Sm) -0.30* 0.04 0.03 -0.09
Trig (St) 0.25* 0.01 0.05 0.02
Trig (Sr) 0.29* 0.11 -0.08 -0.06
HDL (St) -0.09 0.10 0.02 0.04
HDL (Sr) -0.01 0.10 -0.12 -0.11
Apo B 0.39# -0.06 0.07 0.02
Apo Al 0.24 0.05 0.02 0.06
*p<0.05, #p<0.01, **p<0.001
See Tables 5.1 and 5.3 for abbreviations.
Table 5.6. Multiple regression entering apoprotein Al, apoprotein B, the study cho­
lesterol level, triglyceride level, HDL cholesterol level and age as independent varia­
bles and the coronary artery scores as the dependent variables.
Dependent Independent
Variable Variable B SEB Beta Rsq Si?
NORMSEG Apo B -0.0854 0.0260 -0.4469 0.1547 0.0022
CAS Apo B 0.2220 0.0940 0.3497 0.1224 0.0231
mCAS Apo B 0.1808 0.0756 0.3535 0.1250 0.0216
mCSS DOB -0.9300 0.4535 -0.3083 0.0951 0.0469
JENKINS DOB -0.4264 0.2070 -0.3097 0.0959 0.0459
LVS DOB -0.1461 0.0575 -0.3726 0.1388 0.0151
B=regression coefficient, Rsq=coefficient of determination.
SE B = standard error of B, DOB=year of birth. See Tables 5.1 and 
5.3 for other abbreviations.
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Table 5.7. Main Dietary Constituents Measured in Portions.
CONTROLS CASES
Mean SD Mean SD Diff 95% Cl p
DAIRY PRODUCTS
Milk - full 2.9/0.5 1.7/2.5 1.1 -2.4 to 0.01 0.07
- low 2.4/3.9 3.5/5.1 1.1 -0.9 to 3.2 0.28
Addedmilk-high 8.2/12.7 4.0/7.5 4.3 -8.6 to 0.1 0.05*
Addedmilk-low 4.1/9.1 7.3/11.7 3.2 -1.6 to 7.9 0.19
Addedsugar 8.3/12.9 9.3/12.7 1.0 -4.6 to 6.7 0.71
Cream 0.3/0.6 0.2/0.6 0.1 -0.4 to 0.2 0.53
Yoghurt -full 0.4/1.3 0.4/1.1 0.0 -0.6 to 0.5 0.92
-low 0.4/1.2 0.2/0.9 0.1 -0.6 to 0.3 0.53
Cheese -full 3.1/4.0 2.0/3.4 1.0 -2.6 to 0.6 0.20
-low 0.3/1.1 0.4/1.1 0.01 -0.4 to 0.6 0.76
Icecream -full 1.1/1.4 1.0/1.9 0.01 -0.8 to 0.7 0.81
Butter 3.9/8.7 2.5/6.8 1.4 -4.8 to 2.0 0.41
Margarine 20.4/15.2 19.7/11.6 0.6 -6.4 to 5.2 0.83
Eggs - total 1.2/1.7 1.0/1.8 0.2 -1.0 to 0.6 0.63
MEAT
Total Meat 11.3/5.5 9.4/4.1 1.9 -4.0 to 0.2 0.07
Fried Meat 1.7/2.7 1.6/1.8 0.1 -1.1 to 0.9 0.86
Beef 5.1/3.5 4.0/2.7 1.1 -0.2 to 2.5 0.10
Chicken 2.4/2.4 2.1/1.9 0.2 -1.2 to 0.7 0.65
FISH
Total Fish 3.0/1.6 2 1 /2.6 0.3 -1.5 to 0.9 0.60
GBC Fish 1.4/1.6 1.9/2.2 0.5 -0.4 to 1.4 0.26
Shell Fish 0.4/0.9 0.3/0.7 0.01 -0.4 to 0.3 0.61
G BC=grilled+baked+casseroled, high=full cream , low=reduced 
fat
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Table 5.8. Main Dietary Constituents.
CONTROLS CASES
Mean SD
OTHER FAT SOURCES
Mean SD Diff 95% Cl P
Fry/Takeaways 2.1/2.0 1.8/1.8 0.2 -1.1 to 0.6 0.57
Sweets & Bisc 12.5/10.8 9.9/10.1 2.6 -7.2 to 2.0 0.26
Sweets alone 6.6/5.7 3.5/3.3 3.1 -5.0 to-1.1 0.002
Sweet snacks 1.9/3.4 2.3/5.3 0.4 -1.7 to 2.4 0.73
Added oils 1.6/1.9 1.8/3.3 0.3 -1.0 to 1.5 0.68
Nuts 0.6/1.3 0.5/0.9 0.1 -0.6 to 0.4 0.66
SANDWICHES
Meat 1.9/2.8 1.9/2.4 0.1 -1.1 to 1.2 0.90
Cheese 1.5/2.4 1.1/2.2 0.4 -1.4 to 0.6 0.48
Salad 2.0/3.7 1.6/3.0 0.4 -1.9 to 1.0 0.57
CEREALS
Total 37.6/17.2 34.8/10.7 2.9 -8.9 to 3.2 0.35
FRUIT
Total 7.9/7.0 11.6/8.4 3.6 0.2 to 7.1 0.04*
VEGETABLES
Total 17.2/9.2 18.7/8.7 1.5 -2.4 to 5.4 0.46
SALADS
Total 2.1/1.8 2.7/2.9 0.6 -0.5 to 1.7 0.30
CAFFEINE
Coffee 11.9/9.5 10.0/10.01 2.0 -6.3 to 2.4 0.37
Tea 11.6/9.4 11.6/10.0 0.0 -4.3 to 4.3 0.99
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Table 5.9. Differences in the dietary constituents (Significant and borderline signifi­
cant).
CONTROLS CASES
Mean/SD Mean/SD Diff 95% Cl p
TOTAL MEAT 11.3/5.5 9.4/4.1 1.9 -4.0 to 0.2 0.07
SWEETS ALONE 6.6/5.7 3.5/3.3 3.1 -5.0 to -1.1 0.002*
MILK - full 2.9/0.5 1.7/2.5 1.1 -2.4 to 0.0 0.07
- low 2.4/3.9 3.5/5.1 1.1 -0.9 to 3.2 0.28
- added full 8.2/12.7 4.0/7.5 4.3 -8.6 to 0.1 0.05
- added low 4.1/9.1 7.3/11.7 3.2 -1.6 to 7.9 0.19
FRUIT 7.9/7.0 11.6/8.4 3.6 0.2 to 7.1 0.04*
Table 5.10. Previous and current alcohol intake measured in standard portions.
Controls Cases 95% Cl
Alcohol portions/week 14.0+/-15.1 18.3+/-20.2 -2.8 to 11.4
(previous estimated) (n=44) (n=44) p=0.23
Alcohol portions/week 18.5+/-13.4 14.7+/-13.1 -10.3 to 2.6
(dietary diary) (n=32) (n=35) p=0.24
Alcohol 24 hrs before 3.2+/- 1.4 3.1+/- 1.4 -0.8 to 1.2
(n=17) (n=18) p=0.71
CI=confidence interval of the mean difference
Table 5.11. Previous and current alcohol as stated by the subjects in the two groups.
Controls Cases
Previous Alcohol use 44 (92%) 44 (83%) p=0.130 OR=3.0
Current Alcohol use 44 (92%) 35 (66%) p=0.001 OR=7.5
Stopped at diagnosis 8 (18%)
Stopped before diagnosis - 1 (2%)
OR=odds ratio
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Table 5.12. Difference between the number of current and previous number of sub­
jects using alcohol in the case group.
Alcohol No Alcohol
Previous 44 (83%) 9 (17%) Chi square=3.18
Current 35 (66%) 18 (34%) p=0.07
Odds Ratio=2.51 (Yates correction applied)
Table 5.13. Previous and current alcohol intake as documented in the seven day die­
tary diary by the subjects in the two groups.
Controls Cases
Previous 44 (92%) 44 (83%) Chi square=0.01
Diary 32 (66%) 35 (66%) OR=l.l p=0.9
Table 5.14. Correlations between the weekly alcohol intake, assessed in standard 
portions, and CHD risk factors.
Weekly Intake Daily Intake
Controls Cases Controls Cases
Cholesterol 0.34# -0.02 0.42## 0.20
Triglyceride 0.30* 0.34# 0.34* 0.14
Apoprotein B 0.21 -0.10 0.29 0.25
LDL cholesterol 0.28* 0.05 0.40 ** 0.26
HDL cholesterol 0.04 -0.21 0.01 -0.09
Apoprotein A1 0.02 -0.10 -0.02 0.11
MCV 0.30* 0.21 0.27 * 0.10
Packyear 0.38 0.01 0.51# 0.22
Cigarettes/day 0.32 0.21 0.47 * 0.25
Urate 0.41 ** 0.13 0.45## 0.12
MPV -0.20 -0.10 -0.28 * -0.10
PCR 0.26 -0.01 0.35 * 0.05
* p < 0.05, # p < 0.02, ** p < 0.01, ##p < 0.005
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ANGIOGRAPHIC SCORES FOR APOPROTEIN B LEVELS
E S  CAS
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Figure 5.1. Mean coronary atheromatosis score (CAS) and the mean of the averaged 
coronary atheromatosis score (mCAS) for the subjects when grouped into 4 incremen­
tal categories of apoprotein B levels.
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Figure 5.2. Mean number of normal segments (Normseg), coronary artery segments 
without angiographically visible CAD, for the subjects when grouped into 4 incremen­
tal categories of apoprotein B levels.
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CHAPTER 6
PLASMA FIBRINOGEN AND CORONARY HEART DISEASE
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6.1 THE RELATIONSHIP BETWEEN BLOOD FIBRINOGEN LEVEL 
AND ANGIOGRAPHICALLY DEFINED CORONARY DISEASE
Blood fibrinogen may have a major influence on platelet function and have a con­
founding effect on the results of this study. Therefore, an examination of the rela­
tionship between fibrinogen level, platelet function measures and CAD was under­
taken.
6.1.1 Introduction
An association between CHD and blood fibrinogen level has been found in a number 
of larger epidemiological reports.701 These include prospective cohort studies,373,702 
cohort studies in different populations,372,703 population based cross-sectional 
studies,704,705 and case-control studies.706,707 Furthermore, persistently elevated 
fibrinogen levels have been observed in individuals with recurrent MI708 and periph­
eral vascular disease 709
Despite these consistent epidemiological reports, the results of studies examining the 
relationship between the severity of angiographically defined CAD and fibrinogen 
level have not been uniform.374,710' 713 A correlation between fibrinogen levels and 
the number of arteries having haemodynamically significant obstructive CAD le­
sions374 is controversial.711,713 A relationship between mean fibrinogen levels and 
multi-vessel disease has been observed.712 In addition, some cumulative scoring 
systems of CAD severity show an association with fibrinogen levels.374,711 while 
others do not.713 These inconsistencies may have resulted from the numerous 
avenues for bias to give a non-causal relationship, particularly since fibrinogen 
increases as a non-specific response to a diverse variety of stimuli, including in­
flammation and tissue injury which are characteristics of atherosclerotic disease.242 
Indeed, it is conceivable that raised fibrinogen levels result from extensive atheros­
clerotic involvement of the arterial system, particularly if there are recurrent cycles 
of plaque Assuring, fibrin plug formation and repair of endothelial integrity.
This section evaluates the relationship between blood fibrinogen, CHD risk factors 
and both the extent and the severity of angiographically defined CAD. It is proposed 
that if the relationship between CHD and fibrinogen is due to a non-specific response 
to atherosclerosis, those individuals with more extensive CAD will have higher 
fibrinogen levels compared to those with predominantly localised severe disease 
without extensive mural involvement.
6.1.2 Methods
6.1.2.1 Patient Population. The patient population studied consisted of the group 
of 91 male Caucasians, all with documented CAD, undergoing elective coronary 
angiography for evaluation of CHD. The patient group were selected as a serial 
angiographic study group. The selection was based on the patient having CHD and 
documented angiographic CAD. This group was evaluated prior to the case-control 
study and was investigated to determine the significance of certain less established 
risk factors such as blood fibrinogen, which is being discussed in this Chapter. The 
group comprises a different cohort of patients with similar selection criteria to the
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case-control study except there was no age limitation. The mean age was 53.2 years 
(range 35 to 69 years). Patients were excluded on the following criteria: myocardial 
infarct within 5 weeks, valvular heart disease, right heart failure or current use of 
anticoagulants; recent infection, surgery or trauma; any inflammatory disease, dia­
betes, overt renal disease, liver disease or coagulopathy. The patients were unselect­
ed with respect to the severity, nature or duration of symptoms and concurrent drug 
therapy, apart from anticoagulant use.
6.1.2.2 Angiographic Scoring Methods. Coronary angiograms were graded to 
give a measure of the severity and extent of atherosclerotic disease by a semi-quanti­
tative method.207 The methodology is described in detail in Chapter 8.
6.1.2.3 Laboratory Measurements. Laboratory methods used are described in 
Chapter 2.
6.1.2.4 Statistical Analysis. All statistical methods used are described in Chapter 
2. The association between the fibrinogen level and CAD after adjustment for other 
major risk factors was further assessed using analysis of covariance. For the analysis 
of covariance the fibrinogen was defined as the continuous dependent variable, the 
coronary artery scores the independent factor categorised into 4 groups, and the 
major risk factors as the covariates. The time since the last MI, the number of in­
farcts reported and the time from cessation of smoking were skewed to the right and 
were therefore logarithmically transformed before parametric analysis. The fibrino­
gen distribution conformed closely to a normal distribution in our population 
(mean=314 ,median=300 and skewness=1.105).
6.1.3 Results
6.1.3.1 Patient Characteristics. The group values for the major risk factors and
the results of the angiograhic scores are summarised in Table 6.1. Only 2 patients 
were currently smoking and 81% had formerly been tobacco users. The mean inter­
val since cessation of tobacco use was 7.3 (SD+/-12.1) years, although 44% had 
only ceased within one year and 65% within 5 years. The mean cholesterol level was 
5.62 (SD+/-0.96) mmol/1. Twenty seven percent of patients had a triglyceride level 
over 2.0 mmol/1 and 36% with a HDL cholesterol less than 0.9 mmol/1. Only 19% 
of the patients had been informed of a diagnosis of hypertension. One had a systolic 
BP greater than 140 mmHg and three patients had a diastolic pressure greater than 
90 mmHg whilst on drug therapy. All patients were on some form of medication; 
45% were using beta-blockers, 46% were on calcium entry blockers, 30% were on 
nitrates, 8% were on diuretics, 2% were on digoxin and 1% on antiarrhythmics. 
There were no subjects with a fibrinogen level below the reference range for the 
laboratory (150mg/ml), although 19 patients were above this range (400mg/ml).
Seventeen patients gave no history of a previous acute AMI, 55 patients had one 
AMI, 12 claimed to have had 2 AMIs and 4 patients had had 3 AMIs. Three patients 
were uncertain. The ECGs of 58 patients were consistent with a previous AMI and 
28 were indeterminate. Abnormalities on the left ventriculogram indicative of a 
previous MI were seen in 68 patients. The mean time from an AMI was 240 days 
(range 35 to 2990 days, median 110 days, earliest 35 days). Fourteen patients de-
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scribed no angina, 31 had a variable level of angina, 30 had a predictable level of 
exertional angina with normal activity, 13 had angina on minimal exertion and 3 
described intermittent rest pain.
6.1.3.2 Fibrinogen and CHD Risk Factors. For descriptive purposes, fibrinogen 
levels were divided into four groups of increasing amount with approximately equal 
numbers for a graphic examination between fibrinogen and other CHD risk factors 
(Fig. 6.1 and Fig 6.2). Possible associations between fibrinogen and the risk factors 
were examined by linear correlation (Table 6.2). The amount of previous chronic 
cigarette use, the triglyceride level and age were directly related to the fibrinogen 
level in patients with CHD (Table 6.2). The relationship between fibrinogen and 
current tobacco use could not be evaluated since only 2 patients admitted to continu­
ing smoking of tobacco. The fibrinogen level was also inversely and independently 
related to the HDL cholesterol level (Table 6.2). There was no relationship between 
body weight and fibrinogen level.
Multiple regression analysis using fibrinogen as the dependent variable demonstrated 
an independent association between the fibrinogen level and three major risk factors 
for CHD; previous cigarette smoking and age were directly, and the HDL cholester­
ol level inversely associated with the fibrinogen level (Table 6.3). Hypertension, 
cholesterol and triglyceride levels did not demonstrate an independent predictive 
association for fibrinogen level with multiple regression analysis.
6.1.3.3 Age, Risk Factors and Angiographic Score. The age of the patient 
correlated with the level of cholesterol, the systolic BP and the fibrinogen level, and 
inversely with the HDL cholesterol level (Table 6.2). There was a clear predictable 
relationship between age and many of the angiographic scores (Table 6.2). In partic­
ular, a direct but greater correlation between the extent of CAD (CAS) than the 
severity (CSS), a direct correlation with the number of segments with diffuse disease 
and with calcification, and an inverse relation to the number of normal segments 
were present (Table 6.2). These associations are consistent with known and expected 
relationships between age, CAD and risk factors, and give an indication as to the 
validity of the methodology used.
An independent predictive association between the other major risk factors and the 
CAD scores by multiple regression analysis was not demonstrated in this study. The 
only risk factor predictive of the CAS and CSS in the multiple regression analysis 
was age (B=6.8859, SE B=3.2955, 95% confidence interval 0.2667 to 13.5051, 
p=0.04; and B = 14.7407, SE B=5.7151, 95% confidence interval 3.2616 to 
26.2199, p=0.01 respectively for CAS and CSS).
6.1.3.4 Fibrinogen and Coronary Artery Disease. An illustrative presentation 
of the relationship between fibrinogen, divided into four subgroups, and the meas­
ures for extent (CAS) and severity (CSS) of CAD is depicted in Fig 6.3. There is a 
clear increase in the severity score with increasing fibrinogen level when comparing 
the lower and higher groups. There was a modest but significant direct univariate 
correlation between fibrinogen and the number of stenosis >50% and >70%, the 
number of coronary artery occlusions, the CSS and the collateral score (Table 6.2). 
This association between fibrinogen and severity was not present when fibrinogen
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was entered into a multiple regression model after adjusting for other risk factors for 
CHD (viz, age,cigarette packyears, cholesterol, HDL cholesterol and triglyceride 
levels). In this model, the dependent variable was the severity measure and the 
independent variables were fibrinogen and the other risk factors.
The converse was found when fibrinogen was considered the dependent variable. 
The level of fibrinogen was found to be partially dependent on, and predicted by the 
severity of CAD (CSS) along with the age of the patient, volume of previous cigar­
ette use, and the inverse of the HDL cholesterol level, but not the extent of disease 
(CAS) or the severity of left ventricular dysfunction (LVS) (Table 6.3). These signif­
icant associations by multiple regression analysis remained significant for those 
patients not taking beta-blockers or calcium entry blockers.
6.1.3.5 Fibrinogen, Myocardial Infarction and Left Ventricular Damage.
Fibrinogen levels had a modest direct association with the number of AMIs and also 
with the number of total arterial occlusions demonstrated angiographically, and the 
score of wall motion abnormalities (LVS) (Table 6.2). Those patients who had 
evidence of left ventricular damage as measured by wall motion abnormalities on the 
ventriculogram had a higher level of fibrinogen than those with normal function 
(Table 6.4). The group with the highest levels of fibrinogen had on average a signif­
icantly greater degree of LV dysfunction as supported by a direct univariate correla­
tion between fibrinogen and LVS (Table 6.2). Those with LV damage also had a 
greater volume of cigarette intake during their life (Table 6.4). None of the other 
major risk factors assessed were related to the LVS. Furthermore, there was no 
relation between fibrinogen level and the time since the last AMI.
Multiple regression analysis failed to confirm an independent association between 
LV damage and fibrinogen levels when the severity score and other risk factor 
variables were taken into account. The only independent variable associated with the 
LVS determined by multiple regression analysis was the measure of severity of CAD 
(CSS).
6.1.4 Discussion
In males with established CHD, a modest direct linear association exists between 
fibrinogen levels and the severity of CAD but not the extent of coronary atheroma. 
The fibrinogen level in this group of CAD patients is partly dependent on other risk 
factors (age, smoking and HDL cholesterol level) as well as the presence of severe 
stenoses. Given this last observation, it is feasible that an underlying disease process 
may concomitantly cause severe intraluminal obstructive lesions and increased fibri­
nogen levels, such as recurrent mural thrombosis and fibrin formation within and/or 
over atherosclerotic plaques.639,714
A descriptive assessment of the relationship between fibrinogen and other variables 
was made by dividing fibrinogen into 4 groups with an increasing range of values. 
This descriptive illustration supports the modest linear relationships shown in the 
correlation assessment, and, more importantly, demonstrates the poor clinical utility 
of the fibrinogen level for predicting severity or extent of disease in an individual. 
Other studies have also shown a marked overlap of the fibrinogen levels between
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groups having increasing CAD severity.374 The fibrinogen level in such groups also 
had a large standard error of the mean.374
Previous studies evaluating the relationship between fibrinogen and angiographically 
defined CAD have made conflicting observations. A significant association between 
fibrinogen and a measure of CAD has been documented previously711 and multive­
ssel CAD disease patients have higher fibrinogen levels than patients with single 
vessel disease.712 Another study, using multiple linear regression, failed to show any 
predictive relationship between fibrinogen and angiographic CAD.713 The disparities 
between these reports, and with the current study, most likely arise from methodo­
logical differences, particularly in relation to the method of defining CAD. For 
example, the scoring system criteria used in one study713 was derived from clinical 
requirements and lesion haemodynamics, and does not provide a broad gradient 
measure of overall extent and severity of atherosclerosis. In a more recent study,374 
which reported plasma fibrinogen as being an independent predictor of CAD severi­
ty, a number of methodological anomalies exist. For example, alcohol intake was 
entered into the multivariate analysis used in the study even though it was not corre­
lated with fibrinogen levels and it is an equivocal risk factor for CAD. Yet triglyce­
ride levels, which may influence the relationship,713 were not entered. Furthermore, 
patients with severe left main stem arterial lesions were excluded, ex-smokers of 5 
years or more were considered non-smokers, controlled diabetics were included, 
and, even though the blood sugar univariately correlated with fibrinogen, it was not 
entered into the multiple regression analysis. Also, approximately 33% of the male 
group studied did not have significant obstructive CAD (Gensini score of zero). 
Despite these patient population and methodological differences, both our observa­
tions and this report374 support the presence of an independent association between 
severe disease and fibrinogen level, with fibrinogen as the dependent variable. 
Unfortunately neither study can clarify whether the association provides an aetiolog- 
ical link between plasma fibrinogen and obstructive CAD.
The degree of functionally impaired myocardium has a direct and proportional asso­
ciation with fibrinogen. A negative correlation has previously been demonstrated 
between fibrinogen and left ventricular ejection fraction.713 This observation is in 
agreement with the positive association between the LVS and fibrinogen level. 
However, this association would appear to be indirect rather than causal, since the 
only variable independently associated with our measure of left ventricular dysfunc­
tion (LVS) by multivariate analysis is disease severity, the fibrinogen level only 
being related by association with disease severity (CSS).
An increase in fibrinogen occurs in the acute phase of a MI.715'717 In general fibrino­
gen reaches a maximum level within the first week715,716 and in most cases returns to 
pre-infarct levels within 3 to 4 weeks.715 This time course parallels that for the 
healing of necrotic tissue within the myocardium following an infarct.11 This study 
has demonstrated an association between fibrinogen and left ventricular segmental 
dysfunction present beyond such a time frame. However, our multiple regression 
analysis would suggest that chronically elevated levels are more directly related to 
the underlying disease severity. Similarly, the univariate relationship of fibrinogen 
with the number of AMI probably arises indirectly via disease severity, or by 
mechanisms simultaneously leading to severe lesion development, AMI, and in-
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creased fibrinogen production.
Previous studies have established an association between fibrinogen and a number of 
the m ajor risk  fac to rs for CHD. These fac to rs  include ag e ,705,718'720 tobacco  
use,327,703,718'721 blood cholesterol level,372,631,721 and lower socioeconomic status.722 
We have confirmed the presence of an independent direct relationship between the 
fibrinogen level and previous cigarette use by an individual. This study cannot eval­
uate the acute effects of cigarette smoking on fibrinogen levels. The association was 
with the total volume of cigarette intake during the life of the patient, supporting the 
observation that it may take more than 5 years for fibrinogen to return to pre-smok­
ing levels.60 It is of relevance that ex-smokers may be at higher risk of acute coro­
nary events for at least 15 years after stopping.723 Furthermore, it has been suggest­
ed that a substantial part of the relationship between smoking and CHD may be 
mediated through fibrinogen.60 Equally, the converse may be true. Our findings do 
not resolve this question but do demonstrate that long-term smoking directly results 
in a dose dependent increase in fibrinogen. H ow ever, the apparent relationship 
betw een the chronic use o f cigarettes and fibrinogen level may be the resu lt of 
observer/selection bias. There was no validation of the accuracy of the self-reporting 
of tobacco intake, including the current use of cigarettes. Therefore, the association 
may feasibly be related to acute smoking effects that were unreported.
An unexpected observation was the relatively strong and independent inverse asso­
ciation with HDL cholesterol levels. Most previous reports concerning individuals 
with or without CHD have not examined such a possible relationship, or possibly did 
not report the lack of association,705,711'713 and little is available from population 
based studies.372,373,703,718,722 A lack of association has been reported for a normal 
population group,719 and also for CHD patients.374,704 A negative but insignificant 
association using the ’clottable’ fibrinogen method but not with the heat precipitation 
method for fibrinogen measurement has been demonstrated in CHD patients random­
ly selected from a specific population.704 The relationship must remain a tentative 
possibility but does highlight the importance of validation techniques for self report­
ing of tobacco intake to assess under-reporting of past and current tobacco use. This 
is of further importance with regard to the HDL cholesterol level association with 
fibrinogen. Smoking has a well known inverse association with HDL cholesterol 
levels, and under-reporting may introduce sufficient bias to give a false independent 
association between fibrinogen and HDL cholesterol, and reduce the possibility of 
m easuring an association between smoking and the severity o f CAD. The inverse 
association observed in our study indicates an area for further study. Nevertheless, 
the observation has subsequently been confirmed in other studies.724'729, although the 
reason has not been elucidated. The later uniform confirmation of the positive asso­
ciation between HDL cholesterol and fibrinogen level adds further validation to the 
observations of this study.
Increasing age is one of the most powerful predictors for the development of both 
CAD and CHD.202 This is reflected in the results of our univariate and multivariate 
analysis. Population based fibrinogen levels have a positive relationship with age,730 
which also occurs in aging CHD patients.731 It is possible that any increase in fibri­
nogen with age noted in population based studies may in part be due to the develop­
ment of subclinical severe obstructive disease. This would increase the likelihood of
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the fibrinogen level being a reliable prospective predictor of CHD and symptomatic 
events in a "normal" population group.
Apart from age, the risk factors analysed in the present study do not significantly 
contribute to the variance of disease severity or extent within a group of males with 
established CHD. This observation does not negate their possible influence as risk 
factors for the initiation of CHD in a susceptible individual or group, and this ap­
plies equally to the fibrinogen level. However, within such a group they do not 
appear to contribute substantially to the severity and extent of disease expression as 
interpreted angiographically. If the study sample number were to be increased great­
ly in order to detect possible weak associations which were significant in the multi­
ple linear regression analysis, their contribution to the variance of the dependent 
variable would not be remarkably altered. Therefore, even if the sample size con­
tributed to a type II statistical error, increasing the number would not result in a 
relationship that had a substantial clinical value.
A potentially major confounding methodological problem with most angiographic 
studies, including the presently reported observations, is the lack of incident cases 
used to assess the relationship. Lipid measures, hypertension, weight and tobacco 
use will all have undergone possible modification following the initial diagnosis, 
leading to a selection bias and hence limiting the likelihood of necessarily finding 
significant associations. In addition, modification of both the underlying disease as 
well as the risk factors may occur following the long-term use of cardiovascular 
active drugs, such as beta-blockers and calcium entry blockers. This potential prob­
lem may also apply to this assessment of fibrinogen despite the exclusion of individ­
uals with known confounding factors. A possible important association between diet 
and fibrinogen may exist. A direct relation between linoleic acid intake660 and an 
inverse association with dietary cereal719 have been reported. No major influence 
over fibrinogen levels has been noted for cardiovascular medications.60,418 Those 
drugs recorded as being able to modify fibrinogen levels732 were not used by the 
patients with CAD evaluated in this study. A prospective angiographic study is 
required to more appropriately evaluate the observations from our cross-sectional 
study, but with current angiographic methodology a prospective study on normals to 
more reliably evaluate a causal relationship cannot presently be performed.
6.1.5 Summary
1. The above observations do not verify the proposition that an increased 
fibrinogen level is causally associated with a greater extent and/or increased severity 
of CAD. Elevated fibrinogen levels do have a modest relationship with severe CAD. 
This relationship, however, may be due to another process simultaneously leading to 
increased fibrinogen levels and the development of severe stenotic CAD, such as in­
creased platelet reactivity. The plasma fibrinogen level must be taken into account 
when evaluating differences in platelet function between any two groups.
2. They indicate that any relationship existing between fibrinogen and 
CAD is unlikely to be due to a non-specific response to atherosclerotic involvement 
of the coronary arteries. An independent association between fibrinogen and the 
extent of coronary arterial wall involvement, and by inference, atherogenesis, was
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not able to be demonstrated.
3. The fibrinogen level for an individual with CAD is in part directly pre­
dicted by the volume of previous cigarette use, the age of the individual, the severity 
of underlying CAD, and inversely by HDL cholesterol level.
4. The results remain consistent with the observation that a priori high 
fibrinogen levels may be predictive of an increased incidence of CHD events. This 
predictive relationship would appear to be m ediated through an association with 
other risk factors and with CAD severity. W hether there is any causal relationship 
between CHD events and fibrinogen levels still remains to be determined.
6.2 FIBRINOGEN LEVELS IN YOUNG MALES WITH CORONARY
HEART DISEASE
6.2.1 Introduction
Unequivocal epidemiological evidence exists confirming an elevated blood fibrino­
gen level as a risk factor for CHD.372,373,701'707 However, as indicated in section 6.1, 
whether or not an elevated fibrinogen level is a causal risk factor has not been firmly 
established. Raised fibrinogen levels may result from recurrent plaque fissuring 
which occurs in subjects with coronary atheroma.733 This plaque fissuring can lead 
to the episodic growth of coronary stenoses, the plaque expansion initially being due 
to thrombosis within the lesion.733 In addition, there is a substantial body of evidence 
supporting the early involvement of coagulation products, fibrinogen and fibrin in 
particular, in the formation of atheroma.539,714,734'736
One of the epidemiological criteria required to establish causality is to show a bio­
logical gradient between the factor and the outcome 470,737 A univariate association 
between the fibrinogen level and the severity of angiographically defined CAD61 as 
described  in section 6.1 of this thesis supports this concept. The re la tionsh ip , 
however, was not independent of age, previous cigarette use and other risk factors 
for CHD using multivariate analysis.61 In the past, similar methods of assessing the 
relationship have been used by other groups, although the results of those studies 
examining the relationship between the severity of angiographically defined CAD 
and fibrinogen level have not been uniform.374,710'713 There are numerous potential 
areas of bias to account for these inconsistent results, particularly since fibrinogen 
increases as a non-specific response to a diverse variety of stimuli,738'740 including 
inflammation and tissue injury characteristic of atherosclerotic plaques.242 Neverthe­
less, it remains uncertain whether the interaction of fibrinogen with ruptured plaques 
results in the increased plasma level, whether CHD risk factors account for all the 
elevation, or whether a preexisting increased level potentiates thrombus formation 
within the plaque or arterial lumen.
Another criteria for inferring causality is that the disease should follow exposure to 
an increased level of the postulated causative factor, and an increase in magnitude of 
the disease after the exposure.737 If an increased level of fibrinogen is associated 
with a greater likelihood of plaque expansion due to thrombosis within the lesion,
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then an elevated fibrinogen level may predate any association of fibrinogen with 
CAD severity in the early stages of CAD. Therefore, in this section, the relationship 
between fibrinogen levels and angiographically defined CAD in non-diabetic young 
males with premature CHD is evaluated.
6.2.2 Methods
6.2.2.1 Patient Population. The case and control groups consisted of the young 
males who were age, race and socioeconomically matched as described in Chapter 3. 
The exclusion criteria are also described in Chapter 3 and section 6.1 of this thesis.
6.2.2.2 Laboratory measurements. The laboratory methods have been described 
previously61 and are detailed in Chapter 2.
6.2.2.3 Angiographic Scoring Methods. Coronary angiograms were graded to 
give a semi-quantitative measure of severity and extent of angiographically defined 
CAD, as previously described61,207 and detailed in Chapter 8.
6.2.2.4 Statistical Analysis. Statistical methods used are described in Chapter 2.
6.2.3 Results
6.2.3.1 Group comparisons. The mean values for the major risk factors are 
summarised in Table 3.1. All tobacco users were cigarette smokers and there were 7 
and 4 current smokers in the control and case groups respectively. There was a 
significant and predictable difference between the groups for all the major CHD risk 
factors. The fibrinogen was also significantly greater in the case group (275+/-10 vs 
230+/-8 mg/100ml, p=0.001).
6.2.3.2 Correlations. The fibrinogen level in both groups correlated weakly with 
age, and the age distribution of both groups was narrow (Table 6.5). In the case 
group, the fibrinogen level correlated directly with body weight, BMI, scapular skin 
fold thickness, blood glucose level, HbAlC and Hb levels, and inversely with HDL 
cholesterol levels. The control group fibrinogen level correlated directly with Hb, 
He and apoprotein B levels (Table 6.5).
6.2.3.3 Multivariate analysis. Following multivariate analysis, with fibrinogen 
as the dependent variable and those factors having a univariate association as inde­
pendent variables, the Hb remained predictive of fibrinogen levels in the control 
group, and scapular skin fold thickness remained predictive in the CHD group 
(Table 6.6).
6.2.3.4 CAD angiographic scores. The fibrinogen level did not correlate with 
any of the angiographic measures of CAD in the multivariate variate analysis.
6.2.4 Discussion
The results of this study demonstrated that an increased plasma fibrinogen level in 
males with CHD predates any measurable association with CAD severity, an associa-
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tion demonstrable in older male patients with established CHD.61 These results, in 
conjunction with the previous observations (section 6.1),61 were consistent with the 
concept that increased fibrinogen levels are involved in the development of severe 
lesions which form over time in males prone to CHD. Since the increased level was 
present before an association was demonstrable, another epidemiological criteria for 
causation is satisfied. That is, an increase in the magnitude of the disease should 
follow exposure to an increased level of the postulated causative factor.470,737
However, even though the observations support the above concept, the results are 
from two different groups and from separate cross-sectional studies. Therefore, 
other explanations are clearly possible. For example, it is feasible that the disease 
process may concom itantly cause severe intralum inal obstructive lesions and in ­
creased fibrinogen levels, due to recurrent intramural and extramural thrombosis and 
fibrin formation.61,639,714 In addition, an association between fibrinogen levels and 
CHD risk factors is also present at this earlier stage of disease development. Previ­
ous studies have established an association between fibrinogen and a number of the 
m ajor risk factors for CHD including age,705,718'720 tobacco use,372,703,718'721 blood 
c h o le s te ro l ,372,631,721 o b e s ity ,738 d ia b e t ic s ,143,738 b lo o d  su g ar lev e l in n o n ­
diabetics,143,374 lower socioeconomic status,722 and a number of other factors.738 The 
fact that not all of these associations were present in the present study group is most 
likely attributable to the specific population groups studied. Also the size of the 
study group would only allow the detection of more robust relationships and a type 
II statistical error probably accounts for the inability to demonstrate some relation­
ships. Those relationships shown would more likely to be of clin ical relevance. 
N evertheless, an association with risk factors for CHD may still explain the in ­
creased fibrinogen occurring in those with premature CHD.
An association between blood glucose and fibrinogen levels in a non-diabetic popula­
tion has been well documented.143 The association between fibrinogen and H bA lC  is 
novel, but not unexpected.143 A weak relationship with age exists in both groups, 
and the narrow age range in both groups probably explains the minor association.
An im portant feature emerging from this study is that the factors associated with 
fibrinogen levels differ for the males with premature CHD compared to the matched 
controls without CHD. Of particular note, there is a cluster of factors (blood glucose 
level, H bA lC , BMI, body weight and scapular skin fold thickness) related to fibri­
nogen in the univariate correlation not present in the control group. A difference is 
also present after multivariate analysis. An independent relationship with a measure 
of central body obesity, namely scapular skin fold thickness, is unique to the case 
group. One likely explanation for such an unusual relationship is that other factors 
not measured (eg genetic variation) influence the fibrinogen level in one group and 
not the other. The relationship is evaluated in more detail in the following section. 
This study highlights the im portance o f having a greater understanding o f the 
m echanism s, including genetic, which control plasma fibrinogen levels, since the 
factors related to fibrinogen level in two homogeneous and matched groups differ.
8.2.5 Summary
1. Fibrinogen levels are higher in young male patients after the diagnosis
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of CHD than in controls without CHD. The elevated fibrinogen is not associated 
with angiographically defined CAD in the young CHD group.
2. Factors associated with the fibrinogen levels differ between controls 
and cases, with a cluster of factors, viz blood glucose level, H bA lC , BMI, body 
weight and scapular skinfold thickness, being associated with fibrinogen levels in the 
case group.
6.3 POSSIBLE MECHANISMS FOR THE ASSOCIATION BETWEEN
PLASMA FIBRINOGEN AND CHD. PLASMA FIBRINOGEN 
LEVELS, LIPOPROTEINS AND BLOOD GLUCOSE IN YOUNG 
MALES WITH CORONARY HEART DISEASE
6.3.1 Introduction
It is clear from the results presented in this Chapter, and from the literature, that the 
epidemiological evidence for an elevated blood fibrinogen level being a risk indica­
tor for CHD is unequivocal. Nevertheless, a mechanism for the relationship has not 
been elucidated and the question as to whether there is a causal relationship has not 
been fully established.62,372,373,701'707 Moreover, there exists a clustering of the other 
major risk factors that are associated with plasma fibrinogen level, the mechanisms 
of which also remain unexplained. An association between fibrinogen and other 
major risk factors for CHD has been well established.62,143,372,374,631,703,705,718'722,738. 
In addition, an independent inverse association between plasma fibrinogen and HDL 
cholesterol levels in males with CHD was noted in the preliminary studies for this 
thesis.61 At that time most previous reports concerning individuals with or without 
CHD had not examined the relationship.61 Indeed, review articles made no mention 
of a relationship.62,738,740 One possible explanation was that a negative association 
had not been reported .705,711'713 There was also little available inform ation from 
population based studies.372,373,703,718,722 There were reports demonstrating no asso­
ciation in a normal population group719 and in CHD patients.374 A positive associa­
tion with CHD patients using the ’clo ttable’ fibrinogen m easurement method had 
been dem onstrated, but not with the heat precipitation m ethod.704 However, since 
then the association has been substantiated by a number of studies which recently 
have been reported in preliminary form.724'729 In population studies, the fibrinogen 
level correlated positively with total cholesterol,724 also with LDL cholesterol,725,728 
and inversely with HDL cholesterol levels.724,725,727,728
Associations between plasma fibrinogen level and obesity738 and diabetes143,738 are 
well recognised, and even with the blood glucose level in non-diabetics.374,143 Of 
additional interest is an apparent association between plasma fibrinogen and blood 
insulin levels,727,728 as well as body fat distribution.724,727,741'743 However, not all 
studies demonstrate an association with fat distribution744 or do so only with univar­
iate analysis 727
Therefore, in light o f the above inform ation, in this section the relationships of 
plasma fibrinogen levels in non-diabetic young males with premature CHD and the 
well m atched control group are further evaluated in order to further refine our
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understanding of the relationships.
6.3.2 Methods
6.3.2.1 Patient Population. The case and control groups consisted of the young 
males defined in Chapter 3. The exclusion criteria are described in section 6.1.2.1.
6.2.2.2 Laboratory measurements. The laboratory methods have been described 
previously61 in Chapter 2.
6.3.2.3 Anthropomorphic Measures. These measurements are described in full 
in Appendix 2.
6.3.2.4 Glycosylated Haemoglobin. A colourimetric method was used for the 
estimation of Hb glycosylation364'366 and is described in Chapter 2.
6.3.2.5 Statistical Analysis. Associations were evaluated by univariate analysis 
and the details are given in Chapter 2.
6.3.3 Results
6.3.3.1 Group comparisons. The mean values for the major risk factors are 
summarised and comparisons made between the groups in Chapter 3. Of particular 
note, was that all tobacco users were cigarette smokers and there were 7 and 4 
current smokers in the control and case groups respectively. In addition, the non­
diabetic case group had a significantly higher BSL (5.3+/-0.10 vs 4.9+/-0.08 
mmoles/1, p=0.02) and HbAlC level (7.8+/-0.2 vs 7.3+/-0.1, p=0.03) than the 
controls, although the levels were within the normal range. Moreover, the scapular 
skin fold thickness was significantly higher in the case group (17.1+/-0.9 vs 1.8+/- 
0.7 cm, p=0.006), but there was no difference in the weight, height, BMI and tri­
ceps skin fold thickness. Finally the plasma fibrinogen level was also significantly 
greater in the case group (275+/-10 vs 230+/-8 mg/100ml, p=0.001).
6.3.3.2 Correlations. The fibrinogen level in both groups correlated weakly with 
age but the age distribution of both groups was narrow (Table 6.5). The correlation 
with other factors is described in section 6.2.
6.3.33 Multivariate analysis. Multivariate analysis was performed with the 
plasma fibrinogen level as the dependent variable. Those CHD risk factors which 
had a univariate association were entered into the regression equation as the inde­
pendent variables. The Hb remained predictive of fibrinogen levels in the control 
group. Scapular skin fold thickness was independently predictive of fibrinogen level 
in the CHD group (Table 6.7).
6.3.4 Discussion
An independent inverse association between plasma fibrinogen and HDL cholesterol 
levels has been documented in a broad age group of patients with CHD (Section 
6.1).61 This observation has been supported by the early reports from a number of
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other studies.724'729 In the present report of a younger group of males with premature 
CHD, an inverse univariate association was similarly demonstrated, but was not 
independently predictive of the risk factors measured. More importantly, the associa­
tion was not demonstrated in the normal controls. However, in the preliminary study 
described in section 6.1,61 HbAlC and scapular skin fold thickness were not meas­
ured, and hence not included in the multivariate analysis. From the present results, it 
would appear that the relationship between fibrinogen and HDL cholesterol levels 
may be due to a co-morbidity bias. That is, both are associated with each other 
through an association with the cluster of risk factors of central body obesity, 
abnormal glucose homeostasis, hypertension and abnormal lipoproteins. Indeed, that 
link could also be the reason that they are risk factors for CHD.
The inverse association between fibrinogen and HDL cholesterol levels can also be 
supported by a plausible biological explanation, and may well be a direct associa­
tion. A strong positive relationship between plasma lipoprotein lipase (LPL) and 
HDL cholesterol levels has previously been documented.745 Thrombin inhibits 
LPL210 and also appears to stimulate fibrinogen synthesis by an enzymatic mechan­
ism independent of fibrinogenolysis or disseminated intravascular clotting.746 There­
fore, increased thrombin activity, for whatever reason, may increase fibrinogen 
production and increased fibrin breakdown products will further stimulate fibrinogen 
synthesis. The increased thrombin activity will also inhibit LPL activity possibly 
leading to decreased HDL cholesterol levels. Furthermore, fatty acids significantly 
increase the production of fibrinogen,208 while polyunsaturated fatty acids and trigly­
cerides decrease HDL cholesterol levels.747
An association between the blood glucose and fibrinogen levels in a non-diabetic 
population has been documented in the past,143 and an association between fibrino­
gen and HbAlC values had been previously predicted.143 There exists a cluster of 
CHD risk factors (blood glucose level, HbAlC, BMI, body weight and scapular skin 
fold thickness), which together are measures of a group of risk factors which are 
well recognised predictors for CHD.748,749 However, the fibrinogen level univariate- 
ly correlated with the factors in this grouping only in the CHD group, and the asso­
ciation was not present in the control group. Furthermore, the strength of this rela­
tionship was demonstrated when a measure of central body obesity, namely scapular 
skin fold thickness, was independently predictive of the fibrinogen level, an observa­
tion also unique to the CHD group.
An elevated fibrinogen level in populations with a low incidence for CHD is not a 
risk factor for CHD.60 High fibrinogen levels occur in groups where CHD disease is 
rare, suggesting that if increased fibrinogen levels cause CHD, high levels must 
interact with some other characteristic.60 Fibrinogen has a strong relationship with 
hyperglycaemia in diabetics143 and clusters, along with other CHD risk factors, with 
an abnormal lipoprotein profile.750 As discussed, the fibrinogen level, in addition, 
directly correlates with a number of other risk factors. These facts, in combination 
with the observations made in this report, that the fibrinogen level in CHD patients 
with premature CHD is related to specific risk factors and is not related to the same 
factors in a normal group, supports the concept that an elevated fibrinogen level is 
possibly only a causal risk factor for CHD (that is the clinical expression of the 
disease) in individuals with developed CAD having preexisting atheroma, as pre-
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viously suggested.60 Alternatively, the association may be through mechanisms 
giving abnormal glucose homeostasis, abnormal lipoproteins (including low HDL 
cholesterol levels), hypertension and central body obesity, which so often cluster 
together in individuals with CHD.
6.3.5 Summary
1. An inverse association between HDL cholesterol and fibrinogen levels 
in patients with CHD was demonstrated in preparatory study of this Thesis and con­
firmed in the main case-control study. This was a novel observation which has also 
been reported independently by others. The mechanism of this association remains to 
be elucidated.
2. In CHD patients the fibrinogen level appears to have an association 
with other more recently recognised risk factors which cluster together, viz central 
body obesity, abnormal glucose homeostasis and lipid abnormalities. Given these 
observations, the impact of such potential relationships on the results of this Thesis 
are examined in Appendix 2.
6.4 FIBRINOGEN AND IN VITRO PLATELET AGGREGATION
6.4.1 Introduction
6.4.1.1 Fibrinogen’s role in platelet aggregation. Fibrinogen is essential for 
platelet aggregation and occupancy of a receptor by fibrinogen, which occurs only 
after platelet stimulation, is involved in the primary pathway for platelet aggrega­
tion.751'754 Fibrinogen binding to human platelets and platelet aggregability are di­
rectly related.306,754 The platelet membrane GP Ilb/IIIa acts as a receptor for fibrino­
gen755 and forms a complex with purified plasma fibrinogen and may act as the 
fibrinogen binding site required for normal platelet aggregation.756 Prostaglandin 
endoperoxides and thromboxane may play a role in the exposure of fibrinogen recep­
tors on normal platelets.757 Bound fibrinogen then mediates platelet aggregation by 
bridging platelets and/or serving as a cofactor for the aggregating process.758 
However, the precise mechanism how platelet bound fibrinogen is involved in 
aggregation is not fully established.418
Fibrinogen binds to receptors, which are specific and saturable, on the platelet sur­
face during platelet aggregation. The receptors are not exposed on unstimulated 
platelets and fibrinogen is unable to bind to unstimulated circulating platelets 
(Reviewed in references758,759).
Fibrinogen is present on the surface of the platelet. It is also present intracellularly, 
within the alpha-granules from where it is released by an energy requiring secretory 
mechanism which occurs in response to aggregating agonists such as thrombin, 
collagen and ADP.759 The exact function of intracellular platelet fibrinogen is cur­
rently unknown although afibrinogenic platelets appear to function normally with 
exogenous fibrinogen.759
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6.4.1.2 Effect of platelet aggregating agents. ADP stimulation results in rapid 
reversible binding of exogenous fibrinogen to the receptors after platelet stimulation. 
The effect of fibrinogen is greater at lower concentrations of ADP and reversed at 
higher levels.331,760 Platelet fibrinogen secretion arises after aggregation induced by 
ADP, which is dependent on the secretory mechanism.
Aggregation induced by thrombin, however, is independent of a secretory response, 
either preceding or occurring simultaneously with aggregation.759 Although fibrino­
gen binding to stimulated platelets is much greater than that to unstimulated platelets 
regardless of the agonist used, thrombin stimulation induces binding which is much 
greater than that induced by ADP or adrenaline (Reviewed elsewhere758,759). The GP 
Ilb/IIIa receptor appears to play an important role in agonist-induced aggregation of 
platelets.755,761
Even if binding of fibrinogen is a prerequisite for platelet aggregation, additional 
conditions determine the proaggregating properties of fibrinogen.762 Interaction of 
fibrinogen with platelets also differs according to the molecular weight of fibrino­
gen, that with a high molecular weight supports a greater degree of ADP induced 
aggregation.762 The ratio of high m olecular w eight fibrinogen to low m olecular 
w eight fibrinogen in plasma varies during the acute phase reactions,763 indicating 
clear variability in plasma fibrinogen which may lead to variations in platelet interac­
tions between the circulating fibrinogen species.762
6.4.1.3 Clinical observations. The laboratory findings are consistent with the 
epidemiological associations between the level of blood fibrinogen and the measure 
of platelet aggregability.331,631,760,762 A positive correlation between plasma fibrino­
gen and platelet aggregate formation is measurable in patients with both non-vascular 
and vascular disease. Although this may be due to a common association with ill­
ness, the increased platelet aggregate level is reduced follow ing an infusion of 
ancrod, a non-specific defibrinating agent.631
Given the close association between fibrinogen and platelet aggregation briefly de­
scribed above, this section evaluates the relationship between plasma fibrinogen and 
the platelet function test carried out in the case-control groups.
6.4.2 Methods
6.4.2.1 Patient Population. The case and control groups consisted the young 
males defined in Chapter 3.
6.4.2.2 Laboratory measurements, platelet function tests and statistical analy­
sis. These methods have been described previously in Chapter 2.
6.4.3 Results
6.4.3.1 Correlations. The only association between plasma fibrinogen levels and 
platelet function measures in the case group was a positive association between the 
level of fibrinogen and the amount of TXB2 produced in clotted whole blood (Table 
6.8). In the control group, there was a negative association between fibrinogen levels
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and the rate of platelet aggregation in response to ADP and adrenaline, and a posi­
tive relationship between fibrinogen level and LT50ADP value (Table 6.8).
6.4.4 Discussion
A relationship between plasma fibrinogen levels and aggregation responses with the 
aggregating agents adrenaline and ADP was observed in the control group which is 
inconsistent with the laboratory findings of others.752'754 This difference may also be 
related to the presence of platelet activation during blood collection which is in part 
influenced by the blood fibrinogen level and results in less platelet aggregation in 
vitro.
The group with CHD did not show this relationship. In this group, the plasma fibri­
nogen appears to have a greater relationship with arachidonic acid metabolism 
and/or thrombin induced aggregation, given the relationship with the production of 
TXB2 in clotted whole blood.
Once again, since this study is an observational evaluation, the mechanism for these 
differences can not be determined. The results do, however, provide a stimulus for 
evaluating potential causes for such differences. For example, it is possible that the 
molecular structure of fibrinogen in these two groups may differ since fibrinogen 
with a high molecular weight is more responsive to ADP-induced aggregation.762 
Moreover, the beta-fibrinogen gene locus appears to be associated with an increased 
risk of peripheral atherosclerosis.764 Another explanation may relate to the effect of 
blood fatty acid concentrations on fibrinogen and/or platelet aggregability since free 
fatty acids may play a role in the synthesis of fibrinogen 208
6.5 CONCLUSION
From the associations described in this Chapter, and the potential interaction bet­
ween in vitro and in vivo platelet function and plasma fibrinogen, the importance of 
controlling for plasma fibrinogen as a potential confounding factor in any analysis of 
platelet function and the association with CHD, is clearly mandatory.
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Table 6.1. Patient characteristics.
Fibrinogen (mg/lOOml)
Cholesterol (mmol/1)
Triglyceride (mmol/1)
HDL cholesterol (mmol/1)
Smokers (past & present)
Packyears smoking 
Number currently smoking 
Hypertension diagnosed 
Weight (kilograms)
Time since last AMI (days) 
creatinine (mmoles/1)
Number stenoses > 50%
Number stenoses > 70%
Number total occlusions 
Coronary atheromatous score (CAS) 
Coronary stenosis score (CSS)
Left ventricular score (LVS)
314 +/-91 
5.62+/- 0.96 
1.98+/- 0.94 
0.98+/- 0.25 
74 (81%)
37 +/- 24 
2
17 (19%) 
80.3+/-9.1 
240 (35 to 2990) 
94 +/-16 
3.3 +/- 2.3 
2.8 + /-  2.2 
0.9 +/- 0.9 
20.5 +/- 12.8 
30.9 +/- 22.1 
2.7 +/- 2.4
All values expressed as mean +/- SD or number (percentage).
Table 6.2. Univariate correlations with fibrinogen and age (n=91).
Age (years)
Packyears (n=74)
Cholesterol 
HDL cholesterol 
Triglycerides 
Systolic BP
Number of infarcts (n=74) 
Days from infarct (n=74) 
Blood sugar 
Fibrinogen
Number of stenoses >50% 
Number of stenoses >70% 
Number of occlusions 
CAS 
CSS
LV Score 
Normal Segments 
Segments with diffuse disease 
Arteries with distal disease 
Segments with calcification
fibrinogen age
0.21 *
0.21 * 0.07
0.15 0.19*
-0.34 ** -0.36 ##
0.25* 0.07
0.15 0.29*
0.22* -0.13
0.06
0.05
0.21 *
0.21 * 0.22*
0.27# 0.31 **
0.28# 0.03
0.14 0.38##
0.32 ** 0.28 **
0.31 ** 0.07
-0.15 -0.32 **
0.16 0.23*
0.17 0.18*
0.14 0.40##
* p<0.05 # p<0.01 ** p<0.005 ## p<0.001
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Table 6.3. Multiple regression analysis of fibrinogen for associated variables.
Variables B Rsq SE p value 95% Cl of B
HDL -1.633 0.130 0.597 0.009 -2.832/-0.433
Age 82.751 0.263 27.868 0.005 26.747/138.754
Packyears 1.635 0.366 0.585 0.007 0.460/2.810
CSS 1.221 0.419 0.589 0.044 0.037/2.405
B=regression coefficient, Rsq=coefficient of determination 
SE=standard error of B, CI=confidence interval
Table 6.4. Comparison of risk factors between patients with and without left ventricu­
lar wall motion abnormalities.
Wall Motion
Fibrinogen (mg/100ml) 
Cholesterol (mmol/1)
HDL cholesterol (mmol/1) 
Triglyceride (mmol/1) 
Systolic BP (mmHg) 
Packyears (n=18 & 56)
Normal (LVS=0) 
n=23
266 +/-61 
5.92+/-0.89 
1.08+/-0.30 
1.80+/-0.81 
117 +/-11 
25 +1-22
Abnormal (LVS>0) 
n=68
329 +/-9 9 ** 
5.51+/-0.97 
0.94+/-0.23 
2.04+/-0.99 
125 +/-13 
41 +/-24 #
* mean +/- SD, # p<0.02, ** pcO.OOl, BP=blood pressure
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Table 6.5. Univariate associations with fibrinogen in the case-control study groups.
CONTROLS CASES
Age (years) 0.21 p=0.09 0.21 p=0.07
Packyears 0.01 0.17
Cholesterol 0.22 p=0.08 0.01
HDL cholesterol -0.11 -0.27 p=0.03
Triglycerides -0.13 0.02
Apoprotein A -0.08 -0.13
Apoprotein B 0.37 p=0.02 0.12
BSL -0.13 0.39 p=0.004
HbAlC -0.10 0.30 p=0.02
Weight 0.04 0.33 p=0.01
Height 0.04 0.01
BMI 0.01 0.40 p=0.002
Scapular 0.06 0.41 p=0.005
Haemoglobin 0.27 p=0.04 0.28 p=0.03
Haematocrit 0.29 p=0.03 0.18
wcc 0.07 0.06
Pearson correlation coefficients, See Table 6.1 for abbreviations.
Table 6.6. Multiple regression with fibrinogen as the dependent variable and those 
variables with a univariate association as the independent variables.
Independent
Variable_____________ B______ SE B______Beta______ Rsq_______Sig
A. CONTROL GROUP
Haemoglobin 1.6948 0.6820 0.4251 0.1807 0.0192
B. CASE GROUP
Scapular 0.6732 0.2020 0.5135 0.2637 0.0022
See Table 6.1 for abbreviations.
153
Table 6.7. Multiple regression with fibrinogen as the dependent variable and those 
variables with a univariate association as the independent variables as well as pack- 
years.
Independent
Variable_____________ B_______ SE B______Beta______ Rsq______Sig
A. CONTROL GROUP
Haemoglobin 1.6948 0.6820 0.4251 0.1807 0.0192
B. CASE GROUP
Scapular 0.6732 0.2020 0.5135 0.2637 0.0022
B=regression coefficient, Rsq=coefficient of determination. SE=standard error, 
Beta=Beta coefficient, sig=p value. Scapular=scapular skin fold thickness.
Table 6.8. Univariate associations between fibrinogen and platelet function measures.
CONTROLS CASES
Platelet count -0.07 0.05
Platelet Count Ratio 0.15 -0.16
Serum TXB2 -0.16 0.35#
Plasma BTG 0.06 -0.13
MPV -0.15 0.05
PRPPC -0.08 -0.09
LT50ADR 0.15 -0.08
RADR -0.36 * 0.14
LT50ADP 0.33* -0.02
RADP -0.33 * 0.01
LT50COL 0.08 -0.11
RCOL -0.16 -0.27
LAGCOL -0.06 -0.19
Pearson correlation coefficients,
See Tables 6.1 and 6.2 for abbreviations.
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Figure 6.1. Group mean values of lipids (mean +/-SEM) for increasing categories of 
fibrinogen level.
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Figure 6.2. Group mean values of age and smoking (mean +/-SEM) for increasing 
categories of fibrinogen level.
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Figure 6.3. Group mean values of extent (CAS) and severity (CSS) of CAD (mean + /-  
SEM) for increasing categories of fibrinogen level.
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CHAPTER 7
PLATELET FUNCTION AND CORONARY HEART DISEASE
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7. PLATELET FUNCTION TESTS
The results presented in this chapter pertain to the hypothesis that there is an in­
crease in platelet reactivity in males with premature CHD, and that this constitutes a 
measureable risk factor for the disease. The measures include MPV, PCR, BTG, 
plasma TXB2, serum TXB2 and in vitro platelet aggregation. The results for the 
different measures are presented and discussed in detail in each section of this chapt­
er.
As previously emphasised, there appears to be no evidence of continuous activation 
of platelets in patients with stable CHD between acute coronary events,45,298 an 
observation supported by the results in this Chapter. Platelets are involved in the 
progression of atherosclerosis and in the development of thrombosis after atheros­
clerotic plaque rupture.261 These events may involve circulating platelets with altered 
function.765 Unfortunately, the selection of platelet function tests which may be used 
to detect a latent but increased potential for platelet activation as a means of predict­
ing the development of atherosclerosis, or its complications, may be inadequate for 
this purpose.765,766 The need to elucidate which platelet reactions, if any, best predict 
increased risk of AMI has frequently been emphasised.475 Therefore, measures of 
platelet aggregation require further evaluation to establish their utility for such 
purposes.767,768
7.1 MEAN PLATELET VOLUME AND CHD
7.1.1 Introduction
7.1.1.1 Platelet size, volume and density, and platelet function. Normal circu­
lating platelets are heterogeneous in size and density.769'771 It has been postulated 
that this platelet heterogeneity is due to aging of circulating platelets. Platelets were 
thought to change in size, becoming smaller and lighter with aging 770,772 However, 
it would appear that circulating platelets do not change in size773 or density with 
senescence774,775 Large platelets may not be younger platelets, but rather platelets 
with a longer lifespan.773 Platelet heterogeneity may result from the heterogeneity of 
m egakaryocytes,774 which may be due to production factors in the bone 
marrow.774,776,777 Platelet volume may also be determined during thrombocytopoie- 
sis.777 Platelets with a larger mean volume are derived from megakaryocytes with a 
larger mean cytoplasmic volume,778 and this appears independent of aging.771,779
Platelet size and age both appear to be independent determinants of platelet func­
tion.771,776,780 Larger platelets, for example, are more reactive than smaller platelets 
in virro.781,782 This may be due to quantitative differences based on size rather than 
qualitative differences due to aging and other factors.773,783 The response of platelets 
to the aggregating agents thrombin and collagen increases in proportion to their 
M py 776 The release of arachidonic acid metabolites is also quantitatively related to 
their size,783 and the ability of platelets to incorporate arachidonic acid, convert it to 
active metabolites, and release these metabolites, is related to their volume.783 The 
ability of platelets to release unmetabolised arachidonic acid varies inversely with the 
M py 783 There is a linear relationship between TXB2 production and MPV.784
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Furtherm ore, follow ing induction o f throm bocytopenia, the m ean cytoplasm ic 
volume increases in m egakaryocyte populations with a higher than normal mean 
polidy number. Such megakaryocytes generate more TXB2 per volume and the 
larger platelets derived from the large megakaryocytes are more reactive. In addi­
tion, these platelets produce more TXB2 per unit platelet volume.784
An increase in platelet reactivity associated with increased platelet volume has been 
confirmed by other methods used to assess platelet reactivity.776,785,786 The inhibitory 
effects of PGI2 on aggregation are dependent on both platelet volume and platelet 
count.786 This inhibitory effect decreases with an increase in platelet mass and is 
independent of whether it resulted from increased volume or platelet count.786 Fur­
thermore, a decrease in the inhibitory effectiveness of PGI2 on both aggregation and 
the release reaction occurs in the presence of a greater m ass.786 This is also inde­
pendent o f w hether the increased  mass is due to increased  p la te le t volum e or 
number.786
Larger platelets appear to have both increased metabolic as well as functional cap­
abilities. Increased glycogenolysis, glycogen and protein synthesis, and greater 
contents of orthophosphate and nucleotides have been noted in larger and heavier 
platelets.772 Furthermore, larger platelets manifest increased clot retraction ability, 
greater adherence to collagen, increased aggregation with ADP and greater release 
of granule contents in response to ADP.771,781
It is possible that these differences are due to the physical properties of different 
sized particles.785 Large platelets may aggregate more readily than small platelets 
because increased in vitro reactivity may reflect, not differences in platelet function, 
but more frequent collision of larger platelets.785 However, given the preceeding 
discussion, this simple physical proposal is unlikely to be the solitary explanation. 
Platelets separated into size dependent populations also show no differences in the 
rate and extent of clumping in response to ristocetin.776 Furthermore, the absolute 
amounts of ADP and BTG are greater within larger platelets and the amounts secret­
ed in the release reaction have a close correlation with platelet size.776
In summary, even though it is well established that different sized platelets have dif­
ferent metabolic capabilities, and different physical and functional properties, the 
relevance of platelet volume to platelet physiology and pathology remains controver­
sial. The cause of these differences also remains uncertain, although the quantitative 
differences are well established.771
7.1.1.2 The relationship between platelet count and platelet size. An inverse
linear relationship between platelet count and size is well documented.787 The pro­
portion o f larger p latelets (volum es >8 fl) is greater in norm al individuals with 
lower platelet counts, and there are proportionally more small platelets (<8 fl) as 
the platelet count increases.788 Platelet count and volume appear to be inversely but 
not linearly related in normal subjects.779,789,790 This relationship exists in patients 
with low or high platelet counts. Levin and Bessman found that the product of the 
platelet count and size varies substantially within the normal range, although the 
platelet mass increased as platelet count increased.779 At platelet counts less than 450 
109/1, any groups with a difference in platelet count of >80 109/1 had significantly
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different volumes.779 With progressively lower counts the MPV increases. The most 
marked difference in MPV occurs when the platelet count is below 100 1 09/1 and 
there is no difference in MPV with a platelet count above 450 109/1. The platelet 
mass increases in a non-linear manner as the platelet count increases,779 although the 
platelet mass is constant for counts between 100 to 450 109/1 when correcting for 
splenic sequestration of larger platelets and inherent errors in electronic m easure­
ment of MPV.771 In the absence of haemostatic "stress" both the platelet count and 
MPV remain constant over time in a given individual.771
7.1.2 Methodology for the Measurement of Platelet Size
7.1.2.1 Methods available and their limitations. There is a good correlation 
between whole blood and PRP platelet counts, independent of MPV.791 Mean plate­
let volumes in whole blood and PRP also correlate well.791 Platelet volume has a 
log-normal frequency distribution in whole blood platelet populations,356,769,779,781,791 
and the distribution curve appears to be unimodal and is skewed to the right.356,792 
However, the log-normal distribution of platelet volumes may only be present over 
the range 3-15 fl.792 There is satisfactory confirm ation of a unim odal m odel for 
platelet size distributions in the range >2 fl and <20 fl.777
Unfortunately, many technical considerations, such as the full recovery of all plate­
lets in PRP, contamination of PRP by platelet aggregates, and shape change occur­
ring during the processing, make the evaluation of the relevance of platelet physical 
heterogeneity difficult when using PRP as the platelet source.771 The preparation of 
PRP results in the loss of at least 2-5% of platelets791 and possibly 20-40% originally 
present in whole blood.769,781 The necessity of total platelet isolation to avoid exclu­
sion of platelet subsets that would lead to experimental bias and loss of important 
functional subgroups of platelets has been considered.770 Centrifugation does not 
appear to affect shape as substantiated by microscopic methods.356 The platelet size 
d istribu tion  is not m anifestly  in fluenced  by partic le  concen tra tion  (50,000 to 
400,000) or by platelet shape.356 Continuous density gradients may be a method of 
obtaining separated platelets,777 although the method is not ideal for clinical screen­
ing application.771
Further problems arise because of the time dependent changes in platelet volume ex 
vivo that occur after the collection of blood. There appears to be a predictable in­
crease early after venesection,791 although this has not been a consistent finding.788 
In both whole blood and PRP, the MPV can increase between 21 to 31% within five 
minutes of exposure to EDTA.779 This increase may be as low as 2% or possibly up 
to 46%.793 A further 10 to 16% increase in volume occurs over the subsequent two 
hours and following this the volume rem ains constant.779 During this period the 
platelet count changes less than 5%. There is little difference between the MPV 
measurement of whole blood and PRP. Reproducibility studies over a period of three 
months have demonstrated only a 6% variation in MPV during sequential observa­
tion.779 An increase in the MPV caused by EDTA779,793 may be prevented by using 
sodium citrate and PGE1 as the anticoagulant.794
Methodology, anticoagulation and storage time all influence the MPV.793,795 Meas­
urem ent systems for determ ining MPV can give different results with very little
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change in platelet count.793 Different anticoagulants, different concentrations of the 
same anticoagulant795 and different storage times in the same anticoagulant793,795 all 
alter the MPV. Alteration in the shape and the percent distribution of various shaped 
platelets occur at all steps in platelet isolate preparations. The method of venepunc­
ture is of initial importance and smaller gauge needles, prolonged withdrawal and 
simply the insertion of a needle into a vein and application of a tourniquet affect the 
percentage of discocytes present.796 Other variables involved include the type of 
anticoagulant, temperature and pH, fixation method and ’washed’ platelets.356 All 
these factors alter the distribution of platelet shape.781,796
As a result of these and other limitations, measurement of platelet heterogeneity has 
not achieved general practical clinical application.
7.1.2.2 Electrical cell sizing. Changes in MPV can arise from differences in the 
distribution of platelet morphology, particularly when using electrical cell sizing 
(Coulter counter techniques). Existing methods for measuring MPV tend to overes­
timate the size of small platelets and underestimate the size of large platelets.771 A 
decrease in discoid shaped platelets and an increase in ellipsoid platelets with pseu­
dopods results in an apparent increase in MPV of 10 to 30%.797 This is thought to be 
due to the shape change and is not necessarily related to an absolute volume 
change.796 However, the good agreement in values for MPV obtained by different 
laboratories using the Coulter counter technique suggests that the variation in tech­
niques for both the isolation and measurement of platelet physical properties may not 
be of major importance in normal subjects.791,796
Advances in electrical cell sizing have made the MPV a readily available parameter 
in most clinical laboratories.798 When particle shape, electrolyte resistance, electron­
ic amplification and capillary aperture diameter are kept constant, the Coulter coun­
ter produces electrical impulses whose amplitude is proportional to the volume of the 
individual particles passing through its aperture.356 Calibration of the instrument is 
achieved using fixed size latex particles, a method which does not take into account 
the effect of shape change. There usually is no correction for particle concentration 
despite demonstration of an inverse relation between size and platelet count. Howev­
er, the justification for not correcting for these factors when using the Coulter coun­
ter to measure MPV356 is not universally accepted.779,789,790
The Coulter counter model S-Plus counts platelets in whole blood by developing a 
histogram, which is normally skewed to the right of particle volumes in the range 2- 
20 fl. The instrument’s computer software programme extrapolates this curve to a 
smooth log-normal curve and in doing this artificially includes particles >20 fl and 
<2 fl. The platelet count subsequently reported includes all particles within the 
extrapolated curve. The MPV is calculated by integration of the mean of all particles 
under this curve.789,791 If a trough is noted in the histogram at particle volumes less 
than 20 fl then that volume is used as the upper limit for that particular specimen. If 
the histogram can not be smoothed to a log-normal curve, no MPV and possibly no 
platelet count will be reported.789
7.1.2.3 Alternative methods. Microscopic measurements of platelet diameters 
have been performed on peripheral blood smears of platelets in citrated blood or
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with PRP prepared from blood anticoagulated with citrate or EDTA.356 The volume 
is then calculated from the measured diameters. This method is slow, labour inten­
sive and not suitable for general clinical application. The MPV distribution obtained 
by this method correlates with that obtained by electronic sizing and counting,356,780 
although it is probably less sensitive to volume changes.356 The distribution of plate­
let diameters from smears and the apparent volume distribution from the Coulter 
counter are both comparable with a log-normal distribution.356,799
Another method of separating platelets according to size independent of density 
employs the principle of Counterflow centrifugation (centrifugal force opposed by a 
flow force to separate particles) . 782 Other methods of separation of different sized 
platelet fractions have relied on discontinuous density gradients.769,770,772 on continu­
ous density gradients777 and also fluorescent activated cell sorting.777 The separation 
of platelets into subfractions for measurement of MPV introduces the increased 
possibility of introducing artifacts (activation, shape change and even possibly a 
decrease in density).
The applicability of automatic electronic cell sizing for whole blood appears to be 
the preferable clinical screening method for measuring MPV, accepting the limita­
tions of the method. However, it must be emphasised that the MPV is but one aspect 
of the morphological heterogeneity manifested by circulating platelets.771
7.1.3 Platelet Size and Volume in AMI and CHD
Larger platelets, as measured by an increased MPV, have been reported to be more 
active when assessed by changes in platelet aggregation, survival time or the release 
reaction.771,772,776 An increased platelet volume has been observed in patients with 
AMI. 800' 803,794 Furthermore, increases in platelet volume has been documented six 
weeks802 to three months after AMI.54 Using different methodology, a number of 
other studies have also demonstrated a higher MPV in patients with AMI compared 
to controls.804,805 Platelet size may also be a predictor of recurrent MI and death,806 
although it previously was thought not to provide prognostic information.801 In­
creased platelet volume has also been found in patients with chronic stable angina.54 
This is not a uniform observation.804
The cause of a larger MPV in patients with AMI is uncertain, is unassociated with 
diabetes or smoking801 and other known risk factors for CAD such as BP, blood li­
pids, fibrinogen, WCC or plasma viscosity. 806 The observation that there is an 
overall increase in the normal distribution curve of platelet volume mitigates against 
an increased production and consumption of a subpopulation of platelets due to 
AMI.802 Bone marrow megakaryocytes volumes are larger than normal in individu­
als dying of sudden cardiac death and in association with AMI.794 There is no signif­
icant difference between the platelet cytoplasmic volume distribution for patients 
with AMI or sudden coronary death.794 Lower platelet counts have been documented 
in patien ts with AMI compared with con tro ls , 805 although this remains 
controversial.85 Furthermore, patients who have had AMI, and who have a large 
MPV, may also have a lower platelet count.804
Methodological problems related to measuring MPV in infarct patients may account
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for these conflicting observations described.771 Activated platelets undergo shape 
changes that can cause artifactual changes in volume in a resistive particle counting 
system,797 and platelets are activated in AMI.45 This problem can be minimised by 
using PGE1 with sodium citrate to inhibit platelet shape change. However, a large 
MPV and a low platelet count have still been observed in individuals with AMI even 
when these anticoagulants are used.793 Furthermore, if there was simply an artifactu­
al increase in the size of platelets, it would be accompanied by a change in the 
skewedness of the volume distribution.
An additional population of platelets may contribute to the increased MPV observed 
in patients with CHD. A bimodal distribution in the MPV has been noted in an 
infarct group,804 the lower volume group being similar to a normal control group. In 
this study, those individuals with a larger MPV also had lower platelet counts,804 and 
this observation was recently confirmed.805 Alternatively, this apparent bimodal 
distribution may be due to a deficit of small platelets, being an effect rather than a 
cause of AMI.807 A group was followed for 18 months after AMI and the distribu­
tion curves at this time did not differ significantly from those of a control group.807 
Retrospectively plotting the platelet volume distribution from data measured at the 
initial time of the infarction indicated the possibility of a deficiency of platelets in the 
range of 5-12 fl, there being no difference above 12 fl. The difference had disap­
peared by 18 months. This observation supports the concept that the high MPV is 
due to a deficiency of small platelets and is possibly an effect rather than cause of 
AMI. Indeed, others have provided supporting evidence for the postulate that a high 
MPV after an AMI is due to consumption of small platelets.808 Others argue that 
alterations in the entire megakaryocyte-platelet-haemostatic axis precedes the 
MI.794.805,806 increased total aggregated, irreversibly aggregated, reversibly aggre­
gated platelets, and average platelets per aggregate are increased after an AMI.803 
These changes are especially marked in patients later developing cardiac complica­
tions.803 Moreover, men who have a fatal or further non-fatal MI within 2 years of 
an initial MI have a greater MVP 6 months after the first MI than survivors who 
have no further events.806
7.1.4 Methods
See Chapter 2, Chapter 8 and Appendix 1 for a description of the methods and stan­
dardisation.
7.1.5 Results
7.1.5.1 Group comparisons. A significant difference in the values for MPV was 
noted between the case and control groups. The MPV in the case group was signifi­
cantly larger (9.4+/-0.9 fl, median 9.2fl, min=7.0fl, max=12.4fl) than in the 
control group (8.9+/-0.9 fl, median=8.8fl, min=6.8fl, max=11.3fl).
7.1.5.2 Correlations with blood cell indices, CHD risk factors and platelet 
function tests. In the control group, the MPV had a significant inverse linear corre­
lation with the platelet count in blood and the platelet count in PRP (PRPPC) (Table 
7.1). There was also a borderline inverse relationship with the WCC, the cholesterol 
level and the PCR (Table 7.1).
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For the case group, the MPV inversely  corre la ted  w ith the p la te le t count, the 
PRPPC, Hb, He, triglyceride, HDL cholesterol and serum TXB2 levels (Table 7.1). 
No relationship was observed with the plasma BTG level (Table 7.1) or consistently 
with any of the measures of platelet aggregation in either group (Table 7.2).
7.1.5.3 Correlations with plasma fatty acid. Since fatty acids have been shown 
to influence platelet function and membrane content, the relationship of the MPV to 
the plasma fatty acids was evaluated. A positive relationship between the MPV and 
oleic and eicosapentaenoic acids, and negative linear correlation with palmitic was 
present in the control group (Table 7.3). This differed from that observed in the case 
group. A positive correlation between MPV and docosahexaenoic acid, and negative 
correlation with stearic and eicosatrienoic acids was observed in the case group 
(Table 7.3).
7.1.5.4 Regression analysis. To evaluate the independent predictive value of 
those variables linearly correlating with the MPV (platelet count, Hb, He, WCC, 
cholesterol, triglyceride, HDL cholesterol level, palmitic (C16:0), stearic (C l8:0), 
oleic (C18:lw9), eicosopentanoic (C20:5w3) and docosohexanoic acids (C22:6w3), 
they were entered into a multivariate regression model. In the case group, docoso­
hexanoic acid, HDL cholesterol and stearic acid were independent predictors of 
MPV. In the control group, the p late let count and palm itic acid only rem ained 
independently predictive of MPV (Table 7.4).
7.1.5.5 Analysis of covariance. In view of the difference in the group means for 
the MPV and the differing correlation between the MPV and variables between the 
groups, the effect of these variables (p latelet count, Hb, He, W CC, cholesterol, 
tr ig ly ce rid e , HDL ch o les te ro l level, C 16:0 , C 18:0 , C 1 8 :lw 9 , C 20:5w 3 and 
C22:6w3) was measured by analysis of covariance to obtain an adjusted mean. When 
the effect on the variance of these variables was removed, the adjusted means of the 
MPV for the case and control groups was 7.1fl and 7.3fl respectively. The statistics 
for this analysis are described in Table 7.5.
7.1.5.6 Coronary angiography. The MPV in the CHD group was related to both 
the disease severity and to the extent of coronary atherosclerosis measured angio- 
graphically (Table 7.6).
7.1.6 Discussion
The increase in MPV in the CHD case group is consistent with observations made in 
a number of other studies.54,802,804'806 Furthermore, the increase in MPV in the CHD 
group is associated with a lower platelet count, again, a finding in common with 
previous reports.787,804,805 The difference between the two groups is unlikely to be 
due to technical considerations affecting the measurem ent of the MPV, although 
many difficulties exist.356,769,771,779,781,788,791,793,795 Exactly the same methodology 
was applied  to the co llection , processing and m easurm ent o f the MPV in both 
groups. Indeed, since current methods overestimate the size of small platelets, and 
underestimate the size of large platelets,771 the reported differences in the MPV may 
be an underestim ate. In addition, the reproducibility of the measurement of MPV 
using the Coulter Counter technique is very good, with a low intra- and inter-labora-
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tory error.796,789 Thus, it would appear that patients with CHD and a previous AMI 
have a platelet population with a larger MPV. The validity of the observation is 
supported by the consistency of the observation with that in the literature.54,803'806
Although there appears to be little doubt that the MPV is persistently greater in pa­
tients with CHD months after AMI,54,802,806 observations from studies of stable CHD 
without infarction have been equivocal.54,804 The cause of the difference has not been 
elucidated by this study. Being a cross-sectional study, it does not provide informa­
tion about differences due to selective consumption of small platelets,808 aging770,7/2 
or at thrombocytopoiesis.774,776,777 Another consideration in the possible relationship 
between platelet volume and AMI is that the case group were all clinically stable, 
and therefore, it would be unlikely that differences were related to ongoing coronary 
thrombosis. Moreover, other studies have also documented larger platelets in pa­
tients six weeks802 and three54 and six months806 after AMI. Nevertheless, as will be 
discussed, the MPV is influenced by different factors within the blood in each 
group, particularly the plasma fatty acid content. The lack of an association with 
smoking and blood glucose levels is well documented.801
The observation that the platelet count is inversely proportional to the MPV in this 
study has also previously been well documented.779,787,789,790 To ensure that any 
measured differences in the MPV between groups are valid, adjustment for the plate­
let count is recommended.789 This was undertaken using analysis of covariance to 
obtain an adjusted mean which takes into account a number of variables that may 
have resulted in the difference. Blood lipoproteins and fatty acids have been clearly 
demonstrated to influence platelet function, including the platelet membrane content. 
Therefore, since such plasma factors may have a potential influence on the platelet 
volume, those variables related to MPV were also entered into the analysis of covar­
iance. This analysis showed that the adjusted MPVs in the two groups did not differ, 
indicating that those factors associated with the MPV in blood may have caused the 
observed difference.
Previous reports have documented increased in vitro reactivity related to platelet 
size.776,781,782 However, in both our population groups, the MPV (measured in whole 
blood) was unrelated to in vitro measures of platelet aggregation (measured in citrat - 
ed PRP). This negative result may be due to the loss of larger platelets during the 
preparation of PRP by centrifugation. As a result, the cell population used in vitro 
may be different to the in vivo population, with a bias toward smaller lighter plate ­
lets in the supernatant than that in the centrifuged blood used in the aggregation 
studies. A greater percentage of larger platelets may be removed during centrifuga­
tion, resulting in aggregation being less influenced by platelet size, with a conse­
quent dilution of a measurable relationship between aggregation and MPV. This may 
not be important however, since there appears to be little difference in the MPV 
between platelets in whole blood and in PRP.779 Nonetheless, at least 2-5%,791 and 
possibly 20-40%,769,781 of circulating platelets may be lost in the preparation of 
PRP769,781,791
A linear relationship between MPV and TXB2 production has been observed.784 The 
opposite relationship was observed in the present study, and only in the case group, 
despite the fact that the CHD group produced more TXB2 in clotting whole blood
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than the control group. Larger platelets may have more TXB2 synthetase resulting in 
the ability to produce more TX B2,784 which may explain the greater am ount of 
TXB2 produced during clotting in the CHD group. Alternatively, since larger plate­
lets are potentially more reactive than smaller platelets,771,776,781,783,784 the circulating 
larger p la te let may become "exhausted", resulting  in less reactiv ity  ex vivo and 
lower maximum TXB2 production during clot formation.
The MPV has a univariate correlation with the number and severity of angiographic 
defined stenotic lesions and less so with the extent of disease. This association may 
be c a u sa tiv e , re su ltin g  in an in c re a se d  risk  o f CHD e v en ts , as has been 
docum ented .806 A lternatively, the association may arise because the MPV is a 
marker indicating the presence of a pre-thrombotic state.805 Another explanation may 
be that the increased MPV results from the CHD event, such as a AMI.803
7.1.7 Summary
1. The MPV in young males with CHD was greater than in normal control
subjects.
2. An increase in MPV was present in individuals with CHD more than 3 
months after an infarct.
3. The higher MPV occurred without evidence of ongoing in vivo platelet
activation.
4. The MPV in the group with CHD was related to disease severity and 
also to the extent of atheroma within the coronary arteries. This relationship with 
angiographically defined CAD would indicate that the observation is unlikely to have 
occurred by chance.
5. The MPV is therefore an identifiable risk factor in young males with 
established CHD supporting similar conclusions made by others.806 That is, there is 
a statistically  significant difference between a group with disease com pared to a 
group without disease, without there being grounds for inferring causality. As with 
most risk factors, the large overlap between individuals in both groups prevents the 
measurement of the MPV from being a clinical useful parameter for disease identifi­
cation or assessment of severity, at present.
6. O ther interacting influences, namely the content of plasma fatty acid, 
may have resulted  in the difference observed. Hence the increased MPV may be 
only a m arker for another pathophysiologically abnorm ality present to a greater 
degree in the CHD group.
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Table 7.1. Linear correlations with the MPV for controls and cases.
Variable Control Case
DOB 0.01 -0.11
PACKYR -0.06 -0.26
ETOHGM -0.28 * -0.10
WT -0.14 -0.16
HT -0.01 -0.03
BMI -0.14 -0.14
TRICEP 0.01 0.10
SCAP 0.01 0.16
SBP 0.04 -0.02
DBP -0.01 -0.08
BSL -0.01 -0.14
HbAlC -0.19 -0.02
FIBRIN -0.15 0.05
URATE -0.13 0.02
Variable Control Case
CHOL -0.26 * -0.01
TRIG -0.18 -0.29*
HDL -0.05 -0.29*
APOA 0.03 0.16
APOB -0.13 -0.04
Hb -0.01 -0.32 #
He -0.01 -0.30 *
WCC 0.23 -0.09
MCV -0.05 -0.11
PRPPC -0.29 * -0.45 #
PCR -0.24 -0.16
SerTXB 0.03 -0.37 **
BTG -0.17 0.07
PC -0.38 # -0.30 *
DOB=date of birth, packyr=number of years smoking the equivalent of 20 cigarettes 
per day, ETOHGM=portions of alcohol per day, WT=weight, HT=height, BMI=body 
mass index, TRICEPS=triceps skinfold thickness, SCAP=scapula skinfold thickness, 
SBP=systolic BP, DBP=diastolic BP, BSL=blood glucose level, HbAlC=glycosylated 
Hb, FIBRIN=fibrinogen level, URATE=urate level, CHOL=blood cholesterol, 
TRIG=triglyceride level, HDL=HDL cholesterol, APOA=apoprotein A l, 
APOB=apoprotein B, Hb=haemoglobin, Hc=haematocrit, WCC=white cell count, 
MCV=mean red blood cell volume, PRPPC=platelet count in PRP, SerTXB2=serum 
thromboxane B2, BTG=betathromboglobulin, PC=platelet count.
Table 7.2. Linear correlations for controls and cases with MPV and measures of in 
vitro platelet aggregation.
Variable Control Case Variable Control Case
LT50ADR -0.08 0.06 RADR -0.08 -0.20
LT50ADP -0.14 0.02 RADP -0.01 -0.07
LT50COL -0.14 0.25 RCOL -0.01 -0.05
LAGCOL -0.06 0.17
LT50=lag time to 50% of maximal alteration in light transmission with aggregation by 
agonists adrenaline (ADR), collagen (COL) and ADP.
R=maximum rate of change in light transmission with aggregation for each of the 
agonists ADR, COL and ADP.
LAG=the lag phase before shape change with collagen induced aggregation.
See section 2.6 for abbreviations.
*<0.05 #<0.01 **<0.005 ##<0.001
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Table 7.3. Correlations for controls and cases with MPV and plasma fatty acids.
Fattv Acid Control Case Fatty Acid Control Case
Myristic
0 4 :0
-0.12 0.14 Eicosenoic
C20:ln9
-0.08 -0.08
Palmitic
0 6 :0
-0.34# -0.14 Eicosadienoic
C20:2n6
-0.19 -0.28*
Palmitoleic
C16:ln7
-0.18 -0.17 Dihomo-y-linoleic
C20:3n6
-0.18 -0.20
Stearic
0 8 :0
-0.05 -0.25* Arachidonic
C20:4n6
-0.04 -0.15
Oleic
C18:ln9
0.30* 0.13 Eicosapentaenoic
C20:5n3
0.25* -0.01
Linoleic
C20:2n6
0.05 0.12 Docosapentaenoic
C22:5n3
-0.06 0.03
alpha-Linolenic 0.14 
C18:3n6
-0.22 Docosahexaenoic
C22:6n3
0.23 0.41**
Table 7.4. Regression analysis with MPV as the dependent variable and all parameters 
with a linear association entered as the independent variables for each group.
Independent
Variable________ B________SE B________ Beta______________ R sq____ P value
A. Case Group (Independent variables being platelet count, Hb, He, WCC, cholest­
erol, triglyceride, HDL cholesterol, 0 6 :0 , 0 8 :0 , C18:lw9, C20:5w3, C22:6w3).
C22:6w3 0.042 0.011 0.497 0.170 0.0004
HDL 0.169 0.058 0.393 0.253 0.0059
0 8 :0  -0.018 0.007 -0.334 0.355 0.0144
B. Control Group (Independent variables being platelet count, Hb, He, WCC, cho­
lesterol, triglyceride, HDL cholesterol, 0 6 :0 , 0 8 :0 , C18:lw9, C20:5w3, C22:6w3).
PC -0.060 0.025 -0.337 0.134 0.0236
0 6 :0  -0.006 0.003 -0.313 0.231 0.0350
See Tables 7.1 and 7.3 for abbreviations
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Table 7.5. Analysis of covariance with MPV as the dependent variable and Hb, He, 
PC, WCC, cholesterol, triglyceride, HDL cholesterol C16:0, C l8:0, C18:lw9, 
C20:5w3 and C22:6w3 as the covariates (Abbreviations are in Tables 7.1 and 7.3)
(1) Tests of significance for MPV:
Sources of Sums of
Variation_____ Squares_____ DF
Within cells 303.3 40
Regression 1471.0 11
Constant 16.57 1
(2) Regression analysis of within cells:
Covariate_____ B_______Beta
Hb -0.251 -0.621
He 0.094 0.411
PC -0.012 -0.043
CHOL 0.081 0.036
TRIG -19.260 -0.262
HDL -0.093 -0.703
C22:6w3 0.005 0.151
0 8 :0  -0.018 -0.267
C20:5w3 0.001 0.031
C18:lw9 0.002 0.134
0 6 :0  -0.006 -0.167
MS_______ F___________sig F
7.58
133.81 17.4 0.000
16.57 0.22 0.643
Lower95%CI Upper95%CI
-0.372 -0.130
-0.010 0.199
-0.065 0.042
-0.273 0.433
-33.304 -5.214
-0.214 0.029
-0.023 0.033
-0.039 0.003
-0.013 0.014
-0.004 0.009
-0.015 0.003
0.000##
0.075
0.654
0.648
0.008*
0.131
0.725
0.091
0.948
0.474
0.195
Table 7.6. Linear correlations for controls and cases with MPV and angiographic 
measures of CAD.
CSS 0.27 * No. normal segments -0.24 *
mCSS 0.26* No diffuse segments 0.36#
CAS 0.22 No. lesions >50% 0.20
mCAS 0.23* No. lesions >70% 0.36#
No. occlusions 0.10
Jenkins 0.23* No lesions >90%, <100% 0.25*
LVS 0.19 No lesions >75%, <90% 0.12
CS 0.10 No lesions >50%, <75% 0.14
Collaterals 0.23* No lesions >25%, <50% 0.19
No lesions >10%, <25% 0.15
CSS=coronary stenosis score, mCSS=mean CSS, proxCSS=proximal CSS, 
CAS=coronary atheromatous score, mCAS=mean CAS, proxCAS=proximal CAS, 
Jenkins=Jenkins coronary score, LVS=left ventricular score, CS=collateral score, 
collaterals=no arterial segments supplying collaterals, diffuse segments=diffusely 
diseased segments, disdistal disease=distal segments with angiographic disease.
*<0.05 #<0.01
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7.2 PLATELET COUNT RATIO
7.2.1 Introduction
The PCR is a method giving an indirect quantitation of platelet aggregates in blood, 
and was first thought to provide a measure of in vivo platelet aggregates.325,809 
Normal individuals have a PCR close to unity. 809 A lower PCR occurs in various 
forms of vascular disease compared to a "normal" control group.325 However, a 
large overlap in the distribution of the PCR is present within these groups.325 In 
addition, there appears to be a greater variability within patients than within a 
normal population.325,584 This broad distribution limits the sensitivity of the method 
for use within individuals. The nature of the test and the diversity of stimuli affect­
ing platelets makes the technique a diagnostically non-specific functional test. For 
the study of a population group however, the method appears to be 
satisfactory.325,327,810,811
7.2.1.1 Limitations of the PCR measurement methods. Initially there were a 
number of reports that the PCR was significantly lower in patients with vascular dis­
ease and thrombotic disorders.325,327,810 However, doubts as to the internal reprodu­
cibility of the method and the problems of the large between group and within group 
variance in study populations have been raised,584,812 leading to concern about the 
validity of results using the method.327,812 In fact, the methodology used in this assay 
is highly operator dependent.328,813 Nevertheless, reproducible PCR measurements 
have been obtained with narrow normal ranges,328 as a result of changes in method­
ology including very accurate pipetting of blood samples or direct collection of blood 
into the buffered EDTA solutions, using a standardized region of the supernatant for 
counting, collecting a fixed volume, and reducing the amount of EDTA and formalin 
used.328
The technique to measure platelet aggregates is clearly susceptible to inaccuracies 
due to artifacts caused by sample collection and processing .810,812,814 Moreover, 
evidence has emerged that the platelet aggregates measured by this method are 
probably not present in the circulation of the patients.327,810,812,815 Indeed, there is 
evidence that the platelet aggregates are formed during the venipuncture.327,810,814 
Others have found that the PCR in normal subjects is unaffected by the method of 
blood collection and processing when the platelet counts are measured in whole 
blood and not PRP.327 On the other hand, in patients with diseases associated with 
thrombosis, the PCR was found to be significantly lower when blood was collected 
through a needle and tubing when compared to when the PCR is measured in whole 
blood, suggesting that aggregates form during collection.327
Athough it appears unlikely that platelet aggregates are commonly formed in vivo in 
vascular disease states,327,812 the hypothesis that the circulating platelet has the poten­
tial to express greater reactivity in certain disease states remains tenable. That is, the 
formation of platelet aggregates during sampling is a measure by which platelets are 
determined to be more reactive.327
The degree of tourniquet stasis, age, sex and the time of food intake does not appear 
to influence the test results.584 A very small variance within normal subjects corn-
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pared to that among individuals with various disease states has been documented.584 
This would support the concept that there are indeed factors influencing the PCR in 
patients with vascular disease that are absent in normal individuals. The marked 
overlap between "normals" and "abnormals"334 however, makes any clinical inter­
pretation difficult.
Other doubts about the presence of circulating platelet aggregates arise from the lack 
of direct evidence that platelet aggregates are present in the patient’s circulation.810 
Circulating platelet aggregates larger than the capillary diameter would be expected 
to be filtered  out in the m icrocirculation, with the possib ility  of im paired organ 
perfusion.327
7.2.1.2 Platelet count ratio in disorders involving vascular disease. In the 
original study in which the method was applied,325 a significantly lower PCR was 
found in a number of disorders involving vascular disease. The study population 
included patients with transient cerebral ischaemic attacks, AMI, stable angina, acute 
peripheral vascular insufficiency and chronic peripheral vascular disease.325 This 
group was compared to a "normal" and a "patient" control group. The normal con­
tro l g roup had a PCR of 0 .90+ /-0 .02  and the p a tien t co n tro l group a PCR of 
0.88+/-0.01 (mean+/-SEM). However, in the vascular disease groups, apart from 
those patients with a PCR less than 0.70, there was a considerable overlap in values 
between groups, obviously limiting the sensitivity in individuals. In addition, the 
nature of the method and the diversity of potential stimuli affecting the platelets 
during processing make the method intrinsically non-specific.
The utility of the PCR for clinical or research purposes is further confused by the 
failure to support the original finding of a decreased PCR in patients with chest pain, 
AMIs, completed strokes and transient ischaemic attacks.584 A number of research 
groups have observed no decrease in the PCR in individuals with stable angina com­
pared with normal control groups.325,500,584,811,814,816 However, with different meth­
ods, an increase in reversibly aggregated platelets in patients with unstable angina 
and AMI, and an increase in irreversibly aggregated platelets in patients with stable 
angina compared with controls has been documented.817 Scanning electronmicrosco- 
py also reveals the presence of irreversible aggregates in the blood of patients with 
thrombotic episodes.814 The incorporation of red and white blood cells into "platelet 
aggregates" was used to demonstrate more irreversible aggregates.814
In c re a se d  p la te le t  ag g reg a te s  d u rin g  AM I have been  o b se rv ed  by m ost 
investigators.325,327,803,811,818'822 although not all.584 Patients with unstable angina 
have also been shown to have increased platelet aggregates.811 Furtherm ore, in­
creased aggregates have been observed in other vascular conditions associated with 
intravascular thrombosis.325,327,819 Most studies indicate that patients with chronic 
stable CHD do not have a lower PCR, and by inference either circulating aggregates 
or hypersensitive platelets. However, those with unstable CHD do have a lower PCR 
which would indicate that they either have circulating platelet aggregates or that they 
have hypersensitive platelets.
7.2.1.3 Platelet Aggregates in Normal Subjects. Generally it is believed that 
aggregation does not usually occur in vivo in normal subjects.325,496,812 However,
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some investigators have found platelet aggregates in normal population groups. 
Possibly up to 15% of platelets in the normal population may circulate as 
aggregates.584,816 Less than 10% of circulating platelets in the normal population 
may be present as reversible aggregates, while others have observed that about 6% 
of platelets circulate as aggregates which are irreversibly aggregated.817 Platelets 
sensitised in the circulation can more easily undergo activation and aggregate upon 
contact with a thrombogenic surface.823
7.2.1.4 Summary. Normal groups have a broad variation in the PCR in most 
studies, although the PCR in normals may be narrower than originally thought when 
a modified technique is used.328,584 Attention to detail to control confounding factors 
in the methodology may allow differences to be more easily detected, or confirmed 
as being absent. Unfortunately it is difficult to compare studies since there has been 
a wide variation in techniques used, differences in the patient characteristics of the 
populations studied and small numbers in the study groups. Furthermore, when 
comparing a normal population group to a patient study group, the population groups 
have not always been well defined. In addition, drug treatment has not always been 
well documented.
When appropriate methods are used to calculate the necessary sample size to detect a 
true difference between two groups, one finds that at least 30 individuals or greater 
are needed to detect a significant difference in the PCR. There is no documented dif­
ference in the PCR due to age or sex in normal individuals,584 but this does not 
necessarily apply to the patient population with premature CHD. Therefore it is still 
appropriate to have relatively homogeneous study and control groups.
The wide variation in PCR found in patients with stable CHD may be related to 
other factors, or there may even be a bimodal distribution present. None of the 
previous studies have satisfactorily evaluated the PCR in patients with premature 
CHD. Therefore this study has evaluated such a group using methodology that has 
been demonstrated to produce a narrow range for the PCR in a normal population 
group.328 Strict controls to limit confounding methodological factors influencing 
aggregate formation were applied.
7.2.2 Methods
The PCR was determined by a modification of the method of Wu and Hoak325'328 
and is described in Chapter 2.
7.2.3 Results
7.2.3.1 Group comparisons. The case group had a significantly lower PCR than
the control group (0.81+/-. 14 versus 0.87+/-0.08 respectively, p<0.05), although 
there was a large overlap in the values for both groups.
1232 Correlation with blood cell indices and CHD risk factors. In the case 
group, the PCR did not correlate consistently with any of the major risk factors, 
although a significant but weak correlation existed with scapular skinfold thickness 
(Table 7.7). In addition, the PCR did not correlate with any of the blood cell indices
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except for a negative correlation with the WCC in both groups (Table 7.7). Howev­
er, in the control group there was a positive association between the PCR and the 
approxim ate amount of alcohol regularly used, as well as with the blood glucose 
level (Table 7.7).
7.2.33 Correlation with other platelet function tests. The PCR had a border­
line relationship with measures of in vitro aggregation induced by collagen (Table 
7.8). The more reactive that platelets were in vitro, the more that platelet aggregates 
were formed during blood collection in both groups, the PCR being lower. In the 
control group, the greater the serum TXB2 production the more that platelet aggre­
gates formed during blood collection, a circumstance which was not present in the 
case group (Table 7.7).
7.23.4 Correlation with plasma fatty acids. Some plasma FA had a significant 
correlation with the PCR in the case group only. Palmitic acid (C l6:0) positively 
correlated with the PCR whilst oleic (C 18:lw 9), docosapentanoic (C22:5w3) and 
docosahexanoic (C22:6w3) acids negatively correlated with the PCR (Table 7.9). In 
the control group, alpha-linolenic acid (C18:3w6) had a positive association, and 
C22:5w3 had a negative association with PCR, both of which were of borderline 
significance (Table 7.9).
7.23.5 Regression analysis. Those variables which may have influenced the 
PCR or have had a significant correlation with the PCR were entered into the step­
wise regression model to determine the most predictive variable for the PCR (Table 
7.10). In the case group, only oleic acid (C18:lw9), retained a significant predictive 
value for the PCR, whereas in the control group only the blood glucose level and the 
approximate alcohol intake retained a significant (and opposite) association with the 
PCR (Table 7.10).
7.2.4 Discussion
As observed in other studies, the normal group had a narrower range of values for 
the PCR than the group with CHD.328,584 However, the observation of a lower PCR 
in the case group compared to the normal control group differs from some previous 
studies,325,584,816 although not all.817 These other studies evaluated older and more 
heterogeneous CHD groups. Our results infer that platelets from males with prema­
ture CHD are m ore likely to form plate let aggregates during blood co llection . 
N e v e rth e le ss , a sy stem a tic  b ias due to c o lle c tio n  p ro c e d u re s  c an n o t be 
excluded810,812,814 since the method is highly operator dependent.328,813
W hether circulating platelet aggregates are present or absent in vivo in normals is 
controversial.325,496,812,816,817 Our normal group did not have a PCR of unity, indicat­
ing the presence of aggregates in the blood samples. Most available evidence would 
indicate that these aggregates formed during the blood collection.327,810,812,814,815 The 
case group had more platelet aggregates in the blood samples collected. This study 
was not designed to determine when such aggregates appeared, in vivo or during the 
blood collection.
The possibility that the PCR is a measure of ex vivo platelet reactivity can be support-
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ed, although not proven, on a number of grounds. Platelets from normal subjects are 
less influenced by blood collection methods than platelets from patients with vascular 
disorders,327 there is a smaller variance for the PCR in normal subjects328 than in 
patients with vascular disorders,325,584 platelets sensitised in the circulation more 
readily undergo activation and aggregation,823 and the PCR is decreased in condi­
tions where in vivo platelet activation has been proven to occur.325,818"820 In the 
present study, a modest relationship between the PCR and in vitro measures of plate­
let aggregation, but not in vivo measures of platelet activation, was demonstrated. 
These observations further support the proposition that the PCR is a measure of ex 
vivo platelet reactivity, rather than a measure of the presence of in vivo platelet 
aggregates.
Specific factors, such as age and sex, which are associated with in vitro 
aggregation,331 have not been shown to be associated with the PCR.584 Furthermore, 
we have shown no relationship between the fibrinogen level and the PCR, fibrinogen 
being a factor associated with in vitro aggregation measures.331
A similar relationship has been documented between the amount of alcohol used and 
the PCR, as well as a borderline relationship with previous tobacco intake for 
normal subjects with the in vitro aggregation results.331 In fact, the relationship with 
alcohol in the normal control group maintained a predictive association independent 
of the other variables. It is not possible to make any interpretation concerning the 
influence of alcohol in the case group since a major proportion of the subjects had 
changes in their pattern of alcohol use (see Chapter 5). The results, however, sup­
port the proposal of a favourable effect of alcohol on platelet function, and that the 
changes could conceivably reduce thrombotic CHD events.164
Abnormalities of platelet function in vascular disorders have been consistently 
demonstrated and by various methods of evaluation.46,141,824"826 Increased platelet 
sensitivity may be a factor in the development of vascular disease in diabetic pa­
tients.141,824 Although a relationship between the PCR and measures of glucose 
metabolism has not been systematically evaluated in a normal population, a relation­
ship between decreased PCR and diabetes has been documented.825 Our study groups 
were selected on the criteria of not having diabetes or overt glucose intolerance. 
Nevertheless, in the normal group, but not the CHD group, an independent associa­
tion was demonstrated between the PCR and the fasting blood glucose level. The 
significance of this observation is uncertain at present and may simply be due to 
chance from multiple comparisons.
7.2.5. Summary
1. A difference between the control and case groups has been demonstrat­
ed, the PCR being lower in young males with CHD, most of whom have had a 
previous AMI.
2. This difference in the PCR (a functional measure of platelet reactivity) 
appears to be predicted by different factors in the two groups. Whether this is due to 
intrinsic platelet factors, influences within the blood and/or environmental effects, 
remains uncertain.
174
Table 7.7. Correlations between mean PCR, risk factors for CHD and platelet func­
tion measures in the control and case groups.
Controls Cases___________ Controls Cases____________ Controls Cases
DOB -0.17 -0.18 CHOL 0.11 0.18 TXB2 -0.28* -0.18
PACKYR -0.27 0.09 TRIG -0.07 -0.19 BTG 0.10 0.03
ETOHGM 0.35# 0.05 HDL 0.20 0.19 MPV -0.24 -0.16
WT 0.02 0.15 APOA 0.17 0.16
HT -0.03 0.12 APOB -0.02 0.12 Hb 0.14 0.02
BMI 0.04 0.08 BSL -0.57* -0.17 He 0.19 -0.01
TRICEP -0.10 -0.14 HbAlC 0.21 -0.15 MCV 0.38# 0.13
SCAP -0.10 -0.29* FIBRIN 0.15 -0.12 WCC -0.21 -0.45#
SBP -0.12 -0.04 URATE 0.13 -0.03 PC -0.12 -0.03
DBP -0.01 -0.14 PRPPC -0.19 0.06
*<0.05 #<0.01 **<0.005 ##<0.001 
See Table 7.1 for abbreviations
Table 7.8. Correlations between the mean PCR and measures of platelet aggregation 
in the case and control groups.
Controls Cases Controls Cases
LT50ADR 0.27* 0.01 RADR -0.22 0.16
LT50ADP 0.03 0.05 RADP -0.20 0.03
LT50COL 0.22 0.25* RCOL -0.29* -0.14
LAGCOL 0.16 0.34#
*<0.05 #<0.01 **<0.005 ##<0.001 
See Table 7.2 for abbreviations
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Table 7.9. Correlations between the mean PCR and plasma fatty acids in the control 
and case groups.
Controls Cases Controls Cases
Myristic -0.11 0.23 Eicosenoic 0.13 -0.02
Palmitic 0.03 0.26* Eicosatrienoic 0.07 -0.08
Palmitoleic 0.03 -0.01 Dihomo-y-linoleic 0.02 -0.19
Stearic 0.07 -0.14 Arachidonic 0.10 -0.03
Oleic -0.04 -0.30* Eicosapentaenoic -0.03 -0.12
Linoleic 0.03 0.17 Docosapentaenoic -0.25 -0.29*
alpha-Linolenic 0.29 0.12 Docosahexaenoic -0.08 -0.29*
*<0.05 #<0.01 **<0.005 ##<0.001 
See Table 7.3 for abbreviations.
Table 7.10. Regression analysis with the PCR as the dependent variable and the 
parameters having a linear association (MPV, alcohol intake, BSL, MCV and scapular 
skinfold thickness, C16:0, C14:0, C18:lw9, C22:5w3 and C22:6w3) with the PCR in 
either group as the independent variables for each study group.
Independent
Variable B SEB Beta R sq P value
A. Control Group: 
Alcohol 0.250
BSL -0.735
0.088
0.276
0.473
-0.445
0.287
0.481
0.0106
0.0153
B. Case Group: 
C18:lw9 -0.026 0.010 -0.494 0.244 0.0165
See Tables 7.1 and 7.3 for abbreviations
176
7.3 ALPHA-GRANULE RELEASE ASSESSED BY PLASMA 
BETATHROMBOGLOBULIN LEVEL
7.3.1 Introduction
The concept of measuring platelet specific proteins was developed as a method, it 
was believed, for evaluating in vivo platelet function. The assessm ent o f in vivo 
platelet function by other methods such as the platelet survival time is neither specif­
ic nor sensitive enough to evaluate the relationship between platelets and vascular 
disease.94,827,828 The differences from normal in platelet survival time are very small 
and not always reproducible.530,829 In vitro aggregation tests are more useful for 
studying bleeding disorders due to defects in platelet function and for monitoring 
pharm acological agents, but they have not been dem onstrated to be consistently 
useful for identifying thrombotic abnormalities.530 Therefore, the measurement of 
plasma BTG is used as a measure of in vivo alpha-granule release in this study.
7.3.1.1 Human platelet alpha-granule release. BTG and PF4 are released 
follow ing platelet activation and degranulation. Their presence in plasm a can be 
regarded as an in vivo marker of platelet activation.76,77,88,320'324 The major storage 
sites for p la te let secreted proteins are the alpha-granules.830 D uring the platelet 
release reaction the contents of platelet granules are liberated, and this may occur 
without platelet aggregation.830 The proteins released, which include BTG, PF4 and 
fibrinogen, can be identified morphologically in platelets and are the main constitu­
ents o f a subcellular fraction of lysed platelets.311,830 Alpha-granules appear to be 
vesicles sealed by a membrane that possesses GP lib  and GP Ilia  receptors which 
are the same as those on the whole platelet membranes. The proteins are excreted by 
exocytosis from activated platelets.311,337,830 These proteins are broadly divided into 
two groups, those homologous with other plasma proteins, and those proteins specif­
ic for the platelet.830 Proteins secreted by the platelet, but also found in the plasma, 
include fibrinogen, fibronectin, albumin, Factor V, plasm inogen, high m olecular 
weight kininogen, von Willebrand Factor, as well as a number of others.830 Platelet 
specific proteins include PF4, BTG, platelet derived growth factor (PDGF), and 
thrombospondin.311,337,830
The plasma BTG level has a wide "normal" range of reported values varying from 5 
to 65 ng/m l.76,312,323,629 The average platelet content is approxim ately 18mg/109 
platelets.312 BTG has been reported to be present in increased concentrations in the 
plasma of patients with various vascular disorders.76,77,321,323 Interest in alpha-granu­
le proteins is partly related to their proposed roles in normal and perhaps abnormal 
haem ostasis,337 and in tissue repair following their localised release by activated 
p la te le ts .830 The measurem ent of BTG may also be helpful in delineating alpha- 
granule deficiency states.831 BTG is m etabolised by the kidney, and therefore in­
creased levels are found in patients with renal insufficiency,530 and the plasma level 
correlates with creatinine in these patients.832,833 The biological effect of BTG has 
been thought to involve an inhibition of PGI2 production by endothelial cells,834 
although this is of doubtful significance.530,830
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7.3.2 Why measure plasma BTG levels?
Platelets appear to be important in both the genesis and the subsequent thrombotic 
complications of atherosclerotic vascular disease.4,25,115.238.242.299-835 Therefore, nu­
merous methodologies have been employed in attempts to detect platelet activation in 
vivo that may allow identification  of patien ts at risk of developing CAD or its 
throm botic com plications. In this respect, BTG has been extensively evaluated. 
Variation in the plasma levels of BTG can be detected by relatively sensitive RIA 
methods629,836'839 Since BTG is liberated during the sampling process and the prepa­
ration of PPP, methods to limit this problem have also been developed.833,839 Initial 
observations indicated that plasma BTG concentrations are elevated in states asso­
ciated with intravascular platelet aggregation and release,838 as well as in clinical 
conditions with organ damage.629
7.3.2.1 Clinical utility of plasma BTG levels. Increased levels of BTG have 
been found in a wide variety of clinical conditions.299,830,840 Such states include 
venous thrombosis, CAD, AMI, cerebrovascular disease, diabetes, hyperlipidaemia, 
renal failure, the nephrotic syndrome, thrombotic thrombocytopenic purpura, adren­
ergic stim ulation by cold, dissem inated intravascular coagulation and cancer. In 
addition, plasma BTG is also increased in patients with prosthetic heart valves and 
extracorporeal circulation. However, measuring plasma BTG in any of these condi­
tions has little or no practical clinical utility at present.
7.3.2.2 BTG and atherosclerotic vascular disease. Following the initial hopes 
that measurement of plasma BTG may provide a clinically useful tool for predicting 
and/or assessing thrombotic disorders,629,838 a series of subsequent investigations 
have failed to demonstrate any value for this measurement in clinical situations.76' 
83,841-843 ]qot that ajj these studies reported negative findings. Indeed, a number 
demonstrated a positive association with various clinical manifestations of vascular 
disease.76,77,79,82,83,323,842,843 Elevated levels were associated with transient cerebral 
ischaemic episodes and partially predictive of prognosis.842 Increased levels have 
also been found in stable CHD77,82,83 and in acute AMI.76,77,79 Others have interpret­
ed the increased levels of BTG after AMI as being due to platelet interaction with 
previously infarcted myocardium rather than atherosclerotic coronary arteries.841
Patients with documented CHD and stable angina may have a small but statistically 
significant increase in BTG compared with normal controls.323 Others have found no 
change in the levels of BTG in patients with chest pain, AMI or unstable angina,78 in 
patients with CHD and no previous AMI,841 in patients with stable CHD compared 
to those with coronary occlusion or acute myocardial ischaemia 78,82 nor in patients 
after exercise induced myocardial ischaemia.298 In addition, measurement of BTG in 
patients does not detect platelet involvement in acute coronary occlusion.82 Patients 
with stable CHD and the shortest platelet survival time, tend to have higher concen­
trations of BTG and PF4, with a significant correlation between the platelet survival 
measurement and plasma concentrations of these proteins.321 However, the correla­
tion coefficient is low and the overlap with normals is large321 Collectively, these 
studies attest to the doubtful clinical utility of this measurement.
13.23  BTG values in normals. Besides the controversy regarding the actual
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value in the various vascular disease states, the lack of clinical utility arises from the 
large overlap between normal and abnormal population groups.76,530,830 This results 
in very poor specificity and sensitivity for predicting disease in those studies demon­
strating a relationship with atherosclerotic vascular disease. BTG levels in normals 
range  betw een  5 and 65ng /m l, acco u n tin g  fo r 95% o f o b se rv ed  v a lues fo r 
norm als.76,323,629 Reported normal values do vary considerably. For example, the 
BTG level in normals (in ng/ml) has been reported as 24.0+/-1.6,844 17.8 median 
(with 90% of valued occurring in the range 6.6-47.9),530 30.7+/-13.7,836 28.0+/- 
18,845 and 6.0+/-3.6.323
BTG levels are influenced by a number of factors. The BTG level appears to in­
crease with age,629,630,846 although this is not a uniform observation.323 It is possible 
that the age relationship  only applies to the very old629 and not to younger age 
groups.845 No correlation has been found between BTG and the whole blood platelet 
count.323,629 However, the plasma BTG level is proportional to the platelet count in 
some conditions with myeloproliferative abnormalities,629 or when the platelet count 
is high.323 Little temporal variation in the plasma BTG concentration in individual 
subjects has been documented.629 Those studies evaluating BTG levels in patients 
with atherosclerotic vascular disease show substantial overlapping with levels found 
in norm al su b jec ts .76,323,530,830 N onetheless, despite such a wide variation , low 
normal values of BTG may provide good evidence that increased in vivo platelet 
activation is not occurring.530 High plasma levels of BTG can be equated with in­
creased in vivo platelet release only if in vitro release can be excluded and if the 
creatinine is normal.530
7.3.2.4 Possible explanations for the variability of results. The reported values
of BTG in normals and cases show significant variability between laboratories.840 
One reason for the discrepancy between results stems from differences in techniques 
employed in blood collection and preparation of PPP.840 Although age differences do 
not appear to be significant in studies of younger individuals (<50years),629,845 this 
may not be the case in studies of older population groups.629,846 The significant age 
differences between case and control groups in a number of studies may have result­
ed in a biased increase in levels for the case groups, who were older than the control 
subjects.77,79,82,841
Another possible explanation for the variability  may relate to the differences in 
m edications used between cases and controls, as well as between the population 
groups in the different studies. Cardiovascular drugs have the theoretical potential of 
reducing platelet reactivity in vivo.491,507,510,512,513,516,517,519'525,847 However, no effect 
on plasma BTG levels with a combination of a beta-blocker and a calcium channel 
blocker in a group with stable CHD, either in the presence or absence of exertional 
ischaemia has been demonstrated (see Chapter 4 and reference298).
The population groups in many previous studies tended also to be heterogeneus in 
other ways, having mixed gender groups,77,78,79,82,83,841,846 non-angiographically con­
firmed diagnosis of CAD without other objective documentation of disease in some 
of the groups studied,79,82 and, since the degree of left ventricular dysfunction may 
affect BTG levels independent of CAD,841 a measure of the left ventricular function 
has not been reported in the majority of studies. These potential areas of bias are
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directly accounted for in this study.
13.2.5 BTG and acute thrombotic complications of CAD. Platelets are in­
v o lv e d  in the acu te  o cc lu s iv e  isch aem ic  sy n d ro m es o f CH D , nam ely , 
A M I59,91,308,767,807,848'853 unstable ang ina27,45,116 and sudden card iac ischaem ic 
d ea th .15,27,58,238,767,584 These observations provide supportive evidence for those 
s tu d ie s  d e m o n s tra tin g  an in c re ase  in BTG lev e ls  a sso c ia te d  w ith  these  
conditions.76,77,79 Indeed, marked increases in plasma levels of BTG and depletion of 
these proteins from circulating platelets occurs in association with acute in vivo plate­
let activation and release.323 There is no evidence of platelet activation being present 
in patients with stable CHD or non-clinical CAD.45,298 Nonetheless, the possibility 
still exists that individuals with premature CHD possess inactivated platelets but with 
the  p o te n tia l  to m an ife s t h y p e r-re a c tiv e  fu n c tio n  g iven  the ap p ro p ria te  
circumstance.298
7.3.2.6 Summary. The clinical studies described do demonstrate the utility of
measuring BTG levels to differentiate between groups with in vivo platelet activa­
tion, despite the inadequacy of the measurement for diagnosis in individuals.
7.3.3 Methods
7.3.3.1 Reported methods from the literature. A standard method was original­
ly developed to measure the plasm a concentration of BTG in large num bers of 
samples using a RIA technique.839 The RIA method was more specific and sensitive 
than alternative immunological methods.839 The specific details of the method de­
scribed included:
% binding of tracer in :- 
zero standards 
non-specific control 
Detection limit (pg/ml) 
Inter-assay CV % 
Intra-assay CV %
49.2 +/- 4.8
5.7 +/- 0.8 
714 +/-216
14.5 %
13.7 %
The antibody to ligand binding required up to 24 hours incubation to achieve equilib­
rium at 4°c.839)845 A subsequent variation in the methodology allowed quicker pro­
cessing by reducing the incubation period to approximately 60 minutes.839
7.3.3.2 Methodological limitations for the measurement of BTG. Stimulation of 
the release reaction and subsequent in vitro release of BTG can easily occur during 
the collection and processing of PPP prior to measuring the BTG level.833 Tempera­
ture variations, physical trauma and a variety of chemicals all have the capacity to 
promote the release reaction of platelets.840
In the absence of other forms of provocation, the release reaction does not appear to 
occur at 4°C.833 Blood for estimation of in vivo BTG levels should be directly col­
lected  into a m ixture of EDTA and platelet inhibitors, such as prostaglandin E l 
(PGE1) and theophylline, and m aintained at a tem perature of 0-4°C im m ediately 
after collection and during the processing.833
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In addition, the plasma BTG level appears to be sensitive to the venepuncture tech­
nique.844 Even though the potential for BTG release exists when withdrawing whole 
blood through a tube inserted into a vessel,855 venous sampling undertaken appro­
priately and directly via a venepuncture does not influence the plasma BTG levels 
greatly.833,855 EDTA is required to prevent the formation of thrombin, a potent 
aggregator of platelets, during the collection.
EDTA can have an adverse effect on platelets without the modifying influence of 
PGE1, a low temperature and rapid processing.856 Moreover, the effectiveness of 
these modifying factors when platelets are a priori stimulated or processed poorly is 
controversial.856
Centrifuging blood at 1900g, which is recommended, yields PPP rather than platelet 
free plasma. This can result in contamination of the sample with platelets following 
centrifugation, ensuring spuriously high levels of BTG if these platelets are activated 
or lysed following freezing and thawing.857 Recommendations have therefore been 
made to assay the plasma before freezing in order to prevent contamination from the 
lysis of residual platelets following freezing, or alternatively, using high speed cen­
trifugation to produce platelet free plasma before freezing.857 However, sampling 
from the middle layer of plasma may reduce the problem of contaminating platelets 
in the assay sample.858
1 3 3 3  Techniques to diminish methodological limitations. The blood sample 
should be collected immediately into a mixture of an anticoagulant (EDTA) and a 
platelet inhibitor (such as PGE1 and theophylline) at 4°C and maintained at this 
temperature during the processing, including centrifugation at 1900g for 60minutes. 
This method has been demonstrated to give the lowest BTG plasma concentration for 
any given sample.833 The low temperature reduced the release of BTG more than the 
other factors evaluated.833
BTG appears not to be liberated to any extent with passage through a venepuncture 
device, even when forced through a small 23 gauge needle.833 However, it is re­
leased after the blood enters the syringe, and this becomes significant within 7 
minutes without the appropriate anticoagulant, anti-platelet agents and the appro­
priate temperature described above.833 Optimal conditions exist when the blood is 
collected directly into a precooled syringe containing EDTA and PGE1, placed on 
ice immediately and quickly centrifuged at 4°C.
The PPP samples were stored at -70°C and analysed within 6 months. Furthermore, 
blood from controls and patients were collected in a similar time frame and analysed 
simultaneously. Utilisation of PPP following freezing and storing the samples, rather 
than immediate analysis did not appear to have a major impact on the BTG values. 
In addition, the middle-layer plasma, recommended as having the least contamina­
tion of residual platelets after centrifugation,858 was always used. Despite all the 
precautions described above, false positive results do occur because of unsatisfactory 
venepuncture and preparation of PPP.840
7.3.3.4 Biological variation. The concentration of plasma BTG possibly increas­
es with age in normals.629,846 Although the mean plasma BTG value for each 20 year
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cohort increased slightly, the difference only becomes significant for the over 70 
year old compared to the young group.629 In younger normal males and females (less 
than 45 years of age), the BTG level does not vary significantly.845 No variation in 
the BTG level taken over a period of 15 minutes from the one sampling site has been 
observed.845 There is little variation in the level of samples taken weekly or monthly 
over a 3 month period.845
7.3.3.5 Study Method Employed. An RIA kit (Amersham) to measure BTG
levels in PPP was used and the method is described in Chapter 2. The protocol used 
is a modification of a preciously described method.833,839 In particular, the modifica­
tion used involves the utilisation of a more rapid method for determining the BTG 
level by RIA which involves:
1. incubation of the antibody-ligand mixture and hence reaction, for 60 
minutes at room temperature; and
2. following incubation, ammonium sulphate was added to the solution 
prior to centrifugation in order to obtain a precipitate, the antibody bound I125 la­
beled BTG being attached and precipitated by the ammonium sulphate solution.
7.3.4 Results
7.3.4.1 Group comparisons. Differences in the mean plasma BTG levels (+/- 
SD) between the control group (40.3+/-17.3 ng/ml) and the case group (47.0+/- 
36.9 ng/ml) was not significant. The case group had a median of 36, skewness 2.4, 
kurtosis 5.8, a minimum value of 15ng/ml, a maximum value of 190 ng/ml, and 9 of 
53 samples with values above 50ng/ml. The control group had a median of 41, 
skewness 0.3, kurtosis -0.8, a minimum value of 13ng/ml, a maximum value 
76ng/ml, and 12 of 48 samples were above 50ng/ml.
7.3.4.2 Correlations with CHD risk factors. Differences were found in the rela­
tionships between the various major risk factors and the plasma BTG levels in the 
control group compared to the case group. In the control group, the BTG level posi­
tively correlated with systolic and diastolic BP, weight, BMI and cholesterol level, 
while having a negative correlation with HDL cholesterol and apoprotein A values 
(Table 7.11). The BTG level in the case group only had a borderline positive asso­
ciation with systolic and diastolic BP, and possibly a positive association with age 
(Table 7.11). '
7.3.4.3 Correlation with platelet function tests. Different correlations were also 
found between the plasma BTG level and platelet function tests in the two groups. In 
the control group, no relationship was found between BTG levels and the PCR, 
MPV or the PRP platelet count. The BTG level positively correlated with the whole 
blood platelet count and negatively correlated with the serum TXB2 level in the 
control group (Table 7.11). In the case group, the BTG level was only positively 
correlated with the whole blood platelet count and the PRPPC but not the serum 
TXB2 level (Table 7.11). There was no relationship between BTG levels and other 
blood cell indices in either group (Table 7.11).
In the control group, the BTG level was lower when in vitro platelet aggregation was
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greater. In other words, there was a negative correlation with the rates of aggrega­
tion for collagen and adrenaline, and a positive correlation with the time to 50% 
aggregation for collagen and adrenaline, and collagen lag time (Table 7.12). In the 
case group, similar correlations were observed, but only with adrenaline as the 
agonist for aggregation (Table 7.12).
7.3.4.4. Correlation with plasma FA content. The relationship between the 
plasma BTG levels and the content of plasma fatty acids was positive with eicosenoic 
(C20:ln9) and stearic (C l8:0) acids, and negative with palmitic acid (C l4:0) in the 
control group (Table 7.13). This result differed from that in the case group, where a 
negative association with dihomo-y-linoleic (C20:3n6) and eicosapentanoic 
(C20:5n3) acids, and positive association with myristic (C14:0) and palmitic (0 6 :0 ) 
acids existed (Table 7.13).
7.3.4.5 Regression analysis. When the plasma BTG level was considered a 
dependent variable in a regression model, and factors that could influence the plasma 
level, as determined by a linear relationship, were entered as independent variables, 
the plasma content of stearic (0 8 :0 ) and myristic (0 4 :0 ) acids, as well as diastolic 
BP, were independently predictive of the BTG level in the control group (Table 
7.14). Myristic acid and diastolic BP related inversely, and stearic acid related di­
rectly to the plasma BTG level. Age, blood lipids and platelet count were not related 
(Table 7.14). In the case group, the age of the patient inversely, and myristic acid 
directly predicted plasma BTG levels; BP, blood lipids, and platelet count were not 
related (Table 7.14).
There is a known relationship in CHD patients between BP, glucose intolerance, 
specific lipoproteins, body fat distribution, and possibly plasma fatty acids. The 
association between the plasma BTG level and weight and BP in the control group, 
and diastolic BP in the case group may represent an indirect relationship with other 
factors not entered into the regression model. Therefore the fasting blood glucose 
level and HbAlC were entered as independent variables into the regression model. 
In addition, in view of the relationship with in vitro aggregation and the possibility 
of ex vivo platelet stimulation during the collection and processing of samples, 
plasma fibrinogen was also entered into the model. The outcome was that stearic 
acid maintained an independent direct predictive relationship with the plasma BTG 
level in the control group (Table 9). The plasma myristic acid content maintained a 
direct, and age an independent indirect relationship with the plasma BTG level in the 
case group (Table 10).
7.3.4.6 Coronary angiography. Of particular importance, the BTG level did not 
correlate with any of the angiographic measures of CAD in the case group.
7.3.5 Discussion
Using exactly the same methods of collection, processing and measurement of BTG, 
the two study groups had similar mean values. Moreover, the values obtained in the 
study were in the same range of normal as that reported in the literature using simi­
lar methodology.76,312,629 The range for both groups was well below the reported 
increased levels of BTG (viz 91.4ng/ml) which occur following freezing at -26°C.857
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Given the lim itations with the current study, and the probable contribution of an 
indeterminate quantity of BTG released ex vivo during the processing, our observa­
tions do not support the presence of continuous activation of platelets in vivo, as 
measured by plasm a BTG level, in males with prem ature CHD com pared to age 
matched controls without CHD.
A number of observations made in this study in the normal (control) population 
group are consistent with previous reports in the literature. No relationship exists 
be tw een  p lasm a  BTG lev e ls  and age in y o u n g er p o p u la tio n s  o f no rm al 
subjects.323,629,845 Furtherm ore, there was no relationship  betw een plasm a BTG 
levels and the PCR in either the case or control groups.79,844 A weak relationship 
between the level of plasma BTG and some of the plasma lipoproteins (positive with 
total cholesterol; negative with HDL cholesterol and apoprotein A1 levels) is con­
sistent with the general conclusion that there is an increased reactivity of platelets in 
the presence of lipoprotein abnorm alities.65,66,419,423'425,646,627,859'861 Similarly, an 
association with plasma fatty acids may be of relevance given the close relationship 
between fatty acids and platelet reactiv ity .66,627,646,862,863 The plasm a content of 
myristic and stearic acids were independently predictive of the plasma BTG level 
with multivariate analysis, but the major plasma lipoproteins were not. Moreover, 
the different relationship between the plasma BTG level and the plasma fatty acids in 
the control and case groups suggests that there is a difference in platelet response 
between the two groups following exposure to plasma fatty acids (see Appendix 2).
An association between plasma BTG levels and the circulating platelet count was 
found in controls as well as patients, although the relationship  was weak in the 
control group. In the few studies in which it was exam ined, no relationship was 
noted between plasma BTG levels and the circulating platelet count in control sub­
je c ts  w ith  no rm al p la te le t c o u n ts ,323,629 a lth o u g h  th is  is no t a u n iv e rsa l 
observation.864 M ost clinical studies have not com m ented on the relationship. A 
positive association with the whole blood platelet count would be expected if the 
measured BTG was in fact released following the collection and processing of the 
sample. For the same reason a relationship exists between the platelet count and 
serum BTG.323
The major variations between the mean values for plasma BTG levels in normal 
subjects, and the wide range reported in the literature, implies differences related to 
either conditions of measurement or possibly heterogeneity of the "normals" studied. 
A range o f so ca lled  "norm al" values fo r p lasm a BTG betw een 6ng /m l323 to 
31ng/ml629 in well conducted studies remains unexplained, apart from the likelihood 
of contam ination from ex vivo and/or in vitro release. Since in vivo alpha-granule 
re lease  can occur read ily  w ithou t dense g ranu le  re lease  or red u ced  p la te le t 
viability ,865,866 it has been stated that the appearance of BTG in plasm a provides 
sensitive and objective evidence of platelet activation in vivo.323 However, the ob­
servation that untransfused aplastic anaemic patients and idiopathic thrombocytope­
nic patients had plasma BTG levels similar to normals examined by the same meth­
ods,323 suggests that in vitro artifacts may be contributing to the BTG levels meas­
ured in plasma.
A number of other observations indicate that ex vivo release of BTG has occurred.
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The inverse correlation between in vitro measures of platelet aggregation (viz the 
higher the plasma BTG level the less the aggregation response) for blood taken at the 
same venepuncture for both analyses points to the possibility of some degree of 
platelet activation occurring prior to the analysis. The platelet release could occur 
within the circulation or during the collection and processing. Following such activa­
tion, wherever the location, the reactivity of platelets to further stimulation may be 
reduced. This could result in a reduction in aggregation as indicated by the in vitro 
measures. Nonetheless, the study does not evaluate the exact timing of the release of 
BTG, whether in the circulation prior to collection, or subsequently ex vivo and/or in 
vitro. To more accurately evaluate this possibility, at a minimum it would be neces­
sary to measure sim ultaneously p f 4,323’530,830 urinary excretion of the 
m etabolites323,830 and the content of the alpha-granules before and after 
collection.323,830 If it is assumed that some, or possibly all, of the BTG measured 
was formed during processing, then plasma BTG levels may be considered a de facto 
measure of how efficient the collection and processing of the plasma samples was in 
preventing ex vivo platelet alpha-granule release or activation.
Blood taken sequentially from the same venepuncture, to measure plasma BTG and 
to determine TXB2 in the clotted whole blood, demonstrated an inverse relationship 
between plasma BTG and serum TXB2 in normals, but not in the patient group. In 
the normal subjects, it is conceivable that there is a variable and complimentary 
contribution to platelet activation by products of the release reaction and by throm­
boxane. In other words, the more that alpha-granule release contributes to platelet 
activation, the less that thromboxane is required to contribute to platelet activation. 
The absence of a relationship between plasma BTG level and serum TXB2 produc­
tion, and the weaker association between in vitro platelet aggregation and the plasma 
BTG level in the case group, may indicate an alteration in the contribution to aggre­
gation by released alpha-granule products and thromboxane compared to normal 
subjects. If BTG and other alpha-granule constituents were released prior to clotting, 
a reduced anti-heparin effect during subsequent clot formation, may lead to reduced 
thrombin formation and hence reduced TXB2 production. Although this is only 
speculative, it does demonstrate the importance, in fact the necessity of understand­
ing the normal dynamic relationships between the subcellular components of clot­
ting.
Of particular importance, no relationship between plasma BTG levels and the extent 
and severity of angiographically defined CAD was observed. Conflicting results 
have been previously observed using scoring methods and patient populations which 
would reduce the likelihood of determining an exact association.77,841
7.3.6 Summary
This study was not designed to evaluate whether there is in fact a circulating level of 
alpha-granule proteins, nor whether the protein detected are a consequence of in 
vitro release. A study more specifically designed to answer such a question323 has 
reported the lowest "normal" plasma value for BTG available in the literature. 
However, even that study did not conclusively exclude ex vivo release as a cause of 
even the low level of plasma BTG (6 ng/ml) documented by the authors.323 The aim 
of the present study was to compare plasma levels in two groups using the same
185
methodology, acknowledging the probability that the levels observed will reflect in 
part ex vivo alpha-granule release. The relationship between the plasma BTG level 
and the circulating platelet count, the in vitro measures of platelet aggregation and 
the serum TXB2 levels, as well as the fact that the "normal" mean value was greater 
than the lowest previously described value, would indicate that some, if not all, of 
the plasma BTG measured reflects ex vivo release. If this was the case and the 
amount of BTG produced was the same in both groups, and considering that a dif­
ference was found between the case and control group for the PCR (indicating great­
er activation of platelets during blood collection and processing for the case group), 
then one inference is that the increased activation in the case group was not due to an 
exaggagerated release response.
Despite these reservations, the results do indicate the following:
1. There is no measurable difference in the release of BTG from alpha- 
granules following collection and processing of plasma samples in young males with 
or without CHD;
2. There is no evidence that an in vivo process is occurring that causes 
significant release of alpha-granules in young males with stable CHD at a time when 
there is no evidence of acute thrombotic occlusive manifestations of CHD.
3. There is no support for the concept that an alteration in platelet reactivi­
ty associated with alpha-granule release is involved in the pathogenesis of atheros­
clerosis. However, the results do confirm the presence of a qualitative difference in 
the relationship between a measure of platelet function and plasma fatty acids bet­
ween young males with CHD and a normal control group.
4. It is unlikely that the classic CHD risk factors exacerbate or cause 
platelet hyper-reactivity involving alpha-granule proteins, although plasma fatty 
acids may do so.
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Table 7.11. Linear correlations (r value) between BTG levels and potentially asso­
ciated variables in the control and case groups.
Control Case Control Case Control Case
DOB 0.15 0.30# CHOL 0.25 -0.14 TXB2 -0.38* -0.03
PACKYR 0.01 -0.13 TRIG 0.13 0.25 PRPPC 0.16 0.33*
ETOHGM -0.03 0.10 HDL -0.31* -0.17 MPV 0.07 0.05
WT 0.29* 0.03 APOA -0.34* -0.20 MPCR 0.10 0.03
HT 0.19 0.04 APOB -0.06 -0.17 Hb 0.04 0.11
BMI 0.26* 0.12 BSL -0.00 0.08 He 0.13 0.15
TRICEP -0.09 0.04 HbAlC 0.02 -0.00 MCV 0.12 0.16
SCAP -0.18 -0.17 FIBR 0.03 0.18 WCC 0.06 0.21
SBP -0.29* 0.18 URATE -0.06 0.14 PC 0.29* 0.30*
DBP -0.36# 0.22*
*<0.05 #<0.01 **<0.005 ##<0.001 
See Table 7.1 for abbreviations
Table 7.12. Linear correlations (r value) between BTG levels and platelet aggregation 
variables in the control and case group.
Controls Cases Controls Cases
LT50ADR 0.57## 0.39# RADR -0.31* -0.38*
LT50ADP -0.11 -0.04 RADP -0.17 -0.10
LT50COL 0.41** 0.02 RCOL -0.41** 0.09
LAGCOL 0.41** 0.07
*<0.05 #<0.01 **<0.005 ##<0.001 
See Table 7.2 for abbreviations
Table 7.13. Linear correlations (r value) between BTG levels and plasma fatty acids in 
the control and case groups.
Controls Cases Controls Cases
Myristic -0.32# 0.39# Eicosenoic 0.24* 0.10
Palmitic -0.20 0.25* Eicosatrienoic -0.13 0.01
Palmitoleic -0.04 0.07 Dihomo-y-linoleic 0.17 -0.27*
Stearic 0.31* -0.21 Arachidonic 0.08 -0.04
Oleic 0.08 -0.14 Eicosapentaenoic 0.04 -0.28*
Linoleic 0.06 -0.14 Docosapentaenoic -0.05 -0.17
alpha-Linolenic -0.19 -0.12 Docosahexaenoic -0.01 -0.02
See Tables 7.1 and 7.3 for abbreviations
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Table 7.14. Regression analysis with plasma BTG level as the dependent variable and 
DOB, weight, BMI, diastolic BP, systolic BP, cholesterol, HDL cholesterol, triglyce­
ride, apoprotein Al, platelet count, and myristic, palmitic, stearic and eicosenoic acids 
as independent variables.
Dependent Independent
Variable Variable B SEB Beta Rsa Sie
A. Control Group:
BTG 0 8 :0 0.001 0.001 0.376 0.297 0.023
Diastolic BP -0.007 0.002 -0.421 0.419 0.005
0 4 :0 -0.001 0.001 -0.330 0.493 0.050
B. Case Group
BTG 0 4 :0 0.001 0.001 0.664 0.188 0.000
DOB 0.027 0.007 0.515 0.372 0.000
Weight 0.001 0.001 0.313 0.460 0.017
B=regression coefficient, Rsq=coefficient of determination. 
See Tables 7.1 and 7.3 for abbreviations.
Table 7.15. Regression analysis with plasma BTG level as the dependent variable and 
DOB, weight, BMI, diastolic BP, systolic BP, cholesterol, HDL cholesterol, triglyce­
rides, apoprotein A l, platelet count, and myristic, palmitic, stearic and eicosenoic 
acids as independent variables in the control group, as well as blood glucose level, 
HbAlC and fibrinogen levels.
Dependent Independent
Variable Variable B SEB Beta Rsq Sie
A. Control Group: 
BTG C18:0 0.001 0.0002 0.671 0.451 0.0002
B. Case Group: 
BTG C14:0
DOB
0.001
0.022
0.0002
0.007
0.558
0.495
0.158
0.372
0.0008
0.0024
B=regression coefficient, Rsq=coefficient of determination. 
See Tables 7.1 and 7.3 for abbreviations
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7.4 THROMBOXANE
7.4.1 Introduction
Thromboxane A2 (TXA2) is an arachidonic acid metabolite which is generated by 
platelets during aggregation. Arachidonic acid is metabolised by cyclooxygenase to 
form cyclic endoperoxide intermediates (PGG2 and PGH2). PGH2 is subsequently 
metabolised by thromboxane synthase to TXA2, a potent vasoconstrictor and stimu­
lus for ongoing platelet aggregation.577,867 The important role of enhanced throm ­
boxane generation in the circulation for local vasoconstriction, platelet activation and 
arterial thrombosis is widely acknowledged867,868 However, TXA2 is cleared very 
rapidly from the blood stream, the half life of TXA2 being only about 30 secs.869 
Indeed, TXA2 and eicosanoids in general are characterised by episodic production, 
and both metabolic and chemical instability.308,868. Therefore, the measurement of 
TXA2 is difficult, and the use of standard RIA methods impractical.503,868
Quantitative methods have been developed to measure metabolic products of TXA2 
which are present in the circulation longer and reflect the am ount of TXA2 pro­
duced. The very high chemical instability of TXA2 results in the rapid non-enzymat- 
ic hydrolysis of TXA2 and formation of TXB2, the inactive hydration product of 
TXA2.503,868 However, the measurement of TXB2 in peripheral venous plasma does 
not reliably reflect changes in TXA2 synthesis and release in vivo868 because TXB2 
is metabolised within 5 to 7 mins in the circulation, and artifactual release occurs as 
a resu lt o f even a m inim al degree of p la te le t activation  during  the co llection  
process.503,868 The use of ex vivo measurements of plasma TXB2 as a measure of 
TXA2 production in vivo have not been clinically useful due to m ethodological 
p ro b lem s, and they  are p o te n tia lly  m is le ad in g  w hen u ti l is e d  fo r re sea rc h
purposes.503,575,868
At present there are no reliable and sensitive plasm a markers specific for platelet 
production of "in vivo" TXA2, which are not influenced by the collection and pro­
cessing of blood sam ples.504,503,868 Circulating long-lived m etabolic products of 
TXB2, such as 2,3-dinor-TXB2 and ll-dehydro-TX B2, may circumvent the prob­
lems of ex vivo activation, but frequent sampling around a clinical event is required, 
the timing of release is uncertain, and the vascular location and the tissue origin of 
the TXA2 is also uncertain.868 The measurement of stable metabolic products excret­
ed in the u rine has been m ore re liab le  in re flec tin g  the in vivo p roduction  of 
TXA2.503,868,870,871 However, similar potential limitations inherent in the m easure­
ment of these products also exist.868
The ability of platelets from individuals with atherosclerotic vascular disorders to 
form TXA2, and thus TXB2, and the degree of production is controversial.308,835 
Doubts about the validity of many studies relating abnormalities of TXB2 formation 
to a therosclero tic  vascular disease have been convincingly  ra ised ,503.835*868.872 
Immunoreactive TXB2 has been reported to be undetectable in human plasma ob­
tained from healthy volunteers. Methodological difficulties and also sampling arti­
facts are cited as reasons why many studies investigating the endogenous biosynthe­
sis of TXB2 may be invalid.308,503,868 These difficulties, and the variability of TXB2 
measurement, are illustrated by the wide range of TXB2 levels reported, there being
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large differences in levels observed between and within studies.498,628,630,873 Despite 
such potential pitfalls, a number of studies have demonstrated quantitative differenc­
es in TXB2 formation in individuals with vascular disease. Many of these were 
comparison studies in which the same errors would apply to the compared groups. 
Thus, differences in such studies may be qualitatively valid, albeit not quantitatively.
7.4.2 Thromboxane B2 and atherosclerotic vascular disease
The endogenous production of throm boxane and PGI2 appears to be greater in 
apparently healthy older individuals than younger ones.582,874 It has also been ob­
served that atherosclerotic individuals, with evidence of in vivo platelet activation, 
produce increased amounts of thromboxane332,874 and PGI2.874,875 An understanding 
of eicosanoid metabolism in normal subjects and those with clinical manifestations of 
atherosclerosis remains incomplete.308,868
7.4.2.1 Myocardial infarction and sudden ischaemic death. Evidence of plate­
let activation in AMI is supported by reports of platelet aggregates in the major 
e p ic a rd ia l and in tra -m y o c a rd ia l v e sse ls  in p a tie n ts  w ith  sudden  ca rd iac  
death.25,26,854,876 Animal studies have also demonstrated circulating platelet aggre­
gates in the coronary sinus of animals with coronary artery occlusion,877 and platelet 
microthrombi in arterioles and capillaries following experimental coronary occlu­
sion.878 TXA2 is considered one, and possibly a major mediator of platelet involve­
ment.879
An increase in the level of thromboxane has been demonstrated after coronary artery 
occlusion.83,498,853,873,880 Elevated levels of TXB2 have been found in peripheral 
blood881 and coronary sinus blood44,498,882 in association with episodes of myocardial 
ischaemia. An elevation of TXB2 in the coronary sinus has been correlated with lac­
tate production (a measure of myocardial ischaemia), suggesting a relationship bet­
ween TXB2 form ation and ischaem ia.498 Using peripheral venous blood, others 
found higher levels in only 39% of patients with unstable angina or acute AMI and 
the increase was confined to those with recurrent angina at rest and not to patients 
who had stabilised.83 TXB2 levels were not related to the extent of CAD.83
7.4.2.2 Stable and unstable angina. Most studies support the likelihood of plate­
let activation being involved in the syndrome of unstable angina 44,45,873 without sub­
stantiating a causal relationship and establishing the absence of an association with 
stable angina.44,45,298 Alterations in platelet function may also have prognostic impli­
cations for patients with unstable angina.46 There appears to be no relation with in 
vivo TXB2 production and the severity of CAD.44,873
7.4.2.3 Induced myocardial ischaemia. The release of TXB2 into the coronary 
circulation may accompany provocation of myocardial ischaemia with rapid cardiac 
pacing498,499 and sustained isom etric exertion.499 However, the increase in TXB2 
only occurred in those with unstable angina or recent AMI, and not in those with 
either chronic stable angina or non-ischaemic pain.499 When pacing induced ischae­
mia is manifested by the development of angina, a rise in lactate production and/or a 
decrease in lactate extraction, then TXB2 levels increase in the artery and/or the 
coronary sinus in the m ajority of patients.498 U nfortunately the controls were not
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clearly defined and the subjects were given parenteral contrast before the sampling. 
In another study, a much greater increase in arterial and venous TXB2 levels follow­
ing rapid atrial pacing was found in patients with "spontaneous" angina compared to 
those with stable angina.497 As in most studies, a wide variation in levels was found, 
although most patients with unstable symptoms had abnormal plasma TXB2 concen­
tra tio n s .497 The m ajority of stable patients had levels in the norm al range.497 A 
greater increase in TXB2 production in the arterial and coronary venous systems 
following atrial pacing was observed in patients with unstable symptoms compared 
to stable patients with ischaemia induced by pacing.497 Release of TXA2 appeared to 
be greater during spontaneous angina than with pacing in patients with CHD.497 
Others have provided evidence that there is no evidence of platelet activation across 
a normal or an atherosclerotic bed at rest.476 When the coronary blood flow is in­
creased in the presence of obstructive CAD in the epicardial arteries, platelets are 
activated and aggregate more easily.476
7.4.2.4 Summary. There is convincing evidence that TXB2 formation may have 
a role in the pathogenesis of unstable angina, although the possibility of a causative 
relationship remains inconclusive. Furthermore, it appears from the majority of the 
studies discussed, that the activation of platelets and/or the production o f TXB2 
across the cardiac vasculature is independent of the extent of coronary artery ather­
osclerosis,497,873,883 although platelets may be activated in the presence of severe 
obstructive disease and increased coronary blood flow.476
A role for platelet involvement in chronic stable angina of effort, as measured by the 
"in v itro" presence or production  of TXB2, has not been su b stan tia ted .298,308 
H ow ever, the methodology of using peripheral venous blood has been placed in 
question.45,499,868 M easurement of the transcardiac gradient may be more valid as 
peripheral plasma concentrations do not accurately reflect intracardiac concentra­
tions, production or release.44 The methods involved in intracardiac sampling alleg­
edly are valid for measuring plasma TXB2.499,497
Despite the methodological difficulties, in general, these studies are consistent with 
present clinical information which supports the role of platelet activation in unstable 
angina,97,884 a condition in which thrombus form ation occurs in association with 
varying degrees of atherosclerotic coronary arterial narrowing.24,884
7.4.3 Thromboxane and risk factors for atherosclerosis
Numerous studies show that some of the major risk factors have an adverse effect on 
platelets resulting in an increase in platelet reactivity. The effect of these risk factors 
on platelet function, and on prostaglandin and eicosanoid metabolism in particular, 
has attracted considerable attention.
7.4.3.1 Hyperlipoproteinaemia. Platelet m em brane cholesterol content and 
circulating lipoproteins may lead to an altered platelet function.124,128,425,505,628,859,885 
This is discussed in more detail in Chapter 5. Others have found that the major risk 
factors for CAD do not influence platelet TXB2 production.504 M oreover, it has 
been suggested that the capacity of platelets to form TXB2 is not altered per se by 
atherosclerotic vascular disorders, and that the normal homeostatic mechanism can
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be triggered in response to local abnormal stimuli without requiring heightened plate­
let reactivity.504
7.4.3.2 Diabetes mellitus. The literature concerning thromboxane biosynthesis, 
platelet function and diabetes mellitus is also controversial. Reports that platelets 
from diabetic subjects release increased quantities of TXB2 has been extensively 
reviewed.140,141,826 Using methodologies which are allegedly specific and sensitive to 
thromboxane production, without the problems of ex vivo platelet activation, no evi­
dence of a primary disorder in the generation of either throm boxane or PGI2 has 
been documented in insulin dependent diabetes m ellitus.141 However, insulin de­
pendent diabetics have an increased sensitivity  to p la te let aggregation by ADP, 
adrenalin  and co llagen .141,826 M oreover, p latelets from diabetics with vascular 
complications show significantly greater TXB2 synthesis from exogenous arachi- 
donate when compared to platelets harvested from controls and diabetics with no 
complications.826
7.4.3.3 Tobacco consumption. There is some evidence to indicate that tobacco 
may have an adverse effect on platelet reactiv ity .118,121,122,427,430'432,886"890 An im ­
provement in platelet survival time has been observed in smokers, with or without 
CAD, after a period of abstinence from tobacco.320 Smoking tobacco seems to have 
an immediate effect on platelet function, increasing platelet aggregability122 which is 
independent of nicotine concentration.123
7.4.4 Peripheral vascular disease
The involvement of platelets in the formation and/or symptomatic presentation of 
peripheral vascular disease is also currently being intensely investigated. Platelets 
accumulate at points of arterial endothelial damage, forming microthrombi of platelet 
aggregates and fibrin.891 It is postulated that these can become organised and incor­
porated into the vessel wall.891 Furthermore, when platelets are exposed to arterial 
sub-endothelium, they are stimulated to release intracellular contents such as BTG, 
PF4 and ADP, and also to synthesise TXA2.830,1836,840 In severe peripheral atheros­
clerotic vascular disease there may be an increased excretion of the metabolic pro­
ducts of thromboxane (such as urinary secretion of 2,3-dinor-TXB2332,563,870 and 11- 
dehydro-TXB2.870
Atherosclerotic individuals (subjects with peripheral vascular disease and CHD) with 
evidence of increased platelet activation in vivo, produce increased amounts of both 
throm boxane45,332,563 and PGI2.45,875 The endogenous production of thromboxane 
and PGI2 is greater in apparently healthy older individuals than in the young,582 
a lth o u g h  no t as m ark ed ly  in c re a se d  as in su b jec ts  w ith  sev ere  
atherosclerosis.45,563,874,892 Furthermore, in patients with peripheral vascular disease 
this indirect measure of in vivo activation seems to persist for some weeks.582,892 
New platelets which are formed and which have increased reactivity suggest chronic 
platelet activation is occurring. Indeed a subgroup of patients with severe peripheral 
vascular disease have elevated BTG levels, circulating platelet aggregates, shorter 
b leeding  tim es and increased secretion o f the 2 ,3-dinor- and 2 ,3 ,-d inor-6  keto 
metabolic products of TXA2 and PGI2 respectively.332 Some of the patients in this 
study also had CHD, some had insulin dependent diabetes and some were still
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smoking. Therefore, the cause of the platelet activation remains unknown. Despite 
the presence of these confounding factors, evidence of a chronic state of activation 
does exist,893 but the cause of such a state is uncertain.
These findings provide indirect evidence of platelet activation in vivo in such patients 
with angiographically confirmed severe peripheral vascular disease, having rest pain 
with or without ischaemic foot ulceration. However, it is not clear whether the 
atherosclerosis itself caused platelet activation, or whether ischaemia caused the 
platelet activation, and whether increased platelet reactivity aggravated the peripher­
al ischaemia. Nevertheless, the finding would indicate that the pathophysiologic 
mechanisms causing rest pain in peripheral vascular disease are similar to those 
occurring in CHD. The question of a cause or effect association remains unresolved.
7.4.5 Conclusions
Increased platelet eicosanoid metabolism is associated with acute obstructive ischae­
mic coronary artery syndromes. In addition, increased platelet eicosanoid metabo­
lism may be chronically associated with severe peripheral vascular disease.874 A 
persistent increase in thromboxane production does not occur in stable CHD. Per­
suasive evidence exists that abnormal cholesterol metabolism is associated with 
potentially increased thromboxane production. However, the relationship, if any, 
between TXB2 formation and the other major risk factors for atherosclerosis remains 
to be clarified. If platelets have any role in the pathogenesis of coronary atheroscler­
osis, as has been frequently postulated,242 it is possible that risk factors may impact 
on the early subclinical formation of coronary atheroma by enhancing platelet activa­
tion.
Currently, there is equivocal support for the notion that platelets from patients with 
CHD have the potential for increased reactivity, given the appropriate stimuli. Such 
possible stimuli include the major CHD risk factors. Further research to determine if 
increased reactivity of platelets is unequivocally present in patients with CHD is re­
quired. In particular, there is a need to further clarify the relationship between 
thromboxane production and stable CHD.
In this study, the relationship between plasma and serum TXB2 levels and the major 
risk factors in a homogeneous group of young male patients with CHD, and a homo­
geneous control group, is examined. In addition, the relationship of these measures 
to angiographically defined CAD in the patient group has been explored (see Chapter 
8) .
7.4.6 Methods
The methods employed to measure TXB2 are described in Chapter 3, Chapter 8 and 
Appendix 1.
7.4.7 Results
7.4.7.1 Group differences. As was found in one of our preliminary studies,298 
the majority of the plasma TXB2 levels were below the sensitivity of our RIA (viz.
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40 pg per ml). Both groups had less than 10 individuals with any detectable plasma 
TXB2, and this was assumed to be related to ex vivo release. Therefore, the assess­
ment of plasma TXB2 in relation to other parameters was not undertaken.
The case group had a significantly higher serum TXB2 level than the control group, 
although the values in both groups had a broad standard deviation and extensive 
overlap (group means+/-SE were 111+/-12 ng/ml for the case group vs 61+/-9 for 
the control group, p=0.0004).
7.4.7.2 Correlation with major risk factors for CHD. Major qualitative differ­
ences existed between the two groups for the linear relationships between serum 
TXB2 and risk factors for CHD (Table 7.16). In particular, in the normal group 
there was a positive relationship between serum TXB2 and blood glucose level and 
diastolic BP. In the case group, there was a positive relationship between serum 
TXB2 and prior tobacco consumption, BMI and the plasma fibrinogen level (Table 
7.16).
7.4.7.3 Correlation with blood cell indices. The case group had significant 
associations between serum TXB2 levels and other blood cell indices (Hb, He and 
WCC) which were not present in the control group (Table 7.16).
7.4.7.4 Correlation with plasma fatty acids. The control group had consistent 
and qualitatively different relationships between the plasma fatty acid content and the 
amount of TXB2 produced compared to the cases (Table 7.17). Palmitic, palmitoleic 
and eicosenoic acids correlated inversely and eicosadienoic, dihomo-y-linoleic, ar- 
achidonic, eicosapentaenoic, docosohexanoic and docosopentaenoic acids correlated 
directly with the amount of serum TXB2 in the control group only (Table 7.17).
7.4.7.5 Correlation with other measures of platelet function. In the control 
group serum TXB2 levels were associated negatively with plasma BTG levels and 
the PCR. In comparison, in the case group serum TXB2 levels were associated 
negatively with the MPV and positively with the platelet count (Table 7.16). In the 
control group there was a stronger association between serum TXB2 levels and in 
vitro measures of platelet reactivity (platelet aggregation and responses to various 
agonists) than in the case group (Table 7.18).
7.4.7.6 Regression analysis with serum TXB2 as the dependent variable. All 
those parameters which had a linear correlation with serum TXB2 and which could 
possibly influence the formation of TXB2 were entered into a stepwise multivariate 
regression model for both groups. This was carried out to determine which varia­
bles, of those evaluated, independently predicted the level of TXB2 produced during 
clotting of whole blood. In the control group, only some of the fatty acids (eicosotri- 
enoic, eicosenoic and eicosopentaenoic acids) and the blood glucose level maintained 
an independent association (Table 7.19). In the case group only the MPV maintained 
a predictive relationship with serum TXB2 levels (Table 7.19). These results indicate 
qualitative differences between the two groups with regard to mediators of ex vivo 
thromboxane production.
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7.4.8 Discussion
The observations in this case-control study are consistent with previous reports 
show ing no increased  throm boxane production  in vivo in patien ts w ith stable 
CHD.45,298,503 However, clear differences exist between the two groups with regard 
to production of thromboxane during in vitro clotting of whole blood. This increased 
in vitro production is induced by endogenous platelet agonists, although the molecu­
lar environment which occurs during in vivo thrombus formation is not necessarily 
replicated. In addition, the potential effect on thromboxane metabolism by the major 
CHD risk factors may have led to the difference observed.
7.4.8.1 Risk factors and thromboxane. Both nicotine in vitro and smoking in 
vivo inhibit vascular PGI2 synthesis and augment platelet reactivity.894 With ex vivo 
clotting there was no relationship between previous tobacco consumption and TXB2 
production in the control group. Similar observations concerning serum TXB2 and 
smoking have previously been demonstrated in normal subjects.504 No relationship 
has previously been observed between plasma TXB2 levels and smoking habits in 
normal subjects or patients with CHD.83,895 In the group of young males with CHD, 
a linear relationship between serum TXB2 levels and prior tobacco exposure did 
exist. However, the positive association between prior tobacco intake and TXB2 
formation in clotting whole blood was not shown to be an independent predictor with 
multivariate analysis, and the association may be determined by other unmeasured 
mediators or other factors such as plasma fatty acids.
Cholesterol has been reported to enhance the conversion o f arachidonic acid to 
TXB2,867 and an influence of lipoprotein abnorm alities on eicosanoid and prosta­
glandin metabolism is well documented.124,128,505,628,8859,867,885 Furthermore, the rate 
of serum TXB2 production is increased in patients with hypercholesterolaemia,628 a 
positive correlation has been observed between LDL cholesterol and apoprotein B 
levels, and TXB2 formation in clotted whole blood,885 and a negative correlation has 
been observed between serum TXB2 and HDL cholesterol levels.885 Nevertheless, 
others have found no association between major risk factors, apart from an associa­
tion between hypertriglyceridaemia and plasma TXB2 values.895 Both of our study 
groups were neither selected nor excluded on criteria relating to lipoprotein abnor­
malities. Major lipoprotein abnormalities were not present in either group, although 
group mean lipid values for the case group had predictable differences from the 
control group. Since previous cholesterol levels appear to be greater than those 
measured at the time of the study, the levels observed may have been confounded by 
dietary alteration in the case group which has resulted in a reduction in plasma lipids 
following the diagnosis of their disorder, although no patient was taking lipid lower­
ing m edications. Therefore, the lack of an association between lipoproteins and 
serum TXB2 cannot be interpreted reliably. If an association existed previously, then 
the influence must be reversible by dietary modification. Despite these considera­
tions, sim ilar negative results have previously been observed in norm als.504 Fur­
thermore, others have found that the major risk factors for CHD have no influence 
of platelet TXB2 production.504,896 This observation is supported by our current 
observations, particularly when one considers the lack of predictability in the multi­
variate regression analysis.
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One observation of interest is the positive association between the blood glucose 
level and serum TXB2 levels in the control group. Previous studies have shown that 
platelets in diabetic subjects release increased quantities of throm boxane140,826 and 
this was thought to indicate a pathogenic relationship between enhanced platelet 
reactivity and diabetic complications.893 However, the relationship between abnor­
mal platelet function and diabetes is controversial. Altered platelet function may not 
precede the developm ent of m icrovascular com plications in patients with insulin 
depen d en t d iabetes (who lack m acrovascu lar d isease  and have norm al renal 
function).897 The evidence that severe atherosclerosis involving large vessels is 
a s so c ia te d  w ith  a b n o rm a litie s  o f th ro m b o x an e  and  PG I2  b io sy n th e s is  is 
convincing.332,874,875,893,895,898,899 Therefore, alteration in platelet function in diabet­
ics, and for that matter in persons with CHD, may result from the development of 
large vessel atherosclerosis.897 Our observations of a positive association between 
the blood glucose level and the amount of thromboxane produced in clotting whole 
blood in a young non-diabetic male population w ithout clin ical atherosclerosis 
supports those studies indicating a relationship between thromboxane production and 
blood glucose levels independent of the presence of atherosclerosis.140,826
Controversy exists as to the importance of the relationship between serum TXB2 
production and other blood cells. There was no relationship in the control group 
between various blood cell indices and serum TXB2. In the case group, on the other 
hand, there  was an association  betw een blood cell ind ices and serum  TXB2, 
although not sufficiently robust and independent to continue to be predictive of the 
serum TXB2 in the multivariate regression analysis. The necessity for evaluating the 
effect of other blood cell components was validated and discussed in Chapter 4 in 
detail.
In the control group there was a positive relationship between serum TXB2 levels 
and plasm a polyunsaturated fatty acids, and a negative association with palm itic 
acid. The addition of polyunsaturated fatty acids to a diet has been shown to alter 
platelet fatty acid content and reduce TXA2 production.894 In our study the patients 
with CHD have plasma fatty acids profiles which differ from matched controls, and 
the plasma fatty acids in the CHD group are associated with quantitative and qualita­
tive differences in platelet aggregability. These differences are discussed further in 
Appendix 2.
7.4.9 Summary
1. Thromboxane production in clotted whole blood in the case group (with 
CHD) appears to be quantitatively and qualitatively different from the control group. 
There were different influences on TXB2 production due to various plasma constitu­
ents, suggesting that an alteration in the reactivity of the platelet eicosanoid system 
exists in young males with CHD. Blood cell indices appear to play an im portant 
role, as well as the plasma fibrinogen level and the degree of previous tobacco in­
take.
2. In the case group, the most reliable predictor o f serum TXB2 levels 
was a platelet parameter, (viz MPV), rather than external factors in whole blood. In 
contrast, in the control group, serum TXB2 was most reliably predicted by factors
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within the blood, external to the platelet. That is, external influences within the 
milieu of the clot, and in particular, specific plasma fatty acids and the blood glucose 
level influence TXB2 production in the control group.
3. These results support the concept that the platelets of males with prema­
ture CHD function differently to those without clinical atherosclerosis, and that this 
may contribute adversely to in vivo thrombus formation.
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Table 7.16. Linear correlations with serum TXB2 in controls and cases.
Variable Control Case Variable Control Case
DOB 0.10 -0.10 CHOL 0.03 0.06
PACKYR -0.27 0.44# TRIG 0.08 0.19
ETOHGM -0.08 -0.01 HDL 0.11 -0.08
WT -0.01 0.21 APOA -0.06 -0.08
HT -0.28 * -0.14 APOB 0.02 -0.13
BMI 0.18 0.31 * Hb 0.18 0.29*
TRICEP -0.02 0.25 He 0.01 0.26*
SCAP 0.05 0.02 WCC -0.02 0.42##
SBP 0.09 -0.16 MCV -0.25 * -0.17
DBP 0.27* -0.01
BSL 0.26* 0.19 PCR -0.28 * -0.08
HbAlC -0.08 0.16 MPV 0.03 -0.37 #
FIBRIN -0.16 0.34* BTG -0.38 ** -0.03
URATE -0.13 -0.03 PC -0.01 0.43##
See Tables 7.1 for abbreviations.
Table 7.17. Linear correlations between serum TXB2 and plasma fatty acids in con­
trols and cases.
Fattv Acid Control Case Fattv Acid Control Case
Myristic -0.06 -0.11 Eicosenoic -0.26* 0.03
Palmitic -0.25* 0.04 Eicosadienoic 0.48## 0.12
Palmitoleic -0.37# 0.33# Dihomo-y-linoleic 0.29* 0.08
Stearic 0.21 0.07 Arachidonic 0.36# -0.09
Oleic -0.03 0.16 Eicosapentaenoic 0.30* -0.22
Linoleic 0.01 -0.01 Docosapentaenoic 0.38# 0.12
alpha-Linolenic 0.12 0.12 Docosahexaenoic 0.24* -0.36#
See Tables 7.3 for abbreviations 
*<0.05 #<0.01 **<0.005 ##<0.001
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Table 7.18. Linear correlations between serum TXB2 and measures of in vitro platelet 
aggregation for controls and cases.
Variable Control Case Variable Control Case
LT50ADR -0.28# -0.12 RADR 0.17 0.33*
LT50ADP -0.18 -0.11 RADP 0.34# 0.13
LT50COL
LAGCOL
-0.43**
-0.57##
-0.53## RCOL 0.33# 0.09
See Tables 7.2 for abbreviations
Table 7.19. Regression analysis with serum TXB2 as the dependent variable and ALL 
of the parameters with a linear association as the independent variables for each study 
group.
Independent
Variable B SEB Beta R sq P value
A. Control Group:
C20:2n6 0.006 0.001 0.557 0.242 0.0000
C20:ln9 -0.001 0.001 -0.322 0.353 0.0085
BSL 0.026 0.008 0.366 0.455 0.0023
C20:5n3 0.002 0.001 0.326 0.559 0.0077
B. Case Group: 
MPV -0.021 0.007 -0.499 0.249 0.0095
See Tables 7.1 and 7.3 for abbreviations
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7.5 PLATELET AGGREGATION
7.5.1 Introduction
Despite the limitations of in vitro aggregation measures, some recent studies have 
indicated that the assessment of platelet aggregability is potentially a fruitful area for 
further appraisal.59,767,900*902 In particular, increases in spontaneous59 and induced 
aggregation in v/rro768,901,902 are predictive of coronary events and mortality.768 Fur­
thermore, enhanced platelet aggregability is present in the morning after assuming 
the upright posture with a concomitant increase in plasma levels of adrenaline and 
noradrenaline.767 This occurs at approximately the same time as an increased diurnal 
incidence of AMI.223,224,903 Thus, platelet aggregability may be an important predic­
tive risk factor for CHD even when the prevalence of other known risk factors for 
coronary events is low.59 Not only is platelet aggregability predictive of prognosis in 
low risk groups of AMI survivors,59 but it is also predictive in general population 
groups.901,902
Platelets in patients with myocardial ischaemia appear to show more sensitivity to 
aggregating agents than in normal subjects.537,904 An enhanced platelet responsive­
ness to aggregating agents has also been shown in patients both early and late after 
AMI521,537,626,848,849,904 and in patients with unstable angina.905 Indeed, even in pa­
tients with stable CHD after AMI, the in vitro aggregation response of platelets has 
been found to be enhanced in some studies,52,91,660,904,906 although not in all.94 The 
association between in vitro platelet function and CHD requires further examination 
in view of the myriad of possible confounding factors in such a relationship. This 
section examines the results of the in vitro platelet aggregation measures for the two 
study groups. The findings support a growing body o f literature indicating that 
increased in vitro platelet aggregation is an identifiable risk factor for CHD. In addi­
tion, the relationship between aggregation and CHD is extended by evaluating the 
extent and severity of angiographically defined CAD.
7.5.2 Methods
7.5.2.1 Lipoprotein measurement. The m ethods are explained in detail in 
Chapters 2 and 5.
7.5.2.2 Platelet aggregation and standardisation. These methods are described 
in detail in Chapter 2.
7.5.2.3 Angiographic scoring methods. The methods and validation are desribed 
in Chapter 11.
7.5.3 Results
7.5.3.1 Comparison of measures of platelet aggregation. In the case group, 3
patients did not produce any serum TXB2, and, assuming that they had used aspirin, 
their results were not included in the case group’s aggregation measurements. The 
measures used to evaluate the response of platelets to platelet aggregating agents 
indicate that there were significant differences between the two groups in this study.
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There were significantly more individuals in the CAD group who had an aggrega- 
tory response to adrenaline (Table 7.20). There were no significant differences 
between the threshold concentrations of each of the agonists required to achieve 
maximal second phase aggregation when comparing those that aggregated and ex­
cluding the non-responders (Table 7.21). The PRPPC was slightly lower in the case 
group compared to the controls (294 103/ul vs 328 103/ul, p=0.04), however, dif­
ferences in platelet aggregation are negligible over this range in platelet counts.336
There were significant differences between the two groups for other measures of in 
vitro platelet aggregation (Table 7.22). The CHD group had more reactive platelets 
after exposure, in particular, to adrenaline. The time to 50% aggregation was shorter 
for adrenaline and ADP in the case group, but this was only statistically significant 
for adrenaline. The rate of aggregation was faster with all three agonists, although 
again, the faster rate was significant only for adrenaline. The lag time prior to 
aggregation for collagen was shorter in the case group, although only of borderline 
significance. Despite the significant differences between the group values, the var­
iance for both groups was large and there was a considerable overlap in values 
between the two groups.
An interesting result was the lower platelet count in PRP in the case group. On the 
other hand, the MPV in the case group was larger (contributing to a larger platelet 
mass), therefore probably explaining the lower PRPPC. Despite having fewer plate­
lets available for aggregation, platelets in the CHD group aggregated more rapidly in 
response to adrenaline when compared to the control group.
7.5.3.2 Correlations between platelet aggregation and other platelet function
tests. In the control group there was a positive correlation between LT50ADR, 
LT50COL, and LAGCOL values and BTG levels, and a negative correlation bet­
ween RADR and RCOL, and BTG levels (Table 7.23). In other words, the more 
active the in vitro aggregation response, the lower the level of BTG in plasma. The 
case group had similar relationships with the measures for aggregation induced by 
adrenaline only, but not for collagen (Table 7.23).
Also in the control group, there was a positive correlation between the PCR and 
LT50ADR and LT50COL, and a negative correlation with the rate of aggregation 
for adrenaline and collagen (Table 7.23). That is, the lower the PCR, the shorter the 
time to aggregation and the faster the rate of aggregation. In the CHD group the 
PCR was only related positively to LT50COL and LAGCOL, indicating a dimin­
ished relationship between these parameters in the case group compared with the 
control group (Table 7.23).
A negative correlation between serum TXB2 levels and LT50ADR, LT50COL and 
LAGCOL, and a positive relation with RCOL and RADP was present in the control 
group. Thus, the shorter the LT50ADR, the LT50COL, the LAGCOL and the faster 
the aggregation responses with adrenaline and collagen, then the more TXB2 was 
produced in clotted whole blood (Table 7.23). The relationship was similar in the 
case group, but only with the measures using collagen as the agonist, and the 
strength of the relationship was not as strong or consistent when compared to the 
control group (Table 7.23).
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There was no relationship in either the case or control group between the MPV and 
any of the in vitro measures of platelet aggregation (Table 7.23). The PRPPC corre­
lated directly with the various measures of platelet aggregability in both groups 
(Table 7.25).
7.5.3.3 Correlations between aggregation measures and CHD risk factors.
There were significant inverse correlations between measures of increasing platelet 
aggregation and the plasma fibrinogen level, although the relationship was only 
present in the control group and not in the case group. The higher the plasma fibri­
nogen level the lower the measures of aggregability (Table 7.23). In the control 
group, there was no correlation between any of the measures of platelet aggregation 
and blood cholesterol, apoprotein B or triglyceride levels (Table 7.24). However, in 
the CHD group the blood cholesterol level correlated with RADR and RADP, and 
inversely with LT50ADR (Table 7.24). In both groups, HDL cholesterol and apo­
protein A1 levels showed a positive correlation with measures of platelet aggregation 
(Table 7.24).
The diastolic BP correlated with aggregation measures, but only in the control group 
(Table 7.25). However, the majority in the case group were using vasoactive medi­
cations. In the control group, the He was inversely associated with platelet aggrega­
tion (Table 7.25). There were no consistent associations between the measures of 
platelet aggregation and plasma blood glucose levels, alcohol intake, systolic BP, Hb 
and the MCV of red cells in either group (results not shown). The WCC, in the case 
group only, correlated with measures of aggregation (Table 7.25).
7.5.3.4 Regression analysis. To determine which of those variables having a 
linear association with measures of platelet aggregation independently and better 
predicted the degree of aggregability, they were entered into a regression model as 
independent variables with the aggregation measures as dependent variables.
Predictably, the higher the PRPPC the greater the aggregability in the control group 
(Table 7.26). In addition, in the control group, He and fibrinogen levels maintained 
an inverse association with increasing aggregability (Table 7.26). In the case group, 
apoprotein A1 levels had a strong positive association with aggregation, and the 
WCC, serum TXB2 levels and PRPPC also were associationed with aggregation 
(Table 7.26). The aggregation response in the two groups is clearly influenced by 
different factors.
7.5.3.5 Aggregation and angiographic measures of CAD. The only measure of 
aggregation with a consistent association with angiographic measures of CAD was a 
measure of aggregation induced by adrenaline, the severity of CAD being associated 
with the rate of adrenaline-induced aggregation (LT50ADR) (Table 7.27). There was 
no correlation between any of the measures of platelet aggregation in response to 
collagen and the angiographic scores.
7.5.4 Discussion
Aggregation tests using ADP and adrenaline were previously considered to most 
likely differentiate between hypersensitive and "normal" control platelets.334 In this
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study, the p latelets from patients with CHD have been evaluated using in vitro 
methods of platelet aggregation to determine platelet sensitivity to various aggregat­
ing agonists compared to an age-matched control group, and clearly, a difference 
exists. The platelets from patients with prem ature CHD are more susceptible to 
aggregation as reflected by a more rapid response to platelet agonists in PRR This 
was particularly evident with the response to adrenaline, providing support for a 
p o ss ib le  m echan ism  o f in c re a se d  in vivo p la te le t  a g g re g a tio n  p re v io u s ly  
postulated.70,71 Furtherm ore, a consistent and relatively strong relationship with 
angiographic measures of severity and extent of CAD has been demonstrated, sup­
porting recent studies indicating that ADP-induced platelet aggregation may be a 
prognostic indicator of CHD.59,767,901,902
Tests performed in vitro on anticoagulated blood or PRP to measure platelet aggre­
gation in response to platelet agonists are crude measures of the complex and subtle 
interactions that lead to thrombus formation in vivo.901 Such methods of assessing 
platelet hyperreactivity are subject to artifacts produced by blood sampling, the 
anticoagulants used, centrifugation and other parameters in processing the platelets, 
including the aggregation methodology em ployed.58 These are only a few of the 
numerous confounding factors and avenues of potential bias with the methodology 
for in vitro platelet aggregation. These factors not only include the experim ental 
conditions, but also intrinsic and extrinsic factors associated with platelet hypersen­
sitivity, dietary fats, other disease states and many others.58,77,311,312,331,334'337 Given 
such methodological limitations, recent studies have used more sensitive and specific 
immunochemical tests.58,79'80,82,116,285,480,538,908 to evaluate platelets in patients fol­
lowing AM I92 and unstable ang ina.116,538 The utility  of m ost of these m easures 
remains under question.
Giving due consideration to the limitations of in vitro aggregation testing,336 they, 
nevertheless do provide some im portant information concerning the prognosis of 
CHD based on this and other studies.59,767,901,902 Therefore, there is a clear need to 
have a greater understanding of the epidem iology of p la te let aggregation. The 
Northwick Park Heart Study has provided details about the variability of in vitro 
platelet aggregation which needs to be taken into account in any clinical investiga­
tion.331 Platelet aggregability increased with age and fibrinogen levels, it is less in 
women than men at all ages (being partly accounted for by the differences in Hb and 
He), it varies in races (white races having more aggregable platelets than black), it is 
less in male smokers compared with non-smokers, and it has a mild inverse relation­
ship with alcohol intake.331 However, a prospective study of a normal middle aged 
male population showed no relationship with age when subjects within a narrow age 
range were examined,902 in aggreement with the present study.
7.5.4.1 Threshold concentrations of agonists for aggregation. The concentra­
tions of agonists required for various patterns of aggregation vary in a normal popu­
lation.765,909 In addition, an individual may have a different response on different 
occasions.765,909 Furtherm ore, there are no standard norm al values for p la te let 
aggregation apart from those set by individual laboratories.765 This study confirms 
the large variation in the threshold concentrations required to induce aggregation in 
different individuals. Not surprisingly such a measure was unable to differentiate 
between groups, much less between individuals. However, there was a marked dif-
203
ference in the aggregation responses to adrenaline between the two groups. The 
number with no response to aggregation in the control group was significantly great­
er than in the case group. This observation again adds to the argument that adrena­
line may be involved in platelet aggregation in vivo and consequently in the pathoge­
nesis of CHD.71,72,910
7.5.4.2 Collagen-induced aggregation. The effect on collagen induced-platelet 
aggregation of the major CHD risk factors, was examined in both groups. Not sur­
prisingly the aggregability was related to the number of platelets present in PRP in 
both groups, although more so in the case group.
An increased response to collagen (as reflected by the threshold concentration caus­
ing aggregation) has been observed soon after AMI.52 In the same study, a subgroup 
of young patients with CHD, with minimal or single vessel disease, had a persisting 
increased response.52 In addition, whole blood aggregation in response to collagen 
has been found to be associated with a greater release of TXB2 in subjects with MI, 
and this abnormality persists for at least 3-4 months.537 In the current study a similar 
reduction in the threshold concentration of collagen to induce platelet aggregation 
was not observed. Perhaps this is related to the length of time after previous MI. 
Also, the threshold concentration measurements have a marked variation in the 
values obtained between different studies, as already discussed.423,424,911
Other quantitative measures of collagen-induced aggregation in the case group in the 
present study suggest the presence of a mildly increased response to collagen. The 
lag phase was shorter and the rate of aggregation was faster in the CHD patients as a 
group, although the results did not attain statistical significance. One study using 
whole blood impedance aggregometry supports the absence of a difference in platelet 
aggregation between CAD subjects and no CAD subjects at rest.476 No differeces in 
platelet aggregation in response to collagen were observed between subjects with or 
without CAD at rest, although activation of platelets occurred across the coronary 
circulation following rapid atrial pacing.476
Platelet aggregability in the control group was related to the red cell mass but not the 
white cell number in blood. The reverse relationship held in the CHD group, with 
the white cell number having a strong direct relationship with aggregability. Fibri­
nogen levels were unrelated to aggregation in the case group, and had an inverse 
relationship with aggregation in the control group. Both HDL cholesterol and apo­
protein A1 levels were directly related to aggregability in the case group, with the 
relationship of apoprotein A1 being independently associated with some measures of 
aggregation using multivariate analysis. The reason for these relationships remains 
unclear and is discussed below. Of particular interest was the finding that the amount 
of TXB2 produced in serum was directly related to the aggregability of platelets 
caused by collagen. This result is consistent with previous observations.336
7.5.4.3 ADP-induced aggregation. Platelets can be induced to aggregate with 
ADP in the presence of appropriate conditions (eg temperature, pH, carbon dioxide 
and calcium concentration , concentration of ADP and fibrinogen.343'345) There is 
abundant in vitro and ex vivo evidence for a partial dependence of platelet aggrega­
tion in the haemostatic response on free ADP in blood.348 Many previous studies,
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using in vitro methods, have shown increased platelet sensitivity to ADP in patients 
with CH D.191,849,851,912’914 However, in patients w ithout active ischaem ia no dif­
ference has been reported between measures of in vivo aggregation in CHD patients 
and in controls, even when the patients had more reactive platelets in response to 
ADP in vitro.915 Nevertheless, an association between ADP-induced platelet aggre­
gation and AMI, both fatal902 and non-fatal901, has provided support for the concept 
that non-fatal and fatal CHD cases may have similar platelet abnormalities 475
A variety of aggregation responses to ADP have been observed following AMI. 
These include an increased response soon after AMI,849,851,913 increased aggregation 
after an early period of hyporesponsiveness,914 or no increase at all.52 Young female 
survivors of AMI appear to have an increased threshold for aggregation but no dif­
ference in the rate of primary aggregation in response to ADP.851 Increased platelet 
aggregation in response to ADP in patients with AMI is associated with an increased 
level of BTG suggestive of coexisting in vivo platelet activation 912
In the present study various measures of in vitro aggregation responses to ADP were 
not significantly different in patients with CHD and the controls. As with collagen, 
there was a relationship between the platelet number in PRP (as well as in blood) 
and the degree of platelet aggregability in both groups. The aggregability was also 
related to the amount of TXB2 able to be produced in serum in both groups. Again, 
there were also unexplained relationships (in the case group) between the fibrinogen 
level and the red cell count which were inversely related to in vitro aggregation, and 
apoprotein A1 and HDL cholesterol levels which were directly related to platelet 
aggregation. The amount of cholesterol in serum was also directly related to aggreg­
ability to ADP in the case group.
The lack of a difference in ADP-induced platelet aggregation in subjects with and 
w ithout CHD at rest has recently been reported using different m ethodology,476 
results which are supportive of the observations in this study. However, platelet 
activation was greater in the CAD subjects when provoked by rapid atrial pacing.476
7.5A 4 Adrenaline-induced aggregation. An observation of long-standing has 
been that adrenaline in moderate concentrations promotes thrombosis.916 Adrenaline 
potentiates the platelet aggregation response to other agonists.70"72,917 Indeed, adrena­
line is considered by some to not be a primary aggregating agent but a potentiating 
agent for the primary agonists.918 Most agonists which induce secondary aggregation 
only do so at concentrations much greater than physiological levels.919 However, the 
response to low concentrations of one agonist can be potentiated by prior exposure 
of platelets to a similarly low concentrations of another agonist.910,919 Subthreshold 
aggregatory concentration of ADP or collagen, which are in themselves insufficient 
to cause platelet aggregation, may do so with the addition of adrenaline.312 Indeed, 
adrenaline potentiates aggregation induced by a number of agonists70-72,352,353,337 The 
proaggregatory effect of adrenaline probably reflects the true physiological effect of 
adrenaline on human platelets.907 There is a concomitant increase in alpha 2-adre­
noreceptor affinity for adrenaline occurring at the same time as the increase in vitro 
platelet sensitivity to adrenaline .920 It may be that an enhanced affinity of platelet 
alpha 2-receptors to adrenaline may be one mechanism by which platelets develop 
hypersensitivity associated with myocardial ischaemia.905 In patients with unstable
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angina there may be an increase in platelet alpha 2-receptor affinity for adrenaline905 
which coincides with increased platelet aggregation and TXB2 production in re­
sponse to adrenaline.905 During the acute phase of myocardial ischaemia, platelet 
sensitivity to adrenaline and platelet TXA2 generation is increased. Again, this paral­
lels the increase in receptor affinity for adrenaline.905
In this study we observed an increased rate of aggregation in the CHD group in re­
sponse to the adrenaline, and a significantly shorter average time to 50% change in 
light transmission during platelet aggregation. Both these observations indicate a 
greater sensitivity of platelets to adrenaline in the CHD group, even in stable pa­
tients without active ischaemia. There is considerable variability in the responsive­
ness of platelets to adrenaline in apparently normal subjects.354,355,907 Some individu­
als have no bleeding tendency but have platelets with a markedly reduced aggrega- 
tory response to adrenaline,355,907 and the second phase of the aggregatory response 
to adrenaline may be absent in normal subjects.921 In the present study population, 
the platelets from 31% of normals and 8% of patients with CHD did not aggregate 
in response to adrenaline. The fact that there are significantly fewer individuals who 
have no aggregatory response to adrenaline at any one time in the CHD group, 
supports the concept of a persisting and increased sensitivity to adrenaline even 
during stable periods in the natural history of CHD. The absence of a response to 
adrenaline may reflect that it is not a primary aggregating agent. Adrenaline poten­
tiates the platelet aggregation response for other agonists, and this proaggregatory 
effect may be its physiological role in platelet aggregation.70'72
In the present study, in both groups, the amount of TXB2 formed in serum and the 
blood platelet count were directly related to aggregation measures. However, the 
fibrinogen level and red cell mass were related to adrenaline induced aggregation 
only in the control group, which is consistent with previous observations.350,918 Once 
again the relationship with HDL cholesterol and apoprotein A 1 levels was direct and 
significant, although unexplained other than possibilities such as a substitute risk 
factor bias. The serum cholesterol level had a consistent relationship with aggreg- 
ability in the case group but not in the control group, as did the relationship with the 
amount of previous cigarette intake. These aspects are discussed below.
7.5.4.5 Aggregation and other measures of platelet function. The results have 
shown that measures of platelet function which involve ex vivo aggregation have a 
direct relationship with in vitro aggregability of platelets. More reactive platelets, as 
measured by platelet aggregation, produced a greater amount of TXB2 after maxi­
mum provocation in clotted whole blood. This observation dem onstrates that the 
capability of platelets to produce TXB2 in serum correlates with aggregation of 
platelets in vitro. Furthermore, stimulation of platelets by collagen correlated with 
the reactivity of platelets as measured by the PCR. These relationships were weaker 
in the case group than in the control group. In contrast, the plasma BTG level was 
inversely related to in vitro aggregation responses. The higher level of circulating 
BTG in association with less active platelets may be attritubable to prior activation. 
As a result of prior activation, platelets are less reactive on subsequent in vitro chal­
lenge.
Possible explanations for differences between the two study groups in the correla-
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tions found between in vitro aggregation measures and the other parameters of plate 
let function may relate to the differences in the MPV and the PRFPC. The lower 
PRPPC in the case group may indicate the loss of platelets in the form of plate et 
aggregates during centrifugation, or, alternatively, the loss of more plate e s u 
centrifugation due to the slightly higher MPV.
7.5.4.6 Aggregation and CHD risk factors. A relationship between increased 
platelet aggregability and abnormal lipoproteins has been v'ell established in t e 
past.65,66,126’421,423’424,626,627 In a population of healthy males, increased total and 
LDL cholesterol concentrations have been shown to be associated with increase 
sensitivity of platelets to adrenaline and to a lesser extent ADP.423 Hypercholesiero 
laemic individuals generally have enhanced in vitro platelet reactivity compare to 
normal subjects.424,425 There is increased sensitivity to ADP, and in particular a re 
naline, in these subjects.424,426 In normal population groups, however, there is no 
relationship between cholesterol, HDL cholesterol,901 or triglyceride levels, an m 
vitro platelet aggregation. Similar results were observed in the present control g101^  
in which there was no correlation between any measures of platelet aggregation an 
blood cholesterol, apoprotein B and triglyceride levels. In the CHD group, however, 
cholesterol levels did correlate with the rate of aggregation caused by adrenaline an 
ADP. It appears that increased in vitro reactivity of platelets to specific aggregating 
agents exists in male subjects with premature CHD which has some relationship to 
cholesterol levels.
. 145-147
There may also be a relationship between BP and platelet aggregation, 
patient and control populations of this study, the BP was well controlled at the time 
of blood collection and it was the same in both groups. Therefore the relations ip 
between BP and platelets could not be adequately evaluated. Nevertheless, there was 
a positive linear association between diastolic BP and aggregability of platelets in 
response to all three agonists in the control group, an observation consis 
that found in the literature.145"147
Raised levels of plasma adrenaline and hyperglycaemia after AMI may both activate 
platelets, and this could contribute to poor outcome in such patients. n is y> 
the mean blood glucose level and HbAlC levels were significantly higher in the case 
group. However, in our two study populations of non-diabetic males there was no 
consistent relationships between blood glucose level or HbAlC levels and plate et 
aggregability.
7.5.4.7 Limitations. A number of important potential limitations need to be dis 
cussed, particularly given some unexplained and surprising associations, i
pie correlations, there are specific limitations and these associations may si p y 
result from these well recognised problems. Nevertheless, other biases may si y 
lead to unpredicted relationships.
1. Firstly, aggregation studies may be confounded by medications (espe 
dally  aspirin), used by the study subjects. However, it is more probable that t e 
patient group rather than the controls may have accidently or surreptitious y 
aspirin. Moreover, many common cardiovascular drugs in use appear to e 
reduce platelet reactivity.512,519,520 These possibilities would discriminate against an
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increased platelet reactivity in the case group being detected. Nevertheless, despite 
the potential to bias against finding increased platelet reactivity in the CHD group, 
this was indeed observed.
2. The case group had on the average larger platelets (a significantly 
greater group MPV), and this may have resulted in an alteration in the aggregability 
of platelets. However, since the larger platelets in the case group may be partially 
lost during centrifugation, and since larger platelets may be more active, such an 
outcome would also reduce the likelihood of demonstrating a heightened platelet 
reactivity in the case group.
3. The unusual positive association between the apoprotein A1 and HDL 
levels and aggregation requires explanation. An obvious explanation cannot be pro­
vided from the data available in this observational cross-sectional study. The most 
likely cause is a statistical methodological bias and/or confounding factor. For 
example, the platelet population in the cases appears to be morphologically (and 
functionally) different from that in the control group. The removal of platelets resul­
ting from aggregation (or because of their larger size) during preparation of PRP 
could result in a positive association between a "negative" risk factor, that is a factor 
with no relationship to platelet reactiveity, and the remaining platelets.
4. In the current literature, the aggregation response to ADP has a strong­
er relationship with CHD than has been observed for collagen,901,902 thrombin902 or 
adrenalin.902 Our aggregation studies were not significantly different between the 
groups, except for adrenaline, and this observation differs from others.331,901,902
5. The He and fibrinogen levels in the control group were associated with 
a reduction in aggregation, contrary to expectation. This again may be due to the 
preparation methods, since increasing amounts of fibrinogen and red cells in normals 
could cause more aggregation during collection and preparation of PRP. This in turn 
would result in reduced aggregation during in vitro testing. This suggestion is sup­
ported by the observed association between BTG levels measured in the same blood 
sample and platelet aggregability. The BTG level is a sensitive measure of the re­
lease reaction which may have occurred during the collection process.
7.5.5 Summary
1. Young males with premature CHD have different in vitro aggregation 
responses from normal controls, particularly in response to adrenaline.
2. These aggregation responses are influenced by different factors in the 
two groups. Aggregation in the control group was positively influenced by the plate­
let number in the plasma and negatively by the red cell volume in the blood. In the 
case group, aggregation was directly influenced by thromboxane metabolism, by the 
WCC and by apoprotein A1 levels.
3. The results provide further support for recent findings that platelet 
aggregation is predictive of cardiac events and CHD mortality. This concept is 
further strengthened by our observation that there is a significant relationship bet-
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ween the severity of CAD and adrenaline-induced platelet aggregation in young 
males with premature CHD.
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Table 7.20. Aggregation responses to adrenaline in the two study groups.
______________ Aggregation (%)_____ No Aggregation (%)
Controls 33 (69) 15 (31) Fishers’ Test
Cases 46 (92) 4 (8) p=0.0046 *
The numbers are the number of subjects in each group, bracketed numbers are the %. 
Three aspirinated subjects in the case group have not been included.
Table 7.21. Threshold concentrations of agonists to achieve second phase aggregation.
Concentration
12uM 25uM 50uM lOOuM ImM No Aeeree
ADR Controls 6 9 10 1 7 15 C hi-S=l 3.996
Cases 9 11 7 8 11 4 p=0.0156*
ADP Controls 1 14 21 4 2 Chi-S=2.7899
Cases 4 19 19 7 2 p=0.7323
9.5 19 28.5 38 47.5 fue/un
COL Controls 8 23 8 8 1 C hi-S = 5 .1166
Cases 18 22 7 4 1 p=0.2756
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T able 7.22. In vitro p la te le t agg regation  responses in the two study groups 
(mean+/-SE).
Controls Cases 95% Cl of Mean Diff
LT50ADR 230 +/-170 130 +/- 70 156 to 44
(sec) (n=33) (n=46) p=0.001
LT50ADP
(sec)
27 +/- 14 31 +/- 15 -2 to 1
p=0.162
LT50COL
(sec)
138 +/- 69 121 +/- 73 -45 t o l l  
p=0.233
RADR 8.6 +/- 4 13.9+/- 8.8 2.0 to 8.6
(cm/min) (n=33) (n=46) p=0.002
RADP
(cm/min)
27.8 +/- 15.4 32.1+/-26.2 -4.2 to 15.5 
p=0.323
RCOL
(cm/min)
23.4 +/- 12.5 31.2+/-24.0 7.3 to 15.5 
p=0.048
LAGCOL
(sec)
82 +1-55 66 +/- 44 -36 to 4 
p=0.109
Table 7.23. Correlations with platelet aggregation measures in the two study groups.
TXB2 BTG PCR MPV FIBRIN
A. Control Group: 
LAGCOL -0.571- 0.533- 0.160 -0.058 -0.061
LT50ADR -0.398* 0.521- 0.270# -0.082 0.141
LT50ADP -0.176 -0.051 0.025 -0.140 0.334*
LT50COL -0.431- 0.614- 0.219# -0.143 0.087
RADR 0.168 -0.360# -0.221# 0.050 -0.356#
RADP 0.345* -0.326* -0.197 -0.021 -0.331*
RCOL 0.330* -0.455- -0.295# -0.011 -0.157
B. Case Group: 
LAGCOL -0.471- 0.090 0.343* 0.179 -0.190
LT50ADR -0.125 0.355* 0.012 0.062 -0.076
LT50ADP -0.109 -0.038 0.047 0.023 -0.022
LT50COL -0.527- 0.039 0.255# 0.246# -0.109
RADR 0.331* -0.448- 0.157 -0.200 0.145
RADP 0.130 -0.117 0.027 -0.072 0.012
RCOL 0.090 0.046 -0.140 -0.052 -0.276#
Abbreviations are detailed in Chapter 2 and Tables 7.1 and 7.2.
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Table 7.24. Correlations between platelet aggregation measures and CHD risk fac­
tors.
CHOL TRIG HDL APOA APOB
A. Control Group: 
LAGCOL -0.053 0.164 -0.254# -0.173 0.197
LT50ADR -0.056 0.044 0.099 -0.095 0.197
LT50ADP 0.003 -0.040 0.096 0.140 0.030
LT50COL -0.063 0.155 -0.263# -0.243 0.199
RADR 0.096 -0.213 0.081 0.269 -0.091
RADP 0.030 -0.082 0.244# 0.362* -0.260
RCOL 0.208 -0.147 0.278# 0.252 -0.019
B. Case Group: 
LAGCOL -0.147 -0.025 -0.041 0.019 -0.185
LT50ADR -0.272# 0.140 -0.220 -0.447* -0.162
LT50ADP -0.034 -0.057 0.155 0.035 0.029
LT50COL -0.164 0.185 0.047 -0.027 -0.203
RADR 0.421* -0.139 0.266# o Li 0 1 0.352#
RADP 0.266# -0.161 0.280# 0.572- 0.153
RCOL 0.125 -0.071 0.261# 0.370* 0.077
Table 7.25. Linear correlations between platelet aggregation measures and risk factors 
for CHD.
DBP HbAlC He wee PRPPC
A. Control Group: 
LAGCOL -0.235# 0.140 -0.235# 0.190 -0.269#
LT50ADR -0.288# -0.030 -0.286# -0.194 0.178
LT50ADP 0.081 0.291# 0.165 -0.098 -0.259#
LT50COL -0.173 0.124 -0.419- 0.111 0.193
RADR 0.229 -0.192 0.311# 0.199 0.259#
RADP 0.244# -0.093 0.191 0.081 0.244#
RCOL 0.195 -0.144 0.310* 0.053 0.065
B. Case Group: 
LAGCOL -0.007 -0.283# -0.142 -0.350# -0.327*
LT50ADR 0.111 0.054 0.049 -0.069 -0.086
LT50ADP 0.143 0.273# -0.091 -0.181 -0.375*
LT50COL -0.058 -0.187 -0.118 -0.298# -0.374*
RADR -0.175 -0.061 0.013 0.152 0.389*
RADP 0.064 -0.133 0.042 0.129 0.254#
RCOL 0.172 0.058 0.021 0.099 0.273#
# p<0.05, * p<0.02, ~ p<0.005
Abbreviations are detailed in Chapter 2 and tables 7.1 and 7.2.
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Table 7.26. Regression analysis with measures of platelet aggregation as the depend­
ent variable, and serum TXB2, PRPPC, WCC, He, Fibrinogen, DBP, Apoprotein A1 
and Cholesterol values as the independent variables.
Dependent Independent
Variable Variable B SEB Beta R sq P value
A. Control Group: 
LAG He 0.006 0.001 0.852 0.353 0.0001
FIBRIN 0.003 0.001 0.521 0.556 0.0064
LT50COL He 0.005 0.001 0.722 0.521 0.0001
RCOL He -0.007 0.001 -0.842 0.501 0.0000
LT50ADR He 0.005 0.001 0.744 0.553 0.0010
RADR PRPPC 0.002 0.001 0.702 0.429 0.0025
LT50ADP PRPPC -0.001 0.002 -0.561 0.439 0.0021
FIBRIN 0.001 0.001 0.400 0.589 0.0196
RADP He -0.003 0.001 -0.429 0.268 0.0252
PRPPC 0.001 0.001 0.382 0.406 0.0438
B. Case Group:
LAG WCC -1.306 0.580 -0.441 0.194 0.0352
LT50COL TXB2 -0.379 0.091 -0.688 0.311 0.0005
APOA -0.002 0.001 -0.457 0.502 0.0117
RCOL APOA 0.005 0.001 0.640 0.321 0.0007
PRPPC 0.003 0.001 0.437 0.506 0.0128
RADR APOA 0.005 0.001 0.625 0.390 0.0032
RADP APOA 0.006 0.002 0.626 0.391 0.0014
Only variables retaining a significant association are reported.
B=regression coefficient, Rsq=coefficient of determination, SE=standard error of B, 
Beta=beta coefficient. Other abbreviations are detailed in Chapter 2 and Tables 7.1, 
7.2, 7.2 and 7.6.
Table 7.27. Correlation between a measure of adrenaline-induced 
platelet aggregation (LT50ADR) and coronary angiographic scores.
Variable r-value
Normal 0.235
CSS -0.206 *
mCSS -0.284 #
>50% -0.170
>70% -0.198
Jenkins -0.318#
CAS -0.134
mCAS -0.187
CS -0.237
LVS -0.297 #
# p<0.05, * p<0.02 .Abbreviations are detailed in Tables 7.6.
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7.6 SUMMARY
In summary, comparing the two study groups, there is a significant difference in 
measures o f inducible platelet function, that is the PCR, serum TXB2 formation and 
adrenaline-induced platelet aggregation, but not in in vivo measures of platelet func­
tion, namely plasma BTG and plasma TXB2 levels (Table 7.28). These differences 
provide the most reliable evidence for a difference in this study.
Support for a difference in platelet function is also contributed to by the difference in 
the factors correlating with platelet function tests, although because of the multiple 
comparisons, these observations are less reliable. The second avenue of confirm a­
tory support comes from the association of some measures of platelet function with 
angiographic measures of CAD. These will be further discussed in Chapter 11.
There appears to be sufficient evidence to indicate that differences in inducible plate­
let function may be a risk factor as defined by the presence o f a measureable rela­
tionship with the disease and a difference compared to a group without the condi­
tion.
It is possible that a common group of post-AMI patients exist who are at increased 
risk of death or recurrent non-fatal MI,806 and who can be identified by an increased 
p o s itiv e  sp o n tan eo u s  p la te le t  a g g re g a tio n ,59 in c re a se d  in v itro  p la te le t  
aggregation,901,902 an increased platelet release reaction,768 more reactive platelets,806 
or other methods of measuring increased platelet reactivity.46
Table 7.28. Comparison of the group means of the platelet function tests for the case 
and control groups (mean+/-SE)
Controls________________Cases_____________ 95% Cl Mean Diff
P C ( 10/ul) 
PRPPC 
MPV (fl)
PCR
Serum TXB2 
(ng/ml) 
Plasma TXB2 
(ng/ml)
BTG (ng/ml)
254 +/-7 
325 +/-12 
8.88+/-0.14 
0.87+/-0.01 
61 +/-9 
ND
40.3 +1-2.5
245 +/-8 
294 +/-11 
9.4 +/-0.1 
0.81+/-0.02 
111 +/-12 
ND
47.0 +/-5.1
-30.28 to 12.28 
p=0.40 
-63.2 to 1.2 
p=0.05 
0.18 to 0.86 
p=0.003 * 
-0.11 to -0.01 
p=0.01 *
0.120 to 0.40 
p=0.0004 *
NS
PC= platelet count, MPV=mean platelet volume, TXB2=thromboxane B2, BTG=beta- 
thromboglobulin, PCR=platelet count ratio, ND=not detected, NS=not significant.
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CHAPTER 8
THE DIFFERENT PREDICTIVE VALUE OF RISK FACTORS FOR 
ANGIOGRAPHICALLY DEFINED CORONARY ARTERY DISEASE 
IN MALES WITH PREMATURE CORONARY HEART DISEASE
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8.1 VALIDATION OF THE CORONARY ANGIOGRAPHIC 
SCORING SYSTEM
8.1.1 Introduction
Coronary angiography is a technique in which a direct intra-coronary injection of 
contrast medium allows the radiographic visualisation of the coronary arteries. This 
technique was first reported by Mason Sones and his colleagues in 195 9922 and still 
remains the definitive procedure for delineating the coronary arteries and demon­
strating the distribution and severity of coronary atherosclerosis in living humans.923 
The primary goals of coronary angiography are the identification, localisation and 
assessment of disorders of the coronary arteries, primarily coronary atherosclerosis. 
A secondary goal is to assist in determining whether or not a patient is a suitable 
candidate for any of the various forms of revascularisation, such as coronary artery 
bypass surgery.924 Coronary angiography has been extensively utilised in the epide­
miological study of CAD,623 allowing not only the evaluation of CAD based on the 
clinical manifestations, but also a measure of coronary atherosclerosis as measured 
by this technique. Coronary artery atherosclerosis is a diffuse disease which also 
consists of localised intra-luminal obstructive lesions representing the most severe 
manifestation. At present, coronary angiography is used predominantly to identify 
and quantify the more severe segmental disease. Three main approaches for identify­
ing and quantifying severity of CAD are generally used.612,613,617 Firstly, functional 
measures of severity, such as the pressure gradient-flow ratios and coronary flow 
reserve are becoming more useful. Second, and most commonly, anatomic and 
geometric measurements on angiograms are the mainstay of assessment. Finally, 
indirect indicators, such as thallium perfusion scanning, provide valuable clinical 
information particularly related to functional myocardial perfusion.
These measures concentrate on the effect of the stenosis with respect to the en­
croachment into the lumen. However, the study of the extent, as well as severity of 
disease is necessary in order to develop an understanding of the pathophysiology and 
the natural history of CHD. Identification of the clinical, functional, biochemical, 
molecular and anatomical factors that influence plaque stabilisation have important 
clinical consequences.622 Such factors may determine whether an area of atheros­
clerosis remains an innocuous intimal process or becomes a life-threatening lesion. 
The development of generalised atherosclerosis may merely be one contributing 
factor for the development of clinical CHD, with other factors required to change 
the lesion acutely into a significant obstruction. Indeed, the formation of acute 
severe stenoses may have different risk factors and mechanisms than that for the 
development of diffuse intramural coronary atherosclerosis.4,623
8.1.2 The Interpretation and Limitations of Coronary Angiograms
The clinical utilisation of coronary angiograms involves cardiologists or radiologists 
inspecting coronary artery images projected at a 2-3 times magnification. The dis­
ease location is defined in terms of arterial anatomy, and the disease severity is 
specified as the "percentage stenosis".925 The percent stenosis is the percentage of 
segmental reduction in lumen diameter relative to an appropriate nearby "normal" 
diameter. The assessment of severity and distribution of lesions are coupled with
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judgment as to the adequacy of the distal vascular bed for bypass surgery.925
There are serious limitations in this subjective assessment of disease severity611'613,619 
and a number of these are outlined below:
1. Considerable inter- and intra-observer variability exists even for experi­
enced clinicians,926 with up to a 35% variance among experienced angiographers 
evaluating proximal lesions with greater than 50% stenosis.927 There are also signifi­
cant errors in specifying disease location.925 Some consistency of evaluation has been 
found with a four person panel of internationally recognised experts rendering a 
"consensus opinion",925 a situation that is not practical for normal clinical or epide­
miological work. Even with such ideal reporters, clinically very important disagree­
ment occurred in 2/14 cases regarding even the left main stem artery.925 Quantitative 
evaluation of the accuracy of an individual’s and a panel’s visual interpretations of 
coronary arteriogram s have highlighted substantial inaccuracies.618 It has been 
proposed that arteriographic interpretations accurate enough for decisions of major 
importance can only be made using quantitative arteriography, or at least the mean 
value of data from a large panel of angiographers.618
2. Coronary angiography also seriously underestimates the extent and 
severity o f CAD. The majority of careful studies correlating angiographic findings 
and the pathology show important discrepancies.928 Correlations with the anatomic 
pathology and physiological estimates have revealed that haemodynamically import­
ant lesions may not be recognised angiographically and less important lesions can be 
over-estimated.929 Even "normal" areas used as a baseline may be diseased.928,930,931 
Furthermore, many persons have an adequate, if not normal, luminal cross-sectional 
area in the presence of advanced atherosclerosis.622 A possible mechanism for this is 
the compensatory enlargement in stenotic coronary artery segments in the early stage 
of CAD.932 In addition, biological variations of the coronary arteries are a major 
source of error.933 A significant degree of morbidity has been related to the inexac­
tness of the appraisal of severity.928
3. No angiographic quantitative method o f assessment o f the coronary 
arteries adequately measures intramural atherosclerosis 619,934 Alternative methods 
are now being sought.611,612,934'936 Even though measurements from angiograms can 
be perform ed m ore objectively with advanced im aging technology assisted  by 
computers,611 provision of suitable quantitative angiographic methods for epidemio­
logical and clinical measurement are still awaited 619
4. The difficulties described above have also been highlighted by interven­
tional studies using angiographic followup. Even though angiography has been used 
for interventional risk factor studies937,938 and the study of therapeutic mechanical 
interventions,938 numerous problems exist with the utilisation of angiography in the 
evaluation of CHD risk factors,623,939 and even more so when applied to risk factor 
interventional studies.546,939,940 Any study using sequential angiography should take 
into consideration the potential for misdiagnosis of a change by single reading and 
that relevant quality control be formulated to determine reproducibility.940 In addi­
tion, clinical events related to thrombosis may lead to a rapid and significant change 
in severity unrelated to previous atherosclerotic disease severity.941 Indeed there may
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be no relation between progression of CAD and either the severity of stenosis on the 
initial coronary angiography or the elapsed time period.942
8.1.3 Quantitative Analysis of Coronary Angiograms
The clinical and investigational requirement for appropriate quantitative coronary 
angiograms has long been recognised,943*944 and the search for clinically relevant and 
suitable methods continues.616*617’619,945’946 Quantitative analysis of coronary angio­
grams ideally should provide absolute measurement of reference ("normal") and 
stenotic diameters, extent and asymmetry of the obstruction, relative percent diamet­
er and area stenosis, the area of the atherosclerotic plaque, the roughness of the 
arterial segment, mean diameters of normal coronary segments, with all assessed 
from multiple projections.612*614 In addition, the relative and absolute cross-sectional 
narrowing, the functional pressure-flow effect of the stenosis and the coronary and 
stenosis flow reserve ideally should be m easured as part of the clinical 
evaluation .612,614,617 The study of coronary atherosclerosis with these measures 
requires further evaluation with pathological and epidemiological correlates.929 This 
is exemplified by observations that angiographically "normal" segments of the 
coronary artery are not necessarily free of atherosclerosis,611*929*930*935 and, from a 
functional view point, that coronary stenotic lesions of proximal arteries reduce 
resting flow before distal arterial lesions.947
Currently a number of different techniques are available for the quantitative geomet­
ric and morphological densitometric computer-aided analysis of coronary obstruction 
and atherosclerosis.614'923*929,935*946*948 The equipment, procedures and computer 
software required currently are complex and are still being refined for more general 
clinical use.614*619,923*929*935,946,948 Pathological validation of automated videodensito- 
metric and geometric computer algorithms using subtraction angiography has shown 
good correlation with histopathology, much better than group visual evaluation.929 
Videodensitometry can provide an index of coronary luminal area and it would 
appear that results are independent of angiographic projection and luminal shape.935 
Geometric measures can determine the absolute size of the coronary lumen. Abso­
lute luminal sizes determined with geometric measures correlate better with the 
physiologic significance of a coronary artery stenosis than does percentage 
stenosis.43 Computer based quantitative angiographic determinations of stenosis 
severity more accurately represent true luminal measurements,614*617 have closer 
correlation with indices of functional myocardial ischaemia, such as perfusion de­
fects on thallium imaging,615*949 and provide various measures of coronary flow 
reserve.615,948
These methods are currently incomplete, heterogeneous, and are undergoing contin­
uous validation because of the known limitations.614,950'952 Although the methods are 
beginning to have practical applications,947*952 use for clinical and epidemiological 
studies tend to be limited and this has resulted in a search for more appropriate 
methods.931,934*953 Current readily available quantitative coronary angiographic 
techniques only address the severity of discrete segments of an artery and not diffuse 
CAD.612,619 Simple individual lesion measurements are able to be performed quickly 
and accurately on commercially available digital angiographic software packages. 
Evaluation of all angiographically visible atherosclerotic involvement of the arterial
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tree by such methods would be extremely laborious and are as yet not practical,611 
although potentially useful methods are being developed.619 Moreover, significant 
variability of the accuracy of visual and quantitative techniques, albeit less so for the 
latter, exists in comparison to pathological measures.622 A number of other lesions 
such as thrombus and myocardial bridges may mimic atheroma, as angiographic 
visualisation is an indirect technique.623,952 Such problems remain major unresolved 
difficulties for coronary angiographic use in epidemiological studies945
8.1.4 Coronary Artery Disease Scoring Systems
The traditional method of risk stratification in CAD using coronary angiography has 
been primarily based on the number of diseased arteries and left ventricular 
function.620,621 Other methods of improving this prognostic information have been 
proposed,924,954 but not generally utilised as similar indices do not appear to substan­
tially increase the prognostic information.621 However, quantitative coronary angiog­
raphy may contribute independent prognostic information.955 An extent score provid­
ing information about the minimal or moderate lesions may provide additional prog­
nostic information over the conventional angiographic studies.621 Even though the 
prognostic implications of an extent score for CAD are altered by the development 
of AMI or unstable angina, the extent of CAD always remains predictive of survival 
using Cox multivariate analysis.621 A mean initial extent score has been reported to 
be higher in those with progression than without, and a greater extent score was 
found in those with multifocal progression621
8.1.5 Methods of Validation
To validate any angiographic technique a number of standard procedures are 
recommended which are basic to many laboratory methods:614
1. Determine how large are the intra and inter observer variability from 
true values, using ex vivo and in vivo methods.
2. Determine the variability in repeated measures from the true value.
3. Determine the variability of measurement of the same arterial lesions 
repeated over time.
Such validation requires post-mortem material. Alternative methods, such as high- 
frequency epicardial ultrasound measurement, intra-coronary ultrasound measures, 
animal studies and/or ex vivo phantom studies for truly quantitative measures may be 
more exact.614,931,934,952,953
The scoring systems used in the current study are not quantitatively derived and a 
visual estimation has been used. As discussed, the limitations of such techniques 
have been well defined.617,926,945 Validation o f the semiquantitative method in this 
study will involve assessing:
1. Variability in the measurement of the same obstruction on two occa­
sions separated by 6 months and made by the same observer blinded to the identity 
of the angiogram.
2. Comparison between different and validated angiographic scoring sys-
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terns used in the literature.
3. Comparison of observations and results with other studies using the 
same or similar scoring methods.
4. Observation of predictable associations of the scores with known relat­
ed factors, such as a relation with age and other established risk factors.
It is acknowledged that the utilisation of quantitative methods would be preferable, 
and that such methods should be applied in similar studies when they are available. 
The original report207 describing the scoring methods employed in this study demon­
strated that the scoring system differentiated diffuse coronary atheromatous from 
distinct stenoses, "a prerequisite for the analysis of differences in aetiological 
mechanisms".207 This form of differentiation by quantitative angiography requires 
further development of computer assisted digital methods before being used as a 
research or clinical tool.
8.1.6 Description of the Scoring Methods
8.1.6.1 Coronary arterial segments and lesion assessment. Coronary angio­
grams were graded to give a measure of the severity and extent of atherosclerotic 
disease by a previously described semiquantitative method, developed and validated 
by Hamsten and colleagues.207 The coronary arteries were divided into predefined 
segments956 for measurement of the angiographically defined CAD. The CAS was 
used as a semiquantitative measure of the extent of involvement of the coronary 
arterial wall and the CSS was used as a measure of the cumulative severity of all 
distinct stenoses. Segments located distal to a total occlusion in the absence of suffi­
cient post-stenotic contrast filling were not evaluated, nor were segments of hypo­
plastic arteries. The sum of all the CAS and CSS were also divided by the number of 
segments involved since the number of segments for each patient varied. This gave 
mean CAS (mCAS) and mean CSS (mCSS).
8.1.6.2 Grading diffuse atherosclerosis. The definition of angiographic athero­
matous involvement was that described by Hamsten and colleagues.207 Atheromatous 
lesions in each segment were given a score for the extent of vessel wall involvement 
as defined angiographically and another for the degree of intrusion into the arterial 
lumen (Table 8.1). These 2 scores were then multiplied to produce an atheromatous 
segmental score as a measure of the extent of involvement within that segment. The 
CAS consisted of the total sum of each segment’s atheromatous score for all the 
arterial tree.
8.1.6.3 Grading of lesion severity. The reduction in the vessel lumen diameter 
was estimated visually of all the stenotic lesions in each segment. The scores as­
signed are detailed in Table 8.2. The CSS is the sum of the segmental severity score 
for the whole arterial tree defined angiographically
8.1.6.4 Left ventricular function assessment. The left ventriculogram in the left 
anterior oblique view was divided into 5 segments.956 Normal contractility was 
scored as 0, hypokinetic wall motion as 1, akinetic wall motion as 2 and dyskinetic 
wall motion as 3. Each segment was scored and the total summed to give the left 
ventricular score (LVS), being a measure of LV wall motion abnormalities.
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8.1.6.5 Arterial collateral assessment. The collateral score (CS) refers to the 
angiographic filling of any occluded artery. The occluded artery was divided into 
segments in the same way as that for the coronary artery scoring.207,956 If collaterals 
appeared but failed to opacify the occluded segment, the score was 1, for partial 
filling the score was 2 and for full opacification the score was 3. The segment scores 
were added to give the total collateral score. The intra-observer coefficient of varia­
tion for the angiographic scores varied between 2% and 7%, and all the angiograms 
were scored by the one observer.
8.1.7 Angiographic Procedural Methods
Cardiac catheterisation was performed by the percutaneous transfemoral technique 
using Cordis F7 sized catheters. The left ventriculogram was obtained at the begin­
ning of the study. Coronary angiography was recorded on 35mm cine film at a film 
speed of 50 frames per second. The coronary arteries were examined in both the 
right (RAO) and left anterior oblique (LAO) views, at shallow and steep angles, in 
the lateral projection and in the LAO and RAO with craniocaudal angulation. In 
addition, different views were taken when necessary to visualise non-tangential and 
overlapping segments. No nitrates were administered during the procedure. The cine 
films were viewed a second time, using the same Tagarno projector, by the author 
who was blinded to the identification of the repeat angiogram film, 6 months after 
the initial scoring.
8.1.8 Results
8.1.8.1 Repeated measures. No significant variation existed between the values 
(precision) of all the repeated measures (Table 8.3). Furthermore, no significant 
difference existed between the SD of 2 different observations separated in time by 
the one observer. The mean differences of the repeated measures were also small 
(Table 8.4, Table 8.5, Table 8.6). The repeated analysis did show a wide range of 
variability depending on the score concerned, although all showed sufficient accura­
cy to be clinical useful (Table 8.6). All the repeated measures correlated well with 
the initial observations indicating satisfactory reproducibility (Table 8.3). That is, 
the intra-observer variation for the scores on 2 separate scoring times of the same 
films has correlation coefficients (r value) from 0.83 to 0.98 (Table 8.3). Variability 
in the percent mean difference (accuracy) of the angiographic scores ranged from 
0.3% to 2.4% (Table 8.6). Values for the standard error of the differences in the 
angiographic scores varied from 0.6 to 1.6 (Table 8.6), values comparable with the 
reproducibility of quantitative measures.614
8.1.8.2 Biological correlates. The scores had a predicable relationship with age 
in the population groups studied (Tables 5.3, 5.4, 5.5 and 7.2). This relationship 
with age was greater for the extent of CAD than for the severity, an observation 
consistent with pathological studies showing an increase in extent of atheroma with 
age. In addition, age retained a significant relationship with CAS in multivariate 
analysis even in the younger study group with a more narrow age spread, and more 
so in the population with a broader age range (Tables 5.3, 5.4, 5.5 and 7.2). This 
aspect was discussed in detail in Chapter 5.
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8.1.8.3 Comparison with previous studies. The correlations found in the CHD 
patients with the measures of CAD severity and extent, in general are consistent with 
those reported in the literature (Table 8.7). Age is uniformly associated with the 
extent of disease and with the Jenkins score. In addition cholesterol has been found 
to be uniformly associated with extent scores and the Jenkins score, in agreement 
with our observations. Apoprotein B values correlated with extent and Jenkins 
scores, again similar to our results. Apoprotein A1 values and BMI were generally 
unrelated to angiographic measures of CAD. The use of tobacco has been assessed 
by different methods, and not surprisingly the findings have been diverse. However, 
a study591 documenting packyears found a relationship in agreement with ours, 
namely that there is a univariate relationship with the Jenkins score. HDL cholester­
ol and triglyceride levels varied considerably between studies, ours being similar to 
some and different to others (Table 8.7). Measures of extent consistently related to 
age, cholesterol and apoprotein B levels. Severity measures were more varied, 
supporting the possibility that factors other than the traditional risk factors may make 
a predominant contribution to the formation of severe lesions.
8.1.9 Discussion
The utilisation of coronary angiography as an epidemiological tool in the study of 
coronary atherosclerosis has acquired significant attention since its inception, and 
particularly over the last decade.623,952 The quantitation of coronary artery stenoses 
has made significant advances614'618,946 in parallel and of necessity with advances in 
computer technology and digitalisation of analogue information.614,616,617 However, 
from making the initial decision for this study to discriminate between discrete coro­
nary artery stenosis and the extent of atherosclerosis involvement of the arterial tree, 
to the selection of a rationale and established scoring system,207 then to the initial 
presentation of data957'959 and to the form al acceptance of fully review ed 
articles,61,298 there has been little progress in finding a suitable quantitative angio- 
gaphic correlate with pathological CAD extent593 until very recently.619 As a result 
much effort has been put into finding alternative methods of assessing intramural 
atherosclerosis, particularly using intravascular ultrasound 931,934,953
8.1.9.1 Justification of Scoring System Used. The semiquantitative visual scor­
ing method was used in this study because of a variety of reasons: (1) Such methods 
are currently more applicable to clinical and widespread epidemiological use; (2) 
The availability of the computer software, the methodology and equipment required 
for quantitative methods; (3) To quantitatively examine the whole of the arterial tree 
is not a practical proposition at present. Furthermore, no commercial packages are 
available,945 a difficulty which will probably be overcome in due course;619 (4) 
Severe lesions and extensive disease are not limited to proximal large segments, and 
distal segments have been assessed less frequently by quantitative methods; (5) 
Disease extent has an independent adverse prognostic influence and also a positive 
relation with disease progression, independent of disease severity. This results in a 
different natural history for localised stenotic lesions and more extensive disease, 
emphasising the importance of measuring disease extent;621 (6) Visual and quantita­
tive methods have given similar results in the Leiden intervention trial.960
A major flaw affecting angiographic methods is illustrated by the observation that,
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even when using quantitative techniques, a mean decrease in diameter is greater for 
a normal reference diameter than for a stenoses diameter or for overall mean 
values.621
Examining the accuracy and precision of quantitative methods will provide a baseline 
or standard by which to compare methods such as that used in this study. Variability 
in the mean difference (accuracy) of the percentage of the diameter of the stenosis 
for quantitative angiography ranges from 0.1% to 3% and the values for the standard 
deviation of the differences (precision) in the percentage of the diameter of the 
stenosis varies from 2.5% to 6.2%.614 Intra-observer variation on 2 consecutive 
(same) frames has a correlation coefficient (r value) of 0.98 for the quantitative 
analysis for cross-sectional area measurement. For the percentage area stenosis the 
intra-observer variation is approximately 2.6% with an r value of 0.99.614 The vali­
dation of most systems is still incomplete and individual results are described in 
different terms.614 These observations illustrate that scores using summation methods 
can have results with reproducibility similar to quantitative methods.
Since neither a large panel of observers nor satisfactory methods of quantitation of 
diffuse disease are available, the choice of a semi-quantitative measure with one 
reader was made in this study. Despite the inherent limitations of the method chosen, 
the accuracy and validation of the measurements appear to be acceptable for an ex­
perienced angiographer. Nevertheless, in the final analysis, the method used in this 
study is not ideal. The importance of more accurately defining the atherosclerotic 
process in the coronary arteries remains an objective for all researchers in this area. 
However, the eventual method employed may not be angiography, an investigation 
more appropriately called a "luminogram",931 but a method that evaluates the wall of 
the artery as well as the lumen.931,934
8.2 ANGIOGRAPHIC EVIDENCE SUPPORTING THE EXISTENCE OF 
DIFFERENT STAGES IN THE PROGRESSION OF CORONARY 
ARTERY DISEASE
8.2.1 Angiographically Defined Coronary Artery Disease
8.2.1.1 Predictability of progression of CAD. It is well established that CAD 
begins at a young age in predisposed people and may progress rapidly in a signifi­
cant proportion of these individuals.9 Lesion progression is only partly related to the 
initial degree of narrowing.961 The unpredictability of the progression of coronary 
disease to severe lesions encroaching into the arterial lumen was demonstrated early 
in the history of the use of the coronary angiogram.553 Even though the timing of 
progression is difficult to predict for an individual, there appear to be common sites 
of progression which can be more easily anticipated,551,553 and all grades of intralu­
minal narrowing increase over time.562 Progression prone areas of CAD in the 
coronary epicardial arteries have also been demonstrated in autopsy studies of the 
young.962,963 Despite being able to say which areas of the vessel have a common site 
of progression,551 the use of previous angiograms to predict progression in an indi­
vidual has been unhelpful.552 Not only does knowledge of the initial angiographically
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defined pathology not permit accurate prediction of progression, the frequency of 
progression does not appear to be related to the initial number of vessels with greater 
than 50% luminal obstructions or luminal occlusions.552 Lower progression rates in 
single vessel disease compared with two and three vessel disease have been 
reported.961
8.2.1.2 Coronary occlusion. Coronary angiographic follow-up studies have 
shown that coronary arterial occlusion may be related to the degree of stenosis found 
in a first angiographic study independent of time,564 an impression that appears intui­
tively logical. Indeed, the possibility of finding a new occlusion in a second angio­
graphic study is, in part, related to the severity of disease seen in a prior 
angiogram.551 Others have shown that a new coronary occlusion may occur inde­
pendent of time.551,564 Moreover, a new occlusion can not alwas be predicted by the 
severity of previous existing lesions.551 Non-occlusive progression also occurs in 
relation to the severity of the initial segment as well as time, but again, the specifici­
ty for prediction in individuals is low.551
8.2.1.3 Lesion morphology. It would appear, however, that disease severity and 
linear progression over time are not the only factors involved in CAD progression. 
Different lesion morphology also appears to be indicative of factors influencing 
CAD progression. An increased tendency for progression of tubular stenoses and 
ulcerating plaques has been documented.562 All grades of intraluminal narrowing 
increase over time, possibly with milder lesions tending to progress more rapidly.562 
Even in these studies, knowledge of the initial pathology in the coronary artery does 
not permit reliable prediction of where new lesions will occur, and from previous 
angiography one is unable to predict accurately which vessels will be involved in any 
future progression.552
In conclusion, differences in progression cannot be solely explained by differences in 
the degree of narrowing of initial segments even in those studies where progression 
was demonstrated to be, in part, related to the initial degree of narrowing and the 
course of time.961
8.2.1.4 Extent and severity of CAD. The presence of diffuse disease in the 
coronary arteries may be of some help in stratification as to the risk of progression 
in those with single vessel disease, but it appears to be of little help in those with 
two or three vessel disease.961 The extent of CAD, in terms of the number of lesions 
less than or equal to 75% narrowing, may be related to the development of a new 
occlusion.21 The severity of these lesions was not clearly indicated, however, and the 
occurrence of progression and occlusion was also independent of each other.21 
Indeed, CAD progression occurred with or without occlusion and vice versa.21 
Using multivariate analysis, predictors of subsequent new occlusion derived from the 
first catheter included greater than 80% narrowing supplying a non-infarcted seg­
ment, the extent of coronary disease, cigarette smoking and the male sex.21 The 
majority of new occlusions, however, occurred in normal vessels or vessels with 
moderate lesions (less than 75% luminal narrowing).21
Severe lesions supplying normally functioning myocardium have been found to have 
a high rate of occlusion within the time interval between angiograms. Therefore very
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severe lesions with more than 80% luminal narrowing may identify individuals with 
an increases likelihood of coronary occlusion. This is commensurate with the risk of 
re-occlusion in individuals treated with streptokinase for AMI43 and the association 
betw een  severe s tenoses and subsequen t occlusion  in pa tien ts  w ith unstab le  
angina.534 M oreover, spontaneous obstruction of severe coronary artery stenoses 
amenable to PTCA is not uncommon and is time dependent (5% within an average 
of 76 days), although the prediction of a subsequent occlusion was not possible for 
an individual.964
8.2.1.5 Normal or ’near normal’ coronary arteries. Those with normal coro­
nary arteries at the time of an initial coronary angiogram appear to be unlikely to 
develop CAD by the time of a repeat catheter.553 Even though coronary arteries that 
are angiographically normal in individuals without CHD have a low rate of progres­
sion,553 those with some intraluminal disease without a significant luminal obstruc­
tion do have a rate  of progression alm ost equivalent to those individuals with 
CHD.554 Even though progression occurs in old existing atheromatous lesions, new 
areas of significant narrowing frequently occur in previously normal segments555 and 
progression to occlusion is less common in pre-existing moderately severe lesions, 
unless the stenosis is greater than 90% .555 In another study, the m ajority of new 
occlusions (116) were reported to occur in angiographically normal vessels (17 out 
of 116) and with lesions having less than 75% luminal narrowing (66 out of 116).21 
These observations provides further evidence of the low predictive accuracy of 
angiographic criteria to predict which coronary artery lesions will subsequently 
occlude the artery.
8.2.1.6 Significant progression from areas of minimal CAD. There is little 
doubt that CAD is progressive, increases with age, has a rate of progression propor­
tional to the extent and severity of the underlying atherosclerosis, and commonly 
occurs within five to seven years.557 Also, as indicated, the progressive nature of the 
disease is quite episodic556 and progression to occlusive CAD occurs quite common­
ly in areas that have previously been minimally diseased in patients initially without 
clinical disease later requiring coronary angioplasty or CABG.555,557,558 A particular­
ly im portant point that requires emphasis is that the m ajority of these studies sur­
veyed populations that initially did not require revascularistion.
8.2.2 CHD Risk Factors and Progression
Information about the predictability of CAD progression in individuals, or groups, 
according to the presence or absence of risk factors is highly variable. Clinically 
useful and specific identifying factors indicating the risk and timing of progression 
are not clearly distinguished. These include the presence of a family history, obesity, 
h y p e r te n s io n , d ia b e te s , an ab n o rm al ECG and  even  the in it ia l  c o ro n a ry  
angiogram.552 A great deal of variability in the relationship between risk factors for 
coronary disease and progression has been dem onstrated both in older and newer 
angiographic studies. Abnormal glucose tolerance, lipid levels and myocardial lac­
tate production may correlate with widespread progression without any association 
w ith  the age, sex or sm oking hab its o f the p a tien ts  nor the in te rv a l betw een 
studies.965 In early studies, others have found no relationship between disease pro­
gression and individual risk factors.966 Age has not universally been found to be a
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strong predictor of rate of progression, although some studies have shown that the 
m ean age o f those w ith m easurab le  p ro g ressio n  is s lig h tly  low er than those 
without.552 The inconsistencies would appear to be present even prior to the current 
era of intensive risk factor modification that has occurred since the 1980’s in many 
Western cultures.
C holesterol and triglycerides are related  to the progression of CAD967 although 
usually a combination of risk factors must be present.552 Recent reports have provid­
ed more convincing data that at least some lipoprotein levels have consistent predict­
ability for CAD progression. In the Cholesterol Lowering A therosclerosis Study 
(CLAS), a global angiographic score was utilised to assess progression, which is 
associated with total cholesterol, LDL cholesterol, non-LDL cholesterol, triglyce­
rides, apoprotein B, and diastolic pressure by univariate analysis, but only with non- 
HDL cholesterol in placebo treated patients using m ultivariate analysis.968 These 
associations, both for the univariately and multivariately variables, are not helpful 
for predictive purposes in the individual. There is a weak association with progres­
sion and the ra tio  o f to tal cho lestero l or LDL cho lestero l to HDL cholestero l 
levels.968,969
Thus, the relationship and predictability of CAD progression with CAD risk factors 
requires much greater clarification and im proved specificity, given the degree of 
disparity between studies.21,561,562,961 Despite the lack of specificity for CAD risk 
factors predicting progression, modification of these factors has been shown to have 
a beneficial and m easurable influence on CAD progression. Im provem ent in the 
blood lipoprotein profile has been the main target for these studies.268,272,274,970"975 
Multifactor intervention was also found to be of benefit.960,976 Other potential areas 
may include intervention into haemostatic factors,56 psychological factors,977 and a 
combination of lipid and haemostatic variables.978
8.2.3 Time Dependence of Progression
Progression correlates with the duration between coronary angiograms,560,561 time 
being predictive of new occlusions.560 This time factor, however, is only one in­
fluence on the process. There are also time independent factor(s).551,564 Of particular 
relevance, dependence on time does not appear to be present for those developing 
unstable angina in comparison to those who have had stable angina and develop 
progression of their CAD.560
8.2.4 Clinical Symptoms and Progression of CAD
8.2.4.1 Stable symptoms. Clinical symptoms are considered to be indicative of 
CAD progression.560,966 However, angina is not necessarily predictive of progression 
of disease affecting all segments of the coronary artery.965
8.2.4.2 Acute ischaemic syndromes. The occurrence of an AMI and an increase 
in symptoms of CHD is associated with the degree of CAD progression.561 Those 
with an acute infarct occurring between angiographic studies are more likely to show 
progression. Nonetheless, in the same group, progression was also common in those 
with symptomatically stable CAD and for those with improving symptoms.961 Others
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have found that only the proximal location of the stenosis was a significant predictor 
of infarction.979 Nevertheless, AMI due to total coronary occlusions frequently 
developed where previously non-severe lesions were present, and predicting the 
location of a subsequent AMI from a prior angiogram is difficult.979
The percent narrowing, involvement of the left anterior descending artery, the pres­
ence of eccentric and complex lesions, the number of diseased vessels and/or the 
presence of unstable angina are predictive of CAD progression.979 Nevertheless, in 
another study, the majority of lesions which were noted to progress concurrent with 
the development of unstable angina were initially narrowed less than 50%.20 Clearly, 
mild to moderate lesions are subject to acute thrombotic occlusion980,981 and a sub­
stantial number of mild to moderate lesions may be associated with thrombosis and 
AMI.981
8.2.5 Pathology and Progression
At least three important facts arising from autopsy studies of CAD and CHD high­
light the fact that server obstructive lesions develop intermittently and probably 
acutely.
Firstly, individuals with CAD usually have extensive disease by the time they pres­
ent clinically. No difference in the number of major epicardial arteries having severe 
CAD has been found in those with a first anterior or posterior infarct, except in the 
frequency of the involvement of the left main stem coronary artery.982 This observa­
tion is from a cross-sectional necropsy study of patients with a fatal first AMI.982 
Severe and extensive narrowing of the three major coronary arteries was present 
irrespective of whether the infarct involved the anterior or posterior section of the 
ventricle.982 Moreover, individual variation in disease severity within the coronary 
tree was great. In addition, prediction of the most severely narrowed coronary ar­
tery, using the location of the infarct in those suffering their first and fatal AMI, was 
difficult.982 In fact, necropsy studies indicate that CAD is extensive by the time of 
the first MI, irrespective of its location.982
Secondly, those lesions resulting in the clinical manifestations of CAD are not 
simply comprised of an accumulation of the components of atherosclerosis. Acute 
changes occur within the atherosclerotic plaque. A post-mortem angiographic study 
comparing histological findings demonstrated that lesions with angiographic features 
indicating a complicated lesion represent a greater risk for AMI or sudden death than 
do uncomplicated lesions.112 This study suggested that stenoses characterised angio- 
graphically by irregular borders or intraluminal lucences probably have a more 
adverse clinical outcome. Plaque rupture without thrombosis formation was also 
documented,112 a not uncommon finding in individuals dying of non-cardiac causes 
with and without CAD.238
Thirdly, anatomical studies have shown that a substantial percentage of lesions asso­
ciated with coronary artery thrombosis and AMI are moderate in severity,12,559 con­
firming the angiographic observations discussed earlier.
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8.2.6 Limitation of Angiographie Follow-up Studies
8.2.6.1 Selection bias. Patients are usually selected for a second coronary angio­
gram because of new symptoms or clinical events. However, a group of patients 
who were in a stable or improving clinical condition and elected for surgery treat­
ment, consequently had a repeat routine angiogram.961 Progression in this group was 
common, with relatively small differences compared to those who had a repeat 
cardiac catheter for clinical reasons.961
The effect of survival selection may well lead to an underestimation of the amount 
and degree of progression. Significant disease found in an initial study will increase 
the likelihood of this bias as well as reducing the likelihood of those with severe 
disease coming to further angiography increasing. These factors will increase the 
likelihood that those with less severe disease will be detected as having progression 
more frequently than does in fact occur. However, the basis of symptom selection 
would also bias toward overestimating the frequency and degree of progression. The 
significance of this is uncertain in view of reported findings that those without 
symptom deterioration, and even those with symptom improvement, may also have 
lesion progression.551
Another selection bias may occur when those with more severe disease have CABG 
or a PTCA, while those who have mild disease or severe inoperable disease will 
continue with medical treatment.
8.2.6.2 Interpretation error. Technical factors have also been provided major 
limitations in angiographic studies, as previously discussed, particularly in relation 
to the inter- and intra- observer variability for visual imaging.923,926 The interpreta­
tion of the coronary angiogram underestimates the severity of disease in those with 
severe lesions and both under and overestimates mild to moderate lesions.983 Diffuse 
coronary atherosclerosis is often present when coronary angiography reveals only 
discrete stenosis indicating that coronary angiography underestimates the severity 
and extent of CAD.984
8.2.6.3 The angiogram as a "luminogram". The coronary angiogram is not an 
ideal method of studying CAD because of the fact that the method only gives infor­
mation on the lumen of the coronary artery. The limitations associated with this fact 
are discussed in section 8.1.
8.2.7 Summary
Assessment of CAD using coronary angiography is insensitive in predicting the time 
and location of a subsequent new lesion or progression to occlusion. In particular, it 
does not allow accurate prediction of the occurrence or location of a MI in individu­
als with mild to moderate disease.558 The high incidence of progression in vessels 
that are normally minimally diseased has been well documented.20,555,557,558,560 
Patients with mild to moderate disease may develop progression more commonly in 
these areas,557,558 although the progression to total occlusion also occurs frequently 
in very severely narrowed lesions.21,43,555
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Clearly, the "progression o f coronary atherosclerosis is a highly unpredictable pro­
cess that follows a non-linear course and that information about its dynamics derived 
from sequential coronary arteriograms hardly improves prediction o f future progres­
sion'\ 561 The need to determine the factors that do predict new lesion development 
more precisely, and hence the occurrence of life-threatening cardiac events, should 
be a high priority in evaluating the causative mechanisms of CAD and CHD. Given 
the contribution of thrombosis to the development of clinical events, and possibly 
progression, examination of the factors associated with severe stenotic lesions is 
necessary, as is the differentiation of factors associated with the developm ent of 
atherosclerotic disease and those leading to the formation of localised severe steno­
sis. One potential factor for the latter may be a thrombotic tendency in individuals 
with underlying CAD. This has been recognised for most of this century, but has 
only attracted general recognition recently.
8.3 ANGIOGRAPHICALLY DEFINED CORONARY ARTERY
DISEASE AND THE PREDICTIVE VALUE OF CORONARY 
HEART DISEASE RISK FACTORS
This section deals with the potential of CHD risk factors to be differentiated in the 
case and control groups and to also be associated with different aspects of CAD, 
namely, the extent of involvement of the arterial wall and the quantity of severe ste­
noses.
8.3.1 Introduction
Semi-quantitative angiographic scoring systems have been used with the intention of 
discriminating between atherosclerotic disease involving the arterial wall and lesions 
encroaching into the lumen of the artery.61,207,593 In this study a complex scoring 
system has been used to examine the relationship between angiographic measures of 
CAD, the traditional risk factors for CHD and measures of platelet function which 
may also constitute CHD risk factors. Such methods have been used extensively to 
investigate risk factors for CHD, particularly in the evaluation of the relationship of 
lipoproteins and CAD, but have not always produced consistent findings. For exam­
ple, (as discussed in Chapter 5) the majority of angiographic studies have demon­
s tra te d  a p o s itiv e  re la tio n sh ip  betw een  to ta l b lood  c h o le s te ro l lev e ls  and 
CAD206,207,220,365,592"594,600,601 although not all.596,602 An independent relationship 
with angiographically defined CAD and total blood cholesterol values is not main­
tained using multivariate analysis.206,207,590,593 This latter observation was confirmed 
in the current study (Chapter 5). A univariate relationship between apoprotein B and 
LD L  c h o le s te ro l lev e ls  w ith  CAD and CHD has been  w ell 
established,590,592,594,596,597 and an independent relationship is preserved using multi­
variate analysis.206,207,590,593 Again, this finding has been reaffirm ed in the current 
study (Chapter 5). The relationship, however, was due to an association with the 
extent rather than the severity of atherosclerosis, particularly when the angiographic 
classifications are separated sufficiently well by appropriate scoring methods and 
evaluated by multivariate analysis.206,207
As d iscussed  in Chapter 5, the scoring system developed by Ham sten and col-
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leagues207 has specific advantages over other systems in separating the extent of 
involvement of the arterial wall and the influence of discrete severe or obstructed 
lesions. For example, multiple minor lesions within a segment of the coronary artery 
is not uncommon in addition to more severe stenoses and previous studies have 
included mild lesions in the stenosis score.151,590,596 In addition, the severity scoring 
system of Hamsten et al207 gives a maximum of 16 to a segment, so that in the 
presence of an occluded segment, minor lesions make no impact on the stenosis 
score for that segment, and therefore the stenosis scoring system of Hamsten et al207 
is more likely to be related to factors, including thrombosis, which are involved in 
the development of severe and/or occluded lesions.593
8.3.2 Methods
8.3.2.1 Study population. The study population consisted the case-control group 
described in Chapter 3.
8.3.2.2 Angiographic, statistical and laboratory methods. All the methods are 
described in Chapters 2, 5, 7 and 8.1. Also, other factors that impacted on the 
observations and have been included in the analysis are described in Appendix 1, 2 
and 3. These latter factors are the percent plasma content of fatty acids (Appendix 
1), scapular skinfold thickness (Appendix 2), and a psychologically based hostility 
score (the MMPI hostility score, Appendix 3).
8.3.3 Results
8.3.3.1 Number of normal segments. For the number of normal segments, two 
platelet function measures (viz. TXB2 level in clotted whole blood and the PRP 
platelet count) correlated directly and the MPV correlated inversely. The lipid varia­
bles of cholesterol, apoprotein B and percent plasma myristic acid content correlated 
inversely with the number of normal segments. Of the other risk factors, age, the 
packyear of cigarette smoking and the MMPI hostility score also correlated inversely 
(Table 8.8). When the number of normal segments was entered into the regression 
equation as the dependent variable, and the MPV, TXB2, age, packyears of cigarette 
smoking, hostility score, apoprotein B and plasma myristic acid were the independ­
ent variables, only apoprotein B and myristic acid values remained significantly 
predictive (Table 8.10). The PRP platelet count and cholesterol levels were not 
related independent of the MPV and apoprotein B respectively, and had the potential 
for causing problems due to multicollinearity. Therefore they were not included in 
the regression model.
8.3.3.2 Coronary artery extent scores. No platelet function variable correlated 
with the angiographic score of extent of arterial involvement. Cholesterol and 
apoprotein B levels, and plasma myristic content correlated directly, and aracidonic 
acid content inversely with the CAS (Table 8.8). Similar associations were found for 
the mCAS except for the aracidonic acid. Also, HbAlC levels, scapular skinfold 
thickness, diastolic BP and systolic BP were directly related to the extent scores 
(Table 8.8).
CAS and mCAS were separately entered into the regression equation as dependent
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variables and the scapular skinfold thickness, myristic and aracidonic acid content 
and the apoprotein B level were the independent variables. Only the myristic acid 
content and scapular skinfold thickness remained independently predictive (Table 
8.10). The cholesterol level, HbAlc level and BPs were not independent of other 
variables and, again, had the potential for causing problems due to multicollinearity. 
Therefore they were not included in the regression model.
8.3.33 Coronary artery severity scores. Those platelet function variables, 
namely TXB2 and PRP platelet count, were inversely related to the CSS, and 
LT50ADR was inversely related to the mCSS. The MPV was directly related to both 
the CSS and mCSS (Table 8.8). The only lipid variable associated with either score 
was the plasma myristic acid content (Table 8.8). The HbAlC level, age, packyears 
of cigarette smoking and the MMPI hostility score had direct associations with the 
severity scores (Table 8.8).
With multivariate regression analysis, only the LT50ADR value remained predictive 
of the severity scores. The independent variables entered were TXB2, MPV, myris­
tic acid content, age, packyears, hostility score and the LT50ADR (Table 8.10).
8.33.4 The Jenkins angiographic score. The platelet variables which correlated 
with the Jenkins score were the LT50ADR and MPV. Plasma myristic acid content 
and apoprotein B level were directly associated as well as the HbAlC level, age and 
packyears of cigarette smoking (Table 8.9).
With multiple regression analysis, the MPV and LT50ADR value remained indepen­
dently predictive of the Jenkins score as the dependent variable. The independent 
variables were the LT50ADR, MPV, apoprotein B level, myristic acid content, age 
and packyears of cigarette smoking (Table 8.10).
8.33.5 Lesion stenosis scores. The number of individual lesions with a percent 
diameter luminal narrowing that approximated a range of stenoses, for example 
between 75% and 90% diameter narrowing, were also evaluated. The associations 
were similar to those of the cumulative scores, albeit with more overlap (Table 8.9). 
Of particular note was the association of platelet function measures and specific fatty 
acids with the more severe stenoses, and the lipid variables with the less severe 
lesions (Table 8.9).
8.33.6 Other angiographic scores. Only measures of platelet function, namely 
the LT50ADR and PRPPC, correlated directly with the left ventricular score (Table 
8.9). As expected, there was a strong relationship between the number of AMI and 
the LVS (Table 8.9). TXB2 values and the MMPI hostility score correlated with the 
collateral score. The NYHA functional class for angina also correlated with the 
collateral score (Table 8.9).
When the LVS was entered into the regression model as the dependent variable, and 
the number of Mis, LT50ADR and the CSS as independent variables, the number of 
Mis and the LT50ADR value remained predictive of the LVS (Table 8.10).
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8.3.4 Discussion
These results provide an argument for different factors affecting different stages in 
the development of CHD. Factors related to platelet function are more predictive of 
the severity of CAD. Measures of lipid and fatty acid metabolism, and body fat 
distribution appear to be associated more with the extent of involvement of the arte­
rial wall with atherosclerosis. These results depend strongly on the validity of the 
angiographic results and additional discussion of the potential pitfalls of such meas­
ures are addressed below. Moreover, support for different stages/processes in the 
development of CHD arises from the results presented. This observation is discussed 
in the context of other studies also supporting such a proposition.
8.3.4.1 Further evidence for the validity of the angiographic scoring methods.
Firstly, in this analysis there are clinically predictable associations with the angio­
graphic scores. One argument for the validity of the semi-quantitative method for 
the angiographic scores of CAD severity and extent has been provided in the first 
section of this Chapter. Further evaluation of these scores and clinically relevant 
variables confers further strong supporting evidence for the reliability and utility of 
the angiographic measures. The relationship between the functional class for angina 
and the severity and collateral scores highlights the credibility of the scoring system, 
in conjunction, acknowledging the limitations of angiographic scoring methods.611"613 
The lack of association of the angina functional class with the extent scores also 
supports the reliability of the method. Moreover, the LVS being associated with the 
number of previous Mis was expected. The inverse association of age, cholesterol, 
and apoprotein B levels with the number of normal segments also strengthens the 
reliability of the observations. The fact that cholesterol measurements performed 
before the diagnosis had a stronger relationship with the extent of coronary atheros­
clerosis than the cholesterol measurement undertaken during the study further adds 
to the consistency of the associations. The positive correlation between age and the 
extent of atherosclerosis is well documented in the literature.207,593 The relationship 
with disease severity is less consistent, with some studies showing an 
association,61,591,600'602 while others have not shown any correlation 206,207,593
Secondly, there was a reliable degree of internal consistency for the various associa­
tions and the other scoring methods for assessing CAD. Methods of assessing coro­
nary angiograms vary greatly, and differences in results between studies may clearly 
relate to such methodological differences.985 To attempt to internally assess the scope 
of this problem, more than one scoring method was used in this study. There was 
internal consistency between the clinical and laboratory variables and the Jenkins 
score and the CSS. This was maintained for the breakdown into the number of lesion 
of varying severity.
Thirdly, a potential bias can arise from the selection of subjects, particularly if  there 
is little variation in the measured variable, leading to an increased likelihood o f false 
negative results. In this study, subjects with CHD were compared to a normal con­
trol group without CHD determined on clinical grounds and by exercise testing. The 
presence of coronary artery atherosclerosis was not excluded angiographically. This 
could potentially lead to false negative results due to dilution bias if some of the
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controls had CAD which was not clinically apparent. Such dilution bias may result 
in no measurable difference being documented between the groups for some of the 
variables which are true risk factors for coronary atherosclerosis. These factors 
would then not be included in the assessment of the angiographic measures using 
multivariate analysis. Nevertheless, the case group evaluated did have a demonstra­
ble relationship with the more commonly accepted risk factors, and in particular the 
apoprotein B level. Conceding the potential for dilution bias, the validity of a nega­
tive finding is enhanced by the consistency of those positive associations observed 
between the angiographic scores and the separate variables.
Another important area of bias relates to the sample size of the study populations. A 
type II statistical error may have lead to any negative findings, missing a weak rela­
tionship because of an inadequate sample size. However, predictable differences and 
associations of the classic risk factors were able to be detected. That is, clinically 
meaningful and established differences and associations have been determined from 
the sample number used in this study. Weaker and less clinically relevant relation­
ships may have been missed.
Another bias leading to false negative results is the potential for regression dilution 
bias resulting from over-adjustment for variables in multivariate analysis. This could 
result from lack of precision of measured variables compared to less significant 
measures. Also, the problem of multicollinearity (that is, variables measuring the 
same relationship but being identified as separate and independent factors) is well 
recognised in the type of analysis used.
Finally, as discussed earlier, there are serious limitations to the subjective assess­
ment of angiographically defined CAD611'613 and there have been significant advanc­
es in the quantitative assessment of CAD in recent years.614' 618 There has been little 
progress, however, in finding a suitable quantitative angiographic correlate with the 
extent of pathologically defined CAD to be used in epidemiological studies,593 
although valid clinically applicable methods are currently being developed.619 Even 
though the risk of CAD has been primarily based on the number of diseased arteries 
and left ventricular function,620,621 a score expressing the extent o f CAD and provid­
ing information about minimal or moderate lesions may contribute additional prog­
nostic information beyond the conventional angiographic studies .621 The validity of 
the scoring system used in this study appears acceptable,207 although the limitations 
of the method need to be recognised.593,611'613
Appropriate end-points for disease assessment are necessarily required. Anatomic 
CAD may not be the right end point for the expression of some CHD risk factors.985 
There is a high probability that risk factors influence different stages in the devel­
opment of the disease.202 This is part of the hypothesis being explored in this Thesis, 
and the attempted division into intraluminal and intramural disease may help to 
evaluate the existence of different risk factors for different stages in the development 
of disease.
8.3.4.2 Evidence for different stages/processes in the development of CHD. 
The results of the International Antiatherosclerotic Therapy (INTACT) study present 
a possible insight into the mechanisms of disease progression as observed in that
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study.546 The INTACT study confirmed previous experimental studies demonstrating 
a significant reduction in newly formed coronary artery lesions (stenoses and occlu­
sions) in patients on nifedipine compared to placebo, especially in the presence of 
early CAD.546 In addition, there is now good evidence for a number of modifiers, 
such as pretreatm ent with betablockers, and possible triggers, such as vigorous 
exertion, for the developm ent of AM I.986 A proposed explanation will be briefly 
stated and elaborated on subsequently.
Angiographic studies have dem onstrated that progression of CAD involves new 
lesion formation that is not entirely related to the underlying atherosclerosis, impli­
cating additional mechanisms, possibly thrombosis. Pathological evidence supports 
the involvement of thrombus in atherosclerotic disease progression.34,539 Secondly, 
clinical syndromes (unstable angina and AMI) are associated with new lesion devel­
opment, in association with a fissured plaque, and increased thromboxane produc­
tion. M oreover, increased TXB2 production occurs in whole blood clotting in the 
presence of provoked ischaemia (Chapter 4).298 Thirdly, nifedipine appears to reduce 
the development of new lesions546 and pretreatment with betablockers reduces the 
proportion of morning infarction.223,903,986 The results of this Thesis show that the 
com bination o f n ifidepine and m etoprolol reduces the am ount of throm boxane 
produced during whole blood clotting ex vivo (Chapter 4). Also, the prophylactic use 
of aspirin in middle aged men reduces the incidence of non-fatal MI, a thrombotic 
process, but not the development of angina, which is possibily due to a non-thrombo- 
tic process.695 Finally, this angiographic study has dem onstrated an independent 
relationship between platelet function measures and discrete stenotic lesions but not 
extensive intramural disease. A reduction in thromboxane production might reduce 
the likelihood of the production of those new CAD lesions that involve thrombosis.
Such a scenario implies that disease progression, particularly the formation of dis­
crete lesions, has a major non-atherosclerotic component, namely thrombus forma­
tion. The brief review of disease progression discussed in the introduction to this 
Chapter, as interpreted from angiographic studies, supports this concept. Despite 
being able to say which areas of the vessel have a common site of progression,551 the 
use of previous angiograms to predict which vessels in an individual will be involved 
in progression has not been reliable.552'554 Undoubtedly progression occurs in old 
existing atherosclerotic lesions. However, new areas of significant narrowing fre­
quently occur in previously normal segments555 and the progressive nature of the 
disease is quite episodic 556. Indeed, progression of occlusive CAD occurs common­
ly in areas that have previously been minimally diseased in patients without initially 
clin ical disease requiring PTCA or coronary bypass g rafting .555'558 A natom ical 
studies have shown that a substantial percentage of lesions associated with coronary 
artery throm bosis and AMI are moderate in severity.12,559 In summary, a high in­
cidence of progression of CAD in vessels that are normally minimally diseased has 
been well documented,20,555,557,558,560 although the progression to total occlusion also 
occurs frequently in very severely narrow ed lesions.21,43,555 The progression of 
coronary atherosclerosis is a highly unpredictable process that follows a non-linear 
course and information about its dynamics derived from sequential coronary arterio­
grams hardly im proves prediction of future p rog ression .561 The im portance of 
determining the pathological components which contribute to the development of 
acute severe lesions, whether related to the destabilisation of atherosclerotic plaque,
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increased thrombogenicity, and/or other intrinsic or extrinsic factors, is evident.
8.3.5 Summary
1. The observations discussed above make the results of the current study 
of considerable interest. The results indicate that the formation of acute severe ste­
noses have different risk factors and mechanisms than those involved in the devel­
opment of diffuse atherosclerosis, as has been previously proposed.4,623
2. The observations support the concept of different factors influencing 
different stages in the development of the clinical condition. In young males with 
CHD, specific factors are associated with the atherosclerotic component and other 
factors with the stenotic component, and some with both.
3. In young males with CHD, platelet function plays an important part in 
determining the severity of the CAD. Fatty acids, lipoproteins and body fat distribu­
tion play a major part in determining intramural involvement of coronary arteries by 
atherosclerosis, as defined angiographically. In particular, no platelet function 
measure was related to the extent of disease.
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Table 8.1. Grading of Diffuse Coronary Atherosclerosis
Score
Extent
Angiographically normal vessel wall 0
1-2 angiographic plaques 1
>2 plaques located in one or several groups with
normal intervening portions 2
>2 plaques producing continuous irregularities 3
Mean plaque size
Slight indentation (<10% reduction in diameter) 1
Intermediate size indentation (10%-25% reduction
of the vessel diameter) 2
Large plaque (>25% reduction of vessel diameter) 3
Table 8.2. Grading of Severity Score
Score
Normal or lesions reducing lumen diameter <25% 0
Lumen diameter reduced 25%-50% 1
Lumen diameter reduced 50%-75% 2
Lumen diameter reduced 75%-90% 4
Lumen diameter almost occluded 90%-99%, but
antegrade flow still present 8
Arterial occlusion with no antegrade flow 16
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Table 8.3. Relationship Between Repeated Measures (Intra-observer)
Variable Mean SE *r p value
CAS1 18.65 2.59 0.9478 <0.000
CAS2 16.75 2.08
CSS1 27.85 4.30 0.9745 <0.000
CSS2 27.60 4.23
LVS1 2.80 0.39 0.9501 <0.000
LVS2 2.95 0.47
Normal 1 6.65 0.60 0.8297 <0.000
Normal2 6.05 0.54
CS1 5.85 1.13 0.9565 <0.000
CS2 5.20 0.99
Jenkins 1 11.80 1.70 0.9261 <0.000
Jenkins2 10.80 1.55
* Correlation between the first and second measures 
r = the Spearman correlation coefficient.
Table 8.4. Mean Difference of Repeated Measures
Variable Mean Diff SD 95% Cl Diff Mean p value
CAS 1.90 4.35 -8.615 to 4.815 0.5702
CSS 0.25 3.77 -12.454 to 11.955 0.9671
LVS -0.15 0.75 -1.088 to 1.388 0.8076
Normal 0.60 1.46 -2.233 to 1.033 0.4617
CS 0.65 2.10 -3.691 to 2.391 0.6677
Jenkins 1.00 2.81 -5.659 to 3.659 0.6664
Mean diff = mean of the difference between repeated measures. 
Cl diff mean = confidence interval of the difference of the mean.
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Table 8.5. Absolute Mean Difference of Repeated Measures
Variable Mean Diff SD
CAS 3.7 3.8
CSS 2.9 3.1
LVS 0.5 0.6
Normal 1.3 0.9
CS 1.2 1.9
Jenkins 2.3 2.0
Absolute mean difference = mean difference of numerical values without considering 
whether positive or negative.
Table 8.6. Percent Mean Difference of Repeated Angiographic Scores
Variable % Mean Diff SE
CAS 1.8 1.5
CSS 0.4 0.6
LVS -0.3 1.2
Normal 2.3 1.6
Jenkins 2.4 1.2
% mean difference={(xl-x2)/(xl+x2)/2} expressed as a percentage
Table 8.7. Comparison of Correlations from Previous Studies
Age Choi Trig HDL ApoB AdoAI Smoke BMI
1.Extent593 + + + - + - -
Severity - - + + + - -
ZExtent207* + + - + + - -
Severity - - - - - - -
3.Jenkins591 + +# - +#A -
206 - + - - + - -
601 + + + +
4. Severity600 + + + +
5.Severity602 + - - - +
6.Present study
extent* + + - - + - +A
severity* + - - - + - +/- -
Jenkins + +/- - - + - +A
* = same scoring system, # = age < 55 years, A =packyears, + = positive, - = nega­
tive, and +/- = borderline relationship. Blank indicates assessment not evaluated. 
Extent = extent of disease according to the investigator. Severity = severity of disease 
according to investigator. Jenkins = Jenkins severity score.591
238
Table 8.8. Variables correlating with the CAD scores.
ANGIO PLATELET LIPID OTHER
SCORE VARIABLE r VARIABLE r VARIABLES r
Normseg SERTXB2 0.24* CHOL -0.38# AGE -0.23*
MPV -0.24* APOB -0.38# PACKYR -0.44#
PRPPC 0.34# 0 4 :0 -0.35# Ho -0.31*
C18:lw9 0.30*
CAS CHOL 0.29* HbAlC 0.31*
APOB 0.35# SST 0.38**
0 4 :0 0.32* SBP 0.35#
C20:4w6 -0.24* DBP 0.30*
AGE 0.27*
mCAS CHOL 0.33# HbAlC 0.30*
APOB 0.35# SST 0.38**
0 4 :0 0.32# SBP 0.30*
DBP 0.27*
AGE 0.29*
PACKYR 0.31*
CSS SERTXB2 -0.24* 0 4 :0 0.34# HbAlC 0.27*
MPV 0.27* AGE 0.25*
PRPPC -0.31* Ho 0.35*
NYHAFC 0.31*
mCSS LT50ADR -0.28* 0 4 :0 0.36# HbAlC 0.25*
MPV 0.26* AGE 0.25*
PACKYR 0.31*
Ho 0.35#
NYHAFC 0.34#
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Table 8.9. Variables correlating with the CAD scores.
ANGIO PLATELET LIPID OTHER
SCORE VARIABLE r VARIABLE r VARIABLES r
LES100 SERTXB2 -0.26* C14:0 0.26* Hb -0.29*
SBP 0.25*
Ho 0.41#
NYHAFC 0.40**
LES90/99 MPV 0.25* C14:0 0.24* AGE 0.34#
C20:2w6 -0.26* HbAlC 0.27*
C22:5w3 -0.25* BSL 0.33*
FIBRIN 0.26*
LES75/90 C14:0 0.25* PACKYR 0.31*
C16:0 0.24*
C22:5w3 -0.29*
LES50/75 LT50ADR -0.36# CHOL 0.36# AGE 0.31*
SERTXB2 -0.29* TRIG -0.26*
APOB 0.30*
C14:0 0.24*
LES25/50 CHOL 0.30* Hb 0.35#
APOB 0.33# He 0.39#
HbA lC 0.42**
SST 0.52
SBP 0.31*
DBP 0.35#
Ho 0.32*
LES10/25 CHOL 0.37# SBP 0.25*
APOB 0.36# DBP 0.29*
JENKINS LT50ADR -0.31* APOB 0.27* H bAlC 0.25*
MPV 0.24* C14:0 0.32# AGE 0.28*
PACKYR 0.29*
LVS LT50ADR -0.30* No MI 0.43##
PRPPC -0.27*
CS SERTXB2 -0.24* NYHAFC 0.39**
Ho 0.30*
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Table 8.10. Multivariate analysis with the CAD scores as the dependent variable. 
Dependent Independent
Variable_____Variable________ B_______SE B_____ Beta R sq_____P value
NORMSEG APOB -0.142 0.062 -0.537 0.288 0.039
0 4 :0  -0.012 0.005 -0.472 0.508 0.014
(Other variables entered were clotted whole blood TXB2 level, MPV, DOB, cigarette 
packyear and the MMPI hostility score)
CAS SSFT 0.062 0.030 0.357 0.128 0.045
0 4 :0 0.085 0.030 0.487 0.261 0.012
mCAS SSFT 0.051 0.025 0.361 0.251 0.043
0 4 :0 0.069 0.024 0.483 0.251 0.015
(Other variables entered were apoprotein B and C20:4w6)
CSS LT50ADR -31.089 6.770 -0.824 0.678 0.001
mCSS LT50ADR -30.589 6.1397 -0.844 0.713 0.006
(Other variables entered were TXB2 in clotted whole blood, MPV, C14:0, DOB, 
cigarette packyears and the MMPI hostility score).
JENKINS LT50ADR -12.419 3.908 -0.647 0.419 0.007
MPV 0.350 0.150 0.415 0.590 0.003
(Other variables entered were APOB, C14:0, DOB and packyears of cigarettes 
smoked).
LVS No. AMI 1.198 0.557 0.333 0.111 0.038
LT50ADR 1.248 0.534 0.347 0.208 0.015
(Another variable entered was the CSS which had no effect on the relationship)
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CHAPTER 9
GENERAL DISCUSSION
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9.1 SUMMARY
The framework of this thesis is that of an observational study with a cross-sectional 
survey of two homogeneous groups which differ in relation to the outcome of inter­
est, namely CHD. Specific variables under evaluation were measured in both study 
groups and compared for any differences. The study also provided a comprehensive 
examination of the relationship between the specific measures under evaluation 
(platelet function) and various other characteristics that may have a potential in­
fluence on the relationship between the measures being examined and the outcome of 
interest.
The study populations were carefully defined and the limitation of major extraneous 
confounding factors was an important goal. Individuals in each of these populations 
were examined by means of standardised techniques, a common protocol and the 
same interviewer.
The observations presented in this Thesis provide evidence that males with prema­
ture CHD have platelets which are more reactive. Criteria of increased platelet reac­
tivity as well as platelet volume were significantly greater in males with angio- 
graphically proven and stable CHD. Furthermore, measures of this reactivity were 
related to the severity and number of obstructive coronary artery lesions. In contrast, 
a lipoprotein measure, namely apoprotein B, was more predictive of the extent of 
arterial involvement by CAD as defined angiographically. These observations pro­
vide supportive evidence for the hypothesis that the development of CHD in young 
males relates to a combination of thrombogenic and atherogenic risk factors. The 
pathophysiological mechanisms involved in this increased platelet reactivity cannot 
be determined from this study given the cross-sectional observational design with 
retrospective ascertainment of cases.
9.2 CAUSATION AND CHRONIC DISEASE 
9.2.1 Relative Importance of CHD Risk Factors
Undoubtedly men with premature CHD have abnormalities of plasma lipids, LDL 
and total cholesterol, apoprotein B and Al, and lipoprotein (a) ,987,988 and also HDL 
cholesterol and triglyceride levels.988,989 The relative contribution of these to the risk 
of CHD is uncertain, although apoprotein Al and B levels may be better predictors 
of premature CHD than other plasma lipids.607 Because of the diverse nature, and 
more importantly, the non-specific predictive value of these lipid risk factors, much 
effort is now being employed to improve the precision of prediction of risk from 
more refined lipoprotein profiles,990 profiles which may more accurately reflect the 
basic mechanisms that involve lipids in atherogenesis. Unfortunately, the mechan­
isms have not been accurately determined, and, until they are, the likelihood of 
providing accurate predictive measures remains low. Our results are consistent with 
the observations for those lipoproteins measured, and also suffer from the same 
problem of poor sensitivity and specificity in the study groups.
The question as to which of the coronary risk factors are important is a question of
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great practical relevance, both for the clinician and for public health.991 The current 
simplicity in measurement of risk may be incorrect. Identification of risk factors for 
each stage in the development of CHD would be a more productive approach.202 
Identification o f a combination o f different pathophysiological risk factors, that is, 
risk for atherosclerosis co-existing with risk for thrombosis, may indeed provide a 
better approach for improving our precision of CHD risk assessment.
Just as the lipoprotein abnormalities contributing to risk have been difficult to de­
lineate concisely, so to has the identification of thrombogenic risk factors. Many 
potential mechanisms exist which provide a basis for increased thrombogenic risk. 
Besides the presence of platelet function changes, other potential thrombogenic risk 
factors include increased blood viscosity ,63,64 impaired fibrinolysis,40,41,60,316 an 
increased fibrinogen level,60,61 increased coagulation factors, particularly factor 
VII,60 and elevated arterial wall shear stress.992 The interrelationship of these fac­
tors, and even the co-existing influence of abnormal lipoproteins on these factors64 
provide a "tangled web" of risk factors possibly greater than previously proposed.635
The results of this present study show that platelet function appears to be more im­
portant for the development of severe lesion development and lipids are more relev­
ant to lesions with mural involvement. Whether the latter is a prerequisite for the 
former cannot be determined from this observational study. Nevertheless, the asso­
ciation of platelet aggregability and the severity of angiographically defined CAD 
still holds when the other measured risk factors are held constant.
9.2.2 Proving Causality
The epidemiological evidence that increased platelet aggregability is not only a risk 
factor but a causative risk factor is increasing. The need for an ability to predict 
thrombotic risk has previously been reviewed and emphasised.32,54,475,835,878 There is 
a large body of data supporting such a requirement, and the observations in this 
Thesis add to and emphasise the emerging body of knowledge in this area. However, 
any examination of the evidence for this claim requires the application of those cri­
teria for asserting causality which were outlined by Sir Austin Bradford Hill,993 and 
amplified by others.737
In studies of chronic diseases, such as atherosclerosis and CHD, the clinical discov­
ery of the disease is often years or decades after the biologic onset, and the time of 
this onset is unknown.994 Therefore, information necessary to measure the preva­
lence, incidence and duration of the particular disease is not always available, 
making it difficult to determine causative factors for the disease. Not surprisingly, 
the criteria for inferring causation of disease by any specific attribute or agent has 
long concerned clinical epidemiologists. The requirement for procedural and inferen­
tial methods had been stimulated by the now well recognised associations between 
specific measurable attributes of smoking995 and blood cholesterol,996,997 and chronic 
disease occurrence in populations and individuals. However, the problem of multiple 
causation of disease, and the specificity of proposed causative factors for causing 
disease, have provided difficulties for the epidemiological investigation of many 
chronic diseases.998,999 Furthermore, any causative attribute of low biological patho­
genicity may only produce clinical disease with exposure at a given age, if resistance
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is impaired, or in the presence of a pathogenic or nonpathogenic cofactor.737 For 
example, Lilienfeld999 has highlighted the concept of "vectors" occurring in chronic 
disease, as well as in infectious diseases. This consideration is one form in which an 
identified and measurable attribute can be a marker for the true causative factor, and 
is associated with the disease via this secondary dependence.
There are further intuitively apparent limitations in the pursuit of causality.471,737 
The same pathological or clinical state can be produced by different aetiological 
agents. Such agents may be different depending on geographic area, age group, and 
varying patterns of host susceptibility. Indeed, some diseases require the presence of 
two or more agents or cofactors acting to produce the disease state. Equally, a single 
agent may produce different clinical and pathological responses in different settings. 
The nature and severity of the host response following exposure to an agent varies 
with specific host characteristics. These include behavioural patterns, socio-econom­
ic level, age, immunological states, and pathogenic or non-pathogenic cofactors.737 
As well, the interaction of the environment and genetic constitution is often, if not 
always, of importance.
These considerations invariably lead to numerous problems in the design of cause- 
effect research, giving rise to measurable and immeasurable bias.471 Experimentation 
and the determination of biological mechanisms provide the most direct evidence of 
a causal relationship. Unfortunately, this approach to the understanding of the patho­
genesis of chronic disease cannot always be implemented, and much depends on 
biological inferences from epidemiological studies of such diseases. Thus, the ques­
tion arises, when observation reveals an association between variables and disease, 
what aspects of that association should be considered before concluding the presence 
or absence of a causative association. A series of requirements had been proposed 
when their necessity for the investigation of chronic disease became evident.998 This 
epidemiological approach expanded with time. Sir Austin Bradford Hill proposed 
more rigorous criteria, with all of which "we should study association before we cry 
causation".993
A unified concept for a set of criteria for inferring causation has now been well 
established in the epidemiological literature.470,471,737,993 Sir Austin Bradford Hill 
originally proposed 9 criteria for consideration when evaluating whether or not an 
association between a risk factor and disease is causalP1 2345These criteria have been 
defined and presented in detail by Evans737 as:
1. Prevalence of disease should be significantly higher in those exposed to 
the putative cause, than in case controls not so exposed.
2. Exposure to the putative cause should be present more commonly in 
those with the disease than in controls without disease, when all risk factors are held 
constant.
3. The incidence of the disease should be significantly higher in those 
exposed to the putative cause than in those not so exposed as shown in prospective 
studies.
4. Temporally the disease should follow exposure to the putative agent 
with a distribution of incubation periods on a bell shaped curve.
5. A spectrum of host responses should follow exposure to the putative
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cause along with a logical biological gradient from mild to severe.
6. A m easurable host response fo llow ing exposure to the putative cause 
should regularly appear in those lacking this before exposure (e.g. antibody, cancer 
ce lls), o r should  increase  in m agn itude if  p resen t befo re  exposu re ; th is pattern  
should not occur in those not so exposed.
7. Experim ental reproduction of disease should occur in higher incidence 
in anim als or man appropriately exposed to the putative cause than in those not so 
exposed; this exposure may be deliberate in volunteers, experim entally  induced in 
the laboratory, or demonstrated in a controlled regulation of natural exposure.
8. E lim in a tio n  or m o d ifica tio n  o f the  p u ta tiv e  cause  or, o f  the vec to r 
carry ing  it, should  decrease the incidence o f the d isease (e.g. con tro l o f po llu ted  
water or smoke, or removal of a specific agent).
9. P revention  or m odification  o f the h o s t’s response on exposure to the 
putative cause should decrease or elim inate the disease (e.g. im m unization, drugs to 
lower cholesterol, etc.).
10. The whole proposal should make biological and epidemiological sense.
Therefore, the position o f increased platelet aggregability as a risk factor must satis­
fy the criteria outlined if a causal relationship is to be substantiated from an ep ide­
miological perspective.
9.2.3 Prevalence of Disease
The possibility of chronically abnormal platelet function being a risk factor for CHD 
has been a subject o f evaluation for many years.52,55,94,166’624,766,848,851,906,1000,1001 For 
exam ple, younger males with CHD having a norm al coronary angiogram  or single 
obstructive arterial lesions have platelet hyperaggregability.52
9.2.4 Exposure to Potentially Causal Factors
The results o f this Thesis show that, as a group, males with prem ature CHD have a 
m easurably increased platelet reactiv ity  in com parison to m ales currently  w ithout 
CHD. That is, prevalent cases o f males with CHD have evident a greater exposure 
to the putative causal factor, platelet hyperreactivity, than those without CHD.
9.2.5 Coronary Heart Disease Prognosis and Platelet Function
Two recen tly  reported  p rospective studies prov ide fu rther support fo r increased  
platelet aggregability as a risk factor for CHD.901,902 Both studies indicate that non- 
fatal MI and fatal CHD cases may have sim ilar platelet abnorm alities.475 M oreover, 
prognosis after non-fatal MI is significantly worse in patients with high spontaneous 
p la te le t ag g reg a tio n .59 A prev ious case-co n tro l study also  p resen ts  a p rognostic  
association betw een platelet aggregation and vascular d isease.851 The relationship 
betw een severity  o f obstructive coronary  arterial lesions and  the aggregab ility  o f 
platelets in response to adrenaline adds a cohesive dim ension to these observations 
link ing  p la te le t aggregation  and prognosis. W hich p la te le t facto r(s) best p red ic t 
increased risk for M I require elucidation.475 At present the relevant in vitro p latelet 
function  test w hich sim ulates the patho log ica l events o f coronary  throm bosis is 
unknow n.91 N evertheless, further criteria for establishing causality  have been pro-
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vided by these studies. Exposure to the putative cause, that is, increased platelet 
aggregability,901,902 and the subsequent incidence of disease are prospectively relat­
ed.902 Moreover, temporally, the acute coronary events occur after documentation of 
the platelet hyper-reactivity.
9.2.6 "Host" Response and Biological Gradient of Disease
If a true relationship exists between discrete obstructive lesions in angiographically 
defined CAD and increased platelet reactivity, and similarly between extent of le­
sions (but not severity) and a lipoprotein measure, one could expect such observa­
tions to be reflected in the pathology of atherosclerotic lesions in the young. Human 
atherosclerotic lesions differ in the nature and quantities of cells and interstitial 
components of which they are formed. 1002,1003 Clearly, factors other than the lipid 
component and the incorporation of thrombus into an atherosclerotic lesion are also 
clearly involved in the formation of the various parts of atherosclerosis, for example, 
cell necrosis. 1003 The process of necrosis possibly involves modified forms of LDL, 
in particular oxidised LDL which is cytotoxic. 131,260,1003 Nevertheless, an evaluation 
of the pathology of lesions over time does provide support for the differential asso­
ciation of lipoproteins with early lesion development and thrombosis with the devel­
opment of obstructive lesions.
An alteration in the lipid constituents of atherosclerosis occurs with aging, from 
lipid-laden macrophages in pre-puberty, to lipid droplets in smooth muscle cells by 
puberty, and to the beginning of accumulating extra-cellular lipid after puberty. 1002 
In the third and fourth decade of life fibroatheroma develop.Importantly, at this later 
stage, collagenisation and thickening of atheroma are more marked when evidence of 
thrombotic deposits are present on the surface or within lesions. 1002 Moreover, 
endothelium over established human plaques often shows focal denudation injury 
with adhesion of a platelet monolayer.733 In deep intimal injury, thrombus may form 
within plaque altering the configuration and expanding the volume, providing a 
cause of episodic and rapid plaque growth.733 Thrombus formation, or organisation, 
and acute or subacute growth of atherosclerotic plaques commonly occur 
together.40,733
Therefore, both the current understanding of lesion development and our angio­
graphic observations are consistent. Moreover, there is a biological gradient of 
association between lesion severity, the host response, and one putative cause, in­
creased platelet reactivity.
9.2.7 Platelet Function and Coronary Thrombosis
A latent but increased potential for platelet aggregation may contribute to the devel­
opment of CHD because of increased thrombus propagation resulting in coronary 
occlusion and/or acute lesion expansion. Alternatively, long-term diffuse atheros­
clerotic disease progression may be increased because of platelet adherence or 
aggregation on vascular endothelium. Finally, a combination of enhanced coronary 
thrombosis and the potential for acute plaque expansion may both contribute. The 
latter proposal is supported by the pathological studies described above, as well as 
the relationship between heightened platelet reactivity and stenotic lesions observed
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in our study. In addition, clinical observations regarding the time dependent effect of 
chronic platelet inhibition with low-dose aspirin on CHD favours platelets being 
involved in acute lesion and thrombus formation.695 The reduction by aspirin of the 
cumulative incidence and cumulative relative risk for AMI occurs soon after initia­
tion of therapy and does not change over time.695 There is also no treatment effect 
for the development of angina pectoris.695,697 This concept, however, relies on the 
assum ption that angina is a clinical m easure for the outcom e of atherosclerosis 
progression, and this may not be reliable. Furthermore, the follow-up duration of 5 
years may not be sufficient to affect the process.695 Low-dose aspirin also reduces 
the risk of subsequent AMI in patients with established clinical CHD, manifest as 
asymptomatic, and less so with symptomatic myocardial ischaem ia.1004 The results 
of the above studies are consistent with the association of platelet aggregation with 
the development of discrete obstructive lesions and hence disease severity.
Clearly evidence exists that modification of one possible contributing factor, namely 
platelet aggregation, with aspirin, reduces the incidence of one clinical expression of 
severe CAD, namely AMI. It is speculative to propose that the clinical relationship 
can be used as an indicator of the underlying process. However, the prelim inary 
results of a trial assessing the effect of aspirin on atherosclerosis defined by quantita­
tive coronary angiography suggest that aspirin therapy may reduce new lesion forma­
tion but not intramural atherosclerotic progression.1005 Such a finding is very con­
sistent with our results of an association between obstructive lesions and platelet 
aggregation, and also with the clinical data on the prevention of AMI but not angina 
pectoris by aspirin in the Physicians’ Health Study.695 In addition, increased platelet 
aggregation in the morning, and upon rising, may contribute to the increased occur­
rence of AMI at this time.224,903,1006,1007 Aspirin reduces the incidence of AMI in the 
morning.1007
9.2.8 Therapeutic Efficacy of Reducing Platelet Aggregability
The above studies only provide tentative evidence that the incidence of the disease is 
altered by anti-platelet agents, with a reduction in coronary thrombus formation and 
consequently a reduction in severe obstructive lesions. Nevertheless, the response of 
the "host" in terms o f the clinical expression of disease is clearly altered, with a 
marked reduction of CHD events.695,1004,1007 Effectiveness of treatment was estab­
lished before the accumulation of evidence that platelet aggregability may be a risk 
factor for CHD.696,698,992,1008' 1010 Therefore, in retrospect, the inhibition of platelet 
aggregation could be interpreted as the treatment of a risk factor, both for the prim­
ary and the secondary prevention of CHD, in the same way as attempts are made to 
alter lipid metabolism, mainly by lowering blood cholesterol. Considering the suc­
cess of aspirin in the clinical trials showing a reduction in cardiovascular mortality 
for both those without known preexisting disease and those with established disease, 
the importance of arterial thrombosis in the clinical expression and prognosis of 
CHD is undeniable. In light of the therapeutic efficacy of aspirin, the presence of 
throm bogenic risk factor(s), particularly  involving p latelet functions, therefore 
should not come as a surprise. Nevertheless, the thrombogenicity of an ulcerated or 
fissured atherosclerotic plaque may be sufficient without an added need for increased 
platelet aggregability.32
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9.2.9 Biological Plausibility and Experimental Reproduction
The biological plausibility and laboratory evidence in support of the possibility of 
platelet hyperaggregability being a risk factor for CHD and also other forms of 
vascular disease has been reviewed previously32,40'42,733 and are summarised in the 
introduction Chapter of this Thesis.
9.2.10 Summary
The results presented in this Thesis contribute to the criteria required to establish 
causality of a factor in epidemiological terms. Firstly, heightened platelet activation 
is present more often and to a greater degree in individuals with CHD than in a 
control group without CHD. Secondly, there is a biological gradient in the predicted 
disease outcome, namely severity and number of discrete obstructive coronary artery 
lesions and the aggregability of platelets to adrenaline. The overall body of literature 
currently provides a strong argument that a potential for increased platelet aggrega­
tion is a causative risk factor for the clinical expression of CAD, and is manifested 
as the thrombotic complications of this disorder.
9.3 QUALIFICATIONS INFLUENCING THE CONCLUSIONS
9.3.1 Major Limitations
Because of the inherent bias in case-control studies and the very real potential for 
unmeasured and unknown confounding factors, it is necessary to state the main 
limitations of the study.
1. All results reported in this thesis represent associations which do not 
necessarily identify an antecedent or consequent factor.
2. The study variables were based on a single measurement on each indi­
vidual and therefore only approximate the true value for each characteristic meas­
ured.
3. The study did not directly control the behaviour of the individuals being 
examined and depended on voluntary cooperation undertaken in good faith.
4. The study design did attempt to distinguish areas of potential bias in 
order to limit confounding factors, but relied heavily on statistical analysis for the 
adjustment of variables concomitant with, or extraneous to, the measurements of 
interest.
5. Much of the analysis of the study was multivariate, and therefore Type 
I statistical errors are more likely. This is a commonly known limitation of studies in 
which large numbers of statistical tests are performed. Many of the observations, 
therefore, are only suitable for gathering potential associations requiring further 
investigation rather than being inference forming or hypothesis testing.
6. The study populations were carefully defined and hence the observa­
tions cannot be generalised to the entire population of CHD patients.
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9.4 STATISTICAL METHODS AND MULTIVARIATE ANALYSIS IN 
CASE-CONTROL STUDIES
Given the m ajor lim itations described above, in particular points 4 and 5 which 
partly relate to the use of multivariate analysis, further discussion of the appropriate­
ness of the statistical methods utilised is of im portance. The lim itations of case- 
control studies are well recognised,370,471,473,1011,1012 and mandate a concise under­
standing of the limitations of observations arising from studies using such methodol­
ogy.
9.4.1 Specific Limitations of Case-control Studies using 
Coronary Angiography for Assessment
Certain areas of bias exist in case-control studies which are unavoidable, as d is­
cussed in Chapter 4. Furthermore, important limitations to the use of angiographic 
assessment of CAD are well recognised and discussed in Chapter 8. When the use of 
coronary angiography is part of the case-control design, appropriate caution has been 
urged.474 Knowledge is often gained not through a single study but rather through 
several different and consistent sources of information which helps to ensure that the 
conclusions from one study are not peculiar to that study.1013
The discussion following, however, will aim to illustrate how some of these inherent 
limitations are more likely to lead to a false negative outcome in this study by de­
creasing the true differences and associations between the study groups. Moreover, 
the statistical analysis within this study has followed the recommendation that more 
than one approach should be undertaken in the analysis of a single study to also 
en su re  th a t the  re su lts  are not an a r tifa c t o f the s tudy  d esig n  o r s ta t is t ic a l  
methods.1013
9.4.1.1 Retrospective case selection. The retrospective design of a case-control 
study leads to a study beginning w ith a po ten tia lly  un represen ta tive  group of 
cases.471,1014 The diagnosis is made prior to the selection and can lead to a preva­
lence-incidence bias.471 The case group in this study represents cases of non-fatal 
CHD. Also, it is possible that those with less severe disease and/or left ventricular 
dysfunction are underrepresented. Cases of sudden death, large Mis and left ventric­
ular dysfunction, unstable ischaemia following MI, ischaemic induced sudden death 
and/or recurrent MI will more likely not be selected. Severity of CAD, as measured 
by the number of lesions and their degree of encroachment into the lumen are related 
to prognosis of CHD and the aforementioned factors. Given that increased platelet 
aggregation is associated with increased cardiovascular death and with an adverse 
prognosis,901,902 if such groups were absent from the case group because of prem a­
ture death, the likelihood of finding a difference in platelet function would in theory 
be reduced, diluting the results of this study. Since cases of nonfatal CAD undergo­
ing coronary angiography appear to be representative of all non-fatal CHD cases in a 
population,474,1011 then our results demonstrate that not only are those with an in­
creased incidence o f cardiac events, including cardiac death, associated with in­
creased platelet aggregation,901,902 but also cases of non-fatal and clinically stable 
CHD.
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Moreover, CHD risk factor levels are more likely to have been altered compared to 
the pre-morbid levels. The risk factors may be influenced by the physical damage 
associated with a MI, by the medical or surgical treatment of the disease and by 
lifestyle changes that have been strongly encouraged. Indeed, this has happened in 
the case group as illustrated by a decrease in the total blood cholesterol level over 
time. Such changes due to medical treatment and lifestyle adjustments are more 
likely to decrease the potential for determining risk factor differences between the 
groups. Nevertheless, this important area of bias may also be in the opposite direc­
tion. This emphasises the fact that case-control studies are useful mainly as initial 
screening studies in order to determine areas of potential importance requiring more 
detailed investigation.
9.4.1.2 Coronary angiography as an assessment method. The major problem 
with case-control studies, as discussed above, is the various forms of selection bias. 
Such bias may be further enhanced by using angiographic methods of assessment.474 
For example, an elevated cholesterol level may lead to a selection bias for the per­
formance of angiography.474 The case group in this study, however, was not selected 
on the grounds o f the angiography but because they had presented with clinical 
CHD, most having had a MI.
Combining cases with and without a prior MI may also lead to error concerning 
which risk factors are related to atherosclerosis and which lead to the precipitation of 
the clinical event.474 However, the use of angiography in case-control studies allows 
the examination of risk factors specifically associated with MI independent of ather­
osclerosis1011 and with different angiographically defined morphology of CAD.207 
Moreover, the measures can be used to strengthen the evidence for a dose-response 
relation between risk factors and coronary artery atherosclerosis.1011
9.4.1.3 Control group selection. Because the control group did not undergo 
coronary angiography, some individuals in this comparison group may have subclin- 
ical CAD. Such a misclassification of subjects by disease status, that is CAD 
although not CHD, could dilute the degree and/or type of differences or associations 
found, giving a higher possibility of false negative associations for risk factors for 
the development of atherosclerosis. However, such a control group selection bias is 
less likely to affect the risk factor difference(s) (e.g. thrombogenic risk factors) that 
may transform underlying atherosclerotic CAD into the clinical expression of CHD. 
Interestingly, and of particular relevance to our observations, multivariate risk factor 
models using the classic major risk factors, are similar when using either a control 
group from the general population without symptoms, and those with symptoms but 
angiographically definable normal coronary arteries.1011 The selection of the controls 
as a group without clinically expressed disease was undertaken with the knowledge 
that asymptomatic atherosclerosis is very prevalent in Western societies.38,639 Of 
equal importance is the fact that AMI can occur in individuals with minimal angio­
graphically defined CAD. 1015
Given the above observations, the argument could be made that the method of selec­
tion o f controls and cases employed in this study enhanced the chance o f eliciting 
factors that can transform atherosclerosis, which is so prevalent in the asymptomatic 
form even at the age o f our study groups38,639 into the clinically expressed condition.
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9.4.2 Specific Limitations with Multivariate Regression Analysis
In the initial attempt to understand a possible interaction between variables, it is rea­
sonable to follow an exploratory and descriptive approach rather than a strictly 
inferential one.1013 Indeed, as stated earlier, this was the main purpose of the current 
study. Nevertheless, when a dependent variable is used as a focal point in an analy­
sis by one of the forms of multivariate analysis, such as multiple regression analysis, 
it is possible to validate the results because they produce a prediction about the 
dependent variable used as the focus.404 Furthermore, appropriate methodology must 
be employed to reduce the potential violations of the assumptions made when using 
multivariate regression analysis.471,1016
9.4.2.1 Validation of Associations from Multivariate Analysis. The predictions 
arising from multivariate regression analysis can be validated by a number of pro­
cesses,404 for example:
(a) External validation by evaluating the same analysis in another group, 
in one or more control groups, or compare the prediction with previous observations 
in the literature.404 As demonstrated in Chapter 5, the multivariate reduction of 
variables by multivariate regression used to evaluate the relationship of lipoproteins 
and CAD was in general concordant with the literature.
(b) Validation internally, that is within the study design, by demonstrating 
expected findings within other variables in the study.404 Again, such internal valida­
tion has been demonstrated and discussed in Chapter 5. For example, the predictable 
and persistent relationship between age and the angiographic scores is an expected 
observation.
(c) Demonstratable by use of different statistical methods to show that the 
results are not an artifact o f that model.1013 Categorisation of the independent varia­
bles with significant relationships with the angiographic scores and subsequent 
analysis of variance of the mean angiographic scores of these groups demonstrated 
confirmatory results indicating that the correlation and multivariate observations 
were not due to chance or an artifact of the model used.
9.4.2.2 Number of variables in stepwise regression analysis. When many 
variables are being examined in stepwise regression analysis, such methods can find 
significant factors when no real association with the dependent variable exists. In 
general, if there are n observations for the least frequent category of a binary re­
sponse variable, you should not examine more than n/10 variables in order to derive 
a model which is somewhat reliable.1016 Therefore, in this study attempts were made 
to limit the number of independent variables entered into the regression model to 6 
or less.
9.4.2.3 Regression dilution bias. Overadjusting in multivariate analysis can lead 
to false negative results due to the effect of regression dilution bias. This arises for a 
number of reasons. Firstly, if a variable is closer along the pathogenic pathway but 
is not recognised, the factor under examination may not achieve significance and 
both are ignored. Secondly, the effects of collinearity are a well known source for 
false positive associations when the true related variable to the dependent variable is 
not included in the regression model. In addition, entering both of the related varia-
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bles may result in a dilution of the predictive strength of the true associated variable. 
Finally, the presence of very precisely measured variables with less or little predic­
tive value for the dependent variable may be given more significance than a more 
closely related factor which is less able to be precisely measured.
Such problems are often difficult to discern in multivariate analysis. Their preven­
tion requires an understanding of the basic model being used, an intimate knowledge 
of the independent variables and their interrelationships, and of course the disease or 
dependent variable itself. Thus a large degree of clinical and medical scientific 
acumen is often required in this regard. Even then, inappropriate variables will be 
given a predictive association as well as a degree of false negatives from the various 
forms of dilution bias. Therefore, the importance of comparison to other studies and 
replication of results becomes critical. Indeed, knowledge is often gained not 
through a single study but rather through several different and consistent sources of 
information which helps to ensure that the conclusions from one study are not pecu­
liar to that study. 1013
9.4.3 Within Person Variability
There are well recognised sources of variation in measurement that affect compari­
sons made in both clinical and epidemiological studies. This study is concerned with 
ascertaining and describing certain variables in a predefined case group and a control 
group. Comparison of the variables of interest and inferences made from the sur­
veyed data were used to support or negate a proposed hypothesis. Sources of varia­
tion in measurement affect any comparisons to be made quite separately from any 
effect arising from the sample of the population under study. Such possible sources 
of variation include inter-observer variability, observer-patient interactions and intra­
individual variability.549 These possible sources of error emphasise the importance of 
standardisation of study procedures and methodology, as far as possible. The effect 
of within-person variability in measurements leads to the possible misclassification 
of disease, or the bias introduced by the tendency of regression to the mean of those 
variables measured.
Regression to the mean refers to the phenomenon that an extreme variable on its first 
measurement will tend to be closer to the centre of the distribution on later meas­
urements. This variability occurs because of variation in the biological parameter 
being measured, as well as the variation in the measurement itself. 550 Hence, it 
arises not only because of within-person variability, but also inter-observer error and 
observer-patient interactions. This is of particular importance for studies wherever 
the sample is chosen because of the measurement of a biological variable above or 
below a specified level. Even the prospective collection of data is subject to nu­
merous errors which include the effect of regression to the mean and subsequent 
misclassification of persons by disease status. These errors could lead to true rela­
tionships being obscured or attenuated, and in intervention studies, improvement in 
disease status being falsely attributed to treatment.
This centripetal movement of data particularly affects studies which recruit their 
sample after a screening process has demonstrated their above or below normal 
value. Some of these values may be due to random fluctuation of within-person or
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measurement variations, and, as discussed above, will return towards normal levels 
in subsequent measurements, unassociated with any real changes within the individu­
al. This does not apply when the subjects are chosen randomly, since a random 
sample would probably contain a full range of the possible variables available. 
Moreover, if all subjects are selected in a given period or if the selection criteria do 
not involve a single biological measurement(s), as in this study, the problems asso­
ciated with regression to the mean do not arise. In addition, the utilisation of a 
control group having the same measures performed with the same methodology 
reduces the problem.549
9.4.4 Hidden Bias
It is unlikely that all relevant variables have been identified and measured in this 
observational study, a fact that is inherent to the design and always a potential area 
of bias in case-control studies.1012 Some relevant variables may have been excluded 
from the analysis even though they have been measured. Other variables may have 
been included even though they in reality are not important determinants of the 
dependent variable measured. The observations therefore must be interpreted with 
this in mind as one can only use the available data specific to a study. Other relevant 
measures include lipoprotein (a),69 oxidised lipoproteins,260 postprandial lipids,1017 
factor VII,60 plasminogen activating factor inhibitor,32 other haemostatic variables56 
and insulin resistance1018 to name but a few of the legion of potential factors 235
9.5 FINAL CONCLUSIONS
9.5.1 Platelet Function in CHD Patients With and Without Myocardial 
Ischaemia on Exercise Testing
Short-term maximally strenuous exertion may cause in vitro activation of platelets, 
as measured by an increase in plasma BTG, irrespective of the presence or absence 
of ischaemia. However, exercise-induced myocardial ischaemia per se does not 
appear to activate circulating platelets, nor are previously activated circulating plate­
lets associated with exertional ischaemia as assessed by the methods in this study. 
Patients with exertional ischaemia may produce less serum TXB2 at rest than those 
without evidence of ischaemia. Those with exertional ischaemia group have an 
increased production of TXB2 in clotted whole blood following exertion, whereas 
those without ischaemia do not.
9.5.2 Effect of the Combination of Cardiovascular Drugs, Metoprolol and 
Nifidepine, on Platelet Function in Patients with and without 
Myocardial Ischaemia Produced on Exercise Testing
There is no evidence of activated circulating platelets following exertional ischaemia 
and no measurable effect of the drug combination of metoprolol and nifedipine on in 
vivo measures of platelet activity. However, an increase in prostaglandin biosynthe­
sis ex vivo in whole blood, as measured by TXB2, is associated with exercise in­
duced myocardial ischaemia and is suppressed by a combination of a beta-blocker 
and a calcium entry blocker. The drugs may produce their effect by reducing myo-
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cardial ischaemia, BP or, alternatively, by directly decreasing blood cell prostaglan­
din formation. In addition, it may be possible that a reduction of whole blood pros­
taglandin activity during thrombus formation in individuals with myocardial ischae­
mia may contribute to the protective effect of these drugs against acute, and transient 
obstructive thrombotic coronary episodes.
9.5.3 Blood Cells and the Production of TXB2 in Clotting Whole Blood
The amount of TXB2 produced in clotting whole blood is influenced by both platelet 
specific factors and environmental factors in the circulation, both molecular and 
cellular, and these differ in patients with CHD and controls without CHD. Specifi­
cally, there is a relationship between serum TXB2 levels and platelet morphology 
(MPV) as well as blood cell indices in the young CHD group. In patients with stable 
CHD who have no evidence of measurable in vivo platelet activation, serum TXB2 is 
not related to measures of in vivo platelet function. In contrast, in the control group 
serum TXB2 was related to the degree of platelet reactivity as indicated by the 
stronger relationship with in vitro platelet aggregation, the PCR and plasma BTG 
levels.
The observations provide further evidence for potential variation in the ability of the 
platelet to produce TXB2 levels in different disease states.
9.5.4 Association Between Blood Lipids and Angiographically Defined CAD
In males with premature CHD, lipoprotein abnormalities are associated with athero­
matous involvement of the arterial wall, and not with severe lesions encroaching into 
the lumen. The development of generalised atherosclerosis may merely be a contrib­
uting factor to the clinical expression of CAD in the form of CHD. The formation of 
acute severe stenoses may have different risk factors and mechanisms than that for 
the development of diffuse atherosclerosis.
9.5.5 Lipoproteins and Platelet Function
There exists a large but unclear body of evidence implicating a relationship between 
lipoproteins and abnormal platelet function. Consistency in the literature with this 
study adds support for an influence of the blood cholesterol level on adrenaline- 
induced platelet aggregation. However, cholesterol may be a surrogate measure for 
another factor(s) which may have an aetiological relationship with abnormal platelet 
function, such as oxidised LDL.
9.5.6 Dietary Differences Between the Study Groups
The subjects in the case group, on the average, appear to each less fatty foods, less 
dairy products and more fruit than the control group. There was also a reduction in 
the contemporary cholesterol level compared to previous levels in the same group, 
suggesting a change in habitual diet, occurred following the diagnosis. The influence 
of these dietary differences could have lead to reduced platelet reactivity and meas­
ures of aggregation in the case group compared to the control group. However, it 
cannot be excluded that a change in diet, once the previous cholesterol level was
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known, may have lead to enhanced platelet reactivity due to changes in dietary fatty 
acids. For example, an increase in polyunsaturated fatty acids, which are susceptible 
to oxidation, without an appropriate level of antioxidants within the body or within 
lipoprotein molecules such as LDL, may lead to the formation of oxidised LDL 
more easily. Oxidised LDL may then have an adverse influence on platelet function, 
making them more susceptible to aggregation, and thus leading to the differences 
demonstrated in this study. Unfortunately, such a proposition cannot be discounted 
in this observational study.
9.5.7 Platelet Function Differences Between Males With and Without CHD
The MPV in young males with CHD was greater than in normal control subjects and 
the increase was present more than 3 months after an infarct. The higher MPV oc­
curred without evidence of ongoing in vivo platelet activation. The MPV is therefore 
an identifiable risk factor in young males with established CHD supporting similar 
conclusions made by others. That is, there is a statistically significant difference 
between a group with disease compared to a group without disease, without there 
being grounds for inferring causality. As with most risk factors, the large overlap 
between individuals in both groups prevents the measurement of the MPV from 
being a clinical useful parameter for disease identification or assessment of severity, 
at present. This was found to be a feature of all those platelet function measures 
which differed between the two groups.
Other interacting influences, namely the content of plasma fatty acid, may have 
resulted in the difference observed. Hence the increased MPV may be only a marker 
for another pathophysiologically abnormality present to a greater degree in the CHD 
group.
A difference in the PCR between the control and case groups was also demonstrated, 
the PCR being lower in young males with CHD, most of whom have had a previous 
AML This difference (a functional measure of platelet reactivity) appears to be pre­
dicted by different factors in the two groups. Whether this is due to platelet factors 
and/or environmental effects remains uncertain.
There was no measurable difference in the release of BTG from alpha-granules fol­
lowing collection and processing of plasma samples in young males with or without 
CHD. Therefore, it is unlikely that an in vivo process is occurring that causes an 
ongoing release reaction within the circulation without provocation in young males 
with stable CHD at a time when there is no evidence of acute thrombotic occlusive 
manifestations of CHD. It is unlikely that the classic CHD risk factors exacerbate or 
cause platelet hyper-reactivity involving alpha-granule proteins, although plasma 
fatty acids may do so. The results demonstrated the presence of a qualitative dif­
ference in the relationship between platelet function and plasma fatty acids between 
young males with CHD and a normal control group.
Thromboxane production in clotted whole blood in the case group (with CHD) ap­
pears to be quantitatively and qualitatively different from the control group. There 
were different influences on TXB2 production due to various plasma constituents, 
suggesting that an alteration in the reactivity of the platelet eicosanoid system exists
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in young males with CHD. Blood cell indices appear to play an important role, as 
well as the plasma fibrinogen level and the degree of previous tobacco intake.
In the case group, the most reliable predictor of serum TXB2 levels was a platelet 
parameter, (viz MPV), rather than external factors in whole blood. In contrast, in 
the control group, serum TXB2 was most reliably predicted by factors within the 
blood, external to the platelet. That is, external influences within the milieu of the 
clot, and in particular, specific plasma fatty acids and the blood glucose level in­
fluence TXB2 production in the control group.
The young males with premature CHD had different in vitro aggregation responses 
from normal controls, in response to adrenaline. Again, as for other platelet function 
measures, the aggregation responses were influenced by different factors in the two 
groups. Aggregation in the control group was positively influenced by the platelet 
number in the plasma and negatively by the red cell volume in the blood. In the case 
group, aggregation was directly influenced by thromboxane metabolism, by the 
WCC and by apoprotein A1 levels.
These results support the concept that the platelets of males with premature CHD 
function differently to those without clinical atherosclerosis, and that this may con­
tribute adversely to in vivo thrombus formation. The results provide further support 
for recent findings that platelet aggregation is predictive of cardiac events and CHD 
mortality. This concept is further strengthened by our observation that there is a 
significant relationship between the severity of CAD and adrenaline-induced platelet 
aggregation in young males with premature CHD.
9.5.8 Fibrinogen, CHD and Angiographic CAD
Elevated fibrinogen levels do have a modest relationship with severe CAD. This 
relationship, however, may be due to another process simultaneously leading to 
increased fibrinogen levels and the development of severe stenotic CAD. The results 
suggested that any relationship existing between fibrinogen and CAD is unlikely to 
be due to a non-specific response to atheromatous involvement of the coronary arter­
ies. An independent association between fibrinogen and the extent of coronary arte­
rial wall involvement, and by inference, atherogenesis, was not able to be demon­
strated.
The fibrinogen level for an individual with CAD is in part directly predicted by the 
volume of previous cigarette use, the age of the individual, the severity of the under­
lying CAD, and inversely by the HDL cholesterol level. Fibrinogen levels are higher 
in young male patients after the diagnosis of CHD than in controls without CHD. 
The elevated fibrinogen is not associated with angiographically defined CAD in the 
young CHD group. Factors associated with the fibrinogen levels differ between 
controls and cases, with a cluster of factors, viz blood glucose level, HbAlC, BMI, 
body weight and scapular skinfold thickness, being associated with fibrinogen levels 
in the case group. An inverse association between HDL cholesterol and fibrinogen 
levels in patients with CHD was demonstrated in preparatory study of this Thesis 
and confirmed in the main case-control study. This was a novel observation which 
has also been reported independently by others. The mechanism of this association
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remains to be elucidated. Moreover, in male CHD patients with premature presenta­
tion, the fibrinogen level appears to have an association with other more recently 
recognised risk factors which cluster together, viz central body obesity, abnormal 
glucose homeostasis and lipid abnormalities.
The results remain consistent with the observation that a priori high fibrinogen levels 
may be predictive of an increased incidence of CHD events. This predictive relation­
ship would appear to be mediated through an association with other risk factors and 
with CAD severity. Whether there is any causal relationship between CHD events 
and fibrinogen levels still remains to be determined.
9.5.9 Behavioural and Psychological Measures in Males with CHD
In the two groups of CHD patients evaluated in this study, a reproducible univariate 
correlation between the MMPI hostility score and CAD has been demonstrated. The 
relationship, however, was not sufficiently strong, in comparison to other risk fac­
tors or because of an association with the CHD risk factors, to remain independently 
predictive of CAD following multivariate analysis (Appendix 3).
9.5.10 Plasma Fatty Acid, Platelet Function and CHD
The observations in this Thesis indicate that for males with premature CHD, in vitro 
platelet aggregability is in part influenced by the plasma fatty acid composition. Dis­
tinct differences in plasma fatty acid and the relationship to platelet aggregation have 
been demonstrated for the two relatively homogenous groups studied. The CHD 
group have different platelet aggregation responses in comparison to the control 
group (Appendix 1).
9.5.11 The Relationship Between Body Fat Distribution, Plasma Fatty Acids 
and Angiographically Defined CAD
The absence of an association between HbAlC and blood glucose levels and diastolic 
BP with central body fat in the control group, and the presence of this association in 
the case group in the present study, supports the possibility of an aetiological rela­
tionship with altered glucose homeostasis, hypertension, central obesity, plasma fatty 
acid and abnormal lipoproteins, and CHD. The distribution of subcutaneous fat, as 
measured by triceps and scapular skinfold thickness, appears to differ between 
young males with and without CHD who have the same overall body mass meas­
urement. In addition, young non-diabetic males with CHD have increased measures 
of glycosylation of plasma proteins, viz HbAlC. An association between a measure 
of central obesity and measures of blood glucose and HDL cholesterol level are 
observed only in the group with CHD. In the same group, the glycosylation appears 
to be predicted more by the plasma content of C l8 group of fatty acids. The extent 
of angiographically defined CAD is better predicted by the scapular skinfold thick­
ness and myristic acid than other risk factors for CHD which are associated with the 
measure of central body obesity (Appendix 2).
The combination of abnormal glucose homeostasis, truncal obesity and lipoprotein 
abnormalities imparts significant risk for developing CHD. We have demonstrated
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that plasma fatty acid content may contribute to this relationship.
9.5.12 Angiographically Defined CAD and Risk Factors for CHD
The results of this study indicate that the formation of acute severe stenoses has dif­
ferent risk factors and mechanisms than those involved in the development of diffuse 
atherosclerosis, as has been previously proposed.4,623 The observations support the 
concept of different factors influencing different stages in the development of the 
clinical condition. In young males with CHD, specific factors are associated with the 
atherosclerotic component and other factors with the stenotic component, and some 
with both. In young males with CHD, platelet function plays an important part in 
determining the severity of the CAD. Fatty acids, lipoproteins and body fat distribu­
tion play a major part in determining intramural involvement of coronary arteries by 
atherosclerosis, as defined angiographically. In particular, no platelet function 
measure was related to the extent of disease.
9.5.13 Conclusion
The results of this thesis contribute to the criteria required to establish causality of a 
factor in epidemiological terms. Firstly, potentially heightened platelet activation is 
present more often and in greater degree in the group of prevalent CHD cases than 
in a control group without CHD. Secondly, there is a biological gradient in the 
predicted disease outcome, namely severity and number of discrete obstructive le­
sions and the aggregability of platelets to adrenaline. The overall body of literature 
currently provides a strong argument that a latent potential for increased platelet 
aggregation may be a causative risk factor for the clinical expression of CAD as 
manifested in the thrombotic complications.
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APPENDIX 1
PLASMA FATTY ACIDS AND PLATELET REACTIVITY 
IN MALES WITH PREMATURE CORONARY HEART DISEASE
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A l.l PLASMA FATTY ACID PRO FILE AND PLATELET FUNCTION
A 1.1.1 Introduction
That dietary fats probably play an im portant role in the pathogenesis of CHD is 
generally accepted.67,150,162,408,1019' 1021 Studies have concentrated on the relationship 
between diets rich in saturated fats, blood cholesterol and CHD. Many years after 
the initial observations,1022'1024 the possibility that a deficiency of essential fatty acids 
(FA) may p lay  a ro le  in the d ev e lo p m en t o f a th e ro sc le ro s is  and CHD has 
reemerged.379"381,1025,1026 In support of this, two prospective epidemiological studies 
have suggested that a diet high in po lyunsaturated  fats may reduce the risk  of 
CHD 1020>1027
Those reports indicating a relationship between body tissue fatty acids composition 
and CHD are persuasive but not conclusive. It is clear that m ore inform ation is 
needed to support the concept and provide a biological explanation for the relation­
ship. The consistent association between low tissue levels of polyunsaturated fatty 
acids (PUFA) and CHD, in both individuals and populations, does im plicate an 
association with CHD and possibly environmental and/or metabolic factor(s) related 
to body tissue FA com position. Since tissue FA reflect the long-term  intake of 
polyunsaturated fats in the diet,1026 dietary variations of PUFA may be one environ­
m ental factor. A bnorm al FA m etabolism  (e.g. perox idation) may be ano ther 
factor.1026 Alternatively, changes in haemostatic factors may be important since they 
offer a plausible biological link between FA metabolism and CHD.35,36,1023 In the 
light of current knowledge of the thrombotic aetiology of AMI,3 the association may 
be through the occurrence o f arterial throm bosis. The relationship  betw een FA, 
p la te le t  re a c tiv i ty  and a r te r ia l th ro m b o sis  has been  e x te n s iv e ly
Studied 66,67>624’625.657,659.862,971,1028-1036
Even though a large number of important studies have implicated reduced levels of 
certa in  PUFA in body tissues as being risk  ind ica to rs  for the developm ent o f 
CH D,379'381,818,1022,1024"1026,1037' 1039 public health m easures aim ed at altering the 
proportion of PUFA in the diet in order to modify blood lipid levels of a population 
may not necessarily have a favourable effect on platelet function.645,646,1036 Indeed, 
there may be critical upper and lower limits for the content of dietary n-6 PUFA in 
order to induce beneficial effects on platelet function and thrombosis.645,646,1036
It is clear that the effects of the various PUFA on thrombosis and atherosclerosis, 
and in particular the n-6 PUFA, have only partly been elucidated.67 If dietary modi­
fication of the tissue FA is to be advised as a primary and secondary preventative 
measure against CHD, a more complete understanding of the effects of fatty acids on 
platelets and coagulation is required in addition to effects on blood lipids. In this 
section, the relationship between the total FA content of plasma and in vitro platelet 
aggregation in the group of young males with CHD and the age, sex and socioeco­
nomically matched control group, are examined. This evaluation is of importance 
given the difference in platelet function demonstrated between the case and control 
groups.
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Al. 1.2 Methods
A 1.1.2.1 Study populations. The patient population consisted of the case-control 
study groups described in Chapter 3.
A1.1.2.2 Lipoprotein measurement. The methods are described in Chapter 5.
A1.1.2.3 Platelet aggregation. The materials and methods used for platelet aggre­
gation measures are described in Chapters 2 and 6.
Al. 1.2.4 Plasma fatty acid analysis. Plasma samples were stored at -70°C prior 
to analysis. Lipids were extracted from 1ml aliquots of plasma with 9 ml of chloro­
form-methanol (2:1, v/v) and 2.5ml KC1. The lipid extract was filtered to remove 
protein and then evaporated to dryness with nitrogen gas. Lipids were then hydro­
lysed and methylated with 1ml of 14% boron trifluoride in dry methanol at 100°C 
for 2 min. Once the solution reached ambient temperature, 5 ml of water was added 
followed by 5 ml of hexane to extract the methyl esters which were then brought up 
to 40 ul of methylene chloride/butylated hydroxy toluene solution. The FA methyl 
esters were separated by gas-liquid chromatography (GLC) using a 30m x 0.53mm 
I.D. cyanopropyl megabore column and a flame ionisation detector. Nitrogen was 
the carrier gas, column conditions were optimised to separate the peaks of interest 
and the temperature was programmed at 210°C to run isothermally. Peaks were 
identified by comparison with chromatography of authentic FA methyl ester mix­
tures. The standards of FA methyl esters were obtained from Supelco, Inc. (Belle- 
fonte, PA 16823-0048) and Alltech Associates (Deerfield, IL 60015). A Hewlett 
Packard model 3396A integrator was used to calculate the % composition of each 
FA methyl ester peak.1040,1041
To assess the reliability of the methylation process the area under the GLC peak of a 
methylated standard of known concentration was compared to that peak from the 
same FA with known concentration and which was subsequently methylated. A 
standard mixture of 50mg FA methyl ester (Alltech Associates, cat. no. 19026-26) 
was brought up in 1ml of methyl chloride in BHT. In the standard there were 5 
components (C13:0, C15:0, C17:0, C19:0 and C21:0) each of 10mg/ml concentra­
tion. Then 10mg of heptadecanoic acid was methylated at 100°C for 2 min with 1ml 
of BF3/MeOH. The methyl ester was brought up in 1ml of methylene chloride and 
BHT. Both lul of the standard and the sample were injected separately (at 170 to 
200°C, R°C per min, Inj=250°C, det=260°C and attenuation=3). The resulting 
chromatograms were analysed to calculate the % methylation of FA:
% methylation = area of newly methylated C17:0 peak 100 
area of pre-methylated standard C17:0
= 39.57 100 
40.12
= 98.63%
To assess the precision of the measurements, replicate measurements with standard 
FA were undertaken with separate samples from the same mixture of 4 different
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Standard FA (C20:0, C20:l, C20:2, and C20:3). The samples were run through the 
GLC 10 times each. The CV ranged from 0.36% to 0.53% (Table A l.l).
The present literature quotes coefficients of variation (CV) for major component 
fatty acids between 0.9% and 4.4%, with greater variation for trace components 
(content<l%), of the order of 17% to 35%379,1026 Variability in the results were 
determined for the error of the method (replicates), and variability for repeated 
identical sample measures, which includes method variability over time, and also 
within-person variation over time. Replicates of the same blood sample demonstrated 
a CV between 0.9% and 6.2% for the major components, and above 7% for the 
trace components (content<l%) (Table A1.2). The CV for C20:lw9 and C20:2w6 
were unacceptably high but commensurate with the literature,379,1026 whilst the 
remaining FA had CV<10% (Table A1.2). Therefore, caution will need to be 
exercised in the interpretation of results involving C20:lw9 and C20:2w6 with the 
methods used.
A1.1.2.5 Statistical analysis. The statistical methods are described in Chapter 2.
A 1.1.3 Results
A l.1.3.1 Group comparisons. Compared to the control group, the CHD group 
had a higher % of palmitic acid in plasma, and a lower % of oleic, eicosenoic and 
docosopentanoic acids and a lower % of linoleic acid which was of borderline signif­
icance (Table A 1.3).
A l.1.3.2 Correlations between plasma fatty acids and platelet aggregation.
When associations were evaluated by linear correlation, an increased % of palmitic, 
myristic, alpha-linolenic, docosahexanoic, oleic and eicosenoic acids in plasma were 
found to be associated with a reduction in in vitro platelet aggregation in the CHD 
group (Table A 1.4). In contrast, the % of stearic, dihomo-y-linolenic and arachido- 
nic acids correlated positively with some measures of platelet aggregation (Table 
A 1.5). In the control group, only the % of myristic (LAGCOL r=-0.31, LT50ADR 
r=-0.30, LT50COL r=-0.30, RADR r=0.28, all with p<0.05), palmitic (RADR 
r=0.33, p<0.05), and dihomo-y-linolenic acids (LT50ADR r=-0.32, RADR 
r=0.35, both with P<0.05) in plasma were associated with increased platelet 
aggregation. The % of stearic (LT50ADR r=0.40, LT50COL r=0.27, RCOL r=- 
0.28, all with p<0.05) and eicosenoic acids (LAGCOL r=0.49, LT50COL r=0.50, 
RCOL r=-0.36, all with p<0.05) in plasma were associated with decreased platelet 
aggregation in the control group.
A l.1.3.3 Multivariate analysis for aggregation measures and plasma FA. In 
both study groups all of the FA which linearly correlated with platelet aggregation, 
or differed between the two groups, were entered into a stepwise regression model. 
In the case group, stearic, dihomo-y-linolenic and arachidonic acids retained a posi­
tive and independent association with measures of platelet aggregation, while doco- 
sahexaenoic and oleic acids remained independently associated with decreased 
aggregability (Table A 1.5). In contrast, in the control group, myristic acid alone 
remained positively associated with increased platelet aggregability (LT50COL B=- 
0.001, Beta=-0.37; LAG B=-0.001, Beta=-0.38; RCOL B=0.001, Beta=0.46; all
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with P<0.006; and RADR B=0.002, Beta=0.35, p<0.03) and eicosenoic acid was 
associated with decreased aggregation (LT50COL B=001, Beta=0.45; LAG 
B=0.001, Beta=-0.47; RCOL B=-0.001, Beta=-0.32; all with p<0.02). The 
platelet count in PRP (PRPPC) remained positively associated with the rate of 
aggregation in the control group (RCOL B=0.001, Beta=0.32; RADR B=0.001, 
Beta=0.35; both p<0.01).
Al. 1.3.4 Multivariate analysis of platelet aggregation and blood lipids. In light 
of the possible interaction between FA in various lipids and in platelets, each of the 
main lipoprotein indices (cholesterol, triglycerides, HDL, apoprotein B and apopro­
tein Al) and PRPPC were analysed by multiple regression as independent variables 
to determine any potential relationship with aggregation, with the measures of 
aggregation being the dependent variable. Only cholesterol and apoprotein Al re­
tained a possible independent relationship with some of the measures of aggregation. 
These variables were entered into the final regression model. There was no effect on 
outcome of predicting independent variables with the estimated amount of alcohol in 
grams being entered in the regression analysis as an independent variable in the 
control group. Therefore it was excluded from subsequent analysis to reduce the 
number of factors assessed.
Al. 1.3.5 Multivariate analysis of platelet aggregation, fibrinogen, plasma FA 
and blood lipids. Multiple regression analysis was performed with those same FA 
linearly associated with aggregation or differing between the groups, in addition to 
total cholesterol, apoprotein Al and fibrinogen as potentially confounding factors. 
Stearic and dihomo-y-linolenic acids remained positively associated with platelet 
aggregability, while palmitic acid became positively associated with platelet aggrega­
tion. Oleic acid remained associated with decreased platelet aggregation in the CHD 
group (Table A 1.6). In the control group, PRPPC and myristic acid remained asso­
ciated, and arachidonic acid became associated with increased platelet aggregation 
using the same regression model (Table A 1.7). Both stearic and eicosenoic acids 
retained a relationship with decreased platelet aggregation. Thus, a qualitative dif­
ference in the relationship between stearic acid and platelet aggregation exists in the 
two study groups. Males with premature CHD have an increased aggregation re­
sponse in association with an increased % of stearic acid, whereas there was the 
opposite relationship in the young male control group.
A l.1.3.6 Classes of plasma FA - group comparisons. The % content of the FA 
were categorised into the classes n-3, n-6, n-9, saturated FA (SFA), and oleic plus 
docosahexanoic acids (OL+DH). The eicosopentanoic to arachidonic acid content 
ratio (EPA/ARA) and PUFA/SFA ratios were also calculated. Predictably there 
were significant differences between the two groups (Table A 1.8). The values for n- 
9, P/S and OL+DH were significantly higher in the control group compared to the 
case group, while the value for n-6 was of borderline significance. The SFA were 
significantly higher in the case group (Table A 1.8).
A1.1.3.7 Classes of plasma FA - correlations. In the case group, the values for n- 
9 and OL+DH had consistent negative associations with platelet aggregation, and 
for n-6 a positive relation with increased aggregation (Table A 1.9). No consistent 
associations were demonstrated in the control group.
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A l.1.3.8 Classes of plasma FA - multivariate analysis. When the values for n-3, 
n-6, n-9 and SFA classes of FA were analysed with multiple regression analysis, the 
n-6 and n-9 classes were found to have an independent association with some meas­
ures of platelet aggregation, in the case group. There was a positive association with 
increased aggregation in the n-6 class, while in the n-9 class there was a positive 
association with decreased aggregation (Table A1.10). The relationships appeared to 
be related to the rates of aggregation (Table A 1.10). In the control group, none of 
the FA classes or ratios were independently associated with aggregation when as­
sessed by multiple regression analysis. Aggregation in the control group was inde­
pen d en tly  and p o sitiv e ly  a sso c ia ted  w ith  the PR PPC  fo r RA DR (B = 0 .002 , 
Beta=0.71, p<0.005) and RADP (B=0.001, Beta=0.42, p<0.05).
A 1.1.4 Discussion
Distinct differences have been shown in the qualitative relationships between plasma 
FA and in vitro platelet aggregation in response to specific agonists in males with 
prem ature CHD. In fact, cases and controls had different plasm a FA profiles and 
specific FA were associated with differences in platelet aggregability independent of 
established risk factors. The % content of stearic, arachidonic and dihomo-y-linole- 
nic acid were associated with increased platelet aggregability. Additionally, palmitic, 
oleic and docosahexanoeic acids were associated with decreased platelet aggregabili­
ty. Except for arachidonic and docosohexanoic acids, these same FA continued to be 
independently associated with platelet aggregation with the inclusion of other appro­
priate risk factors for CHD and lipids into the m ultivariate regression model for 
CHD patients. Palmitic acid, however, became positively associated with increased 
aggregation. In contrast, using the same analysis, m yristic and arachidonic acids 
were associated with increasing, and stearic and eicosenoic acids with decreasing 
platelet aggregation in the control group. This latter observation is consistent with 
current epidemiological and experimental evidence regarding the effects of saturated 
FA on platelet function,67,1029,1042 but notably different to the CHD group. O f partic­
ular consequence, the n-6 FA as a group were associated with increasing, and n-9 
with decreasing platelet aggregation in the CHD group, but not in the controls.
A 1.1.4.1 Saturated fatty acids. Both experimental624,862,1032'1034 and epidemiolog­
ical observations659,1030,1031,1036 have dem onstrated the throm bogenic potential of 
sa tu ra te d  FA, w hich  m ay in p a rt be m ed ia ted  th ro u g h  in c re a se d  p la te le t  
reactivity.67,625,971,1029 In the control group, the observed association between in ­
creasing plasma myristic acid and the aggregability of platelets is consistent with the 
published data.67,659,769,1030'4,1036 However, in the patient group, stearic and palmitic 
acids were associated with increased platelet aggregability after adjustment for other 
variables.
An explanation for the differences may relate to the fact that the % distribution of 
FA in body tis su e s  and p lasm a  lip id s  is in f lu e n c e d  by m any e x te rn a l 
factors.379,863,900,1043,1044 In particular, the dietary FA content has a considerable in­
flu en ce  on the body FA c o n ten t in c lu d in g  the d is tr ib u tio n  o f  FA in 
plasm a.645,659,1025,1031,1045'1047 Many of the FA measured are metabolic products of 
shorter chain FA, and in humans the production of longer chain PUFA requires the 
dietary intake of essential precursors. Therefore, any significant linear correlations
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between FA and platelet aggregation may be confounded by the relationships bet­
ween the FA them selves. For exam ple, an increase in stearic acid may be at the 
expense of other saturated fats such as myristic and palmitic acids. In such circum­
stances, if an increase in stearic acid is associated with increased platelet aggrega­
tion, then myristic and palmitic acids may inappropriately appear to correlate with 
decreased platelet aggregation. Multiple regression analysis was used to adjust for 
such confounding influences. In fact, with multiple regression analysis, myristic acid 
was found not to be independently associated with decreased platelet aggregation in 
the CHD group, while palmitic acid became positively associated with aggregation, 
and stearic acid maintained a positive independent association.
An association between stearic acid and thrombogenicity has been repeatedly demon­
strated,1032' 1035 but its association with platelet aggregation is contradictory.624,862,1028 
Our results indicate the presence of a qualitative difference in the relationship bet­
ween stearic acid and platelet aggregation in the two relatively homogeneous study 
groups. Previous inconsistencies in the literature may have arisen in part from the 
use of heterogeneous groups. The relatively homogeneous group of CHD patients 
evaluated in this study has a different platelet response to agonists com pared to 
controls, and the measures of aggregation differ in their association with total plasma 
FA content in the two groups. In particular, males with prem ature CHD have an 
increased aggregation response in association with an increased % of stearic acid, 
whereas there was a contrary relationship in the young male control group.
A 1.1.4.2 Unsaturated fatty acids. Linoleic acid appears to be less thrombogenic 
than saturated fats in animals and humans.66,67,862,1035 Reduced platelet aggregability 
has been reported in response to high linoleate diets67,660,971 which effect the fatty 
acid profile of body tissues.67 However, other studies have raised the prospect of a 
positive association existing between a high intake of vegetable fat and increased 
platelet aggregability.645,646,1036 Linoleic acid in both adipose tissue and plasma tri­
glycerides has been reported to correlate positively with A D P-induced p latelet 
aggregation.1036 This supports the possibility of an increase in platelet reactivity to 
ADP and adrenaline following an increase in dietary linoleic acid.645 In addition, 
increases in BTG and ADP-induced platelet aggregation have been observed in 
association with an increase in the PUFA ratio.646 Both high and low levels of lino­
leic acid may have adverse effects on throm bosis.67,645,646,861,1036 In our study, no 
association was demonstrated between platelet aggregation and plasma linoleic acid 
content in either the control or the patient group. However, a linear relationship was 
dem onstrated between the plasma content of metabolic products of linoleic acid, 
namely dihomo-y-linolenic and arachidonic acids in the CHD group and dihomo-y- 
linolenic acid in the control group, and increasing platelet aggregability. Indeed, 
with multiple regression, the plasma content of dihomo-y-linolenic acid maintained 
an independent association in the case group, and arachidonic acid content in plasma 
was associated in the control group with increasing platelet aggregation.
Dihomo-y-linolenic, linoleic acid and eicosopentanoeic acid enriched diets in humans 
have generally been associated with inhibition of platelet aggregation and decreased 
TXB2 formation.66 Nevertheless, feeding purified dihomo-y-linolenic acid to humans 
or animals has resulted in conflicting results with respect to effects on platelet func­
tion.66 Naturally occurring fats and oils contain only minute amounts of dihomo-y-
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linolenic acid and to increase the concentration in plasma or tissues, artificially en­
riched  fats need to be adm inistered.66 H ow ever, population based studies have 
shown significantly lower levels of dihomo-y-linolenic acid in newly diagnosed CHD 
patients1026 and populations at increased risk of developing CHD.380 Furthermore, it 
is feasible that increasing levels of linoleic acid intake may result in greater tissue 
levels of dihom o-y-linolenic and arachidonic acids leading to adverse effects on 
platelet aggregability. In addition, from an understanding of the biochemical actions 
o f arachidonic acid, an increased plasma content of arachidonic acid could be asso­
ciated with increased platelet aggregation. Indeed, a reduction in cellular phospholi­
pid content of arachidonic acid has been shown to result in an inhibition in platelet 
aggregation.66
An im portant observation in the present study was that after the FA were grouped 
together, the n-6 FA as a group m aintained an independent association with in ­
creased platelet aggregability in the case group. Our observations underscore con­
temporary statements against indiscriminate dietary supplementation with linoleic 
acid,67 notably in CHD patients.
A l .1.4.3 Monounsaturated fatty acids. Previous studies have shown a positive 
re la t io n s h ip  betw een  p lasm a c o n ten t o f o le ic  ac id , and in c re a se d  p la te le t 
aggregation,862,1030 and increased clotting.1035 In another study a positive association 
was noted between the plasma concentration of saturated FA, oleic acid and platelet 
ag g reg a tio n .1030 D espite these in itial observations, o ther studies have failed  to 
dem onstrate a sim ilar results.67,1029,1036 The magnitude of platelet aggregation in­
duced by collagen in healthy individuals fed a low fat diet rich in oleic acid is lower 
when compared to those fed a similar diet rich in n-6 PUFA.1046 Under experimental 
conditions, oleic acid does not appear to be thrombogenic, and, indeed may be anti- 
throm bogenic.1035 D ecreased levels of oleic acid in plasm a were observed in the 
present study in the CHD group, and the plasma content was negatively associated 
with measures of platelet aggregability. In the control group oleic acid had no major 
influence on in vitro platelet aggregation. The negative finding in normal individuals 
is consistent with most,67,1029,1035,1036,1046 but not all studies.862,1030
One possible explanation for the difference described may relate to the beneficial 
effect o f oleic acid on oxidation of LDL since oxidised LDL increases p latelet 
aggregation.134 A diet enriched in oleic acid generates oleic acid rich LDL particles 
which are resistant to oxidation.1048 Whatever may be the explanation for the differ­
ent association between oleic acid and platelet aggregation observed in this study, the 
qualitative difference in platelet aggregation between the two groups is further high­
lighted.
A 1.1.4.4 n-3 polyunsaturated fatty acids. The n-3 PUFA have consistently been 
found to have anti-thrombogenic and anti-platelet effects, in particular eicospenta- 
noeic and docosahexaenoic acids.66,67 Ingestion of fish oil rich in n-3 PUFA has 
profound effects on platelet and vessel wall composition and function.67,1049 Asso­
ciated with a decrease in cellular phospholipid concentration of arachidonic acid, the 
bleeding time is prolonged and in vitro platelet function is inhibited.66 The platelet 
lipid content of eicosopentanoeic acid and the EPA/ARA ratio correlate inversely 
with ADP-induced aggregation.1036 This observation is consistent with the decreased
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reactivity of platelets associated with a high EPA/ARA ratio in Eskim os,1049 and in 
individuals fed a mackerel diet.1050 Indeed, the EPA/ARA ratio of plasma FFA may 
be a risk factor for C H D .1039 In addition, the plasma cholesterol and triglyceride 
content of eicospentanoeic acid and the EPA/ARA ratio have an inverse correlation 
with adrenaline-induced platelet aggregation.1036
The relative am ounts of the n-3 PUFA in plasm a is sm all in both o f our study 
groups. In the control group the n-3 PUFA did not have any relationships with plate­
let aggregability. This is not an unexpected observation since the platelet inhibiting 
effects of n-3 PUFA is dose related and in general increased levels appear to be 
needed for the effect to be produced in clinical studies.66,67,0136,1049,1050 In the patient 
group the apparent inverse relation between % docosohexanoic acid in plasma and 
platelet aggregation is an association which appears to not be independent o f other 
factors.
A 1.1.4.5 Fatty acid groups. On account of the number of variables examined, and 
because classes of FA may influence platelet aggregation more than individual FA, 
the FA were grouped into the classes, viz n-3, n-6, n-9 and SFA. In addition, the 
P/S and EPA/ARA ratios were also evaluated. The strongest independent relation­
ship observed for the grouped FA was with the n-6 class which was positively asso­
ciated with increased platelet aggregation, and the n-9 class which was associated 
with decreased aggregation, a finding anticipated from the observations with the 
individual FA.
A 1.1.5 Summary
1. The observations in this section indicate that for males with premature 
CHD, in vitro platelet aggregability is in part influenced by the plasma FA composi­
tion. Many of the published studies are similar to several o f our observations in a 
young male control group, making it probable that the current observations are not 
spurious. The variability in results noted to date in many studies66,67 may arise from 
various causes, including methodological differences and variations due to heteroge­
neous populations.
2. D istinct differences in plasma FA and their relationship with platelet 
aggregation have been dem onstrated in the two relatively hom ogeneous groups 
studied.
3. The possibility that alternate avenues of fatty acid metabolism result in 
the differences in the functional platelet measures arises from the observations in the 
above evaluation. Variation in fatty acid metabolism may therefore contribute to the 
difference in platelet function between the two groups and be a primary thrombogen- 
ic risk factor for CHD. This potentially confounding influence on the results of the 
case-control study indicate the importance of including plasma fatty acid content in 
the final analysis.
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Table A l.l. Replicate measurements of fatty acids (n=10).
C20:0 C20:l C20:2 C20:3
Mean 25.98 26.95 24.93 22.14
Maximum 26.14 27.11 25.09 22.31
Minimum 25.69 26.78 24.80 21.99
SD 0.13 0.10 0.11 0.12
95% conf 0.08 0.06 0.07 0.07
99% conf 0.11 0.08 0.09 0.10
Variance 0.02 0.01 0.01 0.01
CV (%) 0.51 0.36 0.42 0.53
Ten replicate measures were made of known standards to assess the precision of the
GLC methods. The mean of the samples, the maximum and minimum values, the 
standard deviation (SD), the 95% and 99% confidence intervals (conf), the variance 
and the coefficient of variation (CV) are provided.
Table A1.2. Fatty acid replicates measured from the same blood sample (n=14).
C14:0 0 6 :0 C16:lw7 C18:0 C18:1W9 C18:2w6 C18:3w6
Mean 2.12 29.59 3.58 12.27 20.19 20.48 0.44
Max 2.25 30.34 3.80 12.53 20.57 20.87 0.50
Min 1.96 28.51 3.23 12.04 19.88 20.20 0.37
SD 0.09 0.52 0.22 0.15 0.19 0.19 0.04
95% Cl 0.05 0.27 0.12 0.08 0.10 0.10 0.02
99% Cl 0.07 0.36 0.15 0.11 0.13 0.13 0.03
Variance 0.01 0.27 0.05 0.02 0.04 0.03 0.00
CV (%) 4.43 1.76 6.15 1.26 0.95 0.90 9.30
C20:lw9 C20:2w6 C20:3w6 C20:4w6 C20:5w3 C22:5w3 C22:6w3
Mean 0.19 0.29 2.25 5.67 0.57 0.62 1.25
Max 0.29 0.42 2.51 5.94 0.61 0.78 1.42
Min 0.10 0.20 2.20 5.39 0.44 0.53 1.15
SD 0.06 0.07 0.09 0.04 0.01 0.02 0.02
95% Cl 0.03 0.04 0.05 0.08 0.02 0.04 0.04
99% Cl 0.04 0.05 0.06 0.11 0.03 0.05 0.06
Var 0.00 0.00 0.00 0.03 0.00 0.00 0.01
CV(%) 32.98 24.12 3.83 2.77 7.68 10.77 6.41
See Table A l.l for abbreviations and Table A 1.5 for FA names corresponding to the 
FA abbreviations. Var=variance, CI=confidence interval, SD=standard deviation.
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Table A1.3. Plasma fatty acid composition in both groups.
Fattv Acid Control Group Case Group
Myristic (C14:0) 2.61+/-1.32 2.85+/-1.36
Palmitic * (Cl 6:0) 23.51+/-4.59 26.16+/-3.79
Palmitoleic (C16:ln7) 2.31+/-1.00 2.25+/-0.76
Stearic (Cl 8:0) 12.91+/-2.21 12.97+/-1.54
Oleic ** (C18:ln9) 22.02+/-3.35 19.91+/-2.91
Linoleic # (C18:2n6) 20.76+/-3.60 19.59+/-2.96
alpha-Linolenic (C18:3n6) 0.57+/-0.33 0.58+/-0.34
Eicosenoic ## (C20:ln9) 0.99+/-0.83 0.51+/-0.24
Eicosadienoic (C20:2n6) 0.50+/-0.29 0.42+/-0.18
Dihomo-y-linolenic (C20:3n6) 2.21+/-0.76 2.27+/-0.74
Arachidonic (C20:4n6) 7.45+/-2.15 7.22+/-1.71
Eicosapentaenoic (C20:5n3) 0.84+/-0.53 0.86+/-0.42
Docosapentaenoic -  (C22:5n3) 1.05+/-0.39 0.90+/-0.36
Docosahexaenoic (C22:6n3) 2.77+/-1.11 2.98+/-1.01
*p=0.0028, **p=0.0015, #p=0.0861, ##p=0.0002, ~p=0.0543 
Mean % plasma content expressed as mean +/- SD.
Table A1.4. Linear correlations between fatty acids in plasma and platelet aggrega­
tion measures in the case group.
C14:0 C16:0 Cl 8:0 C20:3n6 C20:4n6 C22:6n3 C18:ln9
LAGCOL 0.21 0.27# -0.26# -0.19 -0.13 0.11 -0.03
LT50ADR 0.17 -0.02 -0.44- -0.43- -0.13 0.37* 0.02
LT50ADP 0.14 0.02 -0.38- -0.21 -0.54- 0.04 0.13
LT50COL 0.33* 0.31* -0.24# -0.13 -0.22 0.15 -0.01
RADR -0.22 -0.13 0.33* 0.35* 0.18 -0.43- -0.20
RADP -0.09 -0.10 0.53- 0.28# 0.41- -0.25# -0.31*
RCOL -0.02 -0.12 0.30* 0.04 0.28# 0.01 -0.25#
C18:2n6C18:3n6 C16:ln7 C20:ln9 C20:2n6 C20:5n3 C22:5n6
LAGCOL 0.03 -0.04 0.09 -0.06 0.02 -0.17 -0.09
LT50ADR -0.05 0.33# 0.17 0.34* -0.03 -0.07 -0.16
LT50ADP 0.24 0.03 0.04 -0.01 -0.12 -0.09 -0.15
LT50COL 0.10 0.01 0.04 -0.05 0.06 -0.06 0.07
RADR 0.19 -0.18 -0.16 -0.05 0.08 0.27 0.18
RADP 0.19 -0.37* -0.19 -0.09 0.07 0.19 -0.04
RCOL -0.13 0.19 -0.01 -0.09 0.02 0.05 -0.05
# p<0.05, * p<0.02, ~ p<0.005
See section A 1.1.2.3 for the abbreviations for the aggregation measures and Table 
A 1.1 for the names of FA.
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Table A1.5. Multiple regression with FA as independent variables and aggregation 
measures as dependent variables in the case group.
Dependent Independent
Variable Variable B SEB Beta Rsq Sig
LT50COL 0 8 :0 -0.0005 0.0002 -0.4915 0.2004 0.0036
C22:6n3 0.0006 0.0003 0.3422 0.3151 0.0356
LAG 0 8 :0 -0.0005 0.0002 -0.4055 0.1645 0.0213
RCOL 0 8 :0 0.0013 0.0003 0.8187 0.2660 0.0002
C20:3n6 0.0016 0.0007 0.4545 0.3808 0.0277
LT50ADR C20:3n6 -0.0016 0.0005 -0.5849 0.2546 0.0013
C22:6n3 0.0008 0.0004 0.3677 0.3834 0.0311
RADR C22:6n3 -0.0014 0.0004 -0.5446 0.2420 0.0012
0 8 :0 0.0008 0.0002 0.4560 0.4563 0.0043
LT50ADP C20:4n6 -0.0003 0.0002 -0.4741 0.4561 0.0241
RADP 0 8 :0 0.0008 0.0003 0.4251 0.3319 0.0122
C18:ln9 -0.0004 0.0002 0.3313 0.4189 0.0460
Only FA having a linear relationship with aggregation were entered (viz C l4, C l6, 
C18, C18:ln9, C18:2n6, C20:ln9, C20:3n6, C22:5n3 and C22:6n3 ).
Table A1.6. Multiple regression entering all associated FA, PRPPC, total cholesterol, 
apoprotein A1 and fibrinogen as independent variables in the case group, with aggre­
gation measures as the dependent variables.
Dependent Independent
Variable Variable B SEB Beta Rsq Sig
LT50COL C18:0 -0.0005 0.0002 -0.5594 0.3130 0.0045
LAG 0 8 :0 -0.0007 0.0003 -0.4741 0.2248 0.0193
RCOL Apo A1 0.0044 0.0012 0.5471 0.3168 0.0015
C18:ln9 -0.0003 0.0002 -0.3374 0.5077 0.0386
PRPPC 0.0011 0.0005 0.3329 0.6039 0.0395
LT50ADR C20:3n6 -0.0020 0.0006 -0.7139 0.2268 0.0023
Apo A1 0.0036 0.0013 0.3659 0.3555 0.0144
0 6 :0 -0.0003 0.0001 -0.4779 0.5254 0.0405
RADR Apo A1 0.0042 0.0014 0.5090 0.3741 0.0076
0 8 :0 0.0006 0.0002 0.3945 0.5792 0.0316
RADP C18:ln9 -0.0005 0.0002 -0.4700 0.4342 0.0012
Apo A1 0.0041 0.0012 0.4260 0.6710 0.0030
0 8 :0 0.0005 0.0003 0.2743 0.7311 0.0432
B=regression coefficient, Rsq=coefficient of determination. Only FA having a linear 
relationship with aggregation were entered (viz C14, C16, C18, C18:ln9, C18:2n6, 
C20:ln9, C20:3n6, C22:5n3 and C22:6n3 ). See section A 1.1.2.3 for the abbreviations 
for the aggregation measures and Table A 1.1 for the names of FA. Only significant 
associations are shown. PRPPC=platelet count of PRP.
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Table A1.7. Multiple regression entering all associated FA, PRPPC, total cholesterol, 
apoprotein A1 and fibrinogen as independent variables in the control group, with 
aggregation measures as the dependent variables.
Dependent Independent
Variable Variable B SEB Beta Rsq Sig
LT50Col C20:ln9 0.0012 0.0003 0.5508 0.3326 0.0009
0 8 :0 0.0005 0.0002 0.4646 0.5478 0.0038
C20:4n6 -0.0004 0.0002 0.4125 0.6612 0.0150
LAG C20:ln9 0.0013 0.0004 0.6063 0.3677 0.0013
RCOL 0 4 :0 0.0010 0.0004 0.4994 0.2494 0.0110
RADR PRPPC 0.0019 0.0005 0.6520 0.4923 0.0013
0 8 :0 -0.0005 0.0002 -0.4276 0.6727 0.0190
RADP PRPPC 0.0011 0.0005 0.4250 0.1806 0.0342
B=regression coefficient, Rsq=coefficient of determination. Only FA having a linear 
relationship with aggregation were entered (viz C14, C16, C18, C18:ln9, C18:2n6, 
C20:ln9, C20:3n6, C22:5n3 and C22:6n3 ). See Table A 1.1 for names of FA corre­
sponding to the abbreviations and section A 1.1.2.3 for the aggregation measures. Only 
significant associations are shown. PRPPC=platelet count of PRP.
Table A1.8. Mean values of fatty acid classes and ratios in the two study groups.
Controls Cases 95% Cl DiffMean P
(n=45) (n=49)
n-3 4.66+/-1.64 4.74+/-1.41 -0.55 to 0.71 0.800
n-6 31.49+/-4.64 30.07+/-3.29 -3.06 to 0.22 0.088
n-9 23.09+/-3.45 20.41+/-2.90 -3.98 to -1.38 <0.001*
SFA 39.03+/-4.71 41.98+/-4.38 1.09 to 4.81 0.002*
EPA/ARA 0.12+/-0.08 0.12+/-0.06 -0.03 to 0.03 1.000
P/S 1.55+/-0.27 1.34+/-0.22 -0.31 to -0.11 <0.001*
OL+DH 24.79+/-3.10 22.89+/-3.01 -3.15 to -0.65 0.003*
* significant difference CI=confidence interval for the difference of the means. 
SFA=saturated fatty acids, EPA/ARA=eicosopentanoeic acid/arachidonic acid, 
P/S=polyunsaturated fatty acids/saturated fatty acids, OL+DH=oleic plus docosohexa- 
noeic acids.
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Table A 1.9. Correlations the FA groups and ratios, and measures of platelet aggrega­
tion in the case group.
n3 n6 n9 Sat EPA/ARA P/S OL+DH
LAGCOL 0.01 -0.08 -0.03 0.20 -0.12 -0.19 0.02
LT50ADR 0.21 -0.20 0.23 -0.13 -0.01 0.08 0.31#
LT50ADP -0.04 -0.10 0.13 -0.06 0.25 0.03 0.14
LT50COL 0.11 -0.04 -0.01 0.20 0.06 -0.21 0.05
REPI -0.19 0.36* -0.20 -0.06 0.23 0.08 -0.33#
RADP -0.14 0.42- -0.32* 0.08 -0.13 -0.01 -0.39-
RCOL 0.01 0.01 -0.25# -0.01 -0.16 -0.06 -0.24#
# p<0.05, * p<0.02, ~ p<0.005
Table A1.10. Multiple regression with values for n-3, n-6, n-9 and SFA, apoprotein 
Al, cholesterol, fibrinogen and PRPPC as independent variables and aggregation 
measures as dependent variables in the case group.
Dependent Independent
Variable Variable B SEB Beta Rsq Sig
RCOL Apo Al 0.0043 0.0012 0.5449 0.3168 0.0016
PRPPC 0.0012 0.0005 0.3371 0.5068 0.0366
n-9 -0.0003 0.0002 -0.3366 0.6038 0.0387
RADR Apo Al 0.0050 0.0015 0.6117 0.3741 0.0032
RADP n-9 -0.0007 0.0002 -0.5545 0.4526 0.0001
n-6 0.00051 0.0001 0.5248 0.7140 0.0003
B=regression coefficient, Rsq=coefficient of determination. See Table A 1.7 for the 
abbreviations of the FA groups and section A 1.1.2.3 for the aggregation measures.
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APPENDIX 2
BODY FAT DISTRIBUTION AND CORONARY HEART DISEASE
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A2.1 THE RELATIONSHIP BETWEEN BODY FAT DISTRIBUTION, 
PLASMA FATTY ACIDS AND ANGIOGRAPHICALLY DEFINED 
CORONARY ARTERY DISEASE
A2.1.1 Introduction
Given the multifactorial aetiology of CHD and the degree of inter-dependence of the 
major risk factors, it is clear from the preceding discussions that the relative impor­
tance of risk factors as being independently associated with CHD, much less causa­
tive, can be difficult to discern. Obesity has been one such risk factor.1051 The asso­
ciation of obesity with CHD had been attributed to diabetes, hypercholesterolaemia 
and hypertension .371,387,390,642 M ore recent inform ation, how ever, supports the 
hypothesis that obese individuals are independently at higher risk of developing 
CHD than persons of medium build .383,385,1052' 1057 The nature o f the association 
between obesity and cardiovascular disease is currently being extensively explored, 
and some clarification of the relationship is emerging,383,385,386,635,1055,1056,1058' 1063 
although much requires further investigation.1064
The topographic distribution of fat appears to be more relevant as a risk factor for 
CHD than total body fat.383-384-386-1058' 1065 An association between body fat distribu­
tion, risk factors for CHD and CHD itself has been recognised for many decades.1066 
Prospective studies have revealed a significant relationship between regional body fat 
d istribution and cardiovascular disease incidence.1058,1059,1063 In addition, an in ­
creased proportion of trunk, or abdominal fat, appears to be associated with CHD 
mortality.1058 Waist-to-hip ratio measurement1058,1067,1068 and scapular skinfold thick­
ness1059,1063 are more closely related to CHD risk than measures of body weight or 
height.
The topographic distribution of adipose tissue is also associated with metabolic com­
plications considered to be risk factors for CHD.383,1051,1059,1061,1066,1069 These in­
c lude  in su lin  re s is ta n c e ,1018,1069,1070 h y p e r in s u lin a e m ia ,1062,1069,1071 type II 
d ia b e te s ,1072,1073 h y p e r te n s io n ,383,1069,1074' 1077 a lte re d  b lo o d
lipoproteins,383,386,634,1051,1061,1071,1076'1079 and fatty acid metabolism.385,1080,1081
A great deal of interest has been shown in the possible pathophysiology of these rela­
tionships.383,384,386,1061 Of particular interest is the evidence that upper-body fat is 
metabolically more active,383,395,1080,1081 and is more responsive to adrenergic ago­
nists which stimulate lipolysis.385 This may lead to an excess release of free fatty 
acids1080,1081 which interfere with insulin clearance by the liver.383,385,1082 At present 
the significance of these associations in respect to the aetiology of CHD and of 
atherosclerosis remains uncertain,386,1051 although a number of interesting hypotheses 
have been proposed.383,385,635
This study evaluates the relationship between measures of relative body weight and 
upper-body fatness, the major risk factors for CHD, blood glucose measures and the 
total plasma fatty acid content, in a young non-diabetic male population with angio- 
graphically proven CHD, and in an age and sex matched control group.
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A2.1.2 Methods
A2.1.2.1 Study groups. The patien t population consisted  o f the case-control 
groups described in Chapter 3.
A 2.1.2.2 Anthropometric measures. Body weight corrected for stature , termed 
the body mass index (B M I=w eight/height2), was used to estim ate overall body 
fa tness.1083,1084 The scapular and triceps skinfold thickness were used to give an 
approximation of fat distribution.410,1084
A number of measures of weight indexed to height have been developed to give an 
estim ation o f body fa t.1084' 1086 The BMI has becom e the m ost com m only used 
m easu re  o f fa tn e ss  and red u ces  e rro rs  a sso c ia te d  w ith  h e ig h t and w e ig h t 
tab les.1085,1087 However, the BMI does not take into account differences in body 
com position,1088 fat distribution383 or ethnic differences in heterogeneous popula­
tions.1087 Despite these limitations, good correlations have been reported between 
body fat and weight when corrected for stature in females1087,1089 and males.1087,1090 
In men the BMI appears to be the best easily obtainable anthropomorphic measure 
for estim ating percent body fat in epidem iological studies.1084 The BMI is a less 
reliable measure of body fat when applied to populations of different ethnic origins, 
d if fe re n t n u tr i tio n a l s ta tu s , and  d if fe re n t p h y s ica l a c tiv ity  and p h y s ica l 
fitness.1083,1084,1088 However, when employing the BMI for correlation with other 
indices for an individual, or for comparison between homogeneous groups, then 
comparison of the raw values can be made.1084 Since this study involves relatively 
homogeneous male groups, the BMI has been utilised as a suitable estimate of over­
all body fatness.1083,1084,1088
In adult males, scapular skinfold thickness gives the best correlation with percent 
body fa t.1084 There are clear limitations for the use of skinfold thickness measure­
ments to estimate total body fat and the scapular and triceps skin fold thickness are 
used primarily to give an approximation of subcutaneous fat distribution.1083,1084,1091 
Methodological limitations to the utilisation of skinfold thickness include variation in 
compressibility and fat content of subcutaneous tissues, and thickness of the skin,1092 
an increasingly weaker correlation of skinfold thickness and other measures of body 
fat with age,1093 accumulation of internal body fat and fat within muscle with aging, 
when subcutaneous fat is decreasing,1094 and the compressibility of fat increasing1095 
(although this potential problem maybe over-estim ated1096). Individuals with the 
same triceps skinfold thickness and different arm circum ference may differ as it 
takes more fat to cover a larger limb with a given thickness of subcutaneous fat.1095 
These potential problems can be limited by using an age and sex matched homoge­
neous study group with the measurement being performed by the one experienced 
observer.
A2.1.2.3 Glycosylated Hb. The method is described fully in Chapter 2.
A2.1.2.4 Plasma fatty acid analysis and lipoprotein measures. The methods are 
described in Appendix 1.
A2.1.2.5 Coronary angiography and CAD scoring. The methods are described in
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Chapter 7.
A2.1.2.6 Statistical analysis. The methods are described in Chapter 2.
A2.1.3 Results
A2.1.3.1 Group comparisons. In the two study groups, there were no significant 
differences in body weight, height, BMI, current BP or triceps skinfold thickness. 
There was a very significant difference in scapular skinfold thickness between the 
two groups (Table A2.1). Differences in the major risk factors for CHD have been 
detailed in Chapter 3. The fasting blood glucose and HbAlC levels differed between 
the two groups. The blood glucose was lower in the control group (4.9+/-0.08 vs 
5.3+/-0.10 mmoles/1, p=0.022) and the HbAlC was also lower in the control 
group (7.3+/-0.10 vs 7.8+/-0.2, p=0.031). The case group had a significantly 
greater percent of palmitic acid, and lower content of oleic, eicosenoic and docosa- 
pentaenoic acids in plasma than in the control group (see Appendix 1, Table A 1.2).
A2.1.3.2 Anthropometric measures and CHD risk factors. In the control group, 
body weight had a significant positive correlation with triglyceride (r=0.22), 
HbAlC (r=0.43) and blood glucose levels (r=0.39), and a negative correlation with 
HDL cholesterol (r=-0.30) and apoprotein A1 levels (r=-0.33). There was no 
association with current systolic or diastolic BP, total cholesterol or apoprotein B 
levels. BMI was positively associated with triglyceride (r=0.43), blood glucose 
(r=0.38) and HbAlC levels (r=0.41) and systolic BP (r=0.23), and negatively 
associated with HDL cholesterol (r=-0.26) and apoprotein A1 levels (r=-0.32). 
There was no relationship with total cholesterol and apoprotein B levels. Triceps 
skinfold thickness was not related to any of the risk factors evaluated. Scapular 
skinfold thickness had a borderline relationship with the triglyceride (r=0.27), HDL 
cholesterol (r=-0.26), apoprotein A1 (r=-0.39) and apoprotein B (r=0.36) levels.
In the case group, body weight was related directly to blood glucose levels 
(r=0.32). No consistent relationship between body weight or BMI, and blood lipo­
protein concentrations was present. There was a positive relationship between BMI 
and HbAlC levels (r=0.31) and blood glucose levels (r=0.45), and diastolic BP 
(r=0.24). Again, triceps skinfold thickness was unrelated to any variable. However, 
scapular skinfold thickness was directly related to diastolic BP (r=0.24), HbAlC 
(r=0.25) and blood glucose levels (r=0.45), and negatively related to the HDL 
cholesterol level in the group with CHD (r=-0.29).
In summary, in the control group, relationships between BMI, body weight and 
scapular skinfold thickness, and specific lipoproteins, measures of increased blood 
glucose levels and systolic BP were present. These findings demonstrate distinct 
differences between the case and control groups. In particular, a positive association 
between a measure of central obesity and measures of blood glucose levels was 
evident only in the case group. No relationship was found between the anthro- 
morphic measures and age, previous cigarette intake and alcohol intake.
A2.1.3.3 Anthropometric measures and plasma fatty acids. In the case group, 
body weight had a negative but borderline association with the percent of plasma
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myristic (r=-0.24), palmitic (r=-0.21) and arachidonic acids (r=-0.21). Scapular 
skinfold thickness was significantly and inversely related to the percent of plasma 
myristic (r=-0.35) and palmitic acids (r=-0.36). Oleic acid content was positively 
associated with body weight (r=0.35), BMI (r=0.27), scapular (r=0.47) and triceps 
skinfold thickness (r=0.36) only in the case group.
These relationships differed in the control group. The plasma content of myristic 
(r=-0.24) and palmitic acids (r=-0.26) were negatively associated with body 
weight. The percent of alpha-linolenic (r=0.24), dihomo-y-linolenic (r=0.42), 
arachidonic (r=0.44) and stearic acids (r=0.32) had a positive association with body 
weight. BMI correlated with the percent of plasma stearic (r=0.32), eicosadienoic 
(r=0.26), dihomo-y-linoleneic (r=0.53) and arachidonic acids (r=0.51). There was 
no consistent relationship with the skinfold thickness measures in the control group.
A2.1.3.4 Glucose measures and CHD risk factors. In the control group, the 
HbAlC level correlated positively with triglyceride (r=0.25) and apoprotein B 
levels (r=0.28), and inversely with the HDL cholesterol level (r=-0.25). The blood 
glucose level correlated positively only with the triglyceride level (r=0.25). In 
comparison, the blood glucose measures in the case group were unrelated to any 
lipoproteins. Since the possibility of a metabolic relationship between glucose 
metabolism and plasma fatty acid exists, the association between these factors and 
both blood glucose measures was evaluated. In the control group there was a posi­
tive association between percent dihomo-y-linolenic (r=0.24), arachidonic (r=0.34) 
and alpha-linolenic acids (r=0.27) and HbAlC level, and a negative association 
between percent plasma oleic acid (r=-0.29) and HbAlC levels. These associations 
were not observed in the case group.
A2.1.3.5 Multivariate analysis with HbAlC as the dependent variable. Using 
multivariate analysis, with HbAlC as the dependent variable and the associated 
plasma fatty acid, lipoproteins, blood glucose level and anthromorphic measures as 
the independent variables, HbAlC was predicted negatively by oleic acid and posi­
tively by alpha-linolenic acid values in the control group. In the case group only 
BMI retained a relationship with HbAlC levels (Table A2.2).
A2.1.3.6 Correlations with CAD Scores. The relationship between the extent and 
severity of CAD and plasma lipoproteins, the plasma fatty acid content and the 
anthropomorphic measures was evaluated initially by linear correlation. No relation­
ship existed in the case group between any of the coronary artery scores and BMI, 
body weight, height, triceps skinfold thickness or the blood glucose level. HbAlC 
levels had a weak but significant linear correlation with both the severity (stenosis 
score) and extent (atheromatous score) of CAD (Table A2.3). Scapular skinfold 
thickness correlated with the extent but not the severity of CAD (Table A2.3). In 
addition, CAD severity linearly correlated with age (r=0.25), and the extent of 
CAD correlated with age (r=0.27), cholesterol (r=0.23) and apoprotein B levels 
(r=0.39). The number of normal segments correlated negatively with age (r=- 
0.23), cholesterol (r=-0.33) and apoprotein B levels (r=-0.39). The percent of 
plasma myristic acid was positively associated with measures of both extent and 
severity of CAD, and negatively with the number of normal segments (Table A2.4). 
Oleic acid values correlated positively with the number of normal segments, and
349
aracidonic acid values correlated with the extent of CAD (Table A2.4).
A2.1.3.7 Multivariate analysis with coronary artery scores as the independent 
variables. In order to further evaluate these relationships, multivariate regression 
analysis was undertaken using the angiographic scores as dependent variables. Those 
plasma fatty acid with a linear relationship to one or more angiographic scores 
(myristic, oleic and arachidonic acids), as well as diastolic BP, HDL cholesterol and 
HbAlC levels and scapular skinfold thickness were entered as independent variables, 
in consideration of the possible interrelationships between CAD, hyperglycaemia, 
insulin resistance, central body fat and fatty acid. Myristic acid content of plasma 
and scapular skinfold thickness remained significantly related to the extent of CAD. 
Of the variables examined, only myristic acid content remained independently relat­
ed to the severity of CAD (Table A2.5). BMI and scapular skinfold thickness were 
entered separately and the variance for the extent of CAD was found to be contribut­
ed to by the percent of plasma myristic acid and scapular skinfold thickness (Table 
A2.5). The severity of CAD was predicted only by the percent of plasma myristic 
acid, while the number of normal segments of coronary arteries was predicted nega­
tively by the apoprotein B level and the percent of plasma myristic acid (Table 
A2.5).
A2.1.4 Discussion
The results of this study provide some unique observations not previously reported. 
An association between specific fatty acid, HbAlC values and scapular skinfold 
thickness was observed, but only in subjects with CHD, and not in a normal control 
group. The control group differed further, in that associations were found between 
HbAlC and blood lipoprotein levels and specific plasma fatty acid, which were not 
found in the group with premature CHD. Moreover, convincing relationships bet­
ween a measure of central body fat (scapular skinfold thickness), and a plasma fatty 
acid (myristic acid), with CAD have been defined. A major implication from these 
findings is that the relationship between central body obesity, CHD risk factors and 
abnormal glucose metabolism may be due to abnormalities of fatty acid metabolism 
in those individuals developing CHD.
A2.1.4.1 Central body obesity, CHD risk factors and CHD. Many of the find­
ings in this study are consistent with the current literature in which associations 
between central distribution of body fat and metabolic abnormalities are well de­
scribed.642,383,386 Body weight and BMI cannot be considered clinically significant 
risk factors for CHD in our study group. In contrast, increased central adiposity, as 
measured by scapular skinfold thickness, was found to be a measurable risk marker 
for CHD. The relationship with CHD is strengthened by the fact that an independent 
association between scapular skinfold thickness and the extent of angiographically 
defined CAD was maintained in multivariate analysis. These observations are sup­
ported by a recent angiographic case-control study which demonstrated an associa­
tion between android adipose tissue distribution in females and coronary atheroscler­
osis.1061 Males with excess deposition of fat in the abdominal region were also likely 
to experience increased risk of CHD.1061
In this study, associations between blood glucose measures and scapular skinfold
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thickness were found only in the case group. It needs to be emphasised that this 
association was present in non-diabetic subjects with a modest but nevertheless, 
significantly higher fasting blood glucose and HbAlC levels than the matched 
normal group.
The CHD group differed considerably from the control group in the relationships 
observed between scapular skinfold thickness and plasma lipoproteins. Increasing 
scapular skinfold thickness was associated with a decreased HDL cholesterol level, 
and increased triglyceride and apoprotein B levels in the control group. Apart from 
an association with the HDL cholesterol level, these associations were not observed 
in the CHD group.
The clustering of a relationship between diastolic BP, fasting blood glucose, HbAlC 
and HDL cholesterol levels and scapular skinfold thickness in the case group is con­
sistent with the current literature, and with prevailing concepts regarding regional 
body fat distribution and its relation to CHD.383,749,1051,1058,1059,1066,1069,1097 Moreo­
ver, the observations concerning fasting blood glucose and HbAlC levels and scapu­
lar skinfold thickness are also consistent with the known relationship between glu­
cose metabolism and regional fat distribution.1069
A2.1.4.2 Blood glucose, HbAlC concentrations and CHD in the non-diabetic.
The utilisation of HbAlC measurements to estimate medium term blood glucose 
levels has been well defined in individuals with diabetes mellitus and glucose intoler­
ance.366,1098 A similar graded relationship with blood glucose may occur in non­
diabetics. 1099 In a large non-diabetic adult population, HbAlC values were found to 
be normally distributed, were unrelated to age and correlated with fasting plasma 
glucose in both men and women, and with obesity in women.1100 In the same popula­
tion, after adjusting for age and obesity, HbAlC levels were significantly associated 
with plasma cholesterol, LDL cholesterol, total plasma triglyceride and VLDL 
cholesterol levels in men. 1100 In another study of a normal but heterogeneous male 
group, Hb glycosylation was found to be directly proportional to levels of total and 
LDL cholesterol, and indirectly to HDL cholesterol levels. 1099 Glycosylated Hb 
levels correlated significantly with fasting plasma glucose levels. 1099 Our observa­
tions are similar, in that, in our normal population group, HbAlC levels had a sig­
nificant positive relation with triglyceride and apoprotein B levels, and negative 
association with the HDL cholesterol level.
The results of this study point to a difference in glucose homeostasis in the two 
groups. Even though neither group included diabetics, the CHD group had signifi­
cantly higher blood glucose and HbAlC levels. Higher blood glucose levels, which 
are not at the level of diabetic hyperglycaemia, may be associated with CHD .1097 
This association is particularly strong after a glucose load . 1101,1102 However, the 
relationship between a casual blood glucose level and CHD in non-diabetic males is 
more controversial, with some studies supporting an association, 1103 while others do 
not. 1097 The association appears to be more consistent in women.1097
The negative relationship between HDL cholesterol and HbAlC levels observed in 
this study may relate to the fact that insulin resistance can reduce plasma clearance 
of triglycerides due to impaired activity of lipoprotein lipase, which may further
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increase VLDL levels and reduce HDL cholesterol levels.635 Therefore, a reduced 
HDL cholesterol could be associated with direct or indirect measures of insulin re­
sistance, as is observed in diabetics,1104 and as found in the normal control group in 
the present study and as reported by others.749
A2.1.4.3 Fatty acids and body fat distribution. The mechanisms of the metabolic 
and/or genetic relationships between the various risk factors associated with central 
body fatness, including insulin resistance, are at present only speculative.385 Howev­
er, it is possible that the relationships may be due to the mobilisation of specific fatty 
acid from abdominal fat.383,385 Portal adipose tissue is sensitive to mobilisation of 
free fatty acid due to a preponderance of beta-adrenergic receptors with little alpha- 
adrenergic inhibition.385 Therefore, abdominally obese individuals may have a 
higher portal free fatty acid concentration when mobilisation is stimulated by such 
factors as stress, anger, frustration and smoking.385 The increased lipolysis of portal 
adipose cells in men and post-menopausal women may contribute to abnormal hepat­
ic metabolism due to high portal free fatty acid concentration. Portal free fatty acids 
stimulate gluconeogenesis and inhibit the hepatic binding of insulin,385,1082 processes 
which are dependent on fatty acid oxidation.385 Both hyperinsulinaemia and in­
creased peripheral release of free fatty acid resulting from insulin resistance can 
increase hepatic synthesis and secretion of triglycerides, leading to increased levels 
of VLDL635 and an increase in the metabolic products of VLDL, including apopro­
tein B, LDL and remnant VLDL particles in peripheral blood.385,386 In addition, or 
alternatively, excess portal free fatty acid release may contribute to atherogenesis by 
influencing the fatty acid content of circulating lipoproteins and/or the generation of 
other powerful risk factors.385
Because of this potential mechanism, we examined the relationships between plasma 
fatty acid and the various risk factors associated with central body fatness. An asso­
ciation was demonstrated between three plasma fatty acids (myristic, palmitic and 
oleic acids) and measures of body fat. Other fatty acid (docosapentaenoic and oleic 
acids) were associated with HbAlC and fasting blood glucose levels respectively. In 
addition, given the difference in glucose homeostasis and/or protein glycosylation in 
males with premature CHD compared to normals, the relationship between fatty acid 
and measures of blood glucose was examined. Support for such an evaluation comes 
from an angiographic study of young males with CHD, using multivariate analysis, 
which established a direct association between angiographic severity of CAD and a 
positive oral glucose tolerance test, and levels of palmitic and arachidonic acids in 
adipose tissue and in blood triglycerides.1105 Although the measurement of fatty 
acids differed from this present study, the findings did implicate differences in body 
content of plasma fatty acid and abnormal carbohydrate homeostasis as significant 
risk factors in males with angiographically proven premature CHD.1105 In the same 
study no association was found between disease severity and triceps and abdominal 
skinfold thickness, while scapular skinfold thickness was not measured.1105
A2.1.4.4 Possible explanation of results. The absence of an association between 
HbAlC and blood glucose levels and diastolic BP with central body fat in the control 
group, and the presence of this association in the case group in the present study, 
supports the possibility of an aetiological relationship between altered glucose 
homeostasis, hypertension, central obesity, plasma fatty acid and abnormal lipopro-
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teins, and CHD.383,386,1051
The glycosylation process can affect alm ost all extracellu lar proteins including 
plasma lipoproteins.1099,1106'1108 Therefore any association between H bA lC  and risk 
factors for CHD, and CHD itself, may well be attributed to glycosylation of pro­
teins. The potential significance of the glycosylation of LDL is emphasised by the 
observation that glycated LDL shows an affinity for the apoprotein B receptor in 
human fibroblasts,1107 and that the catabolism of glycated LDL in guinea pigs is 
dim inished.136,1099 The possible interference to lipoprotein metabolism  is further 
highlighted by the decreased ability of glycated LDL to inhibit intracellular hydrox­
ymethyl glutaryl coenzyme A reductase activity.1107 and the fact that glycated LDL 
does not increase cholesteryl ester synthesis which normally occurs with endocytosis 
of LD L.1099 Furtherm ore, under experim ental conditions, glycated LDL is more 
prone to lipid peroxidation, which has emerged as an important factor in atherogene- 
sis.1109,1110
Another interpretation of the present results is that glycosylation of plasma proteins 
including LDL, may be influenced by differences in the composition and/or levels of 
plasm a fatty  acid. A lternatively, the concentrations and content of fatty acid in 
plasma may influence insulin effectiveness, increasing resistance to the action of 
insulin. The outcome of such metabolic events would be to prolong the presence of 
atherogenic LDL particles in the circulation. Therefore, the process of glycosylation 
of LDL may contribute to the increase in plasma LDL concentration, and as a result, 
the increased cholesterol levels observed in hyperglycemic diabetic and non-diabetic 
subjects. 1099The measurement of a glycosylated protein, namely H bAlC, may in fact 
only provide an indirect measure of glycosylated LDL, and hence an association 
between HbAlC and CHD.
A2.1.5 Summary
1. The distribution of subcutaneous fat, as measured by triceps and scapu­
lar skinfold thickness, appears to differ between young males with and without CHD 
who have the same overall body mass measurement. In addition, young non-diabetic 
males with CHD have increased measures of glycosylation of plasma proteins, viz 
HbAlC.
2. An association between betw een a m easure o f central obesity and 
measures of blood glucose and HDL cholesterol level are observed only in the group 
with CHD. In the same group, the glycosylation appears to be predicted more by the 
plasma content of C l 8 group of fatty acids.
3. The extent of angiographically defined CAD is better predicted by the 
scapular skinfold thickness and myristic acid than other risk factors for CHD which 
are associated with the measure of central body obesity.
4. The combination of abnormal glucose homeostasis, truncal obesity and 
lipoprotein abnorm alities im part significant risk for developing CHD. We have 
demonstrated that plasma fatty acid content may play a role in this relationship.
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5. The interactive relationships between glucose metabolism, fatty acid 
metabolism, body fat distribution and lipoprotein abnormalities iluustrates that a 
potential relationship with this group may exist with platelet function. The possible 
confounding influence of these relationships on the main results of the case-control 
study needs to be appropriately assessed in the final analysis.
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Table A2.1. Anthropometric characteristics of the case and control groups.
Controls Cases
BMI (kg/cm2 10-5) 257 +/-5 266 +/-5 NS
Triceps (cm) 11.7+/-0.8 12.5+/-0.7 NS
SSFT (cm) 13.8+/-0.7 17.1+/-0.9 p=0.006
Height (cm) 176.0+/-1.2 175.0+/-1.1 NS
Weight (kg) 80.0+/-1.7 80.8+/-1.5 NS
SSFT=scapular skinfold thickness, triceps=triceps skinfold thickness. Results shown 
are mean+/-standard error of the mean. NS=no significant difference.
Table A2.2. Multiple regression analysis with HbAlC as the dependent variable and 
plasma lipoproteins, fatty acids, and anthropometric measures as the independent 
variables.
Dependent
Variable
Independent
Variable B SEB Rsq Sig
HbAlC (Cases) BMI 0.1695 0.0720 0.1552 0.0254
HbAlC (Controls) C18:ln9
C18:3n6
-0.0105
0.0622
0.0041
0.0275
0.1817
0.3425
0.0185
0.0341
B=regression coefficient, Rsq=coefficient of determination. SE=standard error, sig=p 
value. See Table 9.3 for fatty acid abbreviations.
Table A2.3. Linear relationships between CAD scores and scapula skinfold thickness, 
HbAlC and fasting blood glucose levels in the case group.
Variable Scapular HbAlC BSL
CAS 0.38# 0.31# 0.15
CSS 0.15 0.27* 0.22
mCAS 0.38# 0.30* 0.13
mCSS 0.10 0.25* 0.19
Normseg -0.12 -0.04 -0.01
*=P<0.05, #=P<0.01,
Normseg=number of normal segments, CAS=coronary atheromatous score, 
mCAS=mean CAS, CSS=coronary stenosis score, mCSS=mean CSS, BSL=blood 
glucose level, scapular=scapular skinfold thickness, HbAlC=glycosylated Hb.
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Table A2.4. Linear correlations between CAD scores and plasma 
fatty acids.
Variable 0 4 :0 C18:ln9 C20:4n6
Normal -0.35# 0.30* 0.05
CAS 0.32# -0.13 -0.24*
mCAS 0.33# -0.14 -0.23*
CSS 0.34# -0.13 -0.18
mCSS 0.36# -0.16 -0.17
##P<0.001, #=P<0.01, *P<0.05..1sl 
See Tables 9.3 & 9.5 for abbreviations.
Table A2.5. Multiple regression analysis with CAD scores as the dependent variable 
and fatty acids and CHD risk factors linearly related to angiographic scores, including 
HbAlC and HDL cholesterol levels, diastolic BP and scapular skinfold thickness, as 
independent variables.
Dependent
Variable
Independent
Variable B SEB Rsq Sig
CAS Scapula 0.08808 0.02860 0.1382 0.0043
0 4 :0 0.03054 0.01201 0.2868 0.0162
mCAS Scapula 0.07098 0.02343 0.1385 0.0049
0 4 :0 0.02384 0.00984 0.2756 0.0215
CSS 0 4 :0 0.04366 0.02043 0.1249 0.0403
mCSS 0 4 :0 0.03854 0.01762 0.1300 0.0362
NORM Apo B -0.0939 0.0263 0.1959 0.0014
0 4 :0 -0.0090 0.0033 0.3316 0.0104
See Tables A2.2, A2.3 and A2.4 for abbreviations
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APPENDIX 3
BEHAVIOURAL PSYCHOLOGICAL RISK FACTORS 
IN CORONARY HEART DISEASE
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A3.1 BEHAVIOURAL AND PSYCHOLOGICAL ATTRIBUTES AS RISK 
FACTORS FOR CORONARY HEART DISEASE
A3.1.1 Introduction
A diverse variety of behavioural and psychosocial variables that may characterise 
individuals prone to cardiovascular disease have been identified. These include the 
type A behavioural pattern ,1111' 1114 life dissatisfaction,1115 depression,1115,1116 self 
a b a s e m e n t,1115 a n g e r ,1112,1117 p e rc e iv e d  ch ro n ic  life  s t ru g g le ,1122 s ta tu s
incongruity,1115 self involvement,1121,1122 inadequate social network,1123 and hostili- 
ty in 8-ii2o an(j t^e j-st on.1115
There are pathophysiological models which provide a potential biological basis for 
the increased risk associated with behavioural and psychosocial variables,376,1124'1128 
An example relevant to this Thesis is an enhanced neuroendocrine system resulting 
in an excessive excretion o f adrenaline in response to external/internal stimuli in 
type A cynical individuals.1125 The potential for physiological levels of adrenaline to 
affect platelet function has been demonstrated.71,72 Therefore, possible confounding 
factors responsible for indirectly producing the observed difference in platelet func­
tion may be differences in behavioural factors which influence neuroendocrine 
responses. This section, therefore, considers some o f the m ajor postu lated  be­
havioural and psychological characteristics in the study groups, firstly to determine 
if differences exist and secondly to determine if there is any relationship with angio­
graphic CAD.
A3.1.2 Type A Behaviour and CHD
Type A behaviour is a global constant which is applied to individuals who possess 
many of the defining characteristics, although not necessarily all.1129 Retrospective 
and prospective epidem iological research has linked the global type A behaviour 
pattern with clinical manifestations of CAD, including initial incidence and recur­
rence of M I.203,1115 A structured interview (SI) method, separating persons with 
either a type A or type B behaviour pattern, appeared to predict the development of 
CHD independent of the known CHD risk factors.203 Similar findings were reported 
from a sub-group of the Framingham study.1130 Indeed, the association of CHD with 
type A behaviour appeared to occur also in women when using the specific method 
of assessment chosen by the investigators in the Framingham Study.1130 An addition­
al form of differentiating type A and B behaviour patterns, the Jenkins Activity 
Survey (JAS) was also found to predict CHD events (angina pectoris and Q-wave 
infarctions combined).1131 Variation in the rates of progression of CAD for individu­
als with type A behaviour, com pared with type B behaviours, suggests that be­
havioural factors may play a role post priori in the development of CAD.1132
Overall, current evidence does not support the theory that type A behaviour contrib­
utes directly to atherosclerosis lesion formation.985 More recent studies have failed to 
corroborate the initial observations of an association between type A behaviour and 
CHD. The studies include those from the general population,1133' 1136 persons with 
established CHD,1137' 1139 and angiographic studies.1121,1140 A number of possibilities 
may explain these divergent results, including variation in sampling and measure-
358
ment, differences in the population groups, qualitative changes in the nature of the 
type A behaviour over tim e, and the publicity  given to the concept. One o f the 
potential explanations most explored has been that type A behaviour, as measured by 
current methods, may simply be a diluted marker for other behavioural characteris­
tics that carry the risk for CHD.1141
The type A classification is based on a preponderance of type A characteristics 
which were initially determined by the structured interview method developed by 
Friedman and Rosenman.1142,1143 A factor analysis of the variables specified in the 
structured interview identified more specific components of the type A behaviour 
pa ttern  that appeared to d iscrim inate  betw een cases of CHD and c o n tro ls .1143 
"Competitive drive" and "impatience" were the most discrim inating components. 
The elem ents of com petitive drive that distinguished the groups were "explosive 
v o ice  m o d u la tio n " , "p o te n tia l fo r h o s tili ty "  and "v ig o u ro u s  an sw ers  to 
questions".1143 Self-reports of anger were also discrim inatory. This analysis thus 
provided evidence for a possible association between CHD and anger-hostility as the 
component of type A behaviour engendering the CHD risk. In fact, four of the seven 
significant components were directly related to anger, and the other three could be 
m otivated by anger. Alternatively, of the benign and coronary prone facets of the 
type A behaviour pattern, hostility may best exemplify the latter.1144
A3.1.3 Hostility and CHD
Delineation of a type A personality by the JAS and/or SI method is reported to be 
predictive of future CHD.203,1131,1145 As discussed, the main components of the type 
A p e rso n a lity  p ro f ile  p re d ic tiv e  o f CHD m ay be m easu res  o f a n g e r and 
hostility .1146,1147 Indeed, independent m easures of hostility  also have predictive 
capabilities for the development of CHD in prospective studies,1118,1124,1147 support­
ing the concept that the hostile and cynical type A individuals are the "at risk" group 
within the coronary prone behaviour profile.1125
An hostility complex, com prising interrelated hostility and anger constructs and 
proposed  as the pathogenic com ponent of the type A beh av io u r,1143 has been 
refined.378 The anger-hostility dimension is the dominant characteristic among the 
coronary-prone type A behaviours.1128 The relationship of the type A anger dimen­
sion to the incidence of CHD is also present in the Framingham Study.1130
The hostility-anger items and scales of the psychometric measures used to assess 
Type A b eh av io u r w hich  have been  fo und  to d isc r im in a te  ty p e  A/B 
behaviours,1128,1148 also correlate with enhanced cardiovascular responsiveness of 
type A subjects.1127 Hostility, accompanied by self-reported low anxiety, may be 
linked to specific clinical syndromes of coronary disease.1149 Angiographic studies 
have also show a correlation between hostility/anger constructs and the severity of 
angiographically defined CAD.1147,1150
In summary, there appears to be reasonable evidence that the anger/hostility, and 
therefore this dimension of the type A behaviour, may confer an increased risk for 
CHD.377,1128 The evidence, however, still remains controversial and has not been 
fully validated.1128,1141
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A3.1.3.1 What Measure of Hostility Indicates the Risk for CHD?. The Minneso­
ta Multiphase Personality Inventory (MMPI) hostility score (Ho score) has gained 
considerable support as a risk factor for CHD.1118,1147,1151 Corroboration of the 
potential relationship between CHD and hostility is provided by a similar relation­
ship being demonstrated with other measures of hostility.1152,1153 Another study only 
reports an association in groups who already have CHD or hypertension, and not in 
healthy population groups.1120 Of additional interest is that the MMPI Ho score may 
be associated with factors having broad effects on overall survival as well as the 
development of CHD.1118
Nevertheless, any relationship between CHD and the various hostility measures 
remains tentative. A number of more recent studies report conflicting results, both 
for measures using the MMPI Ho score1154' 1156 or alternative measures of 
hostility.1144 Refinement of a measure of hostility has shown that a hostility measure 
which correlates with indices of neuroticism, as compared to a hostility measure 
unrelated to neurotic tendencies, is inversely related to CHD.1119 The overall hostili­
ty score used in the study was unrelated to CHD.1119
A3.1.3.2 Hostility and CAD Defined Angiographically. Gender, the MMPI Ho 
score of the MMPI and the behavioural type classification (A or B) are the strongest 
independent predictors of the degree of coronary atherosclerosis in an early angio­
graphic study.1147 The MMPI items measuring chronic hate and anger are the most 
significant discriminators.1147. More recently the potential for hostility was shown to 
be associated with severity of atherosclerosis for patients who suppress anger.1152,1153
Diverse factors may be pertinent to the association between CAD and behavioural 
factors, and anger, hostility and aggression are prominent in this regard. Unques­
tionably, evidence of an association between an anger and/or hostility construct and 
CAD has been increasing.1157 Nevertheless, further evaluation is required to deline­
ate the association, if any, as it is apparent that a distinction between the intensity of 
the experience of anger, the anger as a personality trait, how anger is expressed, and 
how frequently it is experienced may be necessary1129,1152,1153,1157 Moreover, the 
association with hostility may be through other factors which are measured in the 
constructs used to assess hostility.1119,1158 The psychological trait of cynicism1158 or 
the specific feature of non-neurotic hostility1119 may be more closely related to 
CAD.
A3.1.4 Potential Mechanisms of Behavioural Factors in CAD
Acute autonomic nervous system changes and neuroendocrine effects376 may provide 
a link between behavioural and psychosocial attributes and the development of 
CAD376 It is hypothesized that recurrent episodes of acute "psychophysiologic" 
reactivity may promote atherogenesis, either through the haemodynamic disturbances 
related to acute rises in heart rate and BP (increasing turbulence and sheer stress 
resulting in increased risk of plaque fissuring) and/or due to increased release of 
certain neuroendocrine hormones.376
Individuals vary greatly in the magnitude of their physiologic response to behaviour­
al stimuli, but any associations with the pathogenesis of CHD remain in the realm of
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research.1126 Type A individuals often exhibit more pronounced cardiovascular and 
neuroendocrine responses (eg. the enhanced release of catecholamines) than Type B 
individuals when challenged by frustrating laborious tasks or other behavioural 
stimuli.1111,1127,1128 Patients with CHD may exhibit greater pressor reactions to 
behavioural stressors than non CHD patients or controls.1159 Aggressive and hostile 
individuals appear to secrete more noradrenaline compared to more passive or 
anxious subjects.1142 Type A subjects exhibit greater muscle vasodilation and in­
creases in noradrenaline, adrenaline and cortisol during mental work, and a greater 
increase in testosterone during reaction time performance compared to type B sub­
jects.1127 Male type A subjects generally respond to overstimulation with a higher 
adrenaline response.1128 Resting levels do not appear to differentiate between type A 
and type B subjects, or persons with CHD.1124
Such changes in the neuroendocrine system may indeed promote atherogenesis by a 
number of possible avenues. For example, haemodynamic disturbance secondary to 
an increase in heart rate and/or an increase in BP may lead to greater turbulence and 
sheer stress on the arterial wall, factors which probably play a role in the pathogene­
sis of CAD.42,1160,1161 Furthermore, the increased release of hormones, such as 
adrenaline, and the effect of these catecholamines on platelet aggregation provide a 
potential pathophysiological mechanism in the atherogenic process71,72 Observations 
such as these provide a stimulus for further research.
A3.1.5 Methodological Limitations in Published Studies
It is clear from the above discussion that not only are the associations between CAD 
and behavioural or psychosocial characteristics of uncertain significance, but also 
that the measures utilised to evaluate the possible relationships have major limita­
tions. In this regard, specific caveats need to be mentioned regarding the methods 
used elsewhere in this study.
(i) Generality and cross-cultural validity of type A measures: Both the SI 
and JAS have been used in studies in many countries and have been found to be pre­
dictive of angina. The information at present is insufficient for women, rural popula­
tions, changes associated with aging and for non-industrialized societies.1124
(ii) Limitations inherent in the type o f instrument: Personality inventories 
are dependent on self-insight, candid-response, response bias, the exclusively 
verbal/symbolic and abstract level of description and the absence of a varied situa­
tional context. Since the JAS was developed as an alternative to the SI, the SI is a 
more valid instrument for the measurements defining type A behaviour, albeit more 
costly and more difficult to implement.1124
(iii) Limited utility o f the structured interview:1124 The SI is allegedly a 
more powerful predictor of CHD incidence than the JAS in a population consisting 
of equal percentages of type A and type B persons.1132 However in the SI, with 
samples having a high percentage of type A personalities, global interview assess­
ments may lose their predictive power due to limited variability in the measurement. 
Furthermore, in a sample of patients with manifest CHD, stylistic behaviour may be 
altered by medications and also from the psychosocial effects resulting from the
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publicity regarding type A behaviour. Finally, subjects may consciously or uncon­
sciously temper stylistic mannerisms in artificial, or what they see as contrived 
circumstances.
(iv) Dilution effect of risk estimation by the presence ofCHD : A potential 
problem for identifying behavioural and psychosocial risk factors with regard to the 
effect on outcome, is the influence of the underlying disease itself on prognosis.319 
This potential confounding factor has been proposed as a cause of previous difficul­
ties in establishing increased cholesterol as an important prognostic predictor in 
patients with established CHD.319 Therefore, some risk factors may be good predic­
tors of disease in non-CHD populations, but a poor predictor in populations with 
established disease, the disease itself mainly determining the frequency of future 
cardiac related events. As previously discussed, studies exist showing that type A is 
predictive for the development of CHD.203,1130,1143 In groups with CHD, these 
measures have not been consistently discriminative, and therefore reliability has been 
questioned, as well as their validity.
The nature, and even possibly the existence, of any relationship between behavioural 
factors and CAD is at present a matter of scientific enquiry rather than an estab­
lished body of evidence establishing a direct or causal association.
A3.1.6 Methods
A3.1.6.1 Introduction. Research findings based on interviews are not uniformly 
successful due to bias arising from subjective interpretations.1162 More objective 
methods of encoding and quantifying information are by self report scales, and self 
report behavioural rating scales.1162 Although bias due to "halo effects", and lenien­
cy and proximity errors are difficult to control for in the latter methods, the inter­
view method is highly dependent on the skills, training and experience of the inter­
viewer, and the responsiveness of the subject.1157 With due regard for the limitations 
of both methodologies, self report rating scales were selected as most appropriate for 
the present study and are detailed below.
A3.1.6.2 Measurement of Type A Behaviour Pattern. The initial method of 
measuring the type A behaviour pattern was by the SI, as defined by Rosenman and 
Friedman.1142,1163 The SI measures the style and manner of delivery of the informa­
tion during an interview by means of numerically graded characteristics. Another 
method, the JAS, measures the content of type A characteristics from a self-adminis­
tered questionnaire, and a graded risk is then assigned.1145,1164 The Framingham type 
A scale also measures the content of type A characteristics from a self-administered 
questionnaire.1130,1165,1166 Each method appears to measure some factor, or factors, 
unique to its own design, with a significant element of overlap.1164,1167,1168 The 
Western Collaborative Group Study provides evidence of a "dose-response" curve 
for the JAS,1164,1167 whereas the SI and the Framingham type A scale did not attempt 
to show such a graded response relationship.1130 However, the SI and the JAS type 
A patterns are not identical, having an agreement of about 68% overall.1164,1167 The 
common aspects of these methods have been delineated as self-reported pressure 
drive, hostility, competitiveness and energy level.1143
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A3.1.6.3 Jenkins Activity Survey. This self report questionnaire has previously 
been shown to validly identify males having the Type A behaviour pattern with over 
72% accuracy.1145 However, self report measures of the global Type A have consist­
ently been found to be more weakly related to CHD endpoints than the Si-based 
assessment.377 With this in mind, and in view of the emergence of a hostility/anger 
complex as the possible "toxic" component of Type A,378 it is important to under­
stand what is being measured by the JAS. Self report measures of the Type A be­
haviour pattern assess only parts of the overall behaviour pattern, and this varies 
from one instrument to another.1169 Independent factor analysis on the JAS items 
shows that it is measuring 3 major and conceptually independent behavioral syn­
dromes which are stable over time, viz: (i) hard driving, (ii) job involvement, and 
(iii) speed and impatience.1170 None of these however, directly assess hostility. This 
method therefore provides a measure of the global Type A behaviour pattern, which 
does not have a strong independent hostility component. Furthermore, the training 
requirements for individuals conducting the SI are appropriately strict and inexperi­
ence leads to invalid interpretation.1169 For these reasons the JAS was selected for 
measurement of the global Type A pattern, with cognizance of the limitations asso­
ciated with the method.
A3.1.6.4 Hostility. The hostility scale (Ho score) from the MMPI has previously 
been validated.1171 However, there is the probability that this self-report question­
naire measures a general mistrust of human nature, or cynicism,1172*1173 rather than 
true hostility. However, importantly, the construct(s) that are being measured by this 
scale are remarkably stable over time.1151 This reproducibility over time enhances 
the usefulness of the method for epidemiological and investigational purposes, even 
though the exact construct being measured may need redefining in future.
Numerous alternative measures of hostility do exist, such as the Buss-Durkee Hostil­
ity Inventory (BDHI).1157 However, for this latter measure, factor analyses do not 
provide empirical support for the validity of the BDHI sub-scales as measures of the 
types of hostility originally proposed by the investigators.1157
A3.1.6.5 Anger. A Multidimensional Anger Inventory (MAI) has been previously 
validated for use in "Westernised" populations.1117 This inventory provides a multi­
dimensional assessment of anger, which includes a subset measure of hostility and 
suppressed anger.1117 The MAI was constructed to contain items measuring specific 
dimensions of anger, namely the frequency, duration, magnitude, the presence of a 
hostile outlook, the range of anger producing situations and the mode of 
expression.1117 Specific items of the MAI were used to measure the hostile outlook 
(MAI hostility score) and suppressed anger (anger-in) for this study, as well as the 
overall score (MAI score).
A3.1.6.6 Study groups evaluated. Three study groups were evaluated. The older 
CHD group is described in section 7.2, and the younger CHD group and the young 
control group are described in Chapter 3. The older and younger groups were con­
sidered together because o f the strong potential to develop psychological and be­
havioural symptoms after a longer period o f having the knowledge o f CHD. For 
example, older patients usually have more symptoms because of more severe dis­
ease, and therefore changes in behavioural measures may occur because of these
363
symptoms resulting in a systematic measurement bias.
A3.1.7 Results
A3.1.7.1 Comparisons between study groups. With regard to
the behavioural measures, there were no significant differences between the older 
and younger CHD groups except for the MMPI Ho measurement. The young normal 
control group had a significantly lower MMPI Ho score than either of the two CHD 
groups (Table A3.1). No other score was different between the control and the two 
CHD groups, although there was a lower JAS in the young normal control group, 
but this did not attain statistical significance with this study sample (Table A3.1).
A3.1.7.2 Correlations with the psychological measures. There
was no relationship between the NYHA classification for functional class of angina 
or the number of MI with any of the psychological measures for the young CHD 
group (mean age 44.6 years). The MMPI Ho score positively correlated with the 
volume of the previous cigarette consumption, alcohol intake, diastolic BP, BMI, 
and cholesterol and HbAlC levels (Table A3.2). There were only sporadic associa­
tions between the other psychological measures and risk factors for CHD (Table 
A3.2). The MMPI Ho score also correlated with the angiographic severity score and 
was of borderline significance in its relation with the coronary atheromatous score 
(Table A3.3). The MMPI Ho score also had an inverse association with the number 
of normal segments (Table A3.3). Predictably, there was a strong association bet­
ween the MMPI Ho score and the MAI hostility score, less so with the MAI score 
and the MAI anger-in score, and the least association with the JAS (Table A3.4).
In the older CHD group with a broad age range (mean 53.2 years), the MMPI Ho 
score correlated (p<0.05) with age and NYHA functional class for angina, associa­
tions which were not significant for the younger group. The associations between the 
risk factors for CHD and hostility were not as many or as strong in the older group 
when compared with the younger CHD group, and only included the BMI and the 
cholesterol level (Table A3.5).
There were no associations of significance between any of the risk factors and the 
psychological measures in the control group without CHD.
More strongly positive and more consistent univariate correlations were observed 
with angiographically defined CAD in the older CHD group than in the younger 
group. The MMPI Ho for score correlated with the number of vessels having 
haemodynamically significant lesions, with the severity of CAD, with the extent of 
CAD and inversely with the number of normal segments (Table A3.6). The stron­
gest correlation was obtained with the severity of CAD, as it was in the young CHD 
group.
Similar to the young CHD group, there was a strong association between the MMPI 
Ho score and the MAI hostility score and the MAI, and the least association with the 
MAI anger-in score and the JAS (Table A3.7). Similar strong associations were ob­
served between these scores in the young control group without CHD (Table A3.8)
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A3.1.7.3 Multivariate regression analysis. In the young CHD group, multivariate 
analysis with coronary artery scores as the dependent variables, and param eters 
having a linear association (Ho, PACKYR, BMI, DBP, CHOL, ETOH and H bA lC) 
as the independent variables, demonstrated no independent association for the MMPI 
Ho score. Similarly in the older CHD group, the MMPI Ho score did not maintain 
an independent predictive relationship with any of the m easures of the coronary 
artery scores. Thus, the predictive utility of the MMPI Ho score was not sustained in 
multivariate analysis in this study.
A 3.1.8 Discussion
Conclusively dem onstrating a consistent, much less causal relationship between 
psychosocial variables, behaviourial factors and CHD has proved to be very diffi­
cult. A meta-analysis of specific variables has indicated a small but reliable associa­
tion between Type A behaviour, depression, anger, hostility, aggression and anxiety, 
and CHD.1115 Nevertheless, a great deal of concern exists about the validity of a 
num ber o f these factors, including hostility (as defined by the MMPI Ho score) 
being risk factors for CHD.1141,1154,1156,1174 Unfortunately, the available methods to 
assess hostility are influenced by the individual’s test-taking attitude, which can bias 
the MMPI profiles.1175 Also, there is serious concern about what can be expected in 
normal subjects using the MMPI Ho score.1175 Furtherm ore, the exact nature of 
what the MMPI Ho score is measuring probably needs further refinement.1158
N evertheless, there is still highly suggestive data to im plicate hostility  as a risk 
factor for CHD, and it is clear that further information about the relationship bet­
ween CHD, hostility and other psychosocial variables is necessary. In this regard, in 
the present study the differences in the measures of hostility in young males with and 
without CHD, the relationship of the MMPI Ho score to angiographically defined 
CAD, the evaluation of alternative measures of hostility and anger, and the interac­
tion of the hostility measures with other risk factor for CHD add further unique 
knowledge for consideration.
A3.1.8.1 Type A Behaviour. The results are consistent with the current body of 
literature indicating that the type A behaviour, measured as a global construct, may 
not be a good predictor of CHD, and in fact may not be a risk factor for CHD at all. 
S im ila r  n eg a tiv e  f in d in g s  w ere o b se rv ed  in the m a jo rity  o f an g io g rap h ic  
studies,209,985,1112 whether using the SI, the JAS or the Bortner scale.985 However, 
the results do need to be interpreted cautiously because the JAS is an inferior meas­
ure of type A behaviour compared to the SI.377 The JAS was chosen because of the 
inherent problems associated with the SI, in particular concern regarding the validity 
of results obtained by less experienced interviewers.1169
A3.1.8.2 Anger. Progress in the understanding of the role of anger in the aetiology 
of CHD requires conceptual clarification of the components of the attitudes within 
what is called anger, and the construction of objective, reliable and valid measures 
of these components.132 However, the purpose of using the measures of anger (MAI) 
and an alternative assessment of hostility (MAI Ho score) in this study was not to 
undertake a comparison or factorial analysis of the MMPI Ho score and anger, but 
to evaluate their comparative relationship to CHD and risk factors for CHD in well
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defined study groups. Furthermore, it is imperative to determine if alternative 
measures of hostility can substantiate the association previously documented between 
the MMPI Ho score and CHD.
Anger and aggression have long been regarded as important factors in CHD. These 
personal characteristics may also be confounding factors in the relationship between 
hostility and CHD. In addition, since the MMPI Ho score may not be measuring 
hostility per se. but other attitudes, behaviours and/or traits, such as cynicism and 
mistrust,1158 the need to validate hostility as a risk factor for CHD is essential. If 
such a relationship is confirmed, attention may then be directed to develop methods 
of intervention. Moreover, when using multiple comparisons to assess relationships 
between variables, the validity of a significant association is enhanced by demon­
strating reproducible unique correlations.
The results demonstrate a clear lack of correlation between CHD and anger, as 
measured by the MAI, as well as suppressed anger measured by this inventory. 
Equally important, the construct in the MAI measuring "hostile-outlook" also had no 
consistent relation to CHD and did not differentiate between cases and controls 
without CHD.
A general measurement of anger, suppressed anger or a hostile-outlook component 
of a general anger construct are not associated with CHD. The methods used in this 
study, however, did not apply a state-trait distinction for anger or hostility. Although 
the MMPI Ho score does have adequate stability over time as reflected in a high 
(r=0.86) test-retest correlation,1157,1171 uncertainty exists as to whether the MMPI 
Ho score reflects a persisting psychological trait in an individual or whether it is in­
fluenced significantly by circumstances at the time of the measurement and which do 
not necessarily reflect a long-term characteristic. Nevertheless, research on hostility 
(and anger) needs to further clarify whether such constructs refer to transitory emo­
tional states and/or relatively stable individual differences in personality traits.1157
A3.1.8.3 Hostility. The consistent association in this study between the MMPI Ho 
score and angiographically defined CAD, in particular, the severity of CAD, sup­
ports the findings of previous studies in different population groups using different 
methods of assessing hostility.1152,1153 The association with severity also supports 
those prospective studies dem onstrating an association with acute cardiac 
events,1118,1147,1151 events which are often related to the severity of the underlying 
CAD. Moreover, in persons with established CHD, extreme hostility appears to 
impair the survival of patients with CHD.1120 Such an observation is consistent with 
an association, whether causal or secondary, between hostility and severity of CAD 
defined angiographically. The relationship of the MMPI Ho score to CAD or CHD 
is, however, controversial,1141 and the results from this study differ from some 
published observations.1141,1154,1156,1174 Others have found that the relationship is 
only present in subgroups, such as hypertensive men.1120
Unfortunately many factors exist which can confound results of studies utilising 
angiographic methods to assess the significance of risk factors for CHD.985 The cho­
lesterol level has been the one consistent risk factor to be associated with angio­
graphically defined CAD in a number of studies, and the presence of a similar rela-
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tionship can be considered supportive of the validity of the angiographic measures 
used.985 In one study with differing results to the present study, the cholesterol level 
and age of the study group were not related to CAD in one study1123 and not evaluat­
ed in the other,1141 contrary to the current study. This lack of association places in 
doubt the validity of the CAD scoring methods used in the two reports. In one study, 
patients who had had a myocardial infarct more than 6 months before the study were 
excluded.1123 This could result in a selection bias, by reducing the number of pa­
tients with more severe disease. Indeed, the fact that the mean occlusion score was 
skewed to the right would support such an interpretation.
Our findings demonstrated the strongest association between the MMPI Ho score 
and disease severity. An important fact in a previous study1123 is that the question­
naire was designed to obtain information on risk behaviour prior to the onset of 
symptoms. In the present study there was an association between the MMPI Ho 
score and the NYHA functional class for angina in the older age CHD group. There­
fore, our study may be biased by the potential of symptoms to cause increased hostil­
ity in the group, with the more severe the disease the more the symptoms. Although 
prospective studies could overcome such a bias, those to date have been conflicting, 
some supporting an association between hostility and CHD,1118,1147,1151 and others
n o t  1144,1154-1156
In the present study, there was no association between the MAI hostility score, 
which gives a measure of hostile-outlook, that is, a state rather than a trait measure­
ment, and CHD or functional capacity. Furthermore, measures of extreme hostility 
do not appear to be a consequence of symptom severity.1120
A3.1.8.4 Risk factors for CHD and Hostility. Using a different measure of hostil­
ity, hypertension, heavy smoking and heavy use of alcohol have been documented to 
be associated with extreme hostility, but not with obesity.1120 In our study, there was 
an association in the younger, but not in the older aged CHD group, between hostili­
ty and both alcohol intake and previous smoking. The potential for an interaction 
between environmentally related risk factors and behavioural characteristics is not 
surprising. Such a relationship provides a source for the link between differing be­
havioural characteristics and CHD. Although, in the analysis by multiple regression, 
the MMPI Ho score was not independently predictive of CAD and therefore may not 
be a casual risk factor for CHD, this may equally indicate that the measure simply 
has a lower order of risk compared to the traditional major risk factors, particularly 
smoking, hypertension and cholesterol levels.
A3.1.8.4 Limitations of an angiographic study. The methods of assessing coro­
nary angiograms vary greatly, and differences in results between studies may clearly 
relate to such methodological differences.985 To attempt to limit this problem multi­
ple scoring methods were used and the results were reasonably consistent. Bias can 
arise from the selection of subjects, particularly if there is little variation in the 
measure applied. In this study, CHD cases were compared to a normal control 
group. Furthermore, the patients evaluated did have a demonstrable relationship with 
other stronger and more accepted risk factors, in particular the cholesterol level. The 
validity of a negative finding is thus supported by the relationship.
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A type II statistical error may very well have lead to any negative findings, missing 
a weak relationship because of an inadequate sample size. However, predictable 
differences and associations of the classic risk factors were able to be detected. That 
is, clinically meaningful and established differences and associations were deter­
mined from the sample number used in the study. Weaker and less clinically relevant 
relationships may have been missed in this study. Even though a predictive relation­
ship between the CAD score and other major risk factors can be demonstrated, 
indicating that any potential relationship between CAD and a measure of hostility is 
less predictive than those other variables entered into the regression analysis, the 
results do not entirely exclude a weaker relationship.
There may be an effect of medications on the psychosocial and behavioural meas­
ures, especially beta-blockers. However, this may only be relevant for the SI and not 
for an administered self-report questionnaire such as the JAS.985
Anatomic CAD may not be the right end point for the expression of some CHD risk 
factors,985 as there is a high probability that there are risk factors for various stages 
in the development of the disease.202
The results of this study support the need for ongoing research into the relationships 
between psychosocial and behavioural factors, and CHD. Further information is also 
required about the interrelations of the different psychological, psychosocial, be­
havioural and personality predictors of CHD.1115
An important outcome of research on the psychological predictors of heart disease in 
more recent times, has been to dispel the image of the coronary-prone individual as 
being a hurried, impatient workaholic.1115 Indeed, contemporary information would 
indicate that the "coronary prone" individuals are more likely to be those with one or 
more negative emotions.1115
A3.1.9 Summary
1. In the two groups of CHD patients evaluated in this study, a reproduc­
ible univariate correlation between the MMPI Ho score and CAD has been shown.
2. The relationship is not sufficiently strong, in comparison to other risk 
factors or because of an association with the CHD risk factors, to remain indepen­
dently predictive of CAD following multivariate analysis.
3. In the case-control study, at least one standard behavioural measure (the 
MMPI Ho score) may be an independent CHD risk factor which was not controlled 
for in the case-control study design. This measure was potentially a confounding 
factor in the assessment of platelet function as a risk factor.
A3.2 HOSTILITY AND PLATELET FUNCTION IN PATIENTS
WITH CORONARY HEART DISEASE
A3.2.1 Introduction
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There exists evidence which is suggestive that mental stress may increase in vivo and 
in vitro platelet reactivity.1174,1176 Indeed, stress and other sympathoadrenal activa­
tion seems to activate or sensitise platelets as measured by a number of different 
methods.1176 An understanding of the biological health consequences of hostility, or 
other similar characteristics, is presently undeveloped.378 Excessive cognitively 
mediated neuroendocrine and cardiovascular responses, and an inadequate parasym­
pathetic antagonism of sympathomimetically mediated responses occur in hostile 
type A persons.378 Although large elevations of plasma adrenaline produced by infu­
sions or hypoglycaemia enhance in vivo platelet function, the effects of any changes 
associated with psychosocial conditions potentially producing increased neuroendo­
crine responses is unclear.1176 Indeed, even though the biological mechanism(s), if 
any, responsible for the adverse health consequences of the hostile trait, state or 
hostility complex is not established.376,378 Nevertheless, one plausible mechanism 
relates to the potential influence of altered platelet function.376
In light of the group differences in the MMPI Ho score between the young control 
group and the young CHD group, and the relationship of the MMPI Ho score with 
angiographically defined CAD, this section evaluated the relationship between meas­
ures of hostility and platelet function.
A3.2.2 Methods
The methods and patient population are described in section A3.1.
A3.2.3 Results
The control group did not have a significant relationship between any measure of 
platelet function and the psychological scores apart from the MMPI Ho score with 
LT50ADR (r=-0.380, p=0.033), anger-in (MAI) with LT50ADP (r=- 
0.351,p=0.01), the JAS with RCOL (r=-0.305, p=0.014), the hostility score of the 
MAI with LT50ADP (r=-0.340, p=0.012) and the MAI with LT50ADP (r=- 
0.341, p=0.030). These measures did not have other significant associations.
The young CHD group had correlations between the MMPI Ho score and the 
LT50ADR, the RADR and RADP (Table A3.9). There were significant correlations 
between MAI and RADP, and JAS with LT50COL (Table A3.9).
A3.2.4 Discussion
A consistent positive relationship between platelet aggregation measures and the 
MMPI Ho score in the young CHD group has been demonstrated. Only isolated 
associations were noted with other psychological measures and no consistency of 
association was noted in the control group. In other words, these associations found 
probably arise from multiple comparisons. Given the association with the MMPI Ho 
score and adrenaline induced platelet aggregation in particular, the MMPI Ho score 
will need to be controlled for in the final comparison analysis and multivariate 
analysis with angiographically defined CAD.
369
Table A3.1. Values for Behavioural Psychological Measures.
Young Controls_____ Young CHD Group Older CHD Group
Ho (MMPI) 15+/- 6 21.2+/- 8.5 23.3+/- 8.7*
JAS 198+/-83 265 +/-80 248 +/-82
MAI 100+/-17 113 +/-20 108 +/- 25
Ho (MAI) 28+/- 6 32 +/- 7 31 +/- 8
Anger 17+/- 5 19 +/- 5 18 +/- 6
* ANOVA F= 16.82, uncorrected pcO.OOOl
Young controls versus young CHD group:
mean difference = 6.2, Bonferroni pcO.OOl 
Young controls versus older CHD group
mean difference = 8.3, Bonferroni pcO.OOl
Ho (MMPI)=hostility score from the Minnesota Multiphase Personality Inventory, 
JAS=Jenkins activity survey, MAI=multidimensional anger inventory, Ho (MAI)= 
hostility score from the MAI, Anger=the anger-in score from the MAI.
Table A3.2. Linear correlations with CHD risk factors in the younger CHD group.
HotMMPH Ho(MAF) MAI Anger(MAH JAS
DOB -0.219 -0.058 0.018 -0.194 -0.026
FC 0.069 0.050 0.149 -0.084 0.048
AMI 0.022 0.049 -0.102 -0.020 0.254
PACKYR 0.486# 0.176 0.083 0.219 0.404*
ETOH mg 0.329* 0.229 0.352* 0.192 0.261
DBP 0.313* 0.335* 0.330* 0.152 0.024
SBP 0.187 0.253 0.251 0.143 -0.143
BMI 0.340* 0.209 0.251 0.148 -0.003
WT 0.127 0.105 0.222 0.280 -0.049
CHOL 0.338* 0.157 0.262 0.378* 0.016
TRIG -0.134 -0.019 -0.026 0.144 -0.259
HDL 0.374* 0.031 0.019 -0.145 0.248
LDL 0.285 0.165 0.284 0.433** -0.016
APOA1 0.552A 0.389* 0.353* 0.068 0.410**
APOB 0.292 0.030 0.159 0.300* -0.009
FIBRIN 0.266 0.229 0.118 0.059 0.033
BSL 0.229 0.404** 0.310* 0.121 -0.203
HbAlC 0.336* 0.313* 0.264 0.140 -0.151
*p<0.05, **p<0.02, #p<0.005, ##p<0.000
Abbreviations are explained in Tables 6.1 and A3.1.
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Table A3.3. Linear correlation between psychological measures and angiographic 
scores in the younger CHD group.
HofMMPIl HotMAIl MAI AngerfMAI) JAS
Normseg -0.308A -0.160 -0.095 -0.142 -0.245
>50% 0.065 -0.206 -0.236 -0.045 -0.090
>70% 0.190 0.037 0.027 -0.028 0.233
CSS 0.349* 0.291 0.239 0.071 0.043
mCSS 0.353* 0.274 0.232 0.054 0.048
CAS 0.232 0.208 0.174 0.131 -0.033
mCAS 0.269 0.192 0.173 0.130 0.007
Jenkins 0.247 0.134 0.138 0.083 -0.009
LVS 0.077 0.124 0.008 -0.006 -0.169
CS 0.297* 0.314* 0.318* 0.183 -0.136
*p<0.05, #p<0.02, Ap<0.005
Abbreviations are explained in Tables 6.3 and A3.1.
Table A3.4. Linear correlation with other behavioural measures in the younger CHD 
group.
HofMMPD HofMAIl MAI Anger(MAI) JAS
Ho - 0.669## 0.626## 0.350* 0.334*
Ho (MAI) 0.669## - 0.840## 0.563## -0.046
MAI 0.626## 0.840## - 0.777## -0.029
ANGER-IN 0.350* 0.563## 0.776## - -0.185
JAS 0.334* -0.046 -0.029 -0.185 -
*p<0.05, **p<0.02, #p<0.005, ##p<0.000
Abbreviations are explained in Table A3.1.
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Table A3.5. Linear correlation with CHD risk factors in the older CHD group.
HotMMPD HofMAD MAI AngerfMAD JAST
DOB -0.249# 0.186 0.244* 0.293# 0.136
FC 0.242# -0.013 -0.016 0.029 -0.028
AMI 0.140 0.134 0.031 0.048 0.210*
PACKYR 0.001 0.111 0.163 0.040 0.128
ETOH mg 0.082 0.043 0.206* 0.219* 0.042
DBP -0.129 0.135 -0.066 0.110
SBP 0.142 0.236 0.267 0.159 -0.058
BMI 0.317* 0.226 0.031 -0.122 -0.142
WT 0.104 0.115 0.192 -0.264 -0.012
CHOL 0.226* -0.042 0.129 0.230* 0.133
TRIG -0.144 -0.071 -0.044 0.006 0.003
HDL 0.174 -0.129 0.029 -0.026 0.040
FIBRIN 0.107 -0.084 -0.304* -0.172 -0.165
BSL 0.186 0.218 0.198 0.186 -0.201
*p<0.05, **p<0.02, #p<0.005, ##p<0.000 
Abbreviations are explained in Tables 6.1 and A3.1.
Table A3.6. Linear correlation with angiographic scores in the older CHD group.
Ho(MMPI) HofMAD MAI Aneer(MAI') JAST
Normseg -0.300A 0.017 0.193* 0.222* -0.102
>50% 0.217* -0.239* -0.302** -0.166 -0.021
>70% 0.248# -0.104 -0.117 -0.065 0.061
CSS 0.395A -0.026 -0.146 -0.142 -0.007
mCSS 0.363A -0.070 -0.166 -0.173 0.002
CAS 0.235* -0.016 -0.138 -0.149 0.048
mCAS 0.240* -0.054 -0.159 -0.179 0.059
Jenkins 0.321A -0.037 -0.106 -0.106 0.066
LVS 0.085 -0.005 -0.088 -0.078 -0.086
CS 0.233* 0.122 0.004 -0.017 -0.096
*p<0.05, **p<0.02, #p<0.005
Abbreviations are explained in Tables 6.3 and A3.1.
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Table A3.7. Linear correlation with other behavioural measures in the older CHD 
group.
HotMMPL HotMAD MAI Anger(MAH JAST
Ho - 0.467## 0.435## 0.302# 0.318#
Ho (MAI) 0.467## - 0.800## 0.622## -0.336#
MAI 0.489## 0.800## - 0.829## -0.408
ANGER-IN 0.388# 0.622## 0.829## - -0.264*
JAS 0.314* 0.336# 0.408## 0.264 -
*p<0.05, **p<0.02, #p<0.005, ##p<0.000 
Abbreviations are explained in Table A3.1.
Table A3.8. Linear correlation with other behavioural measures in the young control 
group.
HofMMPL HofMAH MAI Anger(MAIl JAS
Ho - 0.769# 0.689# 0.547** 0.191
Ho (MAI) 0.770# - 0.881## 0.748# 0.202
MAI 0.689# 0.881## - 0.914## 0.157
ANGER-IN 0.547** 0.563## 0.913## - -0.006
JAS 0.191 0.202 0.157 -0.005 -
*p<0.05, **p<0.02, #p<0.005, ##p<0.000
Abbreviations are explained in Table A3.1.
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Table A3.9. Linear correlation with platelet function in the young CHD group.
HofMMPL HolMAD MAI AneerlMAD JAST
LT50ADR -0.518# -0.155 -0.228 -0.254 -0.029
RADR 0.441# 0.138 0.189 0.235 0.029
LT50ADP -0.201 -0.070 -0.029 -0.023 -0.050
RADP 0.433# 0.251 0.350* 0.277 0.191
LT50COL -0.280 0.007 -0.119 -0.185 -0.310*
RCOL 0.156 -0.066 0.072 0.021 0.226
LAG -0.247 0.020 0.022 -0.159 -0.073
TXB2 -0.106 0.010 -0.210 -0.223 -0.119
BTG 0.176 0.226 0.225 0.074 -0.085
MPV -0.072 -0.071 -0.082 0.017 0.275
PCR -0.011 -0.131 -0.119 -0.170 0.131
Abbreviations are explained in Table 6.1, 6.2 and A3.1.
Table A3.10. Regression analysis with coronary artery scores as dependent variables, 
and parameters with a univariate relation (Ho, ETOH, PACKYR, BMI, DBP, CHOL, 
APOA, RADP, and LT50ADR) as independent variables for the young CHD group.
Dependent Independent
Variable Variable B SEB Beta R sq P value
CSS LT50ADR -25.58 8.460 -0.700 0.504 0.014
mCSS LT50ADR -27.70 7.824 -0.763 0.582 0.006
CAS Nil
mCAS Nil
NORMSEG APOA -0.079 0.034 -0.608 0.370 0.047
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